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Photodynamic	  therapy	  (PDT)	  is	  a	  treatment	  modality	  for	  cancer	  and	  premalignant	  lesions	  
that	  utilizes	  a	  photoactive	  drug,	   the	  photosensitizer,	   in	   combination	  with	   light.	  PDT	  has	  
become	   the	   treatment	   of	   choice	   for	   various	   malignancies.	   Furthermore,	   PDT	   is	   under	  
investigation	  as	  a	  potential	   (palliative)	   treatment	   in	   situations	  where	   the	  possibilities	  of	  
chemo-­‐	  and	  radiotherapy	  are	   limited	  or	  exhausted.	  Since	  both	  photosensitizer	  and	   light	  
have	   to	   be	   present	   to	   cause	   tissue	   damage,	   selective	   damage	   to	   the	   lesion	   can	   be	  
achieved	   by	   controlling	   the	   presence	   of	   either	   one	   of	   them	   to	   the	   treatment	   area.	  
Selective	  damage	  can	  be	  reached	  by	  i)	  choosing	  a	  photosensitizer	  that	  is	  mainly	  present	  in	  
the	  lesion,	  or	  ii)	  preventing	  normal	  tissue	  from	  being	  illuminated.	  However,	  the	  success	  of	  
PDT	   in	   reducing/removing	   (pre-­‐)malignant	   lesions	  has	  been	  variable.	  Treatment	  efficacy	  
can	   range	   form	  non-­‐observable	  effects	   to	   severe	  damage	   to	  normal	   tissue.	  Considering	  
the	  complexity	  of	  both	  the	  execution	  of	  the	  treatment	  and	  damage	  pathways	  involved	  in	  
PDT,	   some	   variability	   in	   treatment	   efficacy	   is	   not	   unexpected.	   However,	   given	   the	   fact	  
that	   clinical	   applications	   of	   PDT	   that	   have	   proved	   successful	   remain	   small	   in	   number,	  
more	  work	  is	  necessary	  to	  optimize	  therapeutic	  efficacy.	  
	  
The	  idea	  of	  using	  sunlight	  for	  treatment	  of	  certain	  (skin)	  abnormalities	  goes	  as	  far	  back	  as	  
ancient	   Egypt	   and	   has	   returned	   repeatedly	   over	   the	   intervening	   centuries.	  
Photosensitizing	  agents	  and	  their	  potential	  use	  in	  treatment	  were	  first	  recognized	  at	  the	  
end	  of	  the	  19th	  century,	  when	  Raab	  and	  Von	  Tappeiner	  discovered	  haematoporphyrins	  in	  
the	   urine	   of	   people	   suffering	   from	   skin	   photosensitivity	   [1,	   2].	   Treatments	   using	   a	  
combination	  of	  light	  and	  a	  photoactive	  agent	  started	  to	  be	  introduced	  into	  the	  clinic	  from	  
1975	   using	   haematoporphyrin	   derivative	   (HpD)	   as	   photosensitizer	   [3].	   With	   interest	  
piqued,	  researchers	  started	  investigating	  the	  mechanisms	  underlying	  the	  seemingly	  toxic	  
combination	   of	   light	   and	   photosensitizer.	   It	   is	   shown	   that	   the	   presence	   of	   a	  
photosensitizer	  molecule	  mediates	  the	  transfer	  of	  energy	  from	  light	  (photons)	  to	  oxygen,	  
thereby	  creating	  reactive	  oxygen	  species	  that	  cause	  tissue	  damage	  [4].	  To	  date,	  PDT	  has	  
been	   clinically	   used	   to	   treat	   various	   malignant	   and	   non-­‐malignant	   conditions,	   ranging	  
from	   superficial	   skin	   lesions	   [5]	   to	   prostate	   cancer	   [6],	   bile	   duct	   cancer	   [7],	   age-­‐related	  
macular	  degeneration	  [8]	  and	  the	  palliative	  treatment	  of	  solid	  head	  &	  neck	  tumors	  [9].	  
	  
FOCUS	  OF	  THIS	  THESIS	  
This	   thesis	   will	   focus	   on	   the	   use	   of	   quantitative	   fiber	   optic	   spectroscopy	   and	   optical	  
imaging	  for	  the	  optimization	  of	  PDT.	  PDT	  has	  been	  under	  investigation	  both	  preclinically	  









understanding	   of	   the	   range	   of	   parameters	   that	   influence	   the	   outcome	   of	   PDT	   will	  
potentially	  contribute	  to	  optimization	  and	  control	  of	  PDT	  treatment	  protocols.	  This	  may	  
result	  in	  an	  improved	  success	  rate	  and	  an	  increase	  in	  the	  adoption	  of	  PDT	  in	  existing	  and	  
new	  clinical	  fields.	  
Recent	   developments	   in	   fiber	   optic	   spectroscopy	   in	   both	   the	   white-­‐light	  
reflectance	   and	   fluorescence	   domains	   have	   paved	   the	   way	   for	   more	   precise	  
measurements	   of	   both	   treatment	   inputs	   and	   local	   tissue	   responses	   during	   and	   after	  
treatment.	   Local	   fiber	   optic	   observations	   are	   combined	   with	   optical	   imaging	   data	   to	  
provide	  a	  multimodality	  analysis	  of	   the	  effect	  of	   various	   treatment	  parameters	  on	   local	  
PDT	   effects	   observed	   during	   and	   directly	   after	   treatment.	   This	   thesis	   focuses	   on	   the	  
application	   of	   quantitative	   fiber	   optic	   spectroscopy	   and	   optical	   imaging	   techniques	   to	  
provide	   insight	   into	  various	  PDT-­‐related	  processes,	  which	  contribute	  to	  the	  optimization	  
of	  therapy	  and	  can	  be	  divided	  into	  the	  following	  sections:	  
	  
 The	   investigation	   of	   the	   relationship	   between	   vascular	   responses	   during	   light	  
fractionated	   ALA-­‐PDT	   and	   treatment	   efficacy	   using	   optical	   imaging	   and	  
spectroscopy.	  
	  
 The	   development	   of	   quantitative	   fiber	   optic	   fluorescence	   spectroscopy	   and	   its	  
application	  in	  measuring	  in-­‐vivo	  photosensitizer	  pharmacokinetics.	  
	  
 A	   comparison	  of	   the	   pharmacokinetics	   and	   spectral	   properties	   of	   chlorin	   e6	   and	  
Bremachlorin	   based	   on	   in-­‐vivo	   measurements	   and	   their	   relationship	   to	   PDT	  
efficacy.	  
	  
Ultimately,	   the	   goal	   is	   to	   use	   results	   from	   these	   and	   further	   investigations	   to	   optimize	  
treatment	   protocols	   for	   PDT	   in	   order	   to	   maximize	   treatment	   efficacy.	   The	   aim	   of	   the	  
remaining	   introductory	   text	   is	   to	   provide	   the	   background	   information	   necessary	   to	  
understand	  the	  underlying	  principles	  of	  the	  work	  covered	  in	  this	  thesis.	  
PRINCIPLES	  OF	  PHOTODYNAMIC	  THERAPY	  
The	  mechanism	  of	  action	  of	  photodynamic	  therapy	  is	  based	  on	  the	  interaction	  of	  visible	  
light,	  photosensitizer	  and	  oxygen.	  Light	  contains	  a	  certain	  amount	  of	  energy	  in	  the	  form	  of	  











to	   directly	   damage	   cells	   and	   tissues.	   Oxygen	   is	   present	   in	   all	   cells	   of	   the	   human	   body,	  
where	   it	  plays	  a	  major	  role	   in	  the	  body’s	  process	  of	  energy	  generation.	  Only	  when	  both	  
oxygen	   and	   light	   are	   in	   the	   presence	   of	   a	   photosensitizer,	   reactive	   oxygen	   species	   are	  
generated	   and	   damage	   is	   inflicted.	   An	   overview	   of	   the	   pathways	   by	   which	  
photosensitizers	   mediate	   the	   transfer	   of	   energy	   from	   photons	   to	   oxygen	   is	   shown	   in	  
figure	   1.1.	   Absorption	   of	   the	   treatment	   light	   is	   followed	   by	   the	   transfer	   of	   a	  
photosensitizer	  molecule	  from	  the	  ground	  state	  into	  an	  excited	  state	  (S1,	  S2	  etc).	  
	  
These	   excited	   singlet	   states	   are	   highly	   unstable	   and	   therefore	   very	   short	   lived	   and	   the	  
molecule	   will	   loose	   the	   excess	   of	   energy,	   which	   will	   happen	   via	   one	   of	   the	   following	  
routes:	   i)	   internal	   conversion	  whereby	  no	  photons	  are	  emitted,	   ii)	   the	  molecule	  will	   fall	  
back	  to	  its	  ground	  state	  whereby	  the	  excess	  of	  energy	  is	  emitted	  as	  fluorescent	  light,	  or	  
iii)	   the	   photosensitizer	   molecule	   is	   transformed	   into	   its	   (excited)	   triplet	   state	   (T1)	   by	  
intersystem	   crossing.	   This	   energetic	   state	   is	   relatively	  more	   stable	   and	   has	   therefore	   a	  
longer	   life	   time.	   This	   means	   that	   it	   has	   a	   higher	   probability	   of	   interacting	   with	   other	  
molecules	   in	   the	   local	   environment	   and	   exchange	   energy	   upon	   collision.	   When	   the	  
photosensitizer	   triplet	   state	   molecule	   directly	   collides	   with	   molecular	   oxygen	   (type	   II	  
reactions),	   highly	   reactive	   singlet	   oxygen	   radicals	   (1O2)	   are	   formed.	   Another	   reaction	  
pathway	  is	  the	  direct	  transfer	  of	  energy	  from	  photosensitizer	  triplet	  state	  molecules	  that	  
leads	  to	  the	  production	  of	  radicals.	  These	  radicals	   interact	  with	  oxygen	  to	  form	  reactive	  
oxygen	  species	  (type	  I	  reactions)	  [4].	  Reactive	  oxygen	  species	  are	  known	  to	  have	  harmful	  
effects	  on	  cells	  and	  cell	  structures,	  including	  damage	  to	  lipid	  membranes	  and	  oxidation	  of	  
amino	   acids	   in	   proteins	   [10].	  Which	   of	   these	   pathways	   occurs	   is	   dependent	   on	   factors	  
such	   as	   type	   of	   photosensitizer,	   oxygen	   concentration	   and	  molecular	   environment	   and	  




Figure	  1.1:	   Jablonksi	  diagram	  for	  photosensitizer	  and	  oxygen	  exited	  states.	  (Image:	  Nishiyama	  et	  al.,	  











The	   first	   clinical	   PDT	   treatments	   were	   introduced	   in	   1976	   by	   Dougherty	   using	  
Hematoporphyrin	   derivative	   (HpD)	   [3].	   Over	   the	   next	   three	   decades,	   several	   first	  
generation	   photosensitizers	   based	   on	   HpD	   were	   developed.	   HpD	   was	   improved	   by	  
purifying	  the	  active	  fraction	  of	  oligomers	  in	  the	  mixture,	  resulting	  in	  Photofrin®	  -­‐the	  first	  
commercial	   clinical	   photosensitizer-­‐	   that	   achieved	   FDA	   approval	   for	   treatment	   of	  
precancerous	  lesions	  and	  palliative	  treatment	  of	  cancers	  in	  the	  esophagus	  and	  tumors	  in	  
the	   bronchii	   [11,	   12].	   A	   major	   drawback	   of	   first	   generation	   photosensitizers	   was	  
significant	   skin	   photosensitivity,	   which	   could	   last	   for	   several	   weeks	   and	   mandates	   the	  
patient	  to	  stay	  in	  the	  (relative)	  dark.	  	  
Several	   second	   generation	   photosensitisers	   were	   subsequently	   introduced:	  
Benzoporphyrin	   derivative	   monoacid	   ring	   A	   (BPD-­‐MA,	   Visudyne®)	   is	   a	   successful	  
photosensitizer	  with	  FDA	  approval	   for	   the	  treatment	  of	  abnormal	  vessels	   in	  various	  eye	  
disorders	   such	   as	   age	   related	   macular	   degeneration	   [8].	   Another	   second	   generation	  
photosensitizer	   is	  m-­‐tetrahydroxyphenylchlorin	   (mTHPC	   or	   Foscan®),	  which	   is	   approved	  
by	  the	  FDA	  and	   in	  Europe	  for	  the	  palliative	  treatment	  of	  head	  &	  neck	  cancers	   [9].	  After	  
systemic	  administration,	  high	  concentrations	  of	  mTHPC	  can	  be	  found	  in	  plasma,	  but	  due	  
to	   its	   lipophilicity,	   photosensitizer	   localization	   in	   (malignant)	   tissue	   remains	   days	   after	  
injection,	   providing	   some	   tissue	   selectivity.	   Drawback	   is	   again	   the	   prolonged	   (skin)	  
sensitivity	   of	   the	   patient,	  which	   can	   lead	   up	   to	   15	   days	   after	   injection,	   and	   the	   lack	   of	  
selectivity	  between	  tumor	  and	  normal	  tissue.	  
Chlorins	  belong	  to	  a	  category	  of	  photosensitizers	  that	  are	  investigated	  in	  chapters	  
5	  to	  7	  of	  this	  thesis.	  Chlorins	  are	  reduced	  porphyrins	  and	  belong	  to	  the	  second	  generation	  
of	   photosensitizers	   [13].	   In	   general,	   these	   second	   generation	   photosensitizers	   show	  
increased	   photo	   activity	   and	   an	   enhanced	   light	   absorption	   in	   the	   red	   region	   compared	  
with	  first	  generation	  photosensitizers,	  which	  allows	  for	  a	  deeper	  penetration	  of	  light	  and	  
consequently	   a	   larger	   effective	   treatment	   volume.	   Chlorin	   e6	   (ce6)	   is	   a	  member	   of	   this	  
family	   and	   has	   been	   studied	   intensively	   for	   over	   two	   decades	   [13-­‐15].	   Ce6	   has	   some	  
advantageous	   properties	   as	   a	   clinical	   photosensitizer;	   it	   has	   low	   toxicity	   in	   the	   dark,	   is	  
excreted	  and/or	  metabolized	  from	  the	  body	  within	  two	  days	  and	  seems	  to	  have	  a	  higher	  
affinity	   for	  cellular	   internalization	   in	  environments	  with	  a	   lower	  pH	  such	  as	  those	  found	  
within	  some	  tumors.	  A	  disadvantage	  of	  ce6	  is	  its	  relatively	  low	  lipophilicity,	  meaning	  that	  
it	   has	   a	   preference	   for	   water-­‐containing	   environments,	   such	   as	   blood.	   Therefore,	   ce6	  
preferentially	  remains	  in	  the	  vasculature	  and	  does	  not	  accumulate	  significantly	  in	  tissue.	  
Cellular	  membranes	   or	   cell	   structures	   where	   reactive	   oxygen	   species	   can	   cause	   severe	  
damage,	   often	   consist	   of	   fat-­‐like	   structures,	   for	   which	   ce6	   lacks	   a	   preference.	   Several	  











photosensitizer.	  Examples	  are	  ce6-­‐PVP,	  where	  ce6	  is	  conjugated	  to	  a	  polyvinylpyrrolidone	  
carrier,	   and	   the	   ce6-­‐derivative	  NPe6	   (mono-­‐L-­‐aspartylchlorin-­‐e6),	  which	   have	   both	   been	  
used	  successfully	  in	  phase	  I	  clinical	  trials	  [16-­‐18].	  
A	   new	   photosensitizing	   compound,	   Bremachlorin,	   consists	   of	   a	   mixture	   of	   ce6	  
(∼80%),	   combined	   with	   the	   photosensitizing	   agents	   purpurin	   5	   (∼15%)	   and	   chlorin	   p6	  
(∼5%),	   which	   are	   both	   by-­‐products	   of	   ce6	   synthesis	   [19,	   20].	   The	   main	   photoactive	  
component	   of	   Bremachlorin	   is	   thought	   to	   be	   purpurin	   5,	   partly	   because	   its	   rapid	  
interaction	   with	   lipo-­‐proteins	   that	   enables	   it	   to	   be	   delivered	   into	   tumor	   cells	   [21].	  
Purpurin	  5	   is	  too	  hydrophobic	  to	  be	  administered	   intravenously,	  but	  combined	  with	  ce6	  
and	  cp6	  is	  achieves	  the	  chemical	  stability	  required	  for	  intravascular	  administration.	  It	  has	  
been	  suggested	  that	  the	  overall	  photosensitizing	  effect	  of	  Bremachlorin	  is	  larger	  than	  its	  
individual	   components.	   Part	   of	   this	   thesis	   is	   the	   comparison	   between	   ce6	   and	  
Bremachlorin.	  	  
Another	   photosensitizer	   that	   is	   the	   focus	   of	   research	   in	   this	   thesis	   is	  
Protoporphyrin	   IX	   (PpIX).	   Contrary	   to	   the	   aforementioned	   photosensitizers,	   PpIX	   is	   an	  
endogenous	  molecule	  which	   can	   be	   activated	   by	   light.	   PpIX	   is	   an	   intermediate	   product	  
formed	   during	   haem	   synthesis	   in	   mitochondria	   [22].	   Under	   normal	   physiological	  
conditions,	   the	   amount	   of	   PpIX	   and	   other	   intermediates	   is	   tightly	   regulated	   by	   various	  
feedback	  mechanisms,	  and	  the	  concentration	  present	   in	  tissue	  is	  too	  low	  to	  be	  used	  for	  
therapy.	   The	   administration	   of	   exogenous	   5-­‐aminolevulinic	   acid	   (ALA)	   bypasses	   the	  
feedback	   mechanism	   controlling	   the	   concentration	   of	   intermediates,	   and	   the	   step	  
transforming	  PpIX	  into	  haem	  becomes	  the	  slowest	  step	  in	  the	  process	  [22].	  This	  leads	  to	  
the	   accumulation	   of	   PpIX	   to	   concentrations	   high	   enough	   to	   allow	   for	   photodynamic	  
therapy.	  PpIX	  can	  accumulate	  in	  any	  tissue	  containing	  cells	  with	  an	  intact	  haem	  synthesis	  
pathway.	   High	   PpIX	   accumulation	   is	   observed	   in	   tissues	   like	   epidermis,	   gastrointestinal	  
mucosa	  and	  various	  other	  organs.	  Muscle,	  connective	  tissue	  and	  cartilage	  show	  low	  PpIX	  
fluorescence.	   The	   increased	   metabolic	   activity	   of	   tumor	   cells	   compared	   with	   normal	  
tissue	   results	   in	   (some)	   selective	   uptake	   in	   tumor	   tissue.	   ALA	   can	   be	   applied	   both	  
systemically	  and	  topically	  [23],	  the	  later	  being	  regularly	  clinically	  used	  in	  the	  treatment	  of	  
(pre-­‐)malignant	  skin	  lesions,	  where	  ALA	  penetrates	  through	  the	  stratum	  corneum	  into	  the	  
epidermis	  [24].	  Research	  has	  been	  done	  on	  how	  deep	  and	  into	  which	  particular	  cell	  types	  
the	  ALA	  still	  generates	  an	  excess	  of	  PpIX.	  Of	  particular	  interest	  are	  endothelial	  cells,	  cells	  
forming	  the	  vessel	  wall.	  Damage	  to	  these	  cells	  will	  directly	  damage	  vasculature,	  which	  is	  











MECHANISMS	  UNDERLYING	  PDT	  INDUCED	  DAMAGE	  
Three	  major	  damage	  pathways	  are	   identified	  by	  which	  PDT	  results	   in	  destruction	  of	   the	  
target	   tissue	   through	  cellular	  and	  vascular	   responses.	  PDT	   is	  also	  known	  to	  activate	   the	  
immune	   system	  and	   induce	   immunological	   responses	   [27].	   Immunological	   responses	   to	  
PDT	   constitute	   an	   ongoing	   research	   topic,	   which	   lies	   beyond	   the	   scope	   of	   this	   thesis.	  
Cellular	  responses	  are	  caused	  by	  direct	  damage	  to	  cellular	  components	  caused	  by	  reactive	  
oxygen	  species.	  Cell	  death	  can	  occur	   in	  different	  ways,	  of	  which	  apoptosis	  and	  necrosis	  
are	   the	   most	   well	   known	   [28].	   The	   way	   in	   which	   a	   cell	   dies	   depends	   on	   the	   cellular	  
structures	  where	  the	  photosensitizer	  is	  localized	  at	  the	  time	  of	  treatment,	  the	  severity	  of	  
the	  damage	  and	  light	  fluence	  rate.	  High	  fluence	  rates	  tend	  to	  induce	  necrosis,	  while	  low	  
fluence	   rates	   are	   associated	   with	   apoptotic	   cell	   death	   [29].	   Apoptosis	   is	   a	   type	   of	  
programmed	  cell	  death	  that	  involves	  a	  chain	  of	  biochemical	  events	  such	  as	  cell	  shrinking	  
and	   nuclear	   and	  DNA	   fragmentation.	   This	   process	   usually	   results	   in	   removal	   of	   the	   cell	  
without	   evoking	   inflammatory	   responses	   [30].	   Apoptosis	   can	   be	   induced	   by	   many	  
pathways,	   such	  as	   excretion	  of	   specific	   hormones	  or	   growth	   factors.	   Intracellular	   stress	  
and	   mitochondrial	   damage	   are	   also	   known	   to	   lead	   to	   apoptosis	   [28].	   Since	   PpIX	   is	  
localized	   in	   mitochondria,	   apoptosis	   is	   thought	   to	   be	   the	   most	   important	   damage	  
mechanism	  of	  PpIX	  PDT	  [31].	  Necrosis	   is	  cell	  death	  that	  usually	  occurs	  from	  acute	  tissue	  
injury.	   It	   involves	   cell	   swelling,	   disruption	   of	   membranes	   and	   cell	   lysis.	   Rupture	   of	   the	  
plasma	   membrane	   may	   release	   the	   necrotic	   cell	   content,	   which	   can	   be	   harmful	   to	  
neighboring	   cells,	   provoking	   an	   inflammatory	   response	   [32].	   Many	   lipophilic	  
photosensitizers,	   like	   ce6,	   are	   localized	   in	   these	   lipid	   membranes,	   where	   PDT	   leads	   to	  
membrane	  disruption,	  resulting	  in	  necrotic	  cell	  death	  [28].	  
Vascular	   responses	   during	   and	   after	   PDT	   include	   constriction	   or	   dilatation,	   and	  
leakage	  of	   fluid	   from	  vessels	   into	  the	  tissue	   [33].	  By	  directly	  damaging	  endothelial	  cells,	  
thrombocytes	   adhere	   to	   vessel	   walls,	   leading	   to	   the	   release	   of	   vasoactive	   components	  
that	   induce	   (temporary)	   constriction	   of	   (mainly)	   arterioles	   [34].	   Severe	   damage	   to	  
endothelial	  cells	  can	  result	  in	  vascular	  leakage.	  Neovasculature,	  which	  is	  the	  main	  type	  of	  
vasculature	  in	  tumors,	  is	  usually	  more	  sensitive	  to	  this	  process	  than	  normal	  vessels.	  When	  
vasculature	  is	  constricted,	  this	  disrupts	  the	  distribution	  of	  oxygen	  and	  other	  nutrients	  to	  
the	   target	   tissue,	   causing	   indirect	   tumor	   damage	   due	   to	   hypoxia	   and	   starvation	   of	  
nutrients.	  It	  is	  suggested	  that	  this	  extra	  indirect	  damage	  is	  necessary	  in	  addition	  to	  cellular	  
damage	   to	   achieve	   complete	   tumor	   destruction	   [35].	   Treating	   neovasculature	   in	   age	  
related	  macular	   generation	  with	   BPD-­‐MA,	  which	   localizes	   in	   the	   vessel	   endothelium,	   is	  
based	  on	  this	  effect	  [8].	  However,	  vascular	  shutdown	  during	  early	  stages	  of	   illumination	  
decreases	   the	   transport	  of	  oxygen	   to	   the	   target	  volume,	  which	   limits	   the	  production	  of	  











response.	   Treatment	   efficacy	   is	   therefore	   dependent	   on	   a	   fine	   balance	   between	   the	  
positive	  and	  negative	  effects	  of	  vascular	  damage.	  Vascular	  responses	  during	  ALA-­‐PDT	  are	  
the	  subject	  of	  chapter	  3.	  
PDT	  DOSIMETRY	  
The	   phototoxic	   effect	   of	   PDT	   is	   based	   on	   the	   interaction	   of	   light,	   oxygen	   and	  
photosensitizer	   and	   a	   positive	   treatment	   outcome	   is	   dependent	   on	   the	   presence	   of	   all	  
three	   components.	   It	   is	   therefore	   important	   to	   gain	   as	  much	   information	   on	   these	   key	  
components	  as	  possible	  before,	  during	  and	  after	  therapy.	  Measuring	  these	  parameters	  is	  
one	  of	  the	  main	  focuses	  of	  this	  thesis.	  The	  process	  of	  monitoring	  and,	  if	  needed,	  adapting	  
(one	   of)	   the	   treatment	   parameters	   is	   called	   dosimetry.	   Figure	   1.2	   shows	   a	   schematic	  
overview	   of	   the	   light-­‐oxygen-­‐photosensitizer	   interaction	   and	   the	   by-­‐products	   of	   this	  
process,	  which	  are	  individually	  all	  candidates	  for	  dosimetric	  monitoring.	  
	  
The	   most	   direct	   way	   to	   monitor	   treatment	   outcome	   is	   by	   measuring	   the	   quantity	   of	  
singlet	   oxygen	   formed	  by	   luminescence	   [36].	  Although	   this	   is	   theoretically	   possible	   and	  
topic	  of	  extensive	  preclinical	  research	  [37,	  38],	  it	  is	  not	  presently	  feasible	  for	  clinical	  use.	  
Another	  possibility	  is	  to	  measure	  the	  three	  key	  components	  in	  the	  measurement	  volume.	  
This	   is	   termed	   explicit	   dosimetry	   [39,	   40].	   However,	   these	   components	   are	   often	  
dependent	  on	  each	  other	  and	  can	  change	  dynamically	  during	  treatment.	  
The	  propagation	  of	  light	  
in	   tissue	   is	   strongly	   influenced	  
by	  the	  processes	  of	  absorption	  
and	  scattering	  and	  as	  a	  result	  is	  
not	   a	   constant	   factor	   within	  
the	   treatment	   volume.	  
Furthermore,	  the	  tissue	  optical	  
properties	  change	  as	  a	  result	  of	  
treatment,	   for	   example	   by	  
changes	   in	   tissue	   oxygenation,	  
blood	   volume	   or	   the	   onset	   of	  
edema	   [41].	   Photosensitizer	  
concentration	   is	  dependent	  on	  
tissue	   type	  and	  vascularization	  
(in	   the	   case	   of	   systemic	  
	  











administered	   photosensitizers).	   During	   treatment,	   the	   triplet	   state	   photosensitizer	  
concentration	   depends	   on	   the	   amount	   of	   light	   available	   to	   activate	   the	   ground	   state	  
photosensitizer	  molecule	  and	  amount	  of	  ground	  state	  molecule	  present,	  which	  decreases	  
over	  time	  due	  to	  interaction	  with	  singlet	  oxygen.	  The	  oxygen	  present	  will	  decrease	  due	  to	  
its	   transformation	   into	  singlet	  oxygen	  and	  reactive	  oxygen	  species.	  However,	   the	  supply	  
of	  oxygen	  by	  vasculature	  is	  likely	  to	  decrease	  due	  to	  vascular	  responses.	  All	  these	  effects	  
and	   interactions	   necessitate	   continuous	   measurements	   of	   all	   parameters,	   which	   is	  
practically	   impossible	   without	   interfering	   with	   treatment.	   The	   determination	   of	  
photosensitizer	  concentration	  is	  the	  subject	  of	  chapter	  5	  and	  chapter	  6.	  	  
	   One	  type	  of	  implicit	  dosimetry	  is	  the	  (continuous)	  measurement	  of	  photosensitizer	  
fluorescence	   during	   treatment	   [39].	   Figure	   1.1	   shows	   that	   an	   excited	   photosensitizer	  
molecule	   can	   return	   to	   its	   ground	   state	   by	   sending	   out	   a	   fluorescent	   photon,	  which	   is	  
relatively	   easy	   to	   detect	   without	   interfering	   in	   treatment.	   Fluorescence	  measurements	  
before	   treatment	   can	   determine	   distribution	   and	   the	   relative	   photosensitizer	  
concentration	   in	   the	   treatment	   area.	   During	   treatment,	   the	   degeneration	   of	  
photosensitizer	  by	  oxygen	   radicals	   (photobleaching)	  may	  provide	   information	  on	   radical	  
formation	   and	   therefore	   effectiveness	   of	   the	   treatment.	   In	   chapter	   2	   we	   perform	   PDT	  
with	  a	  light	  dose	  determined	  by	  the	  measurement	  of	  real-­‐time	  PpIX	  photobleaching.	  
	  
PDT	  ILLUMINATION	  PROTOCOLS	  
The	   success	   of	   photodynamic	   therapy	   is	   dependent	   on	   a	   complex	   interdependency	   of	  
light,	  oxygen,	  photosensitizer	  and	  the	  properties	  of	  the	  target	  tissue.	  Before	  every	  (pre-­‐)	  
clinical	  PDT	  treatment,	  an	  illumination	  protocol	   is	  defined	  which	  dictates	  the	  timeline	  of	  
the	  treatment.	  Injected	  photosensitizer	  concentration,	  local	  fluence	  and	  fluence	  rate	  (and	  
corresponding	   laser	   settings)	   are	   the	   most	   important	   treatment	   parameters.	   Another	  
important	  parameter	  is	  drug-­‐light	  interval,	  which	  indicates	  the	  time	  between	  the	  time	  of	  
photosensitizer	   administration	   and	   the	   start	   of	   illumination.	   This	   period	   is	   critical	   and	  
based	   on	   knowledge	   on	   how	   the	   photosensitizer	   accumulates	   into	   the	   target	   tissue.	   A	  
carefully	  chosen	  drug-­‐light	  interval	  can	  also	  increase	  selective	  damage	  to	  tumor	  by	  taking	  
into	   account	   knowledge	   on	   the	   tumor-­‐to-­‐normal	   ratio	   of	   the	   photosensitizer	  
accumulation.	  Clinically,	  drug-­‐light	  intervals	  vary	  from	  a	  few	  hours	  (ALA	  [42],	  ce6	  [16])	  to	  
four	  days	  (mTHPC	  [9]).	  	  
	   After	   the	   discovery	   of	   re-­‐synthesis	   of	   PpIX	   after	   illumination,	   a	   fractionated	  
illumination	   protocol	   is	   developed	   to	   allow	   the	   re-­‐synthesized	   PpIX	   to	   increase	   PDT	  
damage	   [43].	  This	  has	   resulted	   in	   the	  successful	   clinical	  application	  of	   light	   fractionated	  
ALA-­‐PDT.	   Although	   the	   exact	   mechanism	   of	   light	   fractionated	   ALA-­‐PDT	   is	   not	   yet	   fully	  











second	   light	   fraction	   significantly	   improves	   the	   clinical	   success	   rate	  of	   the	   treatment	  of	  
superficial	   basal	   cell	   carcinomas	   [42].	   In	   chapter	   2	   and	   3	   we	   further	   investigate	   the	  
increased	  efficacy	  of	  fractionated	  ALA-­‐PDT.	  
	   Photosensitizer	  pharmacokinetics	  play	  an	   important	   role	   in	   the	  determination	  of	  
the	   drug-­‐light	   interval.	   In	   chapter	   5	   and	   6	   the	   pharmacokinetics	   and	   localization	   of	  
photosensitizers	  ce6	  and	  Bremachlorin	  are	  carefully	  investigated.	  	  
TISSUE	  OPTICAL	  PROPERTIES	  
Figure	   1.2	   illustrates	   the	   important	   role	   that	   the	   tissue	   optical	   properties	   play	   in	  
monitoring	  and	  optimizing	  photodynamic	  therapy.	  The	  tissue	  optical	  properties	  influence	  
the	  way	   light	   propagates	   in	   tissue	   and	   can	  be	   separated	   into	   effects	   due	   to	   absorption	  
and	  scattering.	  In	  short:	  absorption	  is	  caused	  by	  the	  presence	  of	  molecules	  in	  tissue	  that	  
absorb	   light	   (of	   a	   particular	   wavelength)	   and	   scattering	   is	   a	   result	   of	   refractive	   index	  
differences	   that	   are	   present	   between	   cell	   and	   tissue	   structures.	   Both	   processes	   are	  
described	   in	  more	  detail	  below.	  Knowledge	  of	   the	   tissue	  optical	  properties	   is	   important	  
because	   they	   determine	   the	   distribution	   of	   light	   in	   tissue	   and	   thereby	   determine	   the	  
delivered	   light	   dose	   in	   PDT	   [44].	   Furthermore,	   tissue	   absorption	   and	   scattering	   are	  
measurable	  parameters	  that	  can	  be	  related	  to	  vascular	  physiology	  in	  tissue	  [45].	  Last,	  the	  
detection	   of	   fluorescence	   light	   from,	   in	   case	   of	   PDT,	   the	   photosensitizer	   in	   tissue	   is	  
strongly	  affected	  by	  tissue	  optical	  properties	  [46].	  Knowledge	  of	  optical	  properties	  can	  in	  
theory	  be	  used	  to	  determine	  the	  intrinsic	  photosensitizer	  fluorescence.	  	  
One	   way	   to	   investigate	   the	   absorption	   and	   scattering	   of	   tissue	   is	   to	   illuminate	  
tissue	  with	  white	  light.	  The	  backscattered	  photons	  that	  are	  detected	  have	  interacted	  with	  
the	  tissue,	  and	  the	  (calibrated)	  difference	  between	  the	  light	  used	  to	  illuminate	  the	  tissue	  
and	  the	  detected	  light	  provides	  valuable	  information	  on	  the	  composition	  of	  the	  tissue	  [47,	  
48].	   If	   light	   is	   guided	   through	   a	   (phantom)	   medium	   that	   is	   only	   scattering	   without	  
absorption,	   the	   result	   is	   the	   detection	   of	   a	   reflectance	   spectrum	   that	   theoretically	  
corresponds	  with	  a	  decreasing	  power	  law.	  This	  effect	  is	  illustrated	  in	  figure	  1.3.	  When	  an	  
absorber	   is	   present	   in	   the	   medium,	   a	   local	   minimum	   in	   observed	   in	   the	   reflectance	  
spectrum	  where	   the	  absorber	  exhibits	  an	  extinction	   spectrum.	   I.e.	   less	   light	   is	   collected	  
than	  would	  be	  expected	  in	  the	  absence	  of	  absorption	  when	  only	  scattering	  was	  present.	  
With	  a	  sufficiently	  detailed	  understanding	  of	  the	  absorbers	  present	  and	  knowledge	  of	  the	  
background	   scattering	   properties	   of	   the	   medium	   the	   reflectance	   spectrum	   can	   be	  










LIGHT	  ABSORPTION	  IN	  TISSUE	  
Various	   endogenous	   molecules	   present	  
in	   tissue,	   such	   as	   hemoglobin,	   melanin,	  
cytochrome	   C	   and	   bilirubin	   show	  
significant	   wavelength-­‐dependent	  
absorption	   in	   the	   visible	   region	   of	   the	  
spectrum.	   An	   overview	   of	   the	   main	  
absorbers	   present	   in	   tissue	   is	   given	   in	  
figure	   1.4.	   Hemoglobin	   is	   the	  
predominant	   absorber	   in	   tissue	   and	  
shows	   distinct	   differences	   in	   absorption	  
spectra	   for	   its	   oxygenated	   and	  
deoxygenated	   state;	   the	   double	   peak	  
around	   580	   nm	   is	   particularly	  
characteristic.	  
	  
Absorption	  is	  quantified	  by	  the	  absorption	  
coefficient	   µa,	   which	   is	   defined	   as	   the	  
inverse	   average	   distance	   that	   a	   photon	  
(light)	  can	  travel	  without	  being	  absorbed	  
.	  [mm-­‐1]	  	  	  	  	  	  	  	  	  	  (1.1)	  
Here,	  σa	   is	  the	  effective	  absorption	  cross-­‐
section	   and	   ρN	   is	   the	   number	   density	   of	  
absorbing	   particles.	   The	   higher	   µa,	   the	  
higher	   the	   probability	   a	   photon	   is	   absorbed.	   How	   much	   light	   is	   attenuated	   by	   the	  
presence	  of	  an	  absorber	  is	  described	  by	  Beer’s	  law	  
	   	   	   	   	   	   	  [-­‐]	  	   	   	   	  	  	  	  	  	  	  (1.2)	  
where	   the	   detected	   light	   intensity	   I	   is	   dependent	   on	   the	   original	   light	   intensity	   I0,	   the	  
absorption	  coefficient	  µa	  and	  the	  photon	  path	  length	  <L>.	  By	  spectral	  decomposition	  of	  
the	   measured	   tissue	   absorption	   spectrum	   into	   all	   known	   components	   present	   in	   the	  
tissue,	   one	   can	   determine	   concentrations	   of	   these	   absorbers.	   This	   includes	   the	  
determination	  of	  the	  ratio	  of	  oxygenated	  and	  deoxygenated	  hemoglobin	  present,	  which	  
relates	   to	   the	   tissue	   saturation.	   Furthermore,	   physical	   parameters	   of	   the	  measurement	  
volume,	  such	  as	  vessel	  diameter	  and	  blood	  volume	  fraction	  can	  be	  determined	  based	  on	  
tissue	   absorption	   measurements.	   Variations	   in	   absorption	   and	   scattering	   properties	   of	  
µa λ( ) =σ a λ( )ρN
I λ( ) = I0 λ( )e−µa λ( ) L λ( )
	  
Figure	   1.3:	   Reflectance	   spectra	   detected	   on	   different	  
tissues.	   (…)	   measured	   reflectance	   (-­‐-­‐-­‐)	   scattering	  
component	   (color)	  model	   calculation	   of	   the	  measured	  
data	  based	  on	  best	  values	  for	  µa	  and	  µ’s.	  
	  
Figure	   1.4:	   overview	   of	   oxy-­‐	   and	   deoxyhemoglobin	  
absorption	  spectrum.	  




























































tissue	  are	  under	   investigation	   for	   the	  discrimination	  of	  healthy	  and	  diseased	   tissue	   [48-­‐
51].	  
	  
LIGHT	  SCATTERING	  IN	  TISSUE	  
Light	  propagating	  through	  tissue	  is	  also	  prone	  to	  scattering.	  Scattering	  is	  caused	  by	  spatial	  
fluctuations	  in	  the	  refractive	  index	  of	  cellular	  components.	  When	  light	  crosses	  boundaries	  
between	  tissues,	  cells	  and/or	  cell	  components,	   it	  will	   change	  direction.	  Macromolecules	  
present	  in	  cells	  have	  a	  high	  molecular	  density	  and	  thus	  a	  higher	  refractive	  index	  than	  the	  
cytoplasm.	   Therefore,	   large	   cellular	   components	   with	   lipid	   bilayer	   membranes,	   like	  
mitochondria,	   Golgi	   apparatus	   and	   endoplasmic	   reticulum,	   are	   highly	   scattering	  
components	   of	   cells,	   just	   as	   the	   cell	   nucleus	  with	   a	   high	   concentration	   of	   nucleic	   acids	  
[52].	   The	   scattering	   coefficient	   µs	   can	   be	   defined	   in	   a	   similar	   way	   to	   the	   absorption	  
coefficient.	   It	   is	  the	   inverse	  distance	   light	  can	  travel	  without	  being	  scattered	  and	  can	  be	  
expressed	  as	  
	   	   	   	   	   	   [mm-­‐1]	  	   	   	  	  	  	  	  	  	  (1.3)	  
where	   σs	   is	   the	   effective	   scattering	   cross-­‐section	   and	   ρN	   is	   the	   number	   density	   of	  
scattering	  particles.	  
	   Light	  scattering	  can	  be	  divided	  into	  two	  regimes.	  Rayleigh	  scattering	  occurs	  when	  
the	   scattering	   particles	   are	   smaller	   than	   the	   wavelength	   of	   the	   light.	   This	   type	   of	  
scattering	  is	  isotropic.	  Mie	  theory	  is	  applicable	  to	  light	  scattering	  of	  spherical	  particles	  of	  
all	  sizes,	  but	   is	  generally	  only	  used	  in	  situations	  where	  the	  simpler	  Rayleigh	  theory	   is	  no	  
longer	  valid.	  Mie	  scattering	   is	  anisotropic,	  where	  the	  direction	  of	  the	  scattering	  event	   is	  
indicated	   by	   the	   tissue	   phase	   function	  P(θ,ϕ).	   The	   phase	   function	   can	   take	   on	   various	  
forms,	  but	  as	  a	  simplification	  it	  can	  be	  expanded	  into	  a	  series	  of	  Legendre	  polynomials	  Pn 
(θ),	  	  
	   ,	   	   [-­‐]	  	  	  	   	   	   	  	  	  	  	  	  	  (1.4)	  
where	  gn	  is	  the	  nth	  moment	  of	  the	  phase	  function.	  The	  first	  moment	  is	  the	  anisotropy	  (g),	  
which	  is	  the	  mean	  cosine	  of	  the	  scattering	  angle	  and	  its	  value	  ranges	  from	  -­‐1	  through	  0	  to	  
1.	   This	   corresponds	   respectively	   to	   complete	   backscattering,	   isotropic	   scattering	   and	  
complete	   forward	   scattering	   respectively.	   For	   tissue,	   anisotropy	   values	   range	   between	  
0.85	   and	   0.98	   [53].	   Since	   tissue	   is	   highly	   forward	   scattering,	   the	   reduced	   scattering	  
coefficient	   µ’s,	   is	   often	   defined	   to	   account	   for	   the	   longer	   effective	   distance	   between	  
scattering	  events	  and	  is	  defined	  as	  	  
.	   	   	   	   	   [mm-­‐1]	  	   	   	  	  	  	  	  	  	  (1.5)	  
Similarly,	  the	  second	  moment	  of	  the	  phase	  function	  can	  be	  used	  to	  determine	  the	  phase	  
function	  scattering	  parameter	  γ	  [54,	  55]	  	  
µs λ( ) =σ s λ( )ρN













	   	   .	   	   	   	   	   [-­‐]	   	   	   	  	  	  	  	  	  	  (1.6)	  
Gamma	   is	   also	   a	  metric	   of	   the	   scattering	   angle	   and	   has	   been	   hypothesized	   to	   contain	  
information	  about	  the	  nanoscale	  structure	  of	  tissue.	  
A	  frequently	  used	  model	  for	  tissue	  phase	  function	  is	  the	  Henyey-­‐Greenstein	  phase	  
function,	  which	   is	   introduced	   in	  1941	  to	  describe	  the	   light	  scattering	  of	   interstellar	  dust	  
particles	  [56].	  Bevilacqua	  and	  Depeursinge	  subsequently	  introduced	  the	  modified	  Henyey-­‐
Greenstein	  phase	  function,	  which	  incorporates	  an	  isotropic	  backscatter	  term	  to	  resemble	  
the	  increased	  probability	  for	  backscattering	  that	  has	  been	  reported	  for	  tissue	  [57].	  
	   If	  tissue	  is	  considered	  as	  a	  random	  continuous	  medium,	  rather	  than	  a	  collection	  of	  
spherical	  scatterers,	  analytical	  models	  can	  be	  derived	  to	  describe	  the	  angular	  distribution	  
of	   scattered	   light	   [58].	   This	   interpretation	   of	   tissue	   scattering	   requires	   a	  model	   for	   the	  
refractive	   index	   correlation	   function,	   which	   can	   then	   be	   used	   to	   predict	   the	   scattering	  
properties	   of	   the	  medium.	   Rogers	   et	   al.	   [59]	   have	   recently	   introduced	   a	  model	   of	   the	  
refractive	   index	   correlation	   function,	   which	   belongs	   to	   the	   family	   of	   Whittle-­‐Matérn	  
correlation	  functions.	  This	  model	  provides	  a	   link	  between	  optical	  properties	   like	  µ’s	  and	  
the	  phase	  function	  and	  morphological	  features	  such	  as	  correlation	  length	  and	  variance	  of	  
refractive	  index.	  	  
	   In	   contrast	   to	  physics	  underlying	   scattering	  over	  one	  or	  a	   few	   scattering	  events,	  
when	   light	   travels	   over	   a	   relatively	   larger	   distance	   before	   detection	   (Dist.≥3[µa+µ’s]-1),	  
the	  diffusion	  approximation	  can	  be	  used	  to	  determine	  optical	  properties.	  In	  this	  approach	  
the	   optical	   properties	   are	   considered	   to	   be	   homogenous	   over	   this	   distance	   and	   the	  
diffusion	   approximation	   assumes	   that	   light	   propagation	   is	   not	   sensitive	   to	   the	   tissue	  
phase	   function	   [60].	   The	   distribution	   of	   PDT	   light	   in	   the	   treatment	   volume	   can	   be	  
described	  using	  this	  approximation.	  For	  smaller	  measurement	  volumes,	  the	  photon	  path	  
length	  and	  the	  phase	  function	  have	  to	  be	  considered.	  This	  can	  be	  done	  by	  including	  the	  
first	  two	  moments	  g1	  and	  g2	  of	  the	  phase	  function	  in	  the	  model.	  
FIBER	  OPTIC	  REFLECTANCE	  SPECTROSCOPY	  
Tissue	   absorption	   and	   scattering	   do	   not	   only	   play	   an	   important	   role	   in	   optimizing	   and	  
monitoring	  PDT	  but	  they	  can	  be	  used	  as	  a	  basis	  for	  diagnosis	  of	  abnormal	  and	  malignant	  
tissue.	  One	  way	  to	  determine	  the	  absorption	  and	  scattering	  properties	  of	  tissue	  is	  to	  use	  
fiber	  optic	  reflectance	  spectroscopy.	  White	   light	   is	  transported	  into	  the	  tissue	  by	  optical	  
fibers.	   The	   light	   propagates	   through	   the	   tissue,	   is	   scattered	   and	   absorbed,	   and	   a	   small	  
amount	   of	   it	   completely	   reflected	   back	   exiting	   the	   tissue,	   and	   is	   then	   collected	   by	  














these	   detected	   spectra.	   As	   described	   above,	   this	   forms	   the	   basis	   of	   reflectance	  
spectroscopy.	  Diagnosis	  of	  (pre-­‐)malignant	   lesions	  by	  means	  of	  reflectance	  spectroscopy	  
can	  be	  based	  on	  physiological	  changes	  that	  occur	  when	  tissue	  becomes	  malignant,	  such	  
as	  variations	  in	  blood	  oxygen	  saturation,	  blood	  volume,	  vessel	  diameter	  or	  the	  absence	  or	  
presence	   of	   certain	   absorbers	   [61].	   Changes	   in	   scattering	   can	   also	   be	   utilized	   because	  
these	   reflect	  differences	   in	  morphology,	   suggesting	   variations	   in	   cell	   size	   and	   structure,	  
which	  are	  known	  to	  occur	  when	  a	  cancer	  develops	   [62].	  Various	  approaches	  have	  been	  
used	   to	   detect	   absorption	   and	   scattering	   by	   the	   use	   of	   fiber	   optic	   probes.	   The	   main	  
difference	  between	  different	  techniques	   is	  the	  geometry	  of	  source	  and	  detection	  fibers.	  
Generally	   three	   geometries	   can	   be	   identified:	   probes	   where	   there	   is	   a	   large	   distance	  
between	  source	  and	  detector	  fiber	  (few	  mm	  to	  cm),	  probes	  where	  the	  distance	  between	  
source	  and	  detector	  fiber	   is	  shorter	  than	  the	  transport	  mean	  free	  path	  (mfp)	  of	   light	  (in	  
general	  <2	  mm),	  and	  one	  single	  fiber	  serving	  as	  both	  source	  and	  detector.	  
	  
LARGE	  SOURCE-­‐DETECTOR	  SEPARATIONS	  
Classical	   reflectance	   spectroscopy	  devices	   are	  often	  based	  on	  multiple	  optical	   fibers,	   of	  
which	   one	   serves	   as	   source	   and	   the	   other(s)	   as	   detector	   [63-­‐66].	   Detected	   light	   is	  
scattered	  multiple	   times	   over	   the	   distance	   it	   travels	   from	   source	   to	   detector,	   and	   the	  
exact	  photon	  path	  length	  can	  be	  calculated	  using	  diffusion	  theory.	  Here,	  an	  approximate	  
analytical	   solution	  of	   the	  general	   radiation	   transfer	  equation	   is	  used.	   It	   is	   assumed	   that	  
light	   propagation	   is	   insensitive	   to	   tissue	   phase	   function	   and	   therefore	   does	   not	   have	   a	  
preferential	   direction	   of	   travel.	   Propagation	   of	   light	   is	   modeled	   as	   diffusion	   over	   a	  
concentration	  gradient.	  This	  approximation	  is	  only	  valid	  when	  the	  distance	  light	  travels	  is	  
large	  (>1	  mfp	  to	  neglect	  the	  influence	  of	  the	  phase	  function	  on	  scattering)	  and	  absorption	  
dominates	  over	  scattering	  [60].	  
Systems	   based	   on	   the	   use	   of	   multiple	   fibers	   have	   some	   drawbacks.	   First,	   the	  
measurement	  volume	  is	  relatively	  large	  because	  of	  the	  large	  distance	  the	  photons	  travel.	  
Optical	   properties	   are	   assumed	   to	   be	   homogenous	   within	   the	   measurement	   volume,	  
whereas	  tissue	  is	  know	  to	  be	  heterogeneous.	  Furthermore,	  probes	  with	  this	  geometry	  are	  
often	  large,	  which	  limits	  their	  practicality	  to	  skin	  or	  surgically	  exposed	  tissues.	  Last,	  since	  
the	  diffusion	  approximation	  is	  insensitive	  to	  phase	  function,	  this	  probe	  geometry	  lacks	  the	  
ability	  to	  provide	  information	  on	  the	  fine	  structure	  of	  tissue.	  
	  
SMALL	  SOURCE-­‐DETECTOR	  SEPARATIONS	  
In	  situations	  where	   light	  has	  traveled	   less	  than	  1	  mfp,	  the	  majority	  of	  the	  photons	  have	  
undergone	   too	   few	   scattering	   events	   to	   be	   characterized	   by	   the	   reduced	   scattering	  









diffusion	   approximation	   is	   not	   valid	   for	   these	   short	   source-­‐detector	   separations,	   other	  
approaches	  have	  to	  be	  used	  to	  determine	  optical	  properties	  using	  small	  source-­‐detector	  
probe	   geometries.	   These	   approaches	   can	   be	   analytical	   or	   (semi-­‐)empirical	   based	   on	  
Monte	  Carlo	  (MC)	  modeling	  of	  light	  transport.	  	  
	   The	  most	  well	   known	  analytical	   approach	   to	  determine	   tissue	  optical	   properties	  
from	   reflectance	   close	   to	   the	   source	   is	   the	   P3	   approximation,	   introduced	   by	   Hull	   and	  
Foster	   [54].	   This	   approach	   is	   based	   on	   a	   solution	   of	   the	   Boltzman	   transport	   equation,	  
which	   is	   valid	   for	   small	   source-­‐detector	   separations	   since	   it	   includes	   the	   first	   three	  
moments	  of	  the	  phase	  function.	  However,	  this	  approach	  uses	  assumptions	  for	  the	  higher	  
order	   Henyey-­‐Greenstein	   phase	   function	   and	   therefore	   influence	   the	   determination	   of	  
optical	  properties	  when	  a	  tissue	  has	  a	  different	  phase	  function.	  Recently,	  Vitkin	  et	  al.	  have	  
introduced	   a	   phase	   function-­‐corrected	   diffusion	   approximation	   to	   describe	   diffuse	  
reflectance	  close	  to	  the	  source	  [69].	  This	  approach	  combines	  the	  diffusion	  approximation	  
with	  an	  approximation	  of	  the	  changes	  in	  reflectance	  due	  to	  the	  phase	  function.	  Although	  
this	  method	  showed	  good	  agreement	  with	  MC	  simulations,	  a	  significant	  problem	  is	  that	  
an	   assumption	   about	   the	  phase	   function	  has	   to	  be	  made.	  Recently,	   Liemert	   et	   al.	   have	  
solved	  the	  three-­‐dimensional	   radiation	  transfer	  equation	   in	  an	  anisotropically	  scattering	  
medium	  using	  a	  two-­‐dimensional	  Fourier	  transform	  and	  the	  modified	  spherical	  harmonics	  
method	  [70].	  
One	  of	   the	  most	  widely	  used	  algorithms	   for	   the	  description	  of	  photon	   transport	  
through	  turbid	  media	   is	   the	  MCML	  (Monte	  Carlo	   for	  Multi-­‐Layered	  Media)	  code	  written	  
by	   L.	  Wang	   [71].	   This	   code	   simulates	   absorption	   and	   scattering	   events	   that	   occur	  with	  
photon-­‐tissue	   interactions	   and	   allows	   for	   a	   complete	   analysis	   of	   photon	   paths,	   which	  
results	  in	  the	  reflectance	  signal	  collected	  in	  a	  specific	  probe	  geometry.	  MC	  solutions	  serve	  
as	   a	   basis	   for	   (semi-­‐)empirical,	   geometry-­‐dependent	   models	   to	   derive	   tissue	   optical	  
properties	  or	  can	  be	  used	  to	  create	  look-­‐up	  tables	  for	  the	  correlation	  between	  reflectance	  
and	  optical	  properties.	  MC	  simulations	  are	  used	  by	  Bevilacqua	  to	  determine	  the	  influence	  
of	   the	   first	   two	   moments	   of	   the	   phase	   function,	   combined	   in	   the	   phase	   function	  
parameter	   γ,	   on	   the	   detected	   reflectance	   spectra	   for	   small	   source-­‐detector	   geometries	  
[57].	  Tissue	   refractive	   index,	  absorption	  coefficient,	   reduced	  scattering	  coefficient	  and	  γ	  
can	   be	   empirically	   derived	   from	   the	   reflectance	   signal.	   Palmer	   et	   al.	   have	   developed	   a	  
MC-­‐based	   forward	   and	   inverse	   model	   to	   extract	   absorption	   and	   reduced	   scattering	   of	  
tissue-­‐mimicking	  phantoms	  [72].	  	  	  
	  
SINGLE	  FIBER	  REFLECTANCE	  SPECTROSCOPY	  	  
A	   particularly	   interesting	   probe	   geometry	   for	   performing	   fiber	   optic	   reflectance	  











requires	   an	   empirical	  model	   of	   the	   photon	   path	   length	   to	   be	   able	   to	   determine	   tissue	  
absorption	   and	   phase	   function	   dependent	   reduced	   scattering.	   Quantification	   of	  
absorption	   is	   possible	   using	   Beer’s	   law	   when	   the	   relationship	   between	   single	   fiber	  
diameter	   and	   path	   length	   is	   known.	   Our	   group	   has	   developed	   such	   a	   model	   and	  
implemented	   the	   use	   of	   single	   fiber	   reflectance	   (SFR)	   spectroscopy.	   The	   path	   length	  
model	  contains	  information	  on	  absorption	  and	  reduced	  scattering	  and	  is	  sensitive	  to	  the	  
tissue	   phase	   function	   [73-­‐75].	   A	   single	   fiber	   with	   a	   diameter	   between	   0.2	   and	   2	   mm	  
(dependent	  on	   the	  preferred	  sampling	  volume)	   is	  used	  as	  a	  probe	  and	  detected	   light	   is	  
guided	   to	   a	   spectrometer	   by	   a	   bifurcated	   fiber.	   A	   schematic	   overview	   can	   be	   seen	   in	  
figure	  1.5a.	  	  	  
A	  reflectance	  setup	  using	  a	  single	  fiber	  provides	  simplicity	  and	  a	  small	  probe	  size,	  
combined	  with	  a	  small,	  shallow	  measurement	  volume.	  The	  small	  measurement	  volume	  is	  
advantageous	  when	  measuring	  for	  example	  oral	  mucosa,	  epithelium	  or	  epidermal	  tissue,	  
which	  all	  have	  a	   thickness	  of	  only	  a	   few	  hundred	  micrometers.	  SFR	   is	  more	  sensitive	   to	  
physiological	  and	  morphological	  changes	  due	  to	  the	  development	  of	  premalignant	  lesions	  
in	   those	   tissues	   than	   probe	   geometries	   with	   a	   larger	   measurement	   volume	   are.	   The	  
option	  of	  feeding	  a	  fiber	  optic	  probe	  through	  a	  (biopsy)	  needle	  increases	  the	  number	  of	  
applications;	  fibers	  with	  a	  diameter	  of	  200	  µm	  can	  easily	  be	  fitted	  through	  needles	  used	  
for	   fine	   needle	   aspiration	   (FNA),	   allowing	   interstitial	   measurements	   in	   a	   minimally	  
invasive	  way	  [76].	  By	  first	  detecting	  the	  presence	  of	  (pre-­‐)malignant	  tissue	  in	  front	  of	  the	  
biopsy/FNA	   device	   by	   means	   of	   a	   reflectance	   measurement,	   the	   clinician	   can	   prevent	  
taking	  a	  false	  negative	  biopsy	  where	  the	  patient	  has	  to	  return	  to	  repeat	  the	  procedure,	  or	  
reduce	  the	  number	  of	  biopsies.	  In	  theory,	  future	  biopsies	  could	  consist	  of	  only	  an	  optical	  
measurement,	  but	  practice	  has	  shown	  that	  accurate	  discrimination	  of	  (pre-­‐)malignancies	  
and	  their	  various	  stages	  is	  still	  performed	  best	  by	  a	  trained	  pathologist.	  Last,	  SFR	  is	  highly	  








	   	  









MULTI	   DIAMETER	   SINGLE	   FIBER	  
REFLECTANCE	  SPECTROSCOPY	  
	  The	   influence	   of	   the	   phase	  
function	  on	   reflectance	   intensity	  
measured	   close	   to	   the	   source	  
has	   been	   described	   in	   literature	  
[57,	   68,	   77].	   	   Recently	   Kanick	   et	  
al.	   have	   developed	   a	   method	  
based	   on	   MC	   simulations	   to	  
identify	   a	   novel	   mathematical	  
formula	   of	   the	   reflectance	  
intensity	   in	   terms	  of	  µ’s(λ),	   fiber	  
diameter	   df	   and	   the	   phase	  
function	  parameter	  γ(λ)	  [74,	  78].	  Figure	  1.6	  shows	  the	  relation	  between	  the	  MC	  simulated	  
reflectance	  intensity	  RSF	  and	  the	  dimensionless	  scattering	  µ’sdf	  for	  combinations	  including	  
a	  wide	  range	  of	  µ’s	  and	  df	  and	  various	  phase	  functions.	  
	  
It	   is	   shown	   that	  RSF	   becomes	   insensitive	   to	   the	  phase	   function	   for	   large	   values	  of	  µ’sdf	  
[74],	   as	   can	   be	   seen	   in	   figure	   1.6.	   By	   including	  measurements	   with	   two	   or	  more	   fiber	  
diameters	   df	   [79]	   on	   the	   same	  measurement	   spot,	   one	   can	   discriminate	   the	   effects	   of	  
scattering	   and	   phase	   function	   based	   on	   the	   measured	   reflectance.	   This	   relation	   is	  
described	  by	  the	  empirical	  model	  
RSF =ηlim 1+ ρ3e
−ρ1µs
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and	  both	  µ’s	  and	  γ	  are	  determined.	  Performing	  SFR	  measurements	  with	  two	  or	  more	  fiber	  
diameters	   to	   determine	   scattering	   and	   phase	   function	   information	   is	   known	   as	   multi-­‐
diameter	   single	   fiber	   reflectance	   spectroscopy	   (MDSFR).	   Chapter	   4	   provides	   an	   in-­‐vivo	  
validation	  of	  this	  method.	  	  
	  
	  
Figure	   1.6:	   Single	   fiber	   reflectance	   versus	   dimensionless	  
scattering	   for	   Henyey-­‐Greenstein	   phase	   function	  












FIBER	  OPTIC	  FLUORESCENCE	  SPECTROSCOPY	  
Fiber	   optic	   fluorescence	   spectroscopy	   is	   based	   on	   the	   same	   principles	   as	   reflectance	  
spectroscopy,	   only	   in	   this	   case	  monochromatic	   laser	   light	   is	   transported	   into	   the	   tissue	  
instead	   of	  white	   light.	   This	   light	  will	   be	   absorbed	   by	   endogenous	   fluorophores	   such	   as	  
collagen	   and	   NADH,	   or	   exogenous	   fluorescent	   labeled	   markers	   and	   drugs	   such	   as	  
photosensitizers	  [80].	  These	  excited	  fluorophores	  emit	  light	  of	  a	  longer	  wavelength	  than	  
the	   excitation	   light,	  which	   is	   detected	   by	   optical	   fibers.	   The	   shape	   and	   intensity	   of	   the	  
fluorescence	   spectrum	   contain	   valuable	   information	   on	   fluorophore	   identity,	   its	  
concentration	  and	  the	  local	  environment.	  	  
	   The	  detection	  of	  quantitative,	   intrinsic	  fluorescence	  in-­‐vivo	   is	  complicated	  by	  the	  
influence	  of	  optical	  properties:	  the	  total	  excitation	  light	  available	  to	  induce	  fluorescence	  is	  
influenced	   by	   optical	   properties	   at	   the	   excitation	   wavelength,	   while	   the	   detected	  
fluorescence	  is	  attenuated	  by	  the	  optical	  properties	  at	  the	  emission	  wavelength	  [46,	  81].	  
Over	  the	  years,	  several	  fiber	  optic	  methods	  have	  been	  developed	  to	  extract	  the	  intrinsic	  
fluorescence,	   based	   on	   a	   co-­‐localized	   white	   light	   reflectance	   and	   a	   fluorescence	  
measurement.	   The	   reflectance	   is	   then	   used	   to	   determine	   local	   optical	   properties	   for	  
correction	   of	   fluorescence	   intensity.	   For	   this	   correction	   it	   is	   necessary	   that	   both	  
measurements	   have	   coincident	   measurement	   geometries.	   Multi-­‐fiber	   devices	   with	  
separate	   source	   and	   detector	   fibers	   have	   been	   extensively	   investigated	   [82-­‐84].	   In	   this	  
configuration,	   both	   reflectance	   and	   fluorescence	   light	   is	   diffusely	   scattered	   before	  
detection	  and	  an	  analytical	  method	  can	  be	  applied	  to	  determine	  the	  intrinsic	  fluorescence	  
independent	  of	  probe	  design.	  
 
SINGLE	  FIBER	  FLUORESCENCE	  SPECTROSCOPY	  
When	   collecting	   (superficial)	   fluorescence	   with	   a	   single	   fiber	   probe,	   the	   majority	   of	  
collected	   reflectance	   and	   fluorescence	   photons	   have	   undergone	   not	   enough	   scattering	  
events	   to	   apply	   the	   analytical	   models	   for	   diffusion	   theory.	   Furthermore,	   the	   sampling	  
volume	   of	   reflectance	   and	   fluorescence	   differ	   significantly	   from	   each	   other	   for	   this	  
method.	   Kanick	   et	   al.	   have	   developed	   a	   (semi-­‐)empirical	   model	   to	   account	   for	   the	  
influence	  of	  optical	  properties	   in	  fluorescence	  measurements	  and	  to	  obtain	  the	   intrinsic	  
fluorescence,	  based	  on	  a	   combination	  of	  MDSFR	  and	  SFF	   [81,	  85].	  Correction	   for	   tissue	  
absorption	  is	  taken	  care	  of	  by	  the	  use	  of	  Beer’s	  law,	  
FSF = FSF0 e
−µa,avg LSFFL( )









Further,	   MC	   simulations	   are	   used	   to	   determine	   an	   empirical	   relation	   between	   the	  
fluorescence	   ratio,	   effective	   sampling	   volume	   (V),	   effective	   escape	   probability	   (HmV)	   of	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.	  	  [-­‐]	   	   	   	  	  	  	  	  	  	  (1.9)	  
The	  latter	  three	  terms	  can	  all	  be	  expressed	  in	  terms	  of	  µ’sdf	  at	  the	  excitation	  or	  emission	  
wavelength.	   The	   fluorescent	   ratio	   is	   defined	   as	   the	   total	   emitted	   photons	   collected,	  
divided	   by	   the	   total	   excitation	   photons	   launched.	   The	   correction	   of	   the	   detected	  
fluorescence	  signal	  for	  scattering	  then	  becomes:	  
	  	  
.	  	  	  	  	  	  	  	  	  	  	  	  	  	  (1.10)	  
	  
This	   equation	   describes	   the	   relation	   between	   the	   dimensionless	   fluorescence	   intensity	  
F/df	  and	  the	  dimensionless	  reduced	  scattering	  µ’sdf,	  which	  is	  visualized	  in	  figure	  1.7.	  This	  
relation	  is	  valid	  over	  a	  large	  range	  of	  µ’sdf,	  µa	  and	  different	  phase	  functions	  [81,	  85].	  
With	  the	  correct	  calibration	  procedure,	  the	  intrinsic	  fluorescence	  can	  be	  related	  to	  
Qfµaf,	   which	   is	   the	   product	   of	   the	   fluorophore	   quantum	   yield	   and	   the	   fluorophore	  
absorption	  coefficient.	  In	  situations	  where	  quantum	  yield	  is	  known,	  this	  can	  be	  related	  to	  
fluorophore	  concentration.	  However,	  in	  in-­‐vivo	  situations	  quantum	  yield	  (and	  often	  µa
f	  as	  
well)	  depends	  on	  the	  environment	  in	  which	  the	  fluorophore	  is	  located	  and	  are	  often	  not	  
known	   exactly.	   In	   this	   thesis	   Qfµaf	   is	   defined	   as	   the	   intrinsic	   fluorescence.	   Chapter	   5	  
reports	  on	  the	  application	  of	  SFF	  to	  determine	  photosensitizer	  concentrations	  in-­‐vivo.	  
A	  schematic	  overview	  of	  the	  MDSFR-­‐SFF	  measurement	  setup	  used	  in	  this	  thesis	  is	  
shown	  in	  figure	  1.5b.	  While	  both	  reflectance	  and	  fluorescence	  are	  detected	  by	  the	  same	  
fiber,	  separate	  spectrometers	  are	  needed	  to	  correctly	  analyze	  the	  data.	  The	   intensity	  of	  
	  
Figure	  1.7:	  Relation	  between	  dimensionless	  fluorescence	  intensity	  and	  the	  dimensionless	  scattering	  on	  








































the	  excitation	   laser	   light	   is	  much	  higher	   than	   the	  detected	   fluorescence,	  which	   requires	  
the	  use	  of	  a	  filter	  to	  block	  the	  excitation	  light	  from	  the	  fluorescence	  spectrum.	  However,	  
to	  be	  able	   to	  correctly	  determine	   reflectance,	   the	  complete	  wavelength	   range	  between	  
400	  and	  800	  nm	  needs	  to	  be	   included	   in	  the	  analysis.	  We	  have	  therefore	  separated	  the	  
detection	  paths	  of	  fluorescence	  and	  reflectance,	  in	  such	  a	  way	  that	  the	  probe	  can	  still	  be	  
guided	  through	  a	  needle.	  
	  
An	  important	  application	  field	  where	  measurement	  of	  intrinsic	  fluorescence	  is	  particularly	  
valuable	  is	  the	  determination	  of	  intrinsic	  photosensitizer	  fluorescence	  before	  and	  during	  
photodynamic	   therapy.	   Since	   oxygen	   is	   depleted	   during	   PDT,	   saturation	   levels	   in	   the	  
measurement	   volume	   change,	   and	   consequently	   the	   optical	   properties.	   Intrinsic	  
fluorescence	   allows	   for	   reliable	   quantification	   and	   comparison	   of	   photosensitizer	  
fluorescence	  at	  various	  time	  points	  before,	  during	  and	  after	  PDT.	  
To	  determine	  the	  optimum	  illumination	  time	  after	  photosensitizer	  administration,	  
knowledge	  of	  Qfµaf	  in	  the	  treatment	  volume	  and	  surrounding	  tissue	  is	  essential.	  Based	  on	  
results	  of	  these	  pharmacokinetic	  studies	  in	  which	  photosensitizer	  Qfµaf	  is	  monitored	  over	  
time	  after	   administration	   in	   the	   target	   tissue,	   one	   can	   for	   example	  determine	   the	   time	  
point	  with	  the	  most	  photosensitizer	  present,	  or	  the	  time	  point	  with	  the	  largest	  tumor-­‐to-­‐
normal	  ratio.	  Furthermore,	  photosensitizer	  molecules	  are	  often	  large,	  flat	  structures	  [86].	  
These	   molecules	   have	   the	   tendency	   to	   form	   aggregates	   when	   administered	   in	   high	  
concentrations	   or	   under	   certain	   environmental	   conditions	   [13].	   When	   aggregation	  
happens,	   the	   photoactivity	   of	   the	   drug	   is	  much	   less.	   However,	   the	  molecules	   ability	   to	  
fluoresce	   is	   also	   strongly	   reduced,	   which	   can	   be	   detected	   by	   intrinsic	   fluorescence.	   By	  
measuring	   fluorescence	   after	   photosensitizer	   administration	   in	   specific	   target	   tissues,	   a	  
dose	   escalation	   study	   can	   be	   performed	   to	   determine	   the	   optimal	   photosensitizer	  
concentration	  for	  therapy.	  All	   these	  parameters	  greatly	   influence	  the	  treatment	  efficacy	  
of	  PDT,	  and	  knowledge	  on	  those	  parameters	  can	  be	  used	  to	  optimize	  treatment	  efficacy.	  
THESIS	  OVERVIEW	  
This	  thesis	  focuses	  on	  the	  application	  of	  quantitative	  fiber	  optic	  spectroscopy	  and	  optical	  
imaging	   techniques	   to	   gain	   insight	   in	   various	   PDT-­‐related	   processes,	   and	   how	   this	   can	  












Specific	  parts	  of	  the	  thesis	  are	  dedicated	  to:	  
 The	   investigation	   of	   the	   relationship	   between	   vascular	   responses	   during	   light	  
fractionated	   ALA-­‐PDT	   and	   treatment	   efficacy	   using	   optical	   imaging	   and	  
spectroscopy	  (chapter	  2	  and	  3).	  
 The	   development	   of	   quantitative	   fiber	   optic	   fluorescence	   spectroscopy	   and	   its	  
application	  in	  measuring	  in-­‐vivo	  photosensitizer	  pharmacokinetics	  (chapter	  4).	  
 A	   comparison	  of	   the	   pharmacokinetics	   and	   spectral	   properties	   of	   chlorin	   e6	   and	  
Bremachlorin	   based	   on	   in-­‐vivo	   measurements	   and	   their	   relationship	   to	   PDT	  
efficacy	  (chapter	  5,	  6	  and	  7).	  
The	  individual	  chapters	  describe	  the	  study	  of	  one	  or	  more	  PDT	  parameters	  measured	  in-­‐
vivo	   before,	   during	   and/or	   after	   PDT.	   One	   chapter	   includes	   the	   in-­‐vivo	   validation	   of	   a	  
spectroscopic	  method	  to	  determine	  scattering	  of	  light	  in	  tissue,	  which	  is	  a	  prerequisite	  for	  
quantitative	  fluorescence	  measurements	  that	  are	  also	  discussed	  in	  this	  thesis.	  	  
Chapter	  2	  describes	  the	  use	  of	  in-­‐vivo	  monitoring	  of	  fluorescence	  during	  ALA-­‐PDT.	  
Non-­‐contact	  fluorescence	  measurements	  are	  acquired	  during	   light	  fractionated	  ALA-­‐PDT	  
on	  healthy	  mouse	  thigh	  tissue.	   Instead	  of	  pre-­‐determining	  the	  total	  delivered	  fluence	   in	  
both	   fractions,	   we	   determined	   the	   length	   of	   the	   first	   light	   fraction	   based	   on	   the	  
photobleaching	   kinetics	   of	   the	   photosensitizer	   PpIX.	   Various	   illumination	   schemes	   and	  
fluence	   rates	   are	   investigated	   and	   evaluation	   of	   visual	   skin	   damage	   is	   chosen	   as	   a	  
measure	  for	  treatment	  efficacy.	  
In	  Chapter	  3	  vascular	  effects	  during	  the	  first	  low	  dose	  light	  fraction	  of	  ALA-­‐PDT	  are	  
investigated	  by	  confocal	  microscopy.	  ALA-­‐PDT	   is	  performed	   in	  a	  dorsal	   skinfold	  window	  
chamber.	   Confocal	  microscopy	   is	   used	   to	  measure	   variation	   in	   vessel	   diameter	   and	   red	  
blood	   cell	   velocity	   during	   the	   first	   5-­‐13	   Joules	   of	   the	   treatment.	   Photosensitizer	  
concentration	   in	   the	   window	   chamber	   is	   determined	   by	   spectral	   detection	   using	   a	  
confocal	   microscope.	   Several	   fluence	   rates	   have	   been	   included	   in	   this	   work.	   The	   time	  
and/or	   light	   dose	   needed	   to	   induce	   vasoconstriction,	   together	   with	   the	   time	   vessels	  
remain	   constricted,	   provide	   important	   knowledge	   in	   determining	   PDT	   efficacy	   and	  
developing	  optimized	  treatment	  protocols.	  
The	   application	   of	   MDSFR	   spectroscopy	   in-­‐vivo	   is	   described	   in	   Chapter	   4.	  
Reflectance	  measurements	  are	  performed	  with	  0.4	  and	  0.8	  mm	  fibers	  on	  mouse	  tongue,	  
skin,	   liver	   and	   on	   oral	   squamous	   cell	   carcinoma	   induced	   in	   the	   tip	   of	   the	   tongue.	   The	  
reduced	   scattering	   coefficient	   and	   phase	   function	   parameter	   γ	   are	   measured	   to	  
determine	  whether	  they	  can	  be	  used	  to	  discriminate	  between	  tissue	  types.	  
Chapter	   5	   reports	   on	   the	   in-­‐vivo	   application	   of	   single	   fiber	   fluorescence	  
spectroscopy.	  Pharmacokinetics	  and	  spectral	  variation	  of	  both	  photosensitizers	  chlorin	  e6	  











carcinoma.	   Analysis	   is	   based	   on	   intrinsic	   fluorescence	   spectra.	   Spectral	   variations	   may	  
provide	  information	  on	  photosensitizer	  localization,	  since	  spectral	  shape	  is	  dependent	  on	  
pH,	  which	   is	  known	  to	  vary	  between	  locations.	  Measurements	  are	  performed	  at	  various	  
photosensitizer	  incubation	  times	  to	  gain	  insight	  in	  the	  optimal	  drug-­‐light	  interval	  for	  PDT.	  
A	   microscopic	   analysis	   of	   localization	   of	   chlorin	   e6	   and	   Bremachlorin	   in	   tumor-­‐
including	  tongue	  tissue	  is	  presented	  in	  Chapter	  6.	  Photosensitizer	  fluorescence	  intensities	  
are	  determined	  in	  frozen	  tissue	  slices,	  where	  tumor,	  tumor	  boundary,	  invasive	  tissue	  and	  
normal	   tissue	   are	   discriminated.	   An	   extensive	   comparison	   is	  made	  with	   the	   fiber	   optic	  
results	  obtained	  in	  Chapter	  5.	  Again,	  this	  knowledge	  may	  aid	  in	  finding	  the	  optimal	  drug-­‐
light	  interval	  for	  ce6	  and/or	  Bremachlorin	  PDT.	  
In	  Chapter	  7	  knowledge	  from	  studies	  described	  in	  previous	  chapters	  is	  combined	  
to	  optimize	  PDT	  in	  mouse	  window	  chambers.	  Both	  chlorin	  e6	  and	  Bremachlorin	  are	  under	  
investigation	  with	  various	   incubation	  times	   (chapter	  5	  and	  6).	  Vascular	  effects	  occurring	  
during	   PDT	   are	   analyzed	   (and	   related	   to	   findings	   in	   chapter	   3),	   while	   tumor	  
reduction/grow	   delay	   and	   visual	   tissue	   damage	   are	   used	   as	   indicators	   of	   treatment	  
efficacy.	  
Chapter	   8	   provides	   a	   general	   discussion	  on	   the	   results	   of	   the	   studies	  present	   in	  
this	   thesis,	   and	   how	   they	   contribute	   to	   the	   optimization	   of	   photodynamic	   therapy.	   It	  
concludes	  with	  a	  brief	  insight	  in	  future	  technological	  perspectives.	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Photodynamic	   therapy	   (PDT)	   for	   actinic	   field	   cancerization	   is	   effective	   but	   painful.	   Pain	  
mechanisms	  remain	  unclear	  but	  fluence	  rate	  has	  been	  shown	  to	  be	  a	  critical	  factor.	  Lower	  
fluence	  rates	  also	  utilize	  available	  oxygen	  more	  efficiently.	  We	  investigated	  PDT	  effect	  in	  
normal	  SKH1-­‐HR	  mice	  using	  low	  and	  high	  fluence	  rate	  aminolevulinic	  acid	  (ALA)	  PDT	  and	  a	  
fractionated	   illumination	   scheme.	   Six	   groups	   of	   six	   mice	   with	   different	   light	   treatment	  
parameters	  were	   studied.	  Visual	   skin	  damage	  was	  assessed	  up	   to	   seven	  days	  post	  PDT.	  
Fluorescence	  and	  reflectance	  spectroscopy	  during	  illumination	  provided	  us	  with	  real	  time	  
information	  about	  PpIX	  photobleaching.	  A	  novel	  dosing	  approach	  was	  introduced,	  where	  
we	  used	  a	  photobleaching	  percentage	  instead	  of	  a	  pre-­‐set	  fluence.	  	  
Data	  show	  similar	  total	  and	  maximum	  damage	  scores	  in	  high	  and	  low	  fluence	  rate	  
groups.	   Photobleaching	   of	   PpIX	   in	   the	   low	   fluence	   rate	   groups	   shows	   a	   trend	   towards	  
more	  efficient	  photobleaching.	  Results	   indicate	   that	   low	  fluence	  rate	  PDT	   is	  as	  effective	  
as,	  and	  more	  efficient	  than	  high	  fluence	  rate	  PDT	  in	  normal	  mouse	  skin.	  Low	  fluence	  rate	  
PDT	   light	  protocols	  need	  to	  be	  explored	   in	  human	  studies	   in	  search	  for	  an	  effective	  and	  
well-­‐tolerated	  treatment	  for	  actinic	  field	  cancerization.	  











Non-­‐melanoma	   skin	   cancer	   and	   precursor	   lesions	   are	   a	   steadily	   increasing	   health	   care	  
problem	   [1-­‐5].	   Especially	   extensive	   field	   cancerization	   necessitates	   the	   use	   of	   full	   field	  
treatment	  options,	  such	  as	  photodynamic	  therapy	  (PDT).	  PDT	  using	  topical	  aminolevulinic	  
acid	  (ALA)	  or	   its	  ester	  derivates,	  such	  as	  methyl-­‐ALA	  (Metvix®)	   is	  now	  well	  accepted	  and	  
used	   for	   treating	   actinic	   keratosis	   (AK),	   Bowen’s	   disease	   (BD)	   and	   superficial	   basal	   cell	  
carcinoma	   (sBCC).	   There	   is	   a	   consensus	   on	   the	   use	   of	   PDT	   for	   these	   indications,	   as	  
presented	  in	  recent	  European	  guidelines	  [6-­‐7].	  Topically	  applied	  ALA	  is	  converted	  via	  the	  
haem	   synthesis	   pathway	   resulting	   in	   the	   accumulation	   of	   the	   photosensitizer	  
protoporphyrin	   IX	   (PpIX).	   Illumination	  with	   light	  of	   the	  appropriate	  wavelength	   leads	   to	  
the	  generation	  of	  reactive	  oxygen	  species,	  notably	  singlet	  oxygen.	  This	  results	  in	  a	  range	  
of	   tissue	   effects	   that	   include	   cell	   apoptosis,	   necrosis,	   vascular	   and	   immunological	  
responses.	  The	  effectiveness	  of	  ALA-­‐PDT	  is	  influenced	  by	  many	  variables	  such	  as	  fluence,	  
fluence	   rate,	   light	   source,	   illumination	   scheme,	   the	   application	   time,	   the	   use	   of	   iron	  
chelators	  and	  the	  use	  of	  penetration	  enhancers	  [8-­‐9].	  
Our	  group	  observed	  new	  formation	  of	  PpIX	  in	  time	  after	  single	  illumination	  in	  the	  
past	   and	   subsequently	   investigated	   this	   in	   various	   animal	   models	   [10-­‐12].	   A	   two-­‐fold	  
illumination	   scheme,	   separated	   by	   a	   substantial	   dark	   interval	   and	   a	   small	   first	   light	  
fraction,	  increased	  response	  to	  PDT.	  We	  tested	  this	  light	  fractionated	  scheme	  in	  a	  clinical	  
setting	   in	   sBCC’s	   and	   found	   a	   significant	   improvement	   in	   response	   compared	   to	   single	  
illumination.	   One	   year	   response	   rates	   in	   fractionated	   ALA	   PDT	   were	   97%	   [13]	   and	   in	  
another	   study	  with	  different	   light	   treatment	  parameters,	  5	  year	   response	   rate	  was	  84%	  
[14].	   This	   approach	   appears	   to	   compare	   favorably	   with	   the	   results	   for	   methyl	  
aminolevulinate	   (Metvix®),	  where	   two-­‐year	   response	   rates	   for	  primary	   ‘difficult	   to	   treat’	  
BCC	   are	   76%	   [15]	   and	   78%	   for	   patients	   prone	   to	   complications	   and	   poor	   cosmetic	  
outcome	  with	  conventional	  treatment	  [16].	  	  
	  
The	  main	   disadvantage	   of	   PDT	   is	   that	   it	   is	   often	   a	   painful	   treatment	   [17],	   limiting	   the	  
suitability	   of	   PDT	   as	   a	   treatment	   of	   first	   choice.	   Patients	   report	   a	   burning	   or	   tingling	  
sensation	   that	   sometimes	   leads	   to	   need	   for	   local	   anesthesia	   or	   termination	  of	   therapy.	  
Especially	  treating	  extensive	  field	  cancerization	  with	  actinic	  keratosis	  in	  the	  face	  and	  scalp	  
region	   is	   painful	   for	   the	   patient	   [17-­‐18].	   The	   exact	   mechanism	   underlying	   the	   pain	   is	  
unclear.	   Some	   authors	   suggested	   that	   pain	   increases	   with	   higher	   PpIX	   concentrations,	  
although	   results	   are	   conflicting	   [17,	   19,	   20].	   It	   has	   also	   been	  proposed	   that	   the	  methyl	  
ester	   (Metvix®)	   produces	   less	   pain	   than	   ALA	   [21].	   Recently	   a	   number	   of	   authors	   have	  









scores	  at	  20	  mW	  cm-­‐2.	  Besides	   the	  advantage	   in	  pain	  perception,	   it	   is	  well	  documented	  
that	  using	  lower	  fluence	  rate	  PDT	  results	  in	  more	  efficient	  usage	  of	  the	  available	  oxygen	  in	  
tissue	  [25-­‐30].	  
	  
We	  would	  like	  to	  incorporate	  the	  use	  of	  low	  fluence	  rate	  to	  light	  fractionated	  ALA-­‐PDT	  to	  
maintain	  effectiveness	  while	  minimizing	  pain.	   Therefore	  we	  designed	   the	  present	   study	  
comparing	   high	   and	   low	   fluence	   rate	   PDT	   and	   several	   illumination	   schemes	   in	   hairless	  
mouse	  skin.	  These	  schemes	  were	   in	  part	   the	  same	  as	  used	   in	  previous	  studies	   from	  our	  
group	  at	  50	  mW	  cm-­‐2	  and	  new	  groups	  were	  introduced	  using	  20	  mW	  cm-­‐2.	  We	  delivered	  a	  
cumulative	  total	  fluence	  (first	  +	  second	  light	  fraction)	  of	  100	  J	  cm-­‐2	  and	  lowered	  this	  to	  50	  
J	   cm-­‐2	   since	   this	   is	   the	   range	   of	   fluence	   that	   was	   studied	   previously	   and	   to	   minimize	  
treatment	  time.	  	  
	  
There	  are	  some	  obstacles	  that	  must	  be	  overcome	  when	  using	  lower	  fluence	  rate	  PDT.	  At	  
20	  mW	  cm-­‐2	  treatment	  time	  will	  be	  2.5	  times	  longer	  compared	  to	  50	  mW	  cm-­‐2	  when	  the	  
total	  fluence	  is	  kept	  constant.	  For	  clinical	  purposes	  short	  treatment	  times	  are	  strived	  for.	  
As	   mentioned	   before,	   low	   fluence	   rate	   PDT	   leads	   to	   more	   efficient	   use	   of	   available	  
oxygen.	  This	   indicates	  that	   less	  fluence	   is	  needed	  at	  20	  mW	  cm-­‐2,	  which	  as	  a	  result	  may	  
keep	  treatment	  times	  constant	  [19].	  Here	  a	  question	  arises	  as	  to	  how	  much	  less	  fluence	  
needs	   to	  be	  delivered	  to	  achieve	  the	  same	  effect.	  This	   is	  an	   issue	   for	  both	  the	   first	  and	  
second	   illumination.	  Especially	  dosing	  of	   the	   relatively	   small	   first	   light	   fraction	   is	   critical	  
for	  maintaining	  PDT	  efficacy,	   as	  we	   showed	  previously	   [11],	   necessitating	  us	   to	   employ	  
more	  accurate	  dosing	  than	  using	  a	  predetermined	  fluence.	  
	  
Therefore,	  a	  novel	  dosing	  method	  for	  the	  first	   light	  fraction	  was	  adopted,	  making	  use	  of	  
PpIX	  fluorescence	  measurements.	  During	  the	  photodynamic	  process,	  PpIX	  is	  destroyed	  by	  
singlet	   oxygen,	   in	   a	   process	   termed	   photobleaching.	   In	   ALA-­‐PDT	   the	   rate	   of	   PpIX	  
photobleaching	   is	   directly	   related	   to	   the	   amount	   of	   singlet	   oxygen	   produced	   and	   can	  
potentially	  be	  used	  as	  a	  predictor	  of	  PDT	  induced	  response.	  In	  normal	  mice	  skin	  where	  the	  
variations	   in	   the	   amount	   of	   PpIX	   are	   relatively	   small	   the	   normalized	   extent	   of	  
photobleaching	  can	  be	  used	  a	  predictor	  of	  the	  PDT	  dose	  deposited	  [27-­‐31].	  In	  the	  present	  
study	  we	  have	  used	  a	   fixed	  photobleaching	  percentage	   to	  determine	  when	   to	   stop	   the	  
first	  illumination.	  	  
	  	  
Our	   goal	  was	   to	   investigate	   if	   the	   animals	   that	  were	   illuminated	   at	   20	  mW	  cm-­‐2	  would	  
react	  in	  a	  similar	  way	  to	  fractionated	  ALA-­‐PDT	  as	  the	  animals	  that	  were	  illuminated	  at	  50	  










to	  normal	  hairless	  mouse	  skin	  was	  used	  as	  a	  measure	  for	  efficacy.	  We	  hypothesized	  that	  
20	  mW	  cm-­‐2	  is	  as	  effective	  as	  50	  mW	  cm-­‐2	  in	  inducing	  visually	  assessed	  skin	  damage.	  	  
MATERIALS	  AND	  METHODS	  
ANIMALS	  	  
Thirty-­‐six	  female	  albino	  hairless	  mice	  (SKH1	  HR)	  were	  included	  in	  this	  experiment,	  divided	  
into	  six	  groups	  that	  received	  different	  treatment	  parameters	  as	  described	  below.	  Animals	  
were	   put	   on	   a	   chlorophyll-­‐free	   diet	   two	   weeks	   prior	   to	   treatment	   to	   remove	  
autofluorescence	   from	   pheophorbide-­‐a.	   The	   study	   was	   approved	   by	   the	   animal	  
experimental	  committee	  of	  the	  Erasmus	  University	  Medical	  Centre.	  
	  
ALA	  APPLICATION	  
Animals	  were	   anesthetized	  with	   ketamine	   and	   valium	  before	   the	   application	   of	   20%	   5-­‐
aminolevulinic	   acid	   (ALA,	   Medac,	   Hamburg,	   Germany),	   dissolved	   in	   3%	  
carboxymethylcellulose	  and	  NaOH	  in	  water	  (pH=4)	  to	  the	  skin	  using	  a	  7	  mm	  round	  gauze,	  
and	  occluded	  with	  a	  semi	  occlusive	  dressing	  (Tegaderm®).	  A	  spot	  on	  the	  left	  thigh	  of	  the	  
mice	  was	   chosen	  as	   the	   illumination	  area.	   There	  was	  a	   four	  hour	   interval	  between	  ALA	  
application	   and	   the	   delivery	   of	   the	   first	   light	   fraction.	   Prior	   to	   and	   during	   illumination	  
animals	  were	  again	  anesthetized	  using	  2-­‐3%	  Isoflurane	  in	  100%	  oxygen.	  
	  
GROUPS	  OF	  ANIMALS	  AND	  LIGHT	  TREATMENT	  PARAMETERS	  
We	   used	   six	   different	   illumination	   schemes	   (n=6	   animals	   in	   each	   group).	   For	   delivered	  
fluences	  per	  group	  see	  also	  table	  2.1.	  Groups	  1-­‐3	  served	  as	  control	  groups	  for	  comparison	  
with	  experiments	  performed	  previously	  at	  50	  mW	  cm-­‐2,	  while	  groups	  4-­‐6	  were	  illuminated	  
at	  20	  mW	  cm-­‐2.	  Group	  1	   received	  100	   J	   cm-­‐2	   in	  a	   single	   illumination	  at	  50	  mW	  cm-­‐2.	  All	  
other	  groups	  received	  two	  light	  fractions,	  separated	  by	  a	  dark	  interval	  of	  two	  hours.	  The	  
exact	  duration	  of	  the	  illuminations	  in	  the	  first	  light	  fraction	  in	  groups	  2	  to	  6	  was	  based	  on	  
the	   extent	   of	   PpIX	   fluorescence	   photobleaching	   measured	   during	   PDT	   in	   individual	  
animals.	  This	   individualization	  of	  the	  first	   light	  fraction	  is	  described	  in	  more	  detail	   in	  the	  
data	   analysis	   section	  below.	   Each	  animal	   received	  a	   fluence	   that	  was	  needed	   to	  bleach	  
52%	  of	  initial	  PpIX	  in	  the	  first	  light	  fraction,	  with	  an	  additional	  fluence	  during	  the	  second	  
light	  fraction	  to	  reach	  various	  total	  fluences.	  Groups	  2	  and	  3	  were	  illuminated	  at	  50	  mW	  
cm-­‐2	  to	  a	  total	  dose	  of	  100	  and	  50	  J	  cm-­‐2	  respectively.	  Groups	  4	  and	  5	  were	  illuminated	  at	  









treatment	  scheme	  as	  group	  5	  immediately	  followed	  by	  50	  J	  cm-­‐2	  at	  50	  mW	  cm-­‐2.	  This	  was	  
based	  on	  a	  recent	  study,	   investigating	  the	  use	  of	   low	  fluence	  rates	   for	  the	  treatment	  of	  
sBCC	  where	  PpIX	  photobleaching	  measurements	  were	  used	  as	  a	  method	  of	  determining	  
the	  point	  during	  therapy	  where	  the	  fluence	  rate	  could	  be	  increased	  without	  inducing	  pain	  
[23].	  
	  
PDT	  LIGHT	  DELIVERY	  
The	   experimental	   set-­‐up	   was	   adapted	   from	   that	   which	   we	   used	   previously	   [32],	   to	  
maximize	  the	  amount	  of	  fluorescence	  light	  collected	  from	  the	  tissue	  and	  facilitate	  spectral	  
fitting	  of	   the	  data.	  Figure	  2.1	   shows	  a	   schematic	  overview	  of	   the	  setup.	  During	  PDT,	  an	  
Argon	  Ion	  laser	  (514	  nm)	  was	  used	  as	  the	  treatment	  light	  source	  with	  fluences	  of	  either	  20	  
or	   50	   mW	   cm-­‐2.	   Light	   was	   delivered	   via	   a	   400	   µm	   optical	   fiber	   and	   focused	   on	   a	  
homogenous	  7	  mm	  treatment	  area	  on	  the	  mouse	  skin	  via	  a	  dichroic	  mirror	  using	  a	  micro	  
lens	  (QLT,	  Vancouver,	  BC,	  Canada)	  and	  a	  single	  biconvex	   lens.	  A	  charged	  coupled	  device	  
(CCD)	  camera	  (ORCA-­‐ER,	  Hamamatsu,	  Japan)	  was	  used	  for	  taking	  fluorescence	  images,	  to	  
relocate	  the	  area	  of	   interrogation	  and	  maintain	  a	  constant	  distance	  between	  the	  mouse	  
skin	  and	  the	  head	  of	  the	  spectrograph.	  	  
	  
FLUORESCENCE	  MEASUREMENTS	  
Fluorescence	   intensity	   was	   used	   as	   a	  measure	   of	   the	   PpIX	   concentration	   in	   the	   tissue.	  
Fluorescence	  emission	  was	  collected	  from	  the	  illuminated	  area	  and	  focused	  into	  a	  1	  mm	  
optical	  fiber	  coupled	  to	  a	  spectrograph	  (USB4000,	  Ocean	  Optics,	  Duiven,	  The	  Netherlands)	  
via	  a	  50/50	  beam-­‐splitter.	  Fluorescence	  spectra	  were	  taken	  continuously	  during	  the	  first	  
and	  second	  illumination	  with	  integration	  times	  of	  1000	  ms	  and	  2000	  ms	  for	  50	  mW	  cm-­‐2	  
and	   20	   mW	   cm-­‐2	   respectively,	   without	  
interrupting	   PDT	   light	   delivery.	   Scattered	  
excitation	   light	   was	   blocked	   using	   a	   long-­‐
pass	   filter	   (570	   nm,	  Melles	  Griot,	   Zevenaar,	  
The	  Netherlands),	  placed	  in	  the	  optical	  path.	  
During	  the	  first	  light	  fraction,	  spectra	  
were	   analyzed	   in	   real-­‐time	   as	   described	  
below	   to	   calculate	   the	   percentage	   of	  
photobleaching	   and	   the	   illumination	   was	  
terminated	   automatically	   when	   the	   extent	  
of	   PpIX	   fluorescence	   photobleaching	   had	  
reached	   52%	   of	   its	   initial	   value.	   This	   value	  
	  














Reflectance	   spectra	   were	   obtained	   before	   and	   immediately	   after	   illumination	   for	  
correcting	   the	   fluorescence	   spectra	   for	   changes	   in	   tissue	   optical	   properties	   in	   the	  
fluorescence	  emission	  band.	  Light	  from	  a	  halogen	  lamp	  (0.15	  mW	  cm-­‐2,	  Stortz,	  Tutlingen,	  
Germany)	   was	   filtered	   with	   a	   long-­‐pass	   filter	   (OG	   530,	   Melles	   Griot,	   Zevenaar,	   the	  
Netherlands)	   to	   minimize	   fluorescence	   excitation	   of	   the	   tissue	   during	   reflectance	  
measurements,	   and	  delivered	   via	   another	  optical	   fiber	   and	   focused	  on	   the	   same	  7	  mm	  
treatment	  area	  using	  a	  second	  50/50	  beam	  splitter.	  Reflected	  light	  was	  collected	  using	  the	  
same	   system	   as	   the	   fluorescence	   emission.	   This	   enables	   fluorescence	   and	   reflection	  
measurements	  being	  acquired	  using	  the	  same	  source-­‐detection	  geometry.	  A	  white	  plastic	  
reference	   card	   (Vink,	   Didam,	   The	   Netherlands)	   was	   used	   to	   correct	   spectra	   for	   small	  
changes	  in	  light	  intensity	  and	  spectral	  output.	  	  
	  
DATA	  ANALYSIS	  
The	  reflectance	  spectra	  before	  and	  after	  illumination	  were	  corrected	  for	  changes	  in	  light	  
intensity,	  spectral	  lamp	  output	  and	  background	  with	  the	  use	  of	  the	  reference	  card.	  These	  
spectra	  can	  be	  used	  to	  detect	  changes	  in	  tissue	  optical	  properties	  during	  illumination	  and	  
correct	  the	  PpIX	  fluorescence	  intensity	  for	  this	  with	  a	  method	  first	  suggested	  by	  Wu	  et	  al	  
[33].	  Fluorescence	  spectra	  were	  analyzed	  in	  real-­‐time	  during	  the	  first	  illumination.	  Spectra	  
were	  analyzed	  as	  a	  linear	  combination	  of	  the	  basis	  fluorescence	  spectra	  of	  normal	  mouse	  
skin,	  autofluorescence	  and	  hydroxyaldehyde	  chlorin	  photoproduct	  of	  PpIX,	  using	  a	  single	  
value	   decomposition	   (SVD)	   algorithm.	   The	   output	   of	   this	   analysis	   yields	   information	   on	  
the	  PpIX	  fluorescence	  intensity.	  The	  decrease	  of	  PpIX	  fluorescence	  intensity	  over	  time	  was	  
used	  to	  determine	  the	  rate	  and	  the	  extent	  of	  PpIX	  photobleaching.	  The	  first	  illumination	  
was	  terminated	  when	  the	  PpIX	  fluorescence	  was	  decreased	  by	  52%	  of	   its	  original	  value.	  
The	   spectra	   acquired	   during	   the	   first	   and	   second	   illumination	   were	   analyzed	   more	  
extensively	  after	   the	  end	  of	   therapy.	  The	   fitted	  PpIX	   intensity	  values	  were	  corrected	   for	  
different	   integration	   times	   and	   laser	   light	   intensities	   for	   accurate	   comparison	   and	   if	  
necessary	   corrected	   for	   changes	   in	   tissue	   optical	   properties.	   These	   fluorescence	  
intensities	  were	  normalized	  to	  100%	  at	  the	  start	  of	  the	  first	   illumination	  using	  a	  second-­‐
order-­‐decay	   fit	   [27].	   The	   fluorescence	   intensity	   at	   the	   start	   of	   the	   second	   light	   fraction	  
was	  either	  again	  normalized	  to	  100%,	  or	  presented	  as	  a	  percentage	  of	   the	   fluorescence	  











Damage	  scoring	  was	  performed	  daily	  up	  to	  seven	  days	  post	  PDT	  by	  2	  investigators	  blinded	  
from	  the	  treatment	  schemes	  (by	  HdeB	  and	  AvdP).	  We	  used	  a	  visual	  scoring	  system,	  that	  
we	   have	   described	   previously	   [27],	   with	   a	   zero	   to	   five-­‐point	   scale:	   Grade	   0	   means	   no	  
damage;	  1=minimal	  erythema;	  2=moderate	  erythema;	  3=severe	  edema	  or	  a	  white	  blister;	  
4=thin	   crust	   and	  5=thick	   crust.	   The	   severity	   and	  extent	   of	   PDT	   response	  was	  measured	  
and	  scored	  where	  different	  levels	  of	  severity	  were	  considered	  within	  each	  treatment	  field.	  
The	   overall	   damage	   score	   was	   calculated	   according	   to	   the	   damage	   and	   the	   relative	  
contribution	  of	  each	  region.	  Means	  were	  calculated	  per	  group	  of	  mice	  and	  plotted	  against	  
time.	   The	   distribution	   of	   maximum	   damage	   score	   per	   group	   over	   time	   was	   evaluated	  
using	  daily	  photographs.	  
	  
STATISTICS	  
In	  a	  previous	  experiment	  [11]	  we	  measured	  a	  cumulative	  damage	  score	  of	  17±4	  SD	  (n=19)	  
for	  control	  group	  1	  and	  25±4	  SD	  (n=15)	  for	  control	  group	  2.	  Since	  we	  expect	  20	  mW	  cm-­‐2	  
to	  be	  as	  effective	  in	  inducing	  skin	  damage	  as	  50	  mW	  cm-­‐2,	  the	  expected	  skin	  damage	  for	  
group	  4	  would	  be	  equal	   to	  group	  2.	  A	  power	  analysis	  with	  α=0.05	  and	  β=0.80	  results	   in	  
n=6	  per	  group.	  
For	   calculating	   differences	   in	   total	   damage	   scores	   between	   groups	   Student-­‐
Newman-­‐Keuls	  multiple	   comparisons	   testing	   was	   performed,	   after	   calculating	   the	   total	  
area	  under	  the	  curve	  (AUC)	  for	  subsequent	  daily	  damage	  scores.	  	  
RESULTS	  
REFLECTANCE	  MEASUREMENTS	  
Figure	  2.2	  shows	  the	  average	  reflectance	  spectra	  measured	  immediately	  before	  and	  after	  










Table	  2.1:	  Treatment	  group	  parameters	  
Group	   mW	  cm2	   J	  cm-­‐2	   Delivered	  fluence	  ±	  SD	  (J	  cm-­‐2)	   Illumination	  Time	  
	   	   	   1st	  fraction	   2nd	  fraction	   1st	  fraction	   2nd	  fraction	  
1	   50	   100	   100	   -­‐	   33	  min	   -­‐	  
2	   50	   100	   4.44	  ±	  0.45	   95.56	   1	  min	  29	  sec	   31	  min	  51	  sec	  
3	   50	   50	   5.20	  ±	  1.06	   44.80	   1	  min	  44	  sec	   14	  min	  56	  sec	  
4	   20	   100	   3.67	  ±	  0.34	   96.33	   3	  min	  6	  sec	   80	  min	  17	  sec	  
5	   20	   50	   3.74	  ±	  0.42	   46.26	   3	  min	  7	  sec	   38	  min	  33	  sec	  
6	   20	  +	  50	   100	   4.28	  ±	  0.86	   45.72	  +	  50	   3	  min	  35	  sec	   54	  min	  46	  sec	  
	  
Both	  spectra	  show	  the	  absorption	  features	  that	  are	  expected	  from	  tissue	  in	  this	  region	  of	  
the	  spectrum	  (560-­‐860	  nm).	  Mice	  from	  all	  other	  groups	  showed	  the	  same	  response.	  There	  
is	  very	   little	  change	   in	  the	  absorption	  of	  mouse	  skin	  before	  and	  after	   illumination	  when	  
reflectance	   is	   measured	   in	   this	   geometry.	   Therefore,	   the	   PpIX	   fluorescence	   intensities	  
shown	  in	  this	  study	  are	  not	  corrected	  for	  changes	  in	  tissue	  optical	  properties.	  	  
	  
DELIVERED	  FLUENCE	  IN	  FIRST	  LIGHT	  FRACTION	  
Delivered	  fluences	  in	  the	  first	  and	  second	  illumination	  and	  treatment	  times	  per	  group	  are	  
shown	  in	  table	  2.1.	  Less	  fluence	  is	  needed	  in	  the	  low	  fluence	  rate	  groups	  and	  treatment	  
times	  are	  longer.	  
	  
	   	  
	   	  
Figure	   2.2:	   Reflectance	   intensity	   before	   and	   after	  
PDT	   in	   the	   range	   of	   560-­‐860	   nm.	   Reflectance	   is	  
shown	   as	   arbitrary	   units.	   The	   grey	   line	   represents	  
measurement	  before	  and	  the	  black	  line	  after	  PDT.	  
	  
Figure	  2.3:	  Mean	  normalized	  PpIX	  photobleaching	  in	  
the	  first	  (panel	  a)	  en	  second	  (panel	  b)	  illumination	  in	  
groups	  2	   and	  3	   (50	  mW	  cm-­‐2),	   separated	  by	  a	   dark	  
interval	  of	  2	  hours.	  Error	  bars	  indicate	  one	  standard	  
deviation.	  



























































PPIX	  FLUORESCENCE	  DURING	  ILLUMINATION	  
Figure	   2.3	   shows	   the	   mean	   normalized	   PpIX	   fluorescence	   intensity	   during	   a	   two-­‐fold	  
illumination	   in	   which	   a	   total	   dose	   of	   100	   J	   cm-­‐2	   is	   delivered	   4	   and	   6	   hours	   after	   ALA	  
application	  at	  a	   fluence	   rate	  of	  50	  mW	  cm-­‐2	   (group	  2).	  Data	   from	  the	   first	   light	   fraction	  
(panel	  a)	  and	  second	  light	  fraction	  (panel	  b)	  are	  separated	  by	  a	  2	  hour	  dark	  interval.	  The	  
first	  illumination	  was	  terminated	  when	  the	  intensity	  of	  PpIX	  fluorescence	  had	  bleached	  by	  
52%.	   In	   the	   2	   hour	   dark	   interval	   PpIX	   fluorescence	   increased	   to	   over	   80%	  of	   the	   initial	  
value.	  This	  increase	  is	  subject	  to	  large	  variation,	  as	  indicated	  by	  large	  error	  bars.	  For	  both	  
illuminations	  the	  first	  6	  J	  cm-­‐2	  is	  shown	  for	  clarity:	  the	  second	  light	  fraction	  continued	  on	  
to	  a	  total	  of	  100	  J	  cm-­‐2,	  after	  which	  approximately	  3.2%	  of	  the	  initial	  PpIX	  intensity	  at	  the	  
start	  of	  the	  first	  light	  fraction	  remained.	  	  
	  
Figure	  2.4	   shows	   the	  mean	  normalized	  PpIX	  photobleaching	   for	   the	   first	   illumination	   to	  
illustrate	  differences	  with	  respect	  to	  fluence	  rate.	  	  
	  
The	  20	  mW	  cm-­‐2	  groups	  (4,	  5	  and	  6)	  show	  more	  efficient	  photobleaching	  than	  the	  50	  mW	  
cm-­‐2	   groups	   (2	   and	   3).	   At	   lower	   fluence	   rates,	   less	   fluence	   is	   needed	   to	   bleach	   52%	   of	  
available	  PpIX	  (P=0.002).	  For	  clarity	  only	  the	  first	  6	  J	  cm-­‐2	  is	  shown.	  
	  
	   	  
Figure	   2.4:	   Mean	   normalized	   PpIX	   photobleaching	  
for	   the	   first	   illumination	   for	   different	   fluence	   rates.	  
The	   full	   squares	   indicate	   averages	   at	   50	   mW	   cm-­‐2	  
(groups	   2	   and	   3).	   The	   open	   squares	   indicate	  
averages	  at	  20	  mW	  cm-­‐2	   (groups	  4,	  5	  and	  6).	  At	  20	  
mW	   cm-­‐2	   less	   fluence	   is	   needed	   to	   bleach	   52%	   of	  
available	   PpIX	   (P=0.002).	   Error	   bars	   indicate	   one	  
standard	  deviation.	  
Figure	   2.5:	   Mean	   normalized	   PpIX	   photobleaching	  
for	   the	   second	   illumination	   for	   different	   fluence	  
rates.	  The	  open	  squares	  represent	  averages	  of	  the	  20	  
mW	  cm-­‐2	  groups	  and	  full	  squares	  averages	  of	  the	  50	  
mW	  cm-­‐2	  groups.	  

































































Figure	  2.5	   shows	   the	  mean	  normalized	  PpIX	  photobleaching	   for	   the	  second	   illumination	  
for	   different	   fluence	   rates.	   The	   20	  mW	   cm-­‐2	   groups	   again	   show	   a	   non-­‐significant	   trend	  
towards	   faster	  bleaching	  than	  the	  50	  mW	  cm-­‐2	  groups.	   In	  group	  6,	   (50	   J	  cm-­‐2	  at	  20	  mW	  	  
cm-­‐2	  using	  a	  fractionated	  illumination,	  followed	  by	  50	  J	  cm-­‐2	  at	  50	  mW	  cm-­‐2),	  no	  change	  in	  
bleaching	  rate	  was	  observed	  when	  the	  fluence	  rate	  was	  increased	  from	  20	  to	  50	  mW	  cm-­‐2	  
(data	  not	  shown).	  
	  
DAMAGE	  SCORE	  
Damage	   scores	   for	   the	   first	   seven	   days	   after	   PDT	   were	   measured.	   One	   day	   after	   PDT	  
severe	  edema	  or	  white	  blister	   formation	  was	  visible,	  while	  damage	   increased	  over	   time	  
up	  to	  day	  four	  when	  highest	  damage	  scores	  were	  observed.	  	  
Figure	  2.6	  shows	  the	  mean	  damage	  scores	  for	  each	  group	  of	  animals,	  calculated	  as	  
the	  area	  under	  the	  curve	  (AUC)	  for	  subsequent	  daily	  damage	  scores.	  
All	  fractionated	  groups	  have	  higher	  total	  damage	  scores	  than	  the	  single	  illumination	  group	  
and	  statistical	  differences	  are	   indicated	  by	  arrows	  with	   their	  P-­‐values	   (ANOVA,	  Student-­‐
Newman-­‐Keuls	  test).	  
In	  figure	  2.7	  the	  maximum	  score	  reached	  at	  any	  time	  point	  within	  the	  treated	  area	  
is	  shown	  per	  group	  of	  six	  mice.	  Only	  in	  group	  1,	  where	  a	  single	  illumination	  to	  100	  J	  cm-­‐2	  
at	   50	  mW	  cm-­‐2	   is	   delivered,	   three	  mice	  had	  maximum	   scores	  of	   3,	   representing	   severe	  
edema	  or	  a	  white	  blister.	  In	  all	  other	  groups	  all	  mice	  reached	  maximum	  scores	  of	  either	  4	  





Figure	  2.6:	  Mean	  damage	  score	  for	  seven	  days	  after	  
PDT	  for	  each	  group	  of	  animals,	  calculated	  as	  the	  
area	  under	  the	  curve	  for	  subsequent	  daily	  damage	  
scores.	  Differences	  between	  groups	  are	  illustrated	  





Figure	  2.7:	  The	  maximum	  score	  reached	  
(regardless	  of	  day	  or	  size)	  per	  group	  of	  mice.	  
Only	  in	  group	  1	  (single	  illumination	  group)	  no	  
higher	  damage	  score	  than	  3	  was	  observed.	  
Groups	  2-­‐6	  appear	  to	  be	  similar	  to	  each	  other	  
with	  minimum	  scores	  of	  either	  4	  or	  5	  
(5=maximum	  possible	  score).	   
P < 0.01 P < 0.05 
P < 0.05 












































This	  study	  was	  designed	  to	  investigate	  the	  efficacy	  of	  low	  fluence	  rate	  ALA-­‐PDT	  in	  normal	  
mouse	  skin.	  Our	  primary	  outcome	  was	  visual	  skin	  damage	  and	  this	  model	  has	  previously	  
successfully	  been	  used	  as	  an	  indicator	  for	  clinical	  PDT	  efficacy.	  Our	  results	  show	  that	  low	  
fluence	  rate	  ALA-­‐PDT	   is	  as	  effective	  as	  high	  fluence	  rate	  PDT	   in	   inducing	  skin	  damage	   in	  
normal	  mouse	  skin.	  We	  used	  real-­‐time	  PpIX	  fluorescence	  spectroscopy	  to	  provide	  us	  with	  
more	  insight	  into	  the	  complex	  mechanisms	  and	  interactions	  of	   light,	  PpIX	  formation	  and	  
depletion,	  oxygen	  consumption,	  and	  photoproduct	   formation	  during	  PDT.	  Results	  are	   in	  
line	   with	   the	   concept	   that	   low	   fluence	   rate	   ALA-­‐PDT	   results	   in	   more	   efficient	   use	   of	  
available	  oxygen.	  An	  important	  and	  novel	  modification	  in	  the	  present	  study	  was	  the	  use	  of	  
a	  fixed	  PpIX	  photobleaching	  percentage	  for	  the	  first	  illumination,	  instead	  of	  using	  a	  fixed	  
fluence.	   In	  normal	  mouse	   skin	  using	   the	   light	   treatment	  parameters	  we	  have	   chosen	   in	  
the	   present	   study,	   the	   percentage	   photobleaching	   is	   likely	   to	   be	  well	   correlated	   to	   the	  
amount	  of	  singlet	  oxygen	  formed,	  and	  therefore	  to	  the	  PDT	  dose	  delivered	  in	  a	  single	  light	  
fraction.	  When	  using	  a	   fixed	   fluence	   scheme	   there	   is	   risk	  of	  delivering	   too	  much	  or	   too	  
little	   fluence	   during	   the	   first	   light	   fraction	   due	   to	   inter-­‐individual	   variations	   in	  
photobleaching	  rate.	  Previously	  we	  have	  shown	  that	  this	  results	  in	  less	  PDT	  damage	  [11].	  
For	   this	   reason	   we	   used	   real-­‐time	   fluorescence	   measurements	   to	   determine	   PpIX	  
photobleaching	  as	  a	  way	  of	  standardizing	  the	  effective	  PDT	  dose	  for	  the	  first	  illumination	  
in	  both	  high	  and	   low	  fluence	  rate	  groups.	  We	  stress	   the	   importance	  of	  monitoring	  PpIX	  
photobleaching	   during	   illumination	   since	   it	   makes	   comparing	   the	   different	   illumination	  
schemes	  more	  reliable.	  We	  chose	  to	  deliver	  as	  much	  fluence	  as	  needed	  to	  bleach	  52%	  of	  
available	  PpIX	  for	  the	  first	  illumination,	  based	  on	  previous	  experiments	  in	  normal	  mouse	  
skin.	   It	   is	   important	   to	  note	   that	   the	  normalization	  step	  should	  be	  made	  with	  care.	  The	  
fluorescence	   intensity	   variations	   in	   the	   skin	   of	   normal	   hairless	  mice	   are	   relatively	   small	  
and	  of	  the	  order	  of	  25%	  of	  the	  average	  initial	  PpIX	  intensity	  before	  the	  first	  light	  fraction.	  
To	   accommodate	   large	   variations	   in	   the	   initial	   PpIX	   concentration	   in	   skin	   that	   may	   be	  
present	   in	   other	   (clinical)	   lesions	  would	   require	   a	  more	   thorough	   analysis	   of	   PDT	   dose	  
deposition	  so	  that	  the	  treatment	  parameters	  could	  be	  changed	  accordingly.	  It	  is	  probable	  
that	  the	  ‘optimal’	  bleaching	  dose	  may	  be	  different	  or	  variable	  for	  individual	  patients	  and	  
lesions	   and	   for	   different	   dermatological	   conditions,	   which	   could	   differ	   in	   intrinsic	  
response	   to	  PDT,	  blood	  supply	  and	   thickness	  of	   the	   lesion.	   It	   should	  also	  be	  noted	   that	  
this	   photobleaching	   method	   is	   only	   valid	   for	   photosensitizers	   that	   undergo	  
photobleaching	   mediated	   by	   singlet	   oxygen	   alone.	   For	   instance,	   the	   hematoporphyrin	  











We	   also	   measured	   reflectance	   spectra	   before	   and	   after	   PDT.	   Previously,	   we	   always	  
corrected	  the	  PpIX	  fluorescence	  measurements	  for	  possible	  changes	  in	  optical	  properties	  
of	  the	  tissue	  layer	  the	  emitted	  PpIX	  fluorescence	  has	  to	  travel	  through.	  It	  is	  reasonable	  to	  
assume	  that	  the	  tissue	  absorption	  will	  change,	  due	  to	  PDT-­‐induced	  changes	  in	  blood	  flow	  
and	   saturation.	   Any	   change	   in	   absorption	   of	   this	   tissue	   layer	   will	   bias	   the	   PpIX	  
fluorescence	  intensity	  measurements	  at	  the	  skin	  surface.	  The	  results	  from	  our	  reflectance	  
measurements,	  as	  illustrated	  in	  figure	  2.2,	  indicate	  that	  correcting	  is	  not	  necessary	  when	  
using	  our	  measurement	  method.	  This	  does	  not	  necessarily	  mean	   that	   the	   tissue	  optical	  
properties	   in	   the	   superficial	   skin	   layer	   do	   not	   change;	   it	   is	   possible	   that	   other	  
measurement	  methods	  could	  reveal	  such	  changes.	  The	  measurement	  volume	  over	  which	  
the	   reflectance	  measurements	  are	   taken	   is	  much	  deeper	   than	   the	   superficial	   treatment	  
effect	   of	   PDT.	   The	   influence	   of	   this	   dimension	   mismatch	   will	   be	   the	   scope	   of	   future	  
investigation.	  
	  
We	   were	   able	   to	   reproduce	   the	   results	   that	   we	   have	   found	   previously.	   The	   PpIX	  
photobleaching	   kinetics	   for	   the	   two-­‐fold	   illumination	   schemes	   at	   50	   mW	   cm-­‐2,	   as	  
illustrated	   in	   figure	  2.3,	   show	  a	   similar	  photobleaching	   rate	  as	  previous	   studies	   [10,	  11,	  
27]	   during	   the	   first	   and	   second	   illumination	   as	   well	   as	   a	   comparable	   increase	   in	   PpIX	  
fluorescence	  to	  around	  80%	  of	   the	   initial	  value	  during	  the	  dark	   interval	  and	  subsequent	  
bleaching	   to	   under	   5%	   at	   the	   end	   of	   the	   second	   illumination.	   These	   groups	   of	   animals	  
(groups	  2	  and	  3)	  and	  their	  results	  therefore	  serve	  as	  controls	  for	  the	  20	  mW	  cm-­‐2	  groups.	  
	  
In	   accordance	   to	   several	   previous	   studies,	   we	   found	   that	   illuminating	   at	   lower	   fluence	  
rates	   (20	  mW	   cm-­‐2)	   results	   in	  more	   efficient	   PDT	   than	   at	   higher	   fluence	   rates	   (50	  mW	  	  	  	  
cm-­‐2),	   as	   is	   illustrated	   in	   figure	   2.4	   and	   table	   2.1.	   Using	   higher	   fluence	   rates	   causes	  
depletion	   of	   available	   oxygen	   during	   PDT,	   interrupting	   the	   continuous	   PpIX	  
photobleaching	   process.	   The	   treatment	   time	   for	   the	   first	   illumination	   is	   approximately	  
two	  times	  longer	  in	  the	  20	  mW	  cm-­‐2	  groups	  than	  in	  the	  50	  mW	  cm-­‐2	  groups,	  instead	  of	  2.5	  
times	   as	   would	   be	   the	   case	   if	   the	   photobleaching	   rate	   were	   the	   same.	   However,	   the	  
amount	   of	   fluence	   needed	   (and	   as	   a	   result	   also	   treatment	   time)	   does	   not	   decrease	  
proportionally	  with	   decreasing	   fluence	   rate.	   The	   consequence	   of	   this	   is	   that	   treatment	  
times	  remain	  longer	  at	  lower	  fluence	  rates	  if	  the	  same	  amount	  of	  total	  photobleaching	  is	  
desired.	  Our	   choice	  of	   low	   fluence	   rate	   in	   the	  present	   study	  was	   based	  on	  our	  wish	   to	  
minimize	   pain	   in	   clinical	   PDT.	   Since	   it	   may	   be	   possible	   to	   further	   reduce	   the	   pain	  
associated	  with	   the	   illumination	  by	   further	   reducing	   the	   fluence	  rate,	   it	   is	   interesting	   to	  
consider	  the	  relationship	  between	  fluence	  rate	  and	  the	  fluence	  needed	  to	  achieve	  a	  fixed	  









the	  efficiency	  of	  PpIX	  photobleaching	  was	  even	  higher	  when	  the	  fluence	  rate	  is	  reduced	  to	  
5	  mW	  cm-­‐2	  and	  lower	  for	  fluence	  rates	  above	  50	  mW	  cm-­‐2.	  Finlay	  et	  al	  [26]	  have	  shown	  
that	  the	  efficiency	  of	  photobleaching	  increases	  even	  further	  for	  lower	  fluence	  rates	  in	  rat	  
skin.	  Theoretically	  there	  will	  be	  a	  maximum	  efficiency	  of	  photobleaching	  below	  1	  mW	  cm-­‐
2,	  where	  PDT	  efficiency	  is	  optimal.	  The	  practical	  value	  of	  delivering	  PDT	  at	  these	  very	  low	  
fluence	  rates	  remains	  unclear,	   since	  treatment	   times	  will	   likely	  be	  very	   long	  at	  very	   low	  
fluence	  rates.	  	  
For	  the	  second	  illumination	  we	  also	  observed	  a	  trend	  to	  faster	  photobleaching	  in	  
the	  20	  mW	  cm-­‐2	  groups	  compared	  to	  the	  50	  mW	  cm-­‐2	  groups,	  as	   is	  shown	  in	  figure	  2.6.	  
This	   indicates	   that	   also	   for	   the	   second	   illumination,	   which	   is	   longer	   than	   the	   first,	   low	  
fluence	   rate	   photobleaching	   occurs	   somewhat	  more	   efficiently.	   In	   the	   first	   illumination	  
the	  difference	   is	  much	  more	  obvious	  however.	  This	  may	  be	  explained	  by	  vasodilatation	  
after	  the	  first	  illumination,	  increasing	  oxygen	  availability	  during	  the	  second	  illumination.	  
	  
When	  comparing	  damage	  scores	  between	  groups,	   figures	  2.6	  and	  2.7	   illustrate	  different	  
methods	  of	  damage	  scoring.	  Groups	  1-­‐3	  apply	  illumination	  schemes	  that	  we	  have	  used	  in	  
previous	   experiments	   and	   skin	   damage	   scores	   are	   consistent	   to	   the	   results	   from	   these	  
previous	  experiments,	  while	  groups	  4-­‐6	  were	  the	  low	  fluence	  rate	  groups.	  As	  is	  shown	  in	  
figure	  2.6,	  the	  single	  illumination	  group	  1	  has	  the	  lowest	  total	  damage	  score.	  All	  the	  other	  
groups	  have	  higher	   scores	  with	   the	  highest	   in	  group	  2	   (100	   J	   cm-­‐2	  at	  50	  mW	  cm-­‐2).	  Our	  
special	   interest	   was	   whether	   the	   low	   fluence	   rate	   groups	   (4,	   5	   and	   6)	   would	   score	  
significantly	   better	   than	   the	   single	   group	   and	   not	   significantly	   worse	   than	   the	   control	  
group	   2.	   All	   low	   fluence	   rate	   groups	   have	   a	   significant	   higher	   total	   damage	   score	  
compared	   to	   the	   single	   illumination	   group.	   Groups	   4	   and	   6	   (100	   J	   cm-­‐2	   total)	   are	   not	  
statistically	   different	   from	   group	   2,	   but	   only	   group	   5	   (50	   J	   cm-­‐2	   in	   total)	   is	   borderline	  
statistically	   worse	   than	   group	   2.	   Total	   differences	   between	   all	   fractionated	   groups	   are	  
small	  however.	  A	  small,	  but	  statistical	  difference	  may	  not	  necessarily	  represent	  a	  clinically	  
relevant	  difference.	  	  
We	  used	  damage	  to	  normal	  mouse	  skin	  as	  a	  substitute	  for	  clinical	  effect,	  because	  
this	   model	   previously	   proved	   to	   be	   a	   good	   translational	   model	   [10-­‐11,	   13,	   27].	   In	   the	  
present	  study	  we	  extended	  the	  previously	  used	  model	  by	  measuring	  maximum	  damage,	  
which	  is	  likely	  to	  be	  also	  indicative	  of	  PDT	  effect.	  It	  is	  important	  however	  to	  realize	  that	  in	  
a	  clinical	  setting,	  PDT	  effect	  is	  based	  on	  destruction	  of	  dysplastic	  tissue	  instead	  of	  normal	  
tissue	  and	  in	  human	  skin	  instead	  of	  mouse	  skin.	  
	  
From	  figure	  2.7	  it	   is	  clear	  that	  in	  the	  single	  illumination	  (group	  1)	  maximum	  scores	  were	  










apparent	   difference	   in	   score	   between	   these	   fractionated	   groups.	   A	   difference	   in	   the	  
results	   in	   this	   scoring	  method	  and	   the	  one	   illustrated	   in	   figure	  2.6	   is	   that	  group	  5	   (50	   J	  	  	  
cm-­‐2)	  has	  three	  animals	  with	  highest	  maximum	  damage	  scores	  and	  does	  not	  appear	  to	  be	  
worse	   than	   any	   other	   group.	   Combining	   the	   different	   damage	   scoring	   methods,	   there	  
appears	   to	   be	   no	   difference	   between	   high	   and	   low	   fluence	   rate	   groups	   in	   terms	   of	  
inducing	  visual	  skin	  damage.	  
	  
Taking	  the	  results	  from	  this	  study	   into	  account	  when	  designing	  a	  clinical	  trial	  comparing	  
low	  and	  high	  fluence	  rate	  light	  fractionated	  PDT,	  there	  are	  additional	  considerations.	  As	  is	  
clear	  from	  our	  results	  there	  is	  no	  proportional	  relationship	  between	  fluence	  and	  fluence	  
rate	  for	  a	  fixed	  bleaching	  percentage.	  This	  means	  that	  treatment	  times	  will	  remain	  longer	  
at	   lower	   fluence	  rates	  when	  the	  same	  amount	  of	  PpIX	  bleaching	   is	  used	  as	  a	   treatment	  
metric.	  	  
The	   clinical	   implications	   of	   this	   are	   important	   because	   treatment	   times	   for	   the	  
second	  illumination	  could	  be	  substantially	  longer	  using	  lower	  fluence	  rates.	  The	  duration	  
of	  the	  first	   illumination	   is	   in	  the	  order	  of	  a	  few	  minutes	  so	  differences	  will	  be	  small	  and	  
clinically	   irrelevant.	   In	  group	  2	  (100	  J	  cm-­‐2	  at	  50	  mW	  cm-­‐2)	  the	  second	  illumination	  takes	  
31	  minutes	  and	  at	  the	  end	  on	  average	  3.2%	  (SD	  1.5)	  of	  initial	  PpIX	  is	  left.	  For	  group	  5	  (50	  J	  
cm-­‐2	  at	  20	  mW	  cm-­‐2)	   the	  second	   illumination	   takes	  40	  minutes,	   leaving	  7.7%	  (SD	  2.7)	  of	  
PpIX.	   In	   group	   6	   (50	   J	   cm-­‐2	   at	   50	  mW	   cm-­‐2	   followed	   by	   50	   J	   cm-­‐2	   at	   50	  mW	   cm-­‐2)	   the	  
second	   illumination	  takes	  56	  minutes	  and	  2.9%	  (SD	  1.0)	  of	  PpIX	   is	   left.	   Interestingly,	  the	  
bleaching	  rate	  does	  not	  change	  at	  the	  point	  when	  fluence	  rate	  is	  increased.	  Probably	  the	  
amount	   of	   oxygen	   is	   no	   longer	   the	   limiting	   factor	   for	   PpIX	   photobleaching	   but	   the	  
concentration	   of	   PpIX	   is.	   It	   is	   unclear	   however	   what	   the	   biological	   advantage	   is	   of	  
illuminating	  tissues	  with	  very	   little	  PpIX	  content.	  An	  interesting	  extension	  of	  the	  present	  
study	  would	  be	  to	  use	  a	  fixed	  remaining	  PpIX	  percentage	  to	  stop	  the	  second	  illumination,	  
but	  it	  will	  be	  difficult	  to	  determine	  this	  percentage.	  
	  
It	   is	   also	   important	   to	   recognize	   that	   mouse	   skin	   is	   considerably	   thinner	   compared	   to	  
human	   skin.	   Theoretically,	   deeper	   layers	   of	   skin	   may	   need	   higher	   total	   fluences	   since	  
fluence	   rate	   decreases	   exponentially	   in	   tissue	   with	   increasing	   depth.	   Especially	   in	   the	  
deeper	  bases	  of	  sBCC	  the	  fluence	  at	  depth	  may	  be	  an	  important	  consideration.	  Also	  the	  
variation	  in	  vascularisation	  of	  tumor	  tissue	  results	  in	  variable	  light	  absorption	  and	  oxygen	  
supply.	   Therefore	   it	   theoretically	   makes	   sense	   to	   have	   a	   clinical	   illumination	   scheme	  
based	  on	  the	  illumination	  scheme	  of	  group	  6	  (50	  J	  cm-­‐2	  at	  20	  mW	  cm-­‐2	  followed	  by	  50	  J	  
cm-­‐2	  at	  50	  mW	  cm-­‐2).	  Effectiveness	   is	  expected	  to	  be	  maintained,	  pain	  is	  expected	  to	  be	  











In	  conclusion	   the	  present	  study	  shows	   that	   low	   fluence	  rate,	   light	   fractionated	  ALA-­‐PDT	  
appears	   to	   be	   as	   effective	   in	   inducing	   visual	   skin	   damage	   in	   mouse	   skin,	   while	   PpIX	  
photobleaching	   occurs	   more	   efficiently.	   This	   in	   part	   limits	   the	   duration	   of	   therapy,	  
although	   lower	   fluence	   rate	   PDT	   does	   result	   in	   longer	   illuminations	   when	   the	   same	  
amount	  of	  photobleaching	  is	  desired.	  There	  is	  need	  for	  further	  investigations	  that	  should	  
include	   a	   clinical	   trial	   investigating	   pain	   and	   clinical	   efficacy	   using	   low	  and	  high	   fluence	  
rate	   fractionated	   PDT,	   while	   performing	   PpIX	   fluorescence	  measurements.	  Maintaining	  
high	   efficacy	   of	   therapy	   should	   be	   the	   most	   important	   consideration,	   while	   pain	   and	  
treatment	  time	  must	  be	  carefully	  weighted	  against	  each	  other.	  Thickness	  of	  lesions	  must	  
be	   taken	   into	  account	  when	   interpreting	   the	   results	   from	   the	  present	   study	  because	  of	  
differences	  in	  thickness	  between	  mouse	  and	  human	  skin.	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In	   a	   previous	   study	   it	   is	   shown	   that	   for	   topically	   applied	   ALA-­‐PDT,	   PpIX	   concentration	  
correlates	   with	   vascular	   changes	   including	   vasoconstriction	   and/or	   vascular	   leakage	   of	  
small	  vessels	  and	  arterioles	  in	  the	  mouse	  epidermis	  and	  dermis.	  In	  this	  study	  we	  report	  on	  
vascular	  responses	  induced	  by	  ALA-­‐PDT	  for	  different	  fluence	  rates,	  including	  both	  changes	  
in	   vessel	   diameter	   and	   dynamics	   in	   blood	   flow	   in	   arterioles,	   imaged	   using	   intra-­‐vital	  
confocal	  microscopy	  in	  skinfold	  chambers	  in	  hairless	  mice.	  Our	  interest	  is	  in	  the	  dynamics	  
of	  vascular	  changes	  in	  the	  early	  stages	  of	  illumination.	  We	  have	  determined	  the	  total	  PDT	  
dose	   to	  be	  relatively	   low,	  13	   J	  cm-­‐2,	  and	  fluence	   rates	  of	  26,	  65	  and	  130	  mW	  cm-­‐2	  were	  
investigated.	  Local	  vascular	  effects	  occurred	  very	  soon	  after	  the	  start	  of	   the	  therapeutic	  
illumination	   in	   ALA-­‐PDT.	   In	   this	   study,	  we	   did	   not	   find	   a	   significant	   difference	   between	  
fluence	   rates.	   Arterioles	  were	   particularly	   sensitive	   to	   vasoconstriction	   during	   low	  dose	  
PDT,	   often	   resulting	   in	   complete	   vasoconstriction.	   When	   we	   observed	   complete	  
vasoconstriction,	  this	  coincided	  with	  changes	  in	  RBC	  velocity.	  Since	  the	  therapeutic	  effects	  
of	  PDT	  are	  dependent	  on	  a	  fine	  balance	  between	  the	  need	  for	  oxygen	  during	  illumination	  
and	   disruption	   of	   the	   vasculature,	   the	   results	   of	   the	   present	   study	   add	   to	   our	  
understanding	  of	   acute	   vascular	   effects	   during	  ALA-­‐PDT	  and	  aid	  our	   efforts	   to	  optimize	  
PDT	  using	  porphyrin	  pre-­‐cursors.	  	  











Photodynamic	   therapy	   (PDT)	  using	   topically	  applied	  porphyrin	  precursors	   is	  a	   treatment	  
modality	   used	   for	   various	   (pre-­‐)malignant	   skin	   lesions	   [1,	   2].	   The	   precursor	   5-­‐
aminolevulinic	  acid	  (ALA),	  and	  its	  esterified	  derivatives	  methyl	  aminolevulinate	  (MAL)	  and	  
hexyl	   aminolevulinate	   (HAL),	   are	   taken	   up	   by	   cells	   and	   converted	   into	   the	   endogenous	  
photosensitizer	  protoporphyrin	  IX	  (PpIX)	  by	  means	  of	  the	  haem	  cycle	  [3].	  The	  application	  
of	  an	  excess	  of	  exogenous	  ALA	  leads	  to	  the	  accumulation	  of	  therapeutic	  concentrations	  of	  
PpIX.	  During	   illumination,	   PpIX	  mediates	   the	   transfer	   of	   energy	   from	   light	   to	  molecular	  
oxygen,	   resulting	   in	   the	  generation	  of	   reactive	  oxygen	   species	   (ROS).	   These	  ROS	  have	  a	  
very	   short	   lifetime	   and	   diffusion	   radius	   and	   cause	   damage	   to	   nearby	   critical	   tissue	  
structures	  through	  a	  combination	  of	  cellular,	  vascular	  and	  immunological	  pathways	  [4,	  5].	  	  
Since	   the	   formation	   of	   reactive	   oxygen	   species	   is	   the	   initiator	   of	   local	   tissue	  
damage	   during	   PDT,	   tissue	   oxygenation	   and	   therefore	   the	   local	   blood	   supply	   plays	   an	  
important	  role	  in	  determining	  tissue	  response	  to	  PDT.	  The	  role	  of	  the	  local	  blood	  supply	  
during	   PDT	   is	   multifaceted.	   Some	   (mainly	   intravenous	   administered)	   photosensitizers	  
directly	  target	  the	  vasculature,	  which	  upon	  illumination	  results	  in	  irreversible	  damage	  to	  
vessels	   and	   thereby	   destruction	   of	   the	   illuminated	   tissue.	   However	   vascular	   shutdown	  
and	   blood	   flow	   changes	   during	   early	   stages	   of	   illumination	   decrease	   the	   transport	   of	  
oxygen,	   which	   then	   limits	   the	   production	   of	   singlet	   oxygen	   and	   therefore	   reduces	   the	  
effect	   of	   the	   local	   cellular	   and	   immunological	   response.	   Treatment	   efficacy	   is	   therefore	  
dependent	   on	   a	   fine	   balance	   between	   the	   positive	   and	   negative	   effects	   of	   vascular	  
damage.	  Here,	  light	  dose	  and	  fluence	  rate	  play	  an	  important	  role	  in	  optimizing	  PDT	  [6,	  7].	  
	  
Although	   the	   porphyrin-­‐precursor	   ALA	   is	   usually	   topically	   applied	   to	   the	   skin,	   the	  
precursor	   penetrates	   into	   the	   epidermis	   and	   dermis.	   We	   have	   recently	   shown	  
accumulation	  of	  significant	  amounts	  of	  PpIX	   in	  vessel	  and	  arterial	  walls	   in	  subcutaneous	  
tissue	   after	   topical	   application	   of	   ALA	   on	   skin	   [8].	   In	   this	   circumstance	   the	   vasculature	  
itself	   is	   a	   target	   for	   photodynamic	   therapy,	   and	   the	   effects	   of	   illumination	   on	   the	  
vasculature	  have	  to	  be	  taken	  into	  account.	  	  
To	   overcome	   the	   problem	   of	   direct	   vascular	   shutdown	   and	   increase	   treatment	  
efficacy	  during	  ALA-­‐PDT,	   different	   illumination	  protocols	   are	  developed.	  We	  and	  others	  
have	   shown	   that	   illumination	   with	   a	   lower	   fluence	   rate	   results	   in	   more	   PDT	   induced	  
damage	   in	   normal	  mouse	   skin	   [7,	   9].	   In	   a	   hypoxic	   environment,	   the	   synthesis	   of	   nitric	  
oxide	   stagnates,	   leading	   to	   direct	   local	   vasoconstriction	   and	   with	   that	   only	   enhancing	  
hypoxia	  in	  the	  area	  [10].	  Low	  fluence	  rate	  PDT	  is	  coupled	  with	  lower	  oxygen	  demand	  and	  








alternative	   illumination	   scheme	   that	   we	   and	   others	   are	   investigating	   is	   fractionated	  
illumination	  with	  long	  dark	  intervals.	  In	  this	  approach	  a	  maximal	  efficacy	  is	  achieved	  when	  
a	  small	  fluence	  is	  delivered	  first,	  separated	  from	  the	  second	  fluence	  by	  a	  dark	  interval	  of	  
>90	  min	  [6].	  Although	  the	  mechanism(s)	  underlying	  this	  increased	  efficacy	  is	  not	  yet	  fully	  
elucidated,	   an	   ischemia/reperfusion	   injury	   mechanism	   and/or	   increased	   reperfusion	   in	  
the	  dark	   interval	  do	  not	  seem	  to	  be	  significant	  factors	  [11].	  We	  have	  recently	  shown	  in-­‐
vitro	   that	   cell	   kill	   after	   light	   fractionated	   PDT	   shows	   a	   strong	   dependence	   on	   the	  
concentration	  of	  PpIX	  at	  the	  time	  of	  the	  first	   illumination	  [12];	  only	  cells	   incubated	  with	  
low	   concentrations	   of	   ALA	   show	   enhanced	   cell	   death.	   These	   findings	   support	   the	  
hypothesis	  that	  the	  positive	  effect	  of	  light	  fractionation	  is	  based	  on	  a	  cellular	  mechanism	  
that	  leads	  to	  sub-­‐lethally	  damaged	  cells	  after	  the	  first	  light	  fraction,	  after	  which	  these	  cells	  
become	  more	  susceptible	  to	  a	  second	  light	  fraction	  two	  hours	  later.	  
	  
In	   order	   to	   understand	   the	   interaction	   between	   PDT	   induced	   vasculature	   effects	   and	  
tissue	   destruction,	   knowledge	   on	   vascular	   effects	   during	   and	   immediately	   after	   PDT	   is	  
crucial.	  Various	  authors	  have	  reported	  on	  monitoring	  blood	  flow	  during	  and/or	  following	  
ALA-­‐PDT,	  showing	  little	  consistency	  in	  results	  [13-­‐17].	  However,	  these	  studies	  show	  large	  
variation	   in	  experimental	  design	  on	   for	  example	   the	  average	  volume	  over	  which	   flow	   is	  
determined	  and	  direct	  response	  versus	  long-­‐term	  (clinical)	  response.	  In	  a	  previous	  study	  it	  
is	   shown	  that	   for	   topically	  applied	  ALA-­‐PDT,	  PpIX	  concentration	  correlates	  with	  vascular	  
changes	  including	  vasoconstriction	  and/or	  vascular	  leakage	  of	  small	  vessels	  and	  arterioles	  
in	  the	  epidermis	  and	  dermis	  [8].	  In	  this	  study	  we	  report	  on	  vascular	  response	  induced	  by	  
ALA-­‐PDT	   for	   different	   fluence	   rates,	   including	   both	   changes	   in	   vessel	   diameter	   and	  
dynamics	   in	   RBC	   velocity	   in	   arterioles,	   imaged	   using	   intra-­‐vital	   confocal	   microscopy	   in	  
skin-­‐fold	   chambers	   in	   hairless	   mice.	   While	   previous	   studies	   investigated	   variations	   in	  
vessel	   diameter	   pre-­‐	   and	   post	   PDT,	  we	   included	  measurements	   of	   vessel	   diameter	   and	  
RBC	   flow	   velocity	   during	   PDT	   illumination.	  We	   show	   that	   situations	   occurred	   in	   which	  
vessel	  diameter	  analysis	  showed	  an	  uninterrupted	  blood	  supply,	  while	  flow	  had	  come	  to	  a	  
standstill.	  Furthermore,	  we	  analyzed	  the	  relation	  between	  PDT	  illumination	  fluence	  rate,	  
PpIX	  accumulation	  in	  tissue	  and	  vascular	  reactions	  in	  skin-­‐fold	  observation	  chambers.	  	  
MATERIALS	  AND	  METHODS	  
EXPERIMENTAL	  DESIGN	  
This	   study	   focuses	   on	   the	   analysis	   of	   vasculature	   during	   and	   following	   ALA-­‐PDT	   using	  










skin-­‐fold	   observation	   chamber.	   Imaging	   was	   done	   from	   the	   subcutis,	   where	   the	   larger	  
vessels	  were	  located,	  towards	  the	  epidermis.	  Red	  blood	  cells	  (RBCs)	  from	  a	  donor	  mouse	  
were	  labeled	  with	  FITC	  isomer	  I	  and	  injected	  in	  the	  chamber-­‐bearing	  mouse.	  The	  mouse	  
was	   fixated	   under	   a	   confocal	   microscope,	   where	   high	   speed	   scanning	   of	   1D-­‐line	  
perpendicular	   to	   the	  vessel	  provided	   information	  on	  RBC	  velocity.	  This	  1D-­‐scanning	  was	  
performed	   during	   the	   PDT	   illumination	   and	   repeated	   2	   hours	   after	   the	   end	   of	   the	  
therapeutic	  illumination.	  PDT	  was	  performed	  using	  an	  external	  light	  source	  and	  according	  
to	   different	   illumination	   parameters,	   which	   are	   described	   in	   detail	   below.	   The	   spatial	  
distribution	  of	  PpIX	  and	  514	  nm	  bright-­‐field	   transmission	   images	  were	   recorded	  before,	  
directly	  after	  and	  2	  hours	  after	  illumination.	  	  
	  
ANIMAL	  MODEL	  
Dorsal	  skin-­‐fold	  window	  chambers	  were	  prepared	  on	  the	  back	  of	  21	  inbred	  albino	  hairless	  
mice	   (SKH1	   HR,	   Charles	   River,	   Someren,	   the	   Netherlands)	   under	   general	   anesthesia	  
(ketamine,	  100	  mg	  kg-­‐1	  b.w.	  and	  xylazine,	  20	  mg	  kg-­‐1	  b.w.	   in	  a	   volume	  mixture	  of	  2:1:1	  
saline,	   ketamine,	   xylazine)	   [8].	   Both	   sides	   of	   the	   chamber	  were	   covered	  with	   a	   12	  mm	  
cover	  slide	  of	  0.13-­‐0.16	  mm	  thick.	  Two	  to	  four	  days	  after	  operation,	  mice	  were	  included	  in	  
the	  experiment.	  The	  window	  chamber	  frame	  is	  employed	  to	  immobilize	  the	  mice	  on	  the	  
intra-­‐vital	   microscope,	   to	   reduce	   motion	   artifacts	   during	   microscopy.	   Freshly	   prepared	  
ALA	  cream	  (20%	  (v/v)	  ALA	  (Fagron	  BV,	  Capelle	  a/d	  IJssel,	  The	  Netherlands)	  was	  dissolved	  
in	  water	  containing	  3%	  carboxymethylcellulose	  and	  NaOH)	  was	  applied	  to	  the	  skin	  surface	  
and	   occluded	   using	   a	   cover	   slide	   and	   incubated	   for	   4	   hours.	   During	   and	   after	   the	  
incubation	  period	  animals	  were	  placed	  in	  a	  dark	  and	  warm	  environment.	  The	  committee	  
on	   Animal	   Research	   of	   the	   Erasmus	   MC	   approved	   the	   experimental	   protocol.	   Animal	  
Housing,	   experiments	   and	   euthanization	   were	   performed	   in	   accordance	   with	   the	  
guidelines	  of	  this	  committee.	  
	  
RED	  BLOOD	  CELL	  LABELLING	  
Red	  blood	  cells	  for	  labeling	  were	  obtained	  from	  a	  donor	  mouse.	  The	  labeling	  procedure	  is	  
described	  in	  detail	  elsewhere	  [18,	  19].	  Every	  experiment	  day	  required	  one	  donor	  mouse,	  
bringing	   the	   total	   to	   n=7	  mice.	   Red	   blood	   cells	  were	   isolated	   (centrifuging	   7	  min,	   2000	  
rpm,	   supernatant	   removed)	   and	  washed	  with	   physiological	   saline	   twice.	   The	   cells	  were	  
added	   to	   0.5	   ml	   solution	   of	   5	   mg	   ml-­‐1	   fluorescein	   isothiocyanate	   (FITC)	   isomer	   I	   in	  
phosphate	   buffer	   solution	   (PBS)	   and	   incubated	   for	   2	   hours	   at	   room	   temperature.	  
Afterwards,	  cells	  were	  centrifuged,	  the	  excess	  solution	  was	  removed	  and	  washed	  twice	  in	  
PBS,	  with	  1%	  BSA	  added.	  Cells	  were	  then	  suspended	  in	  physiological	  saline	  (27	  µl	  RBC	  in	  








labeled	  RBCs	  that	  facilitated	  the	  measurement	  of	  individual	  fluorescent	  RBCs	  while	  having	  
enough	  labeled	  cells	  passing	  during	  a	  measurement	  series	  to	  perform	  statistical	  analysis.	  	  
	  
INTRA-­‐VITAL	  CONFOCAL	  IMAGING	  
All	   imaging	  was	   performed	  using	   a	   confocal	   intra-­‐vital	  microscope	   (Zeiss	   LSM510META,	  
Carl	   Zeiss	   B.V.	   Sliedrecht,	   the	   Netherlands).	   An	   overview	   of	   the	   complete	   window	  
chamber	   was	   made	   with	   bright-­‐field	   transmission	   mode	   and	   recorded	   with	   a	   20x	  
magnification	  (514	  nm	  excitation	  light).	  Higher	  magnification	  (200x)	  fluorescence	  (488	  nm	  
excitation)	   and	   transmission	   images	   were	   taken	   of	   a	   field	   of	   view	   including	   arterioles.	  
These	   recordings	   were	   performed	   pre,	   post	   and	   2	   hours	   after	   PDT	   illumination.	   PpIX	  
fluorescence	   was	   excited	   using	   the	   514	   nm	   laser	   of	   the	   confocal	   microscope	   and	  
fluorescence	   spectral	   emission	   was	   detected	   between	   601	   and	   676	   nm	   using	   lambda	  
mode	  to	  determine	  spatial	  distribution	  of	  photosensitizer.	  	  
	  
VESSEL	  DIAMETER	  AND	  RBC	  VELOCITY	  DETERMINATION	  
To	  determine	  vessel	  diameter	  and	  RBC	  flow	  velocity	  before,	  during	  and	  after	  PDT,	  a	  line	  
(256	  pixels)	   of	   interest	  was	   selected,	   perpendicularly	   to	   the	   vessel	   of	   interest.	   This	   line	  
was	   scanned	   1000	   successive	   times,	  with	   a	   scan	   time	  of	   approximately	   1.6	  ms	   per	   line	  
(dependent	  on	   line	  size).	  488	  nm	  excitation	   light	  was	  used	  for	  excitation	  of	  FITC-­‐labeled	  
red	  blood	  cells.	  Fluorescence	  was	  collected	  through	  a	  505-­‐550	  nm	  band	  pass	  filter,	  while	  
transmitted	   light	  passed	   through	  a	  530	   short	  pass	   filter	   to	  block	   the	  external	  PDT	   light.	  
Pixel	   size	   and	   scan	   times	   were	   carefully	   recorded	   for	   further	   analysis.	   Line	   scans	   were	  
made	  pre	   and	  post	   PDT,	   and	   2	   hours	   after	   illumination.	  During	   PDT	   illumination,	   a	   line	  
scan	   sequence	   was	   measured	   after	   every	   0.75	   J	   cm-­‐2	   delivered	   light	   dose.	   After	  
illumination,	  this	  line	  scan	  sequence	  was	  continued	  for	  3	  more	  cycles	  to	  capture	  possible	  
fast	   recovery	   effects.	   The	   focal	   depth	   of	   the	   line	   scan	  was	   placed	   in	   the	   center	   of	   the	  
vessel	  by	  having	  fluorescent	  RBCs	  in	  the	  whole	  width	  of	  the	  vessel	  in	  focus	  (or	  as	  many	  as	  
possible).	   Combined	   with	   an	   optical	   slice	   thickness	   of	   19	   µm,	   this	   covered	   the	   whole	  
vessel	  lumen.	  	  	  
	  
PDT	  ILLUMINATION	  PROTOCOL	  
PDT	   illumination	   was	   performed	   using	   an	   external	   laser	   source	   (Visulas,	   630	   nm,	   Carl	  
Zeiss)	   coupled	   into	   a	   fiber	   and	   imaged	   through	   a	   system	   of	   lenses	   to	   illuminate	   the	  
complete	   skin	   observation	   chamber	   from	   the	   skin	   side,	   while	   positioned	   under	   the	  
confocal	  microscope.	  	  Four	  different	  illumination	  parameters	  were	  investigated:	  group	  A	  










received	  13	  J	  cm-­‐2	  with	  a	  fluence	  rate	  of	  26	  mW	  cm-­‐2,	  and	  group	  C	  (n=6)	  received	  13	  J	  cm-­‐2	  
with	   a	   fluence	   rate	   of	   130	   mW	   cm-­‐2.	   Group	   D	   (n=4)	   served	   as	   a	   control	   group	   with	  
illumination	  parameters	  equal	  to	  group	  A,	  using	  mice	  that	  did	  not	  receive	  ALA.	  Values	  for	  
fluence	  and	  fluence	  rate	  were	  chosen	  to	  be	  comparable	  with	  previous	  studies	  using	  514	  
nm	   treatment	   light,	   based	   on	   differences	   in	   PpIX	   absorption	   and	   photon	   energy	   [20].	  
Since	   our	   interest	   is	   in	   the	   dynamics	   of	   vascular	   changes	   in	   the	   early	   stages	   of	  
illumination,	  we	  determined	  the	  total	  PDT	  dose	  to	  be	  relatively	  low,	  13	  J	  cm-­‐2.	  
	  
DATA	  ANALYSIS	  
All	   data	   analysis	  was	   performed	  using	   a	   custom	  program	  written	   in	  Matlab	   2009a	   (The	  
Mathworks,	  Natick,	  MA,	  USA).	  To	  determine	  spatial	  PpIX	  concentration,	  we	  analyzed	  the	  
spectral	  mode	  images.	  These	  consist	  of	  eight	  fluorescence	  emission	  images	  of	  consecutive	  
emission	  bands	  (spread	  11	  nm,	  range	  601-­‐677	  nm).	  For	  each	  pixel,	  intensity	  values	  of	  the	  
spectral	   mode	   images	   form	   an	   emission	   spectrum,	   to	   which	   basis	   spectra	   for	  
autofluorescence	   and	   PpIX	   fluorescence	   were	   fitted	   with	   a	   non-­‐linear	   least	   squares	   fit	  
method.	  Basis	  spectra	  were	  obtained	  by	  averaging	  recorded	  spectra	  from	  three	  group	  D	  
or	   group	   A/B/C	   mice	   for	   autofluorescence	   and	   PpIX	   fluorescence	   respectively.	  
Transmission	   images	  were	   used	   to	   draw	   regions	   of	   interest	   located	   in,	   bordering	   on	  or	  
away	  from	  the	  arteriole,	  over	  which	  the	  average	  PpIX	  fluorescence	  was	  determined.	  The	  
intra-­‐arteriole	  and	  vessel	  wall	  areas	  covered	  approximately	  40x160	  µm,	  while	  the	  areas	  in	  
normal	  tissue	  were	  larger.	  	  
The	  vessel	  diameter	  was	  determined	  from	  the	  transmission	  light	  image	  in	  the	  1D-­‐
line	   scan	   images	   using	   a	   custom	  Matlab	   procedure.	   The	   1000	   consecutive	   lines	   form	   a	  
gray	   scale	   image,	   which	   was	   converted	   to	   binary	   by	   the	   use	   of	   Otsu’s	   thresholding	  
method,	  dividing	  a	  gray	   scale	   image	   into	   foreground	  and	  background	   (tissue	  and	  vessel	  
resp.	   in	   this	   case)	   [21].	   The	   vessel	   diameter	  was	  determined	  as	   the	   average	  number	  of	  
pixels	  determined	  being	  vessel,	  multiplied	  by	  pixel	  size.	  	  
RBC	  velocity	  was	  determined	  from	  the	  number	  of	  subsequent	   lines	  showing	  RBC	  
fluorescence,	  where	  more	   lines	   indicate	  slower	  RBCs.	  This	  method	   is	  described	   in	  detail	  
elsewhere	  [22].	  Since	  the	  exact	  configuration	  of	  the	  blood	  cell	   in	  the	  vessel	   is	  unknown,	  
the	   average	   RBC	   diameter	   was	   set	   to	   5±3	   µm	   (the	   average	   RBC	   diameters	   are	  











We	   were	   able	   to	   measure	   RBC	   velocity	   and	   vessel	   diameter	   during	   the	   complete	   PDT	  
illumination	   in	  16	  of	   the	  21	  mice;	   two	  died	  before	  or	  during	   illumination,	   three	  window	  
chambers	   moved	   out	   of	   focus	   during	   measurement.	   Figure	   3.1,	   3.2	   and	   3.3	   show	   the	  
three	  cases	  that	  we	  observed:	  no	  change	  in	  vessel	  diameter	  and	  flow	  (figure	  3.2,	  group	  D),	  
partial	   vasoconstriction	   (figure	   3.3,	   group	   A),	   or	   complete	   vasoconstriction	   (figure	   3.1,	  
group	  B).	  	  
	  
VESSEL	  DIAMETER	  
Analyzing	  the	  changes	  in	  vessel	  diameter	  showed	  results	  consistent	  with	  previous	  studies	  
[8,	   23].	   14	  out	  of	   16	  mice	   showed	  a	  decrease	   in	   vessel	   diameter	   (diameter	  post	  PDT	   is	  
65%±46%	   of	   the	   diameter	   pre	   PDT),	   while	   six	   mice	   showed	   complete	   vessel	   occlusion	  
directly	  after	  PDT.	  Variations	  in	  vessel	  diameter	  during	  PDT	  are	  shown	  in	  figure	  3.4,	  where	  
every	   line	   indicates	   a	   singe	   mouse.	   Figure	   3.1	   shows	   an	   example	   measurement	   series	  
resulting	  in	  complete	  vasoconstriction.	  Confocal	  measurements	  2	  hours	  after	  PDT	  were,	  in	  
many	   cases,	   complicated	   by	   edema	   formation,	   limiting	   the	   possibility	   to	   focus	   the	  
microscope	  on	  the	  field	  of	  view.	  
	  
Figure	  3.1:	  Exemplary	  measurement	  series	  of	  complete	  vascular	  constriction.	  Left)	  Squares,	  overview	  of	  the	  
area	  under	   investigation	  before,	  after	  and	  2	  hours	   later.	  Right)	  Line	  scans	  before,	  during	  and	  2	  hours	  after	  
PDT	  illumination.	  In	  this	  special	  case	  re-­‐appearance	  after	  2	  hours,	  but	  no	  flow.	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Figure	  3.2:	  Exemplary	  measurement	  series	  of	  control	  animal.	  Left)	  Squares,	  overview	  of	  the	  area	  under	  
investigation	  before,	  after	  and	  2	  hours	  later.	  Right)	  Line	  scans	  before,	  during	  and	  2	  hours	  after	  PDT	  
illumination.	  Without	  applying	  ALA,	  no	  vascular	  reaction	  is	  visible.	  
	  
Figure	   3.3:	   Exemplary	  measurement	   series	   of	   partial	   vasoconstriction.	   Left)	   Squares,	   overview	  of	   the	  area	  
under	   investigation	  before,	  after	  and	  2	  hours	   later.	  Right)	  Line	  scans	  before,	  during	  and	  2	  hours	  after	  PDT	  
illumination.	  A	  reduction	  in	  vessel	  diameter	  during	  PDT	  can	  be	  seen,	  and	  the	  decrease	  of	  fluorescent	  dot-­‐size	  
at	  the	  2	  hour	  time	  point	  indicates	  an	  increase	  in	  RBC	  velocity.	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Vascular	  constriction	  seemed	  to	  be	  present	  in	  all	  PDT	  groups,	  although	  reactions	  in	  the	  26	  
(figure	   3.4b)	   and	   130	   mW	   cm-­‐2	   (figure	   3.4c)	   group	   were	   more	   pronounced.	   The	  
accumulation	  of	   PpIX	   in	   tissue	   varied	  between	   individual	  mice,	   due	   to	   variations	   in	   the	  
capacity	  to	  take	  up	  and	  convert	  ALA	  into	  PpIX.	  However,	  the	  average	  PpIX	  levels	  for	  the	  
three	   groups	   did	   not	   vary	   significantly	   as	   shown	   in	   figure	   3.5	   (P>0.1).	   	   The	   correlation	  
between	  PpIX	  level	  and	  relative	  vessel	  diameter	  change	  as	  described	  previous	  [8],	  did	  not	  
significantly	  show	  in	  present	  work,	  as	  shown	  in	  figure	  3.6.	  
	  
RED	  BLOOD	  CELL	  VELOCITY	  
When	  comparing	  changes	  in	  RBC	  velocity	  (figure	  3.7)	  with	  changes	  in	  diameter	  (figure	  3.4)	  
during	  illumination,	  we	  found	  that	  in	  all	  cases	  reaching	  total	  occlusion,	  this	  was	  preceded	  
by	  a	  sharp	  decrease	  in	  velocity	  to	  zero.	  When	  the	  vessel	  did	  not	  completely	  constrict,	  RBC	  
velocity	  stayed	  relatively	  constant,	  as	  shown	  in	  figure	  3.7.	  The	  large	  error	  bars	  on	  velocity	  
measurements	   could	   be	   explained	   by	   different	   geometries	   in	  which	   the	   RBCs	   travelled	  
through	  the	  vessel.	  RBC	  flow	  velocity	  was	  calculated	  using	  an	  average	  RBC	  diameter	  of	  5	  
µm,	  while	  the	  diameter	  of	  the	  RBC	  passing	  the	  line	  ranged	  from	  2	  to	  8	  µm.	  The	  resulting	  
variation	  could	  be	  assigned	  to	  variations	  in	  RBC	  flow	  velocity	  in	  one	  line-­‐scan	  image.	  	  
	  
	  
Figure	   3.4:	   Relative	   vessel	   diameter	   change	   vs	   delivered	   PDT	   fluence.	   Every	   line	   indicates	   one	   animal.	  
Measurements	   before	   illumination	   (Fluence	   =	   -­‐1),	   during	   illumination	   (Fluence	   =	   0-­‐13)	   and	   directly	   after	  
illumination	  ends	  (Fluence	  =	  13-­‐15).	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  3	  	  
From	  the	  six	  mice	  showing	  complete	  occlusion,	  one	  mouse	  showed	  the	  re-­‐appearance	  of	  
the	   vessel	   2	   hours	   later.	   This	   2	   hour	   measurement	   sequence	   is	   shown	   in	   figure	   3.1.	  
Although	   not	   occluded	   anymore,	   RBCs	   had	   come	   to	   a	   standstill.	   We	   observed	   this	  
phenomenon	  in	  only	  one	  mouse.	  The	  observation	  that	  changes	  in	  vessel	  diameter	  did	  not	  
necessarily	   correlate	   with	   changes	   in	   RBC	   velocity	   calls	   for	   discussion	   on	   how	   local	  
vascular	  changes	  during	  and	  after	  ALA-­‐PDT	  could	  be	  influencing	  treatment	  efficacy.	  	  
	  
	   	  
Figure	   3.5:	   PpIX	   concentration	   in	   vessel	   wall	   for	  
three	  different	  groups	  does	  not	  vary	  significantly.	  
Figure	   3.6:	   PpIX	   concentration	   in	   vasculature	   vs.	  
relative	  change	  in	  vessel	  diameter.	  
	  
Figure	   3.7:	   Relative	   RBC	   velocity	   change	   vs	   delivered	   PDT	   fluence.	   Every	   line	   indicates	   one	   animal.	  
Measurements	   before	   illumination	   (Fluence=-­‐1),	   during	   illumination	   (Fluence=0-­‐13)	   and	   directly	   after	  
illumination	   ends	   (Fluence=13-­‐15).	   2	   hours	   after	   illumination	   is	   plotted	   at	   Fluence=20.	   Errorbars	   indicate	  
variation	  of	  RBC	  velocities	  passing	  the	  linescan	  during	  one	  time	  point.	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When	   relating	   diameter	   to	   RBC	  
velocity,	  we	  were	  only	  able	  to	  consider	  
variation	  per	  mouse	  during	  illumination	  
to	   avoid	   artifacts	   arising	   from	   intra-­‐
animal	  variation	  in	  blood	  pressure.	   It	   is	  
shown	   in	   figure	   3.8	   that	   in	   general	  
larger	   diameters	   were	   related	   to	   a	  
higher	   RBC	   velocity,	   as	   was	   expected	  
from	   the	   Poiseuille	   equation.	   The	   RBC	  
velocity	  measurements	  presented	  here	  
were	  consistent	  with	  what	  is	  previously	  
measured	   in	   skin-­‐fold	   window	  
chambers	  [17,	  24].	  
DISCUSSION	  
In	   this	  paper	  we	  have	  shown	  that	  delivering	  a	   low	  fluence	  of	  ALA-­‐PDT	  resulted	   in	  acute	  
vascular	   response	   during	   the	   therapeutic	   illumination.	   One	   significant	   advance	   of	   the	  
present	   study	  over	  our	  previous	  approaches	   [8,	  23]	   to	  monitor	  acute	  vascular	  effects	   is	  
the	  incorporation	  of	  measurement	  of	  RBC	  velocity	  rather	  than	  simply	  measuring	  changes	  
in	  the	  diameter	  of	  blood	  vessels.	  We	  applied	  a	  fluence	  of	  13	  J	  cm-­‐2,	  comparable	  to	  the	  first	  
small	   light	   fraction	   used	   in	   light	   fractionated	   PDT.	   We	   observed	   vasoconstriction	   of	  
arterioles	  under	  investigation	  occurring	  in	  77%	  of	  the	  mice,	  independent	  of	  fluence	  rate.	  
Furthermore,	   we	   observed	   a	   drop	   in	   RBC	   velocity	   immediately	   before	   vessel	   diameter	  
reduction	   set	   in.	   However,	   this	   drop	   in	   velocity	   was	   only	   present	   when	   total	   vessel	  
constriction	   occurred.	   Interestingly,	   incomplete	   vasoconstriction	   did	   not	   lead	   to	  
significant	  changes	  in	  RBC	  velocity.	  In	  a	  previous	  study	  we	  show	  no	  significant	  difference	  
between	   vascular	   effects	   after	   low	   (5-­‐10	   J	   cm-­‐2)	   or	   high	   (100	   J	   cm-­‐2)	   fluence	   PDT,	  
indicating	  that	  the	  vascular	  effects	  set	  in	  early	  during	  treatment	  [8].	  
	  
Although	   PpIX	   in	   tissue	   is	   not	   concentrated	   in	   the	   vasculature	   like	   intravenously	  
administered	   photosensitizers	   are,	   we	   have	   recently	   shown	   that	   endothelial	   cells	   of	  
epidermal	   and	   dermal	   vasculature	   do	   generate	   PpIX	   after	   the	   topical	   administration	   of	  
ALA	  [8].	  Therefore	  it	  is	  reasonable	  to	  expect	  acute	  vascular	  responses	  in	  endothelial	  tissue	  
during	   PDT.	   Furthermore,	   when	   PDT	   illumination	   is	   started	   and	   there	   is	   a	   significant	  
accumulation	  of	  PpIX	  in	  and	  around	  endothelial	  cells,	  the	  depletion	  of	  molecular	  oxygen	  
	  
Figure	   3.8:	   Vessel	   diameter	   vs	   RBC	   velocity.	   Colors	  
represent	  different	  groups	  and	  symbols	  individual	  mice	  
within	  them.	  
	  


































results	  in	  a	  hypoxic	  environment.	  This	  hypoxia	  inhibits	  the	  synthesis	  of	  endogenous	  nitric	  
oxide.	  The	  higher	  the	  fluence	  rate,	  the	  faster	  all	  oxygen	  is	  depleted	  and	  the	  faster	  hypoxia	  
sets	   in.	   Fukumura	   et	   al.	   [10]	   investigated	   the	   effect	   of	   nitric	   oxide	   inhibition	   on	   tumor	  
microvasculature	   and	   found	   a	   decrease	   in	   RBC	   velocity	   on	   the	   venular	   side	   of	   the	  
microvasculature,	  accompanied	  with	  a	  decrease	  of	  vessel	  diameter	  on	  the	  arteriolar	  side.	  
Both	  effects	  result	  in	  a	  significant	  decrease	  in	  blood	  flow	  and	  therefore	  reoxygenation	  of	  
the	   tissue.	   The	   fact	   that	   we	   also	   observed	   vascular	   shutdown	   in	   the	   low	   fluence	   rate	  
group	   (group	   B)	   suggests	   that	   PDT	   efficiently	   inhibited	   the	   production	   of	   nitric	   oxide	  
species	   by	   endothelial	   cells.	   This	   impairment	   leads	   to	   a	   reduction	   of	   vessel	   relaxation	  
properties	  [25].	  Furthermore	  inhibition	  of	  NO	  formation	  seems	  to	  play	  an	  important	  role	  
in	   various	   immunological	   responses	   [26,	   27],	   but	   since	   these	   responses	   do	   not	   evoke	  
direct	  vascular	  changes,	  discussion	  is	  beyond	  the	  scope	  of	  this	  study.	  
	  
COMPARISON	  WITH	  OTHER	  WORK	  
A	  number	  of	  previous	  studies	  have	  investigated	  vascular	  changes	  during	  ALA-­‐PDT.	  For	  the	  
most	  part	  these	  have	  been	  based	  on	  techniques	  that	  monitor	  changes	  in	  blood	  flow,	  RBC	  
velocity	  or	   tissue	  oxygenation	   in	   relatively	   large	  measurement	   volumes	  on	   the	  order	  of	  
millimeters:	   in	   diffuse	   correlation	   spectroscopy	   the	   measurement	   volume	   is	  
approximately	   1	  mm	   [16]	   and	   in	   laser	   Doppler	   flowmetry	   the	  measurement	   volume	   is	  
significantly	  greater	  than	  1	  mm	  [13].	  In	  the	  present	  study	  we	  have	  measured	  RBC	  velocity	  
in	  a	  single	  vessel	  with	  a	  diameter	  of	  less	  than	  150	  µm.	  This	  complicates	  direct	  comparison	  
between	  studies,	  since	  the	  in	  a	  larger	  measurement	  volume,	  effects	  we	  observe	  might	  be	  
counteracted	  by	  other	  vessels.	  Furthermore,	  measuring	  larger	  volumes,	  as	  is	  the	  case	  for	  
methods	  based	  on	  diffuse	  optical	  techniques,	  can	  be	  misleading	  because	  a	  local	  (vascular)	  
PDT	  effect	  might	  be	  overshadowed	  by	  the	  response	  of	  surrounding	  tissue	  to	  PDT.	  In	  cases	  
where	   we	   observe	   a	   decrease	   in	   RBC	   velocity,	   this	   is	   usually	   followed	   by	   complete	  
constriction	  of	  the	  vessel,	  resulting	  in	  a	  RBC	  velocity	  of	  zero.	  Becker	  et	  al.	  [16]	  showed	  a	  
rapid	   drop	   in	   relative	   blood	   flow	   within	   1-­‐4	   J	   after	   starting	   PDT	   illumination	   with	   a	  
maximum	   of	   approximately	   50%	   reduction	   (topically	   applied	   ALA,	   illuminated	  with	   635	  
nm	  laser	  light,	  [75	  35	  10]	  mW	  cm-­‐2	  with	  a	  total	  light	  dose	  of	  [80	  80	  37.5]	  J	  cm-­‐2),	  followed	  
by	  a	  recovery	  and	  overshoot	  of	  the	  relative	  blood	  flow.	  Both	  time	  and	  magnitude	  of	  the	  
increase	   and	   decrease	   are	   fluence	   rate	   dependent;	   high	   fluence	   rate	   results	   in	   large	  
decrease	  after	  ~4	  J,	  followed	  by	  a	  moderate	  increase,	  while	  a	  low	  fluence	  rate	  results	  in	  
small	  decrease	  at	  ~1	  J,	  followed	  by	  a	  large	  overshoot	  of	  the	  blood	  flow.	  The	  time	  span	  of	  
flow	  decrease	  of	  the	  two	  highest	  fluence	  rate	  is	  in	  the	  order	  of	  our	  total	  illumination	  time	  
and	   a	   possible	   explanation	   that	   we	   do	   not	   see	   a	   successive	   increase	   in	   RBC	   velocity.	  








illumination	   does	   not	   reconcile	  with	   the	   blood	   flow	   increase	   observed	   by	   Becker	   et	   al.	  
[16].	  Furthermore,	  we	  are	  focusing	  on	  a	  single	  vessel,	  while	  it	  might	  be	  hypothesized	  that	  
by	  constriction	  of	  certain	  arterioles	  the	  flow	  velocity	   in	  neighboring	  vessels	   increases.	   In	  
our	  experiment,	   velocity	   increase	   is	  not	  observed	  during	  or	  after	  deposition	  of	   the	  PDT	  
dose	  in	  any	  of	  the	  vessels	  under	  investigation.	  Schacht	  et	  al.	  [17]	  used	  an	  incoherent	  light	  
source	   (580-­‐740	   nm,	   100	   mW	   cm-­‐2),	   measured	   centerline	   (maximum)	   RBC	   velocity	   in	  
vessels	  and	  found	  almost	  complete	  reduction	  of	  RBC	  velocity	  and	  vessel	  density	  0.5	  hours	  
after	   high	   fluence	   (100	   J	   cm-­‐2)	   ALA-­‐PDT,	   accompanied	  with	   a	   strong	   decrease	   in	   vessel	  
density.	  However,	   after	   low	   fluence	   (10	   J	   cm-­‐2)	  PDT,	   comparable	   to	  our	  experiment,	  no	  
significant	  changes	  were	  observed.	  Our	  measured	  initial	  mean	  RBC	  velocities	  show	  a	  large	  
variation.	  Considering	  that	  for	  vessels	  <90	  µm	  the	  ratio	  between	  centerline	  RBC	  velocity	  
and	  mean	  RBC	  velocity	  approximately	  1.6	  [28],	  our	  data	  is	  comparable	  with	  RBC	  velocities	  
reported	  by	  Schacht	  et	  al.	  [17].	  Leveckis	  et	  al.	  [29]	  showed	  a	  decrease	  in	  vessel	  diameter	  
of	  the	  cremaster	  muscle	  microcirculation	  within	  the	  first	  20	  minutes	  after	  [178	  300]	  mW	  
cm-­‐2,	   violet	   light,	  100	   J	   cm-­‐2	  ALA-­‐PDT,	  but	  no	   reaction	   for	   the	  105	  mW	  cm-­‐2	  group.	  This	  
vascular	  response	  was	  much	  stronger	  on	  the	  arteriolar	  side	  than	  for	  the	  venular	  side,	  and	  
recovery	  for	  the	  arteriolar	  side	  was	  faster.	  Herman	  et	  al.	  [13]	  did	  not	  find	  any	  significant	  
effects	   of	   ALA-­‐PDT	   on	   blood	   flow	   of	   colon-­‐26	   tumors	   implanted	   in	  mice	   (633	   nm	   laser	  
light,	  200	  mW	  cm-­‐2,	  [50	  100	  150]	  J	  cm-­‐2).	  	  
Wang	  et	  al.	  [30]	  concluded	  that	  ALA-­‐PDT	  causes	  a	  reduction	  in	  blood	  flow,	  based	  
on	  comparison	  of	  PpIX	  fluorescence	  measured	  in	  patients	  and	  the	  results	  of	  mathematical	  
simulations	  of	  PDT.	  They	   found	   that	   for	   fluence	   rates	  of	  both	  20	  and	  150	  mW	  cm-­‐2	   the	  
simulations	  needed	  a	  stepwise	  decrease	  of	  blood	  flow	  velocity	  to	  correspond	  with	  patient	  
measurements.	   It	   remains	   difficult	   to	   discriminate	   between	   local	   and	   regional	   vascular	  
effects	   during	   PDT,	   since	   the	   interrogation	   volume	   is	   dependent	   on	   measurement	  
techniques	   and	   considering	   that	   various	   mechanisms	   can	   induce	   vascular	   effects	   (e.g.	  
direct	  vascular	  damage,	  response	  to	  inflammation	  or	  hypoxia).	  Our	  localized	  data	  may	  aid	  
the	   modeling	   of	   local	   effects	   and	   their	   impact	   on	   the	   generation	   of	   reactive	   oxygen	  
species,	  and	  therefore	  PDT	  efficacy.	  
	  
COMPARISON	  WITH	  OUR	  PREVIOUS	  WORK	  
We	  have	  previously	  shown	  acute	  vascular	  effects	  after	   low	  dose	  ALA-­‐PDT,	  and	  observed	  
that	  an	  inhomogeneous	  distribution	  of	  PpIX	  may	  influence	  the	  variation	  in	  response	  of	  the	  
local	  vasculature	   [8].	  Even	  though	  ALA	   is	   topically	  applied	  to	  the	  skin,	   it	  penetrates	   into	  
the	  dermis	   including	   the	  endothelial	   cells	   lining	   the	  microvasculature.	  These	  endothelial	  
cells	  synthesize	  PpIX	  and	  are	  therefore	  prone	  to	  direct	  PDT	  damage,	  which	  then	  leads	  to	  










hypoxia	  and/or	   inflammatory	   responses	   involving	  nitric	  oxide.	   In	   the	  present	  study	  PpIX	  
fluorescence	   intensities	   in	   the	   vascular	   endothelial	   cells	   showed	   a	   larger	   spread	   than	  
previously	   found,	   while	   changes	   in	   vessel	   diameter	   were	   only	   loosely	   related	   to	   PpIX	  
fluorescence	   in	   vessel	   wall	   or	   vasculature.	   We	   combined	   local	   information	   on	   vessel	  
diameter	  and	  RBC	  velocity.	  The	   increase	   in	  vessel	  diameter	  measured	   immediately	  after	  
illumination	   for	   the	   control	   group	   D	   of	   this	   study	   is	   observed	   previously	   [8].	   On	   closer	  
inspection	  our	  data	  showed	  a	  decrease	  in	  vessel	  diameter	  during	  the	  illumination,	  while	  
the	  vessel	  dilated	  rapidly	  directly	  after	  the	  illumination	  ends.	  Small	  temperature	  changes	  
during	   the	   control	   illumination	  may	   explain	   the	   cause	   of	   this	   vessel	   constriction,	  which	  
was	   compensated	   for	   immediately	   after	   the	   end	   of	   the	   illumination.	   Before	   complete	  
vessel	   constriction	   was	   observed,	   RBC	   velocity	   decreased	   over	   a	   time-­‐span	   of	   30-­‐75	  
seconds,	  while	  no	   significant	   velocity	   changes	  were	  observed	  when	   the	  vessel	  was	  only	  
partially	   constricted.	   This	   suggests	   that	   complete	   constriction	   of	   the	   vessel	   is	   not	  
instantaneous	   over	   the	   whole	   vessel	   length,	   causing	   changes	   in	   RBC	   velocity	   up-­‐	   or	  
downstream	   from	   the	   already	   constricted	   region.	   In	   all	   but	   one	   case,	   complete	  
vasoconstriction	  remained	   for	  at	   least	  2	  hours	  after	   illumination.	   In	   the	  one	  case	  where	  
the	  vessel	  dilated	  again,	  only	  particular	  segments	  of	  the	  vessel	  were	  visible	  in	  the	  window	  
chamber.	  It	   is	  not	  surprising	  that	  RBCs	  were	  not	  flowing	  in	  these	  segments.	  Future	  work	  
will	  be	  dedicated	   to	  analyze	   these	   local	   vascular	   changes	  during	   illumination	   in	  a	   larger	  
field	  of	  view.	  	  
	  
LIMITATIONS	  -­‐	  LOCALIZED	  MEASUREMENT	  
It	   is	   important	   to	  note	   that	   in	   the	  present	   study	  we	  mainly	   focused	  on	   the	   response	  of	  
arterioles.	   This	   is	   because	   previous	   studies	   showed	   that	   these	   vessels	   show	   the	   largest	  
variations	  in	  vessel	  diameter	  in	  response	  to	  PDT.	  The	  choice	  of	  which	  individual	  vessel	  to	  
investigate	   is	   nevertheless	   an	   important	   consideration.	   There	   is	   no	   guarantee	   that	  
vascular	  effects	  will	  occur	  at	  the	  chosen	  location.	  One	  should	  therefore	  keep	  in	  mind	  that	  
the	  present	  study	  showed	  dynamic	  variation	  during	  PDT	  in	  a	  rather	  specific	  region	  of	  the	  
vasculature.	  Information	  on	  vessel	  diameter	  up-­‐	  and	  downstream	  of	  our	  field	  of	  view,	  was	  
collected	  using	  low	  magnification	  images	  of	  the	  whole	  window	  chamber	  acquired	  before	  
and	  after	  PDT.	  
	  
LIMITATIONS	  -­‐	  EXACT	  CALCULATION	  OF	  VESSEL	  DIAMETER	  
For	  every	  time	  point,	   the	  diameter	  was	  determined	  as	  the	  average	  diameter	  of	  all	  1000	  
scans	  performed	  per	   time	  point.	  To	  discriminate	  between	  vessel	  and	  background	   in	   the	  
transmission	  image,	  we	  used	  a	  threshold	  value	  determined	  using	  Otsu’s	  method	  [21].	  This	  








We	  are	  aware	  that	  the	  result	  of	  using	  an	  automated	  threshold	  method	  depends	  heavily	  
on	  the	  image	  quality.	  Therefore,	  we	  drew	  the	  automatically	  determined	  vessel	  borders	  in	  
the	  transmission	  image.	   In	  situations	  where	  calculated	  vessel	  border	  did	  not	  correspond	  
with	   what	   we	   expected	   based	   on	   visual	   examination,	   the	   threshold	   was	   adjusted	  
manually.	   Evaluating	   the	   changes	   in	   diameter	   over	   time	   for	   all	   cases	   did	   not	   show	  
deviating	  patterns	  based	  on	  manual	  or	  automatic	  thresholding.	  	  	  
	  
LIMITATIONS	  -­‐	  REPORTING	  ON	  THE	  RBC	  VELOCITY	  
The	  RBC	  velocity	  over	   the	  diameter	  of	   the	   vessel	   is	   expected	   to	   show	  a	   velocity	  profile	  
dependent	  on	  vessel	  diameter.	  RBCs	  close	   to	   the	  vessel	  wall	  are	  slowed	  down	  by	  sheer	  
stress,	  while	  the	  velocity	  is	  expected	  to	  be	  highest	  in	  the	  centerline	  of	  the	  vessel.	  For	  our	  
calculations,	  we	   averaged	   all	   RBCs	   in	   focus.	   RBC	   velocity	   values	   in	   this	   study	   therefore	  
represented	   real	   average	   values.	   This	   complicates	   comparison	   to	   average	   centerline	  
values,	  often	  used	  in	  literature.	  
	  
CONCLUSION	  
In	   conclusion,	  we	   have	   shown	   that	   during	   PDT	   illumination	   acute	   local	   vascular	   effects	  
occurred	   very	   soon	   after	   the	   start	   of	   the	   therapeutic	   illumination	   in	   ALA-­‐PDT.	   We	  
observed	   coincident	   changes	   in	   both	   vessel	   diameter	   and	  RBC	   velocity.	   Arterioles	  were	  
particularly	  sensitive	  to	  vasoconstriction	  during	  low	  dose	  PDT,	  often	  resulting	  in	  complete	  
vasoconstriction.	   Since	   the	   therapeutic	   effects	   of	   PDT	   are	   dependent	   on	   a	   fine	   balance	  
between	  the	  need	   for	  oxygen	  during	   illumination	  and	  disruption	  of	   the	  vasculature,	   the	  
results	   of	   the	   present	   study	   add	   to	   our	   understanding	   of	   acute	   vascular	   effects	   during	  
ALA-­‐PDT	  and	  aid	  our	  efforts	  to	  optimize	  PDT	  using	  porphyrin	  pre-­‐cursors.	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Multi	   diameter	   single	   fiber	   reflectance	   (MDSFR)	   spectroscopy	   is	   a	   non-­‐invasive	   optical	  
technique	   based	   on	   using	  multiple	   fibers	   of	   different	   diameters	   to	   determine	   both	   the	  
reduced	   scattering	   coefficient	   (µs’)	   and	   a	   parameter	   γ	   that	   is	   related	   to	   the	   angular	  
distribution	   of	   scattering,	   where	   γ	   =	   (1-­‐g2)/(1-­‐g1)	   and	   g1	   and	   g2	   the	   first	   and	   second	  
moment	   of	   the	   phase	   function,	   respectively.	   Here	   we	   present	   the	   first	   in-­‐vivo	   MDSFR	  
measurements	  of	  µs’(λ)	  and	  γ(λ)	  and	  their	  wavelength	  dependence.	  MDSFR	  is	  performed	  
on	   nineteen	   mice	   in	   four	   tissue	   types	   including	   skin,	   liver,	   normal	   tongue	   and	   in	   an	  
orthotopic	   oral	   squamous	   cell	   carcinoma.	   The	   wavelength-­‐dependent	   slope	   of	   µs’(λ)	  
(scattering	  power)	  is	  significantly	  higher	  for	  tongue	  and	  skin	  than	  for	  oral	  cancer	  and	  liver.	  
The	   reduced	   scattering	   coefficient	   at	   800	   nm	   of	   oral	   cancer	   is	   significantly	   higher	   than	  
that	  of	  normal	  tongue	  and	  liver.	  Gamma	  generally	  increases	  with	  increasing	  wavelength;	  
for	  tumor	  it	  increases	  monotonically	  with	  wavelength,	  while	  for	  skin,	  liver	  and	  tongue	  γ(λ)	  
reaches	   a	   plateau	   or	   even	   decreases	   for	   longer	   wavelengths.	   The	   mean	   γ(λ)	   in	   the	  
wavelength	   range	   400-­‐850	   nm	   is	   highest	   for	   liver	   (1.87±0.07	   )	   and	   lowest	   for	   skin	  
(1.37±0.14).	   Gamma	   of	   tumor	   and	   normal	   tongue	   falls	   in	   between	   these	   values	  where	  
tumor	   exhibits	   a	   higher	   average	   γ(λ)	   (1.72±0.09)	   than	   normal	   tongue	   (1.58±0.07).	   This	  
study	  shows	  the	  potential	  of	  using	   light	  scattering	  spectroscopy	  to	  optically	  characterize	  












Reflectance	  spectroscopy	   is	   frequently	  used	   to	  determine	   the	  absorption	  and	  scattering	  
coefficients	   of	   biological	   tissue.	   A	   range	   of	   fiber	   optic	   devices	   with	   different	   probe	  
geometries	   have	   been	   developed	   to	   retrieve	   these	   optical	   properties,	   within	   various	  
regimes	  of	  tissue-­‐light	  propagation	  [1-­‐3].	  The	  absorption	  coefficient	  of	  tissue	  is	  related	  to	  
physiological	   parameters	   such	   as	   micro-­‐vascular	   blood	   oxygenation,	   blood	   volume	  
fraction	  and	  micro	  vessel	  diameter,	  as	  well	  as	  to	  the	  concentration	  of	  chromophores	  such	  
as	   bilirubin	   and	   cytochrome	   C.	   Scattering	   in	   tissue	   results	   from	   variations	   in	   refractive	  
index	  between	  the	  various	  cell	  and	  tissue	  components	  and	  their	  surroundings.	  	  
At	  large	  source-­‐detector	  separations,	  light	  transport	  can	  be	  considered	  diffuse	  and	  
is	  therefore	  only	  dependent	  on	  the	  absorption	  coefficient	  (µa)	  and	  the	  reduced	  scattering	  
coefficient	   (µs’),	   given	   by	   ( )1, 1 gss −= µµ 	  where	   ( )θcos1 =g 	  is	   the	   first	   moment	   of	   the	  
scattering	   phase	   function	   (PF),	   also	   called	   the	   scattering	   anisotropy.	   At	   these	   large	  
distances,	   light	   transport	   is	   insensitive	   to	   the	  exact	  shape	  of	   the	  PF.	  However,	   in	  device	  
configurations	   with	   small	   source-­‐detector	   separations,	   an	   additional,	   PF	   dependent	  
variable	   γ	   is	   necessary	   to	   describe	   the	   effect	   of	   large	   angle	   scattering	   events	   on	   the	  




	   	  	  	  	  	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (4.1)	  
where	  g2	  is	  the	  second	  Legendre	  moment	  of	  the	  PF	  [5].	  	  
	  
Our	   group	   has	   previously	   developed	   single	   fiber	   reflectance	   spectroscopy	   (SFR),	   where	  
one	  fiber	  serves	  as	  both	  source	  and	  detector.	  One	  advantage	  of	  this	  geometry	  is	  that	  SFR	  
is	  sensitive	  to	  superficial	  tissues	  and	  their	  microvasculature,	  which	  are	  susceptible	  to	  early	  
changes	  in	  morphology	  caused	  by	  (pre-­‐)malignant	  disease.	  Furthermore,	  the	  diameter	  of	  
a	  single	  fiber	  probe	  is	  such	  that	  it	  can	  be	  easily	  guided	  through	  the	  working	  channel	  of	  an	  
endoscope	   to	   sample	   internal	   organs.	   The	   analysis	   of	   SFR	   spectra	   is	   performed	   using	   a	  
semi-­‐empirical	   model	   (cf.	   equation	   4.2)	   that	   describes	   the	   PF-­‐dependent	   relationship	  
between	   SFR	   signal	   and	   the	   dimensionless	   reduced	   scattering	   (which	   is	   defined	   as	   the	  
product	  of	  the	  reduced	  scattering	  coefficient	  and	  the	  fiber	  diameter	  µs’df)	  [6].	  This	  semi-­‐
empirical	  model	  was	  based	  on	  Monte-­‐Carlo	  simulations	  and	  validated	  in	  tissue	  mimicking	  
phantoms	  [8,	  9].	  SFR	  spectroscopy	  allows	  us	  to	  determine	  tissue	  absorption	  without	  prior	  
knowledge	  of	   the	   scattering	  coefficient	   [10].	  Recently,	   SFR	  has	  been	  extended	   to	  multi-­‐
diameter	  single	  fiber	  reflectance	  spectroscopy	  (MDSFR),	  in	  which	  two	  fiber	  diameters	  can	  
be	  used	  to	  determine	  the	  µs’	  and	  γ	  [7,	  11,	  12].	  An	  MDSFR	  measurement	  consists	  of	  several	  









individually	   corrected	   for	   absorption	   [10],	   resulting	   in	   the	   reflectance	   in	   the	  absence	  of	  
absorption, 0SFR ,	   for	   every	   SFR	  measurement.	   The	   co-­‐localized,	  multi-­‐fiber	   diameter	  
0
SFR
values	  are	  then	  simultaneously	  fitted	  to	  the	  model	  described	  in	  equation	  4.2,	  
( ) ( ) ( )( )


































ηλ λµ 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  (4.2)	  
where	  ηlim	  is	  the	  diffuse	  limit	  of	  the	  single	  fiber	  collection	  efficiency	  and	  [p1 p2 p3]	  are	  γ(λ)-­‐
dependent	   coefficients,	   the	   values	   of	  which	   are	   derived	   from	  Monte	   Carlo	   simulations.	  
The	  spectral	  shape	  of	  µs’(λ)	   is	  constrained	  according	  to	  a	  biologically	  realistic	  power	  law	  
decay.	  Solving	  the	  equation	  with	  two	  unknown	  variables	  for	  two	  different	  fiber	  diameters	  
allows	  wavelength	  dependent	  quantification	  of	  both	  µs’	  and	  γ.	  The	  MDSFR	  approach	  has	  
been	   validated	   both	   in-­‐silico	   and	   in	   optical	   phantoms	   containing	   polystyrene	  
microspheres	  over	   a	  wide	   range	  of	   biologically	   relevant	   values	   for	  µs’(λ)	   and	   γ(λ),	  with	  
and	  without	  the	  presence	  of	  absorbers	  [7,	  12].	  
	  
In	   the	   current	   study	   we	   present,	   for	   the	   first	   time,	   differences	   in	   the	   wavelength	  
dependence	   of	   µs’	   and	   γ	   in-­‐vivo,	   measured	   using	   MDSFR.	   We	   have	   acquired	   MDSFR	  
spectra	   in-­‐vivo	   from	   tumor,	   normal	   tongue	   tissue,	   skin	   and	   liver	   in	   an	   orthotopic	  
xenograft	   model	   for	   oral	   cancer	   in	   mice	   using	   consecutive	   SFR	   measurements	   of	   two	  
different	  fiber	  diameters	  (0.4	  and	  0.8	  mm).	  	  
MATERIALS	  AND	  METHODS	  
MDSFR	  REFLECTANCE	  MODEL	  
First,	   the	   Beer-­‐Lambert	   law	   is	   used	   to	   correct	   the	  measured	   SFR	   intensities	   SFR (df)	   for	  
absorption	  to	  obtain	   0SFR (df)	  :	  
( ) LfSFfSF TissadRdR ,e)( 0 µ−= 	  	   	   	   	   	  	  	  	  	  	  	  	   	   	  	  	  	  	  	  	  	  (4.3)	  
where	   0SFR (df)	   is	  given	  by	  equation	  4.2,	  µa, Tiss	   is	   the	  absorption	  coefficient	  of	   tissue	  and	  






, λ( )d f( )
0.18 0.64+µad f( )
0.64 .	   	   	   	  	  	  	  	  	  	  	  	  	  	  	   	   	  	  	  	  	  	  	  	  (4.4)	  
The	  absorption	   coefficient	  of	   tissue	   is	   expressed	  as	   the	   sum	  of	   the	  absorption	  of	  blood	  
µa,blood	  and	  the	  absorption	  of	  bilirubin	   µabil :	  	  











The	  absorption	  coefficient	  of	  blood	  can	  be	  described	  as	  the	  product	  of	  the	  specific	  blood	  
absorption	  coefficients	  and	  blood	  volume	  fraction:	  
µa,blood λ( ) =Ccor λ( ) × bvf StO2µaHbO2,spec λ( )+ 1− StO2( )µaHb,spec λ( )#$ %& 	   	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  (4.6)	  
where	   StO2	   is	   the	   blood	   oxygen	   saturation,	   bvf	   is	   blood	   volume	   fraction	   assuming	   the	  
concentration	  of	   hemoglobin	   in	  whole	  blood	   to	  be	   150	   g	   L-­‐1,	   and	  µa
HbO2,spec and	  µa
Hb,spec 	  are	  
the	  specific	  absorption	  coefficients	  of	  oxygenized	  and	  deoxygenized	  blood,	   respectively.	  
Ccor	  is	  the	  correction	  factor	  that	  accounts	  for	  flattening	  of	  spectral	  features	  resulting	  from	  
the	   inhomogeneous	   distribution	   of	   blood	   in	   tissue	   and	   the	   confinement	   of	   blood	   in	  
vessels	  [13,	  14].	  For	  whole	  blood,	  the	  correction	  factor	  is	  given	  by:	  
Ccor = 1− exp µa,blood λ( )Dv"# $%{ } / µa,blood λ( )Dv"# $% 	   	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	   	   	  	  	  	  	  	  	  	  (4.7)	  
and	   is	   related	   to	   the	   average	   vessel	   diameter	  Dv.	   The	   total	   tissue	   absorption	   µa,tiss	   can	  
then	   be	   described	   as	   the	   absorption	   of	   blood	   µa,blood,	   dependend	   on	   blood	   volume	  
fraction,	  and	  the	  absorption	  of	  bilirubin,	  which	   is	   the	  product	  of	   the	  specific	  absorption	  
coefficient	  µa
bil,spec 	  and	  the	  bilirubin	  concentration	  cbil:	  	  
µa,Tiss λ( ) = µa,blood λ( )+ cbilµabil,spec λ( ) 	   	   	  	  	  	  	  	  	  	   	   	   	  	  	  	  	  	  	  	  (4.8)	  
The	   small	   but	   distinct	   gfp	   fluorescence	   emission	   peak	   present	   in	   the	   white	   light	  
reflectance	   spectra	   of	   tumor	  was	   accounted	   for	   using	   a	   fit	   component	  EmGFP(λ)	   to	   be	  
included	  in	  the	  reflectance	  model:	  	  
( ) ( )λµ GFPGFPLfSFfSF EmcdRdR Tissa += − ,e)( 0 	  	  	  	   	  	  	  	  	  	  	  	  	  	   	   	   	  	  	  	  	  	  	  	  (4.9)	  
This	  EmGFP	  basis	  spectrum	  was	  previously	  acquired	  by	  fluorescence	  measurements	  of	  the	  
tongue	  tumors,	  corrected	  for	  optical	  properties	  and	  system	  transmission.	  We	  attempted	  
to	  include	  the	  absorption	  of	  gfp	  (determined	  from	  in-­‐vitro	  cells)	  in	  the	  SFR	  analysis	  in	  the	  
same	   way	   bilirubin	   is	   treated	   in	   equation	   4.8.	   This	   did	   not	   result	   in	   a	   significant	  
improvement	  of	  the	  fit,	  and	  gfp	  absorption	  was	  therefore	  omitted	  form	  the	  fit	  procedure.	  
	  
The	   aim	   of	   this	   first	   step	   of	   the	   analysis	   is	   to	   remove	   the	   effects	   of	   absorption	   on	   the	  
individual	  SFR	  spectra.	  It	  was	  shown	  previously	  that	  accurate	  absorption	  coefficients	  from	  
individual	  SFR	  spectra	  can	  be	  obtained	  without	  prior	  knowledge	  of	   the	   tissue	  scattering	  
properties	  [7,	  10]	  if	  an	  optimized	  set	  [p1 p2 p3 CPF]	  is	  used,	  i.e.	  p1=1.55,	  p2=0.969,	  p3=6.82,	  
and	   CPF=0.944.	   The	   background	   scattering	   model	   used	   in	   this	   first	   step	   of	   individual	  

















































λµ aaaas 	  .	  	   	  	  	  	  	  	  	  	   	   	  	  	  	  	  (4.10)	  
This	  model	   allows	   sufficient	   degrees	   of	   freedom	   to	   correct	   for	   the	   physically	   incorrect	  
assumption	   that	   [p1 p2 p3 CPF]	   are	   independent	   of	   γ.	   This	   aspect	   of	   the	  model	   will	   be	  









the	   individual	  SFR	  spectra,	   the	  MDSFR	  analysis	   is	  performed	  by	  solving	  equation	  4.2	   for	  
multiple	   fiber	   diameters	   simultaneously.	   Here,	   the	   reduced	   scattering	   coefficient	   is	  


















λµ 	   	  	  	  	   	   	   	   	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (4.11)	  
and	   equation	   4.2	   and	   Equation	   4.4	   are	   adapted	   to	   yield	   a	   wavelength-­‐dependent	   γ	   by	  
replacing	  the	  coefficients	  [p1 p2 p3]	  with	   23221 31.257.063.0 γγγ === ppp 	  in	  equation	  4.2	  [11]	  
and	   6.068.0 γ=PFC 	  in	  equation	  4.4.	  A	  Levenberg-­‐Marquart	  non-­‐linear	  fit	  procedure	  is	  used	  
to	  estimate	   the	  variables	  µs’(λ)	   and	  γ(λ)	   from	  the	  MDSFR	  spectra	  of	   two	  different	   fiber	  
diameters	  simultaneously.	  	  
Finally,	  since	  the	  MDSFR	  analysis	  yields	  estimates	  of	  µs’(λ)	  and	  γ(λ),	  these	  values	  
can	  now	  be	  used	  in	  the	  individual	  SFR	  fits	  to	  re-­‐estimate	  the	  absorption	  coefficient.	  In	  the	  
first	  step,	  the	  absorption	  coefficient	  was	  estimated	  without	  knowledge	  of	  the	  scattering	  
properties	  by	  assuming	  fixed	  (wavelength	  independent)	  values	  for	  [p1 p2 p3 CPF]	  and	  using	  
a	  4th	  order	  polynomial	   for	  µs’(λ);	   the	  accuracy	  of	  that	  approach	   is	  now	  verified	  by	  using	  
the	  extracted	  wavelength	  dependent	  estimates	  of	  γ	  and	  using	  a	  biologically	  realistic	  shape	  
for	  µs’(λ),	  i.e.	  a	  power	  law.	  
	  
EXPERIMENTAL	  SETUP	  
The	   illustration	   in	   figure	  4.1	   represents	   a	   single	  probe-­‐unit	   of	   the	  MDSFR	   spectroscopic	  
setup.	  During	  reflectance	  measurements,	  white	  light	  emitted	  by	  a	  halogen	  light	  source	  	  
(HL-­‐2000-­‐FHSA;	   Ocean	   Optics;	  
Duiven,	   NL)	   is	   directed	   through	   the	  
first	   fiber	   of	   a	   quadfurcation	   into	   a	  
solid	   core	   fiber	   optic	   probe	   and	  
guided	   onto	   the	   tissue.	   A	   small	  
fraction	  of	  the	  light	  is	  reflected	  from	  
the	   tissue	   into	   the	  acceptance	  cone	  
of	  the	  probe	  fiber	  and	  directed	  via	  a	  
second	   fiber	   of	   the	   quadfurcation	  
into	   a	   spectrometer	   (SD-­‐2000;	  
Ocean	   Optics;	   Duiven,	   NL)	   for	  
detection	  and	  further	  analysis.	  After	  
the	  reflectance	  measurement,	  a	  low	  
power	  fluorescence	  measurement	  is	  
performed,	   using	   a	   405	   nm	   laser	  
directed	  into	  another	  fiber	  of	  the	  quadfurcation	  to	  illuminate	  the	  tissue	  through	  the	  same	  
	  
Figure	  4.1:	  Schematic	  diagram	  of	  the	  measurement	  setup.	  
Reflectance	   and	   fluorescence	   are	   measured	   through	   a	  
single	   fiber	   of	   either	   0.4	   or	   0.8	  mm.	   Two	   identical	   setups	  










probe.	   The	   emitted	   fluorescence	   is	   then	   guided	   through	   the	   last	   fiber	   of	   the	  
quadfurcation,	  which	  leads	  through	  a	  450	  nm	  long-­‐pass	  filter	  into	  a	  second	  spectrograph	  
(QE-­‐65000;	  Ocean	  Optics;	  Duiven,	  NL).	  The	  fluorescence	  measurement	  is	  incorporated	  to	  
ensure	   the	  presence	  of	   tumor	   cells,	   retro-­‐virally	   infected	  with	   gfp,	   in	   the	  measurement	  
volume.	   The	   complete	   MDSFR	   system	   consists	   of	   two	   identical	   probe-­‐units	   containing	  
fiber	   diameters	   of	   0.4	   and	  0.8	  mm.	   The	   fiber	   probes	   are	   sequentially	   placed	   in	   contact	  
with	   the	   tissue	   under	   investigation.	   	   All	   probes	   are	   polished	   under	   an	   angle	   of	   15o	   to	  
minimize	   internal	   specular	   reflections	   from	   the	   probe	   tip.	   A	   calibration	   procedure	   was	  
performed	   as	   described	   previously	   [7],	   consisting	   of	   a	  measurement	   in	  water	   in	   a	   dark	  
container	  (Iwater)	  and	  a	  measurement	  in	  a	  liquid	  phantom	  containing	  20%	  Intralipid	  diluted	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  (4.12)	  
and	   simILI 	  is	  the	  absolute	  SFR	  signal	  obtained	  through	  Monte	  Carlo	  simulations.	  
	  
ANIMAL	  MODEL	  
The	   study	   protocol	   was	   approved	   by	   the	   Animal	   Welfare	   Committee	   of	   the	   Leiden	  
University	  Medical	   Center.	   Housing	   of	   BALB/cByJ	   nu/nu	   female	   mice	   (aged	   4-­‐6	   weeks;	  
Charles	   River	   Laboratories),	   the	   experiments	   and	   euthanazation	   were	   performed	   in	  
accordance	   with	   the	   guidelines	   of	   this	   committee.	   Chlorophyll	   free	   food	   and	   sterilized	  
water	  were	  provided	  without	  restriction.	  A	  set	  of	  19	  mice	  were	  injected	  with	  OSC19	  cells	  
lenti-­‐virally	   transfected	  with	   luc	   and	   gfp	   (6x104	   cells,	   Biocat,	   Heidelberg,	  Germany)	   [15,	  
16].	   After	   an	   incubation	   period	   of	   10-­‐13	   days,	   animals	  were	   included	   in	   the	   study	   and	  
anesthetized	   with	   2-­‐3%	   Isoflurane.	   Reflectance	   spectra	   were	   acquired	   from	   tumor,	  
normal	   tongue	   tissue	   (both	   five	   measurements),	   and	   skin	   and	   liver	   (both	   three	  
measurements).	   The	   consecutive	  measurements	  were	   taken	   by	   removing	   and	   carefully	  
repositioning	   the	   fiber	   between	   measurements,	   without	   imparting	   undue	   pressure	   on	  
each	  tissue.	  For	  tumor,	  the	  fiber	  tip	  was	  positioned	  directly	  on	  top	  of	  the	  visible	  tumor.	  An	  
additional	  MDSFR	  measurement	  of	  liver	  was	  carried	  out	  immediately	  before	  animals	  were	  
sacrificed.	   After	   the	   animals	  were	   sacrificed,	   the	   tongue	  was	   harvested	   for	  microscopic	  
tissue	  analysis.	  	  
	  
DATA	  REDUCTION	  AND	  STATISTICAL	  ANALYSIS	  
To	  verify	  the	  presence	  of	  tumor	  tissue	  in	  the	  measurement	  volume	  with	  the	  probe	  on	  top	  
of	   the	   tumor,	   co-­‐localized	   fluorescence	   spectra	   are	   acquired	  with	   both	   the	   0.4	   and	   0.8	  









high,	  qualitative	  analysis	  of	  these	  spectra	  was	  sufficient	  to	  exclude	  measurements	  where	  
tumor	  tissue	  was	  not	  present	  in	  the	  measurement	  volume.	  Two	  animals	  did	  not	  develop	  a	  
visual	   tumor,	  and	   lacked	  gfp	   fluorescence	   in	  all	   five	  tumor	  measurements	   for	  both	  fiber	  
diameters.	  These	  animals	  were	  excluded	  from	  the	  analysis	  of	  optical	  properties	  of	  tumor	  
tissue.	  	  
Variation	  in	  probe	  pressure	  and	  probe	  location	  in	  consecutive	  measurements	  may	  
lead	   to	   slight	   variations	   in	   outcome,	   which	   can	   interfere	   with	   a	   proper	   analysis	   of	   the	  
averaged	  MDSFR	  data.	  Therefore,	  all	  SFR	  spectra	  with	  R(800	  nm)	  deviating	  >2σ	  from	  the	  
average	  value	  of	  R(800	  nm)	  of	   the	  consecutive	  measurements	  on	  each	  tissue	  site,	  were	  
removed	   from	   the	   analysis	   after	   the	   first	   analysis	   step.	   To	   account	   for	   remaining	  
variations	   in	   subsequent	   SFR	   measurements,	   the	   standard	   deviation	   of	   R(800	   nm)	   for	  
each	  fiber	  diameter	  was	  used	  as	  a	  weight	   factor	   in	  the	  non-­‐linear	  MDSFR	  fit	  procedure.	  
Therefore,	   SFR	   fiber	  measurements	   with	   large	   variations	   contribute	   less	   to	   the	   best-­‐fit	  
outcome.	   Statistical	   analysis	   of	   optical	   properties	   for	   various	   tissues	   is	   done	   by	   using	   a	  
paired	  Student	  T-­‐test	  with	  P<0.05	  as	  the	  level	  of	  significance.	  
RESULTS	  
After	  an	  incubation	  period	  of	  10-­‐13	  days,	  17	  
mice	   had	   a	   visible	   tumor	   at	   the	   tip	   of	   the	  
tongue.	   Figure	   4.2	   shows	   a	   representative	  
example	   of	   a	   combined	   confocal	  
fluorescence	   and	   bright-­‐field	   transmission	  
microscopy	   image	   of	   a	   frozen	   section	   cut	  
vertically	   through	   the	   center	  of	   the	   tongue.	  
In	   this	  example	   the	   fiber	   tip	  was	  positioned	  
in	  contact	  with	  the	  surface	  of	  the	  tongue	   in	  
the	   upper	   left	   region	   of	   the	   image	   where	  
tumor	   cells	   are	   close	   to	   the	   surface	   of	   the	  
tongue.	  The	  image	  shows	  a	  thin	  but	  variable	  
layer	   of	   epithelium	   overlying	   the	   gfp-­‐
fluorescent	  tumor	  at	  the	  tip	  of	  the	  tongue.	  A	  
total	   of	   588	   reflectance	   spectra	   taken	   from	  
19	  mice	  were	  analyzed	  in	  this	  study.	  	  
	  
Figure	   4.3	   shows	   representative	   reflectance	  
	  
Figure	   4.2:	   Confocal	   fluorescence	   microscopy	  
image	  of	  mouse	  tongue,	  using	  488	  nm	  excitation	  
and	   520-­‐540	   nm	   detection,	   showing	   the	  
distribution	  of	  gfp-­‐expressing	  OSC	  tumor	  in	  green	  












spectra	  of	  tumor,	  tongue,	  skin	  and	  liver	  tissue,	  together	  with	  their	  best	  fits	  and	  calculated	  
absorption-­‐corrected	  reflectance	   0SFR 	  for	  a	  0.8	  mm	  fiber	  (after	  the	  3
rd	  analysis	  step,	  based	  
on	  power-­‐law	  scattering	  and	  wavelength-­‐dependent	  γ).	  	   	  
In	  this	  example,	  the	  spectra	  taken	  on	  skin	  show	  a	  significantly	  higher	  reflectance	  
over	   the	  whole	  wavelength	   range	   compared	   to	   normal	   tongue	   and	   tumor	   tissue,	  while	  
reflectance	  for	   liver	   is	   lowest.	   0SFR spectra	  (dashed	  lines	   in	   figure	  4.3)	  of	  five	  consecutive	  
co-­‐localized	  measurements	  per	  fiber	  diameter	  are	  averaged,	  and	  these	  averaged	  spectra	  
and	  their	  standard	  deviations	  serve	  as	  input	  for	  the	  MDSFR	  analysis.	  Figure	  4.4	  shows	  the	  
average	   0SFR 	  spectra	   of	   normal	   tongue	   tissue	   in	   a	   single	  mouse,	   fitted	  with	   the	  MDSFR	  
model.	  As	  expected,	  a	  larger	  fiber	  diameter	  results	  in	  a	  higher	  reflectance.	  	  
	   	  
Figure	  4.5:	  µs’	  (a)	  and	  γ	  (b)	  for	  different	  tissues,	  measured	  in	  one	  representative	  mouse.	  
	  
	  












































	   	  
Figure	   4.3:	   Typical	   0.8	   mm	   SFR	   data.	   Plotted	   are	  
the	   measured	   RSF	   (black	   dots),	   individual	   SFR	   fits	  
(solid	   lines)	   and	   calculated (dashed	   lines)	   for	  
normal	  tongue,	  tumor,	  skin	  and	  liver	  tissue.	  
	  
Figure	  4.4:	  Averaged	  SFR	  spectra	  of	  normal	  tongue	  
tissue;	  fiber	  diameters	  are	  0.4	  and	  0.8	  mm.	  
	  






















































Figure	   4.5a	   and	   b	   show	   µs’(λ)	   and	   γ (λ)	  
resulting	   from	   MDSFR	   fits	   on	   different	  
tissues	   for	   a	   representative	   mouse.	   For	   all	  
locations,	   μs’	   decreases	   with	   increasing	  
wavelength	   [17].	   It	   is	  helpful	   to	  describe	  µs’	  
in	   terms	   of	   two	   parameters,	   the	   reduced	  
scattering	  coefficient	  at	  800	  nm	  µs’(800nm),	  
and	   its	   wavelength	   dependent	   slope,	   which	  
is	   often	   termed	   the	   scattering	   power	   (resp.	  
a1	  and	  a2	  in	  equation	  4.11).	   	  
	  
It	  has	  been	  shown	  that	  the	  scattering	  power	  
is	   related	   to	   the	   refractive	   index	   correlation	   function	   of	   the	   measured	   tissue,	   and	  
therefore	  has	  a	  direct	  relation	  with	  tissue	  structure	  [18-­‐20].	   In	  general	  we	  can	  conclude	  
from	  all	  measurements	  that	  skin	   is	  most	  easily	  distinguishable	  from	  the	  other	  tissues	  by	  
having	   a	   higher	   value	   for	   the	   scattering	   power.	   The	   differences	   between	   tumor	   and	  
normal	  tongue	  tissue	  are	  more	  subtle,	  but	  tumor	  tends	  to	  have	  a	  lower	  scattering	  power	  
than	  normal	  tongue	  tissue.	  Liver	  also	  shows	  a	  very	  low	  scattering	  power.	  The	  wavelength	  
dependence	  of	  γ	  (figure	  4.5b)	  shows	  an	  increase	  with	  wavelength	  for	  the	  low	  wavelength	  
region,	   for	  all	   tissue	   types.	   For	  higher	  wavelengths,	  γ	   either	  plateaus	  or	  decreases	  after	  
reaching	   a	   maximum,	   except	   for	   tumor	   tissue,	   for	   which	   γ	   continues	   to	   increase	   with	  
wavelength.	  
	  
In	  figure	  4.6,	  we	  show	  the	  average	  γ(λ)	   for	  the	  four	  different	  tissue	  types,	  based	  on	  the	  
measurements	  on	  all	   19	  mice.	   Figure	  4.7a-­‐c	   show	   the	  median	  and	  quartiles	  of	  µs’(800),	  
the	  scattering	  power,	  and	  γ	  averaged	  over	  the	  400-­‐850	  nm	  wavelength	  range,	  for	  normal	  
tongue,	  tumor	  tissue,	  skin	  and	  liver.	  	  
Both	  figure	  4.6	  and	  figure	  4.7c	  clearly	  show	  that	  γ	  is	  lowest	  for	  skin	  and	  highest	  for	  
liver.	  Furthermore,	  γ	   for	  tumor	  increases	  monotonically	  with	  increasing	  wavelength,	  and	  
increases	  more	  over	  the	  measured	  wavelength	  range	  than	  for	  normal	  tissue,	  although	  this	  
difference	   is	   not	   significant.	   Table	   4.1	   summarizes	   the	   average	   values	   for	   scattering	  
power,	  µs’(800)	  and	  average	  γ	  for	  the	  four	  tissue	  types.	  
	  
	  
Figure	   4.6:	   Gamma	   per	   tissue,	   averaged	   over	  
n=19.	  




























From	   figure	  4.7a	  and	   table	  4.1,	   it	   can	  be	   seen	   that	   the	   scattering	  powers	  of	   tumor	  and	  
liver	  are	  significantly	   lower	   than	   for	  normal	   tongue	  and	  skin	   (Paired	   t-­‐test,	  P<0.05).	  The	  
µs’(800nm)	  for	  tumor	  is	  significantly	  higher	  than	  for	  normal	  tongue	  and	  liver.	  The	  average	  	  
value	  for	  γ	  of	  skin	  differs	  significantly	  from	  all	  other	  tissues.	  	  	  
	  
An	  interesting	  observation	  is	  that	  although	  the	  reflectance	  is	  highest	  for	  skin,	  the	  µs’(λ)	  is	  
not.	   This	   suggests	   that	   the	   angular	   distribution	   of	   scattering	   represented	   by	   γ(λ)	   can	  
strongly	  influence	  the	  observed	  reflectance.	  The	  low	  γ(λ)	  for	  skin	  indicates	  that	  scattering	  
is	   more	   directed	   backwards	   for	   skin	   than	   for	   other	   tissues,	   resulting	   in	   a	   higher	   total	  
reflectance.	  For	  liver	  the	  opposite	  occurs;	  the	  low	  reflectance	  in	  this	  tissue	  is	  not	  a	  result	  
of	   a	   low	   µs’(λ),	   but	   the	   high	   γ(λ)	   which	   indicates	   that	   most	   of	   the	   scattered	   light	   is	  
directed	  forward.	  	  
DISCUSSION	  
In	   this	   paper	   we	   have	   presented	   the	   first	   in-­‐vivo	   measurements	   of	   µs’(λ)	   and	   γ(λ)	  
obtained	   using	   multi-­‐diameter	   single	   fiber	   reflectance	   spectroscopy.	   We	   determined	  
µs’(λ)	   and	   γ(λ)	   	   for	   four	   different	   types	   of	   mouse	   tissue,	   including	   skin,	   liver,	   normal	  
tongue	  and	  oral	  squamous	  cell	  carcinoma.	  Measurements	  of	  µs’(λ)	  and	  γ(λ)	  show	  distinct	  
differences	  between	  tissue	  types.	  	  
	  
	   	   	  
Figure	   4.7:	   Average	   scattering	   power	   (a),	   µs’	   (800nm)	   (b)	   and	   Gamma	   (c)	   of	   19	   mice,	   for	   four	   different	  
tissues.	  
Table	  4.1:	  Scattering	  power,	  µs’(800nm)	  and	  average	  γ	  for	  four	  different	  tissues	  
	   Scattering	  power	   µs’	  (800nm)	  [mm-­‐1]	   γ 
Normal	  tongue	   0.63±0.35	   0.64±0.25	   1.58±0.07	  
OSC	  tumor	   0.13±0.16	   0.90±0.29	   1.72±0.09	  
Skin	   0.86±0.49	   0.81±0.37	   1.37±0.14	  





























































COMPARISON	  TO	  PREVIOUS	  STUDIES:	  µS’(λ)	  
A	   number	   of	   previous	   studies	   have	   performed	  measurements	   to	   determine	   the	   optical	  
(scattering)	   properties	   of	   tissues	   in	   ex-­‐vivo	   and	   in-­‐vivo	   tissue	   samples.	   The	   often	  
significant	   limitations	  of	  measuring	   tissue	  optical	   properties	   in	   ex-­‐vivo	   samples	   are	  well	  
recognized	   [21].	   The	  measurement	   of	   tissue	  optical	   properties	   in-­‐vivo	   has	   for	   the	  most	  
part	  been	  based	  on	   the	  use	  of	  diffuse	   reflectance	   spectroscopy	  or	   the	  measurement	  of	  
interstitial	  fluence	  rate	  and	  angularly	  resolved	  radiance	  [21].	  A	  range	  of	  tissue	  types	  have	  
been	   investigated,	   in	   general	   for	  wavelengths	   above	   630	  nm.	   In	   the	  wavelength	   region	  
between	  630	  and	  850	  nm	  the	  reduced	  scattering	  coefficient	  typically	  ranges	  from	  0.4-­‐1.31	  
mm-­‐1,	  with	  tissues	  such	  as	  brain	  and	  stomach	  yielding	  higher	  values.	  These	  values	  are	  well	  
within	  the	  range	  of	  those	  found	  in	  the	  present	  study.	  Thus	  far,	  the	  only	  data	  reported	  for	  
shorter	   wavelengths	   is	   in	   the	   stomach	   [22]	   where	   the	   absolute	   value	   of	   µs’	   is	   slightly	  
higher	  than	  the	  range	  we	  obtained	  for	  our	   investigated	  tissues,	  but	   this	   is	   likely	   to	  be	  a	  
consequence	  of	  the	  different	  tissue	  type.	  	  
The	   scattering	   power	   is	   related	   to	   the	   shape	   of	   the	   refractive	   index	   correlation	  
function	  and	  has	  recently	  been	  suggested	  to	  be	  an	  important	  factor	   in	   identifying	  tissue	  
structure.	  Ex-­‐vivo	  data	  of	   various	  organs	  have	  been	  published	   [23,	  24].	  Yi	   and	  Backman	  
have	   reported	   for	   rat	   liver	   a	   scattering	   power	   of	   1.64±0.11,	   measured	   by	   inverse	  
spectroscopic	   optical	   coherence	   tomography	   on	   excised	   organs.	   Hall	   et	   al.	   found	   the	  
scattering	  power	  for	  fixed	  muscle	  tissue	  slices	  of	  mice	  to	  be	  1.30±0.12	  by	  measuring	  the	  
angular	  distribution	  of	  light	  scattered	  through	  the	  sample,	  and	  fitting	  these	  observations	  
to	   Monte	   Carlo	   simulations	   to	   obtain	   the	   optical	   properties	   of	   the	   sample	   under	  
investigation.	  Although	  our	   in-­‐vivo	  scattering	  powers	  are	   low	  compared	  to	  these	  values,	  
they	   are	   still	   within	   the	   range	   of	   0<a2<2,	   which	   is	   typical	   for	   tissue	   [25].	   A	   recently	  
published	   paper	   on	   in-­‐vivo	   measurements	   of	   the	   correlation	   length	   in	   colorectal	   field	  
carcinogenesis	   reported	   scattering	   powers	   of	   0.2<a2<0.5	   [26].	   This	   aligns	   well	   with	   the	  
relatively	   low	   a2	   values	   we	   have	   found	   in	   the	   present	   in-­‐vivo	   study.	   Whether	   the	  
differences	   in	   scattering	   power	   are	   related	   to	   differences	   between	   in-­‐vivo	   and	   ex-­‐vivo	  
scattering	   properties	   or	   due	   to	   differences	   in	   the	   optical	   methods	   remains	   a	   topic	   of	  
investigation.	  
	  
COMPARISON	  TO	  PREVIOUS	  STUDIES:	  γ(λ)	  
We	   observe	   marked	   differences	   when	   comparing	   our	   findings	   of	   the	   wavelength	  
dependence	  of	  γ	  to	  the	  in-­‐vivo	  data	  published	  by	  Thueler	  et	  al.	  [22].	  We	  have	  extracted	  γ	  
values	  between	  1.2	  and	  1.9	  with	  γ	  generally	  increasing	  with	  wavelength;	  γ	  varied	  between	  
1.5	   and	   1.9	   for	   tongue	   and	   tumor	   tissue,	   and	   between	   1.2	   and	   1.5	   for	   skin,	  which	   are	  










measurements	   on	   stomach	   epithelium	   with	   an	   approximately	   constant	   γ	   with	   values	  
around	  2.0,	  and	  a	  slight	  increase	  in	  the	  low	  wavelength	  region.	  Whether	  these	  differences	  
in	   γ	   are	   related	   to	   differences	   between	   tissue	   types	   or	   due	   to	   differences	   in	   the	   used	  
optical	  methods	  remains	  to	  be	  investigated.	  
It	   is	   interesting	   to	   consider	   that	   the	   spectral	   shape	   of	   γ	   can	   be	   linked	   to	   the	  
correlation	  function	  of	  the	  refractive	  index	  in	  the	  tissue	  under	  investigation.	  The	  spectral	  
shape	  of	  γ	  is	  determined	  by	  the	  first	  two	  Legendre	  moments	  of	  the	  phase	  function,	  which	  
are	   wavelength	   dependent.	   The	   phase	   function	   and	   its	   derived	  metrics	   anisotropy	   (g1)	  
and	   γ	   are,	   similar	   to	   the	   (reduced)	   scattering	   coefficient,	   related	   to	   the	   refractive	   index	  
correlation	  function	  [20,	  23].	  The	  tissue	  refractive	  index	  correlation	  function	  has	  recently	  
been	   modeled	   by	   the	   Whittle-­‐Matérn	   correlation	   function,	   which	   contains	   three	  
variables:	  the	  deterministic	  factor	  D,	  the	  length	  scale	  of	  the	  correlation	  lc,	  and	  the	  scaling	  
factor	  Nc.	  While	  the	  scattering	  power	  is	  directly	  related	  to	  the	  deterministic	  factor	  D,	  the	  
length	   scale	   of	   the	   correlation	   lc	   is	   related	   to	   both	  µs’	   and	   γ.	   In	   theory	   it	   is	   possible	   to	  
express	   γ	   and	   its	   wavelength	   dependence	   in	   terms	   of	   lc,	   and	   use	   the	   combined	  
measurements	  of	  µs’	  and	  γ	  to	  calculate	  the	  physical	  properties	  of	  the	  correlation	  function,	  
D	  and	  lc.	  However,	  this	  is	  beyond	  the	  scope	  of	  this	  paper	  and	  will	  be	  presented	  in	  future	  
work.	  
	  
STEP-­‐ANALYSIS	  OF	  FIT	  PROCEDURE	  
MDSFR	  is	  based	  on	  the	  reflectance	  in	  the	  absence	  of	  absorption.	  In	  the	  vast	  majority	  of	  in-­‐
vivo	   situations,	   where	   absorption	   is	   present,	   one	   first	   needs	   to	   determine	   the	  
contribution	   of	   absorption	   to	   the	   total	   reflectance	   intensity	   using	   the	   model	   that	   we	  
previously	   developed	   for	   individual	   SFR	  measurements.	   To	   achieve	   this,	   our	   analysis	   of	  
tissue	   absorption	   and	   scattering	   in	   an	   individual	   SFR	   measurement	   was	   based	   on	   a	  
background	  scattering	  model	  consisting	  of	  a	  polynomial	  (n=4),	  together	  with	  an	  optimized	  
set	  of	  wavelength-­‐independent	  coefficients	  representing	  γ	  [10].	  The	  choice	  of	  such	  a	  non-­‐
physical	   background	   scattering	  model	   is	   necessary	   in	   order	   to	   correct	   for	   the	   ill-­‐posed	  
assumption	   that	   γ	   is	   wavelength	   independent;	   the	   background	   scattering	  model	   needs	  
sufficient	   freedom	   in	   this	   first	   step	   to	   correct	   for	   this	   assumption.	   It	   is	   important	   to	  
emphasize	  that	  in	  the	  first	  step,	  we	  only	  need	  to	  remove	  the	  effect	  of	  absorption	  on	  the	  
individual	   SFR	   spectra	   by	   implementing	   the	   approach	   reported	   previously	   [11].	   The	  
MDSFR	  analysis	  itself	  is	  then	  performed	  with	  the	  physically	  realistic	  power-­‐law	  scattering	  
model	  (that	  follows	  from	  the	  definition	  of	  the	  Whittle-­‐Matérn	  correlation	  function),	  which	  
yields	  values	  for	  the	  reduced	  scattering	  coefficient	  (defined	  by	  the	  scattering	  power	  and	  
µs’(800nm))	  and	  γ.	  To	  verify	  that	  the	  absorption	  was	  correctly	  estimated	  in	  the	  first	  step,	  









SFR	  measurements	  using	  the	  power-­‐law	  scattering	  model	  and	  the	  extracted	  wavelength-­‐
dependent	  γ.	  We	  found	  that	  the	  absorption	  spectra	  extracted	  in	  the	  first	  step	  were	  almost	  
identical	   to	   the	  absorption	   spectra	  extracted	  using	   the	  power-­‐law	  scattering	  model	  and	  
the	  wavelength	  dependent	  γ,	  as	  indicated	  by	  an	  average	  Pearson	  correlation	  coefficient	  of	  
R2=0.99	  between	  extracted	  absorption	  spectra.	  	  
Clearly	   when	   more	   information	   becomes	   available	   about	   the	   wavelength	  
dependence	   of	   γ,	   that	   knowledge	   could	   be	   used	   to	   spectrally	   constrain	   γ	   and	   thus	  
complete	  an	  MDSFR	  fit	  in	  a	  single	  step	  fitting	  routine.	  
	  
LIMITATIONS	  
A	  -­‐	  Probe	  replacement	  
A	  potential	  limitation	  of	  the	  present	  study	  is	  caused	  by	  the	  fact	  that	  multiple	  fibers	  with	  
different	  diameters	   are	  used	   sequentially.	   Therefore,	   slight	  differences	   in	  measurement	  
volume	  are	  not	  only	  due	  to	  different	  fiber	  diameters	  but	  can	  also	  occur	  from	  measuring	  a	  
slightly	  different	  spot	  in	  each	  measurement.	  Sequentially	  measuring	  the	  exact	  same	  tissue	  
location	   with	   the	   exact	   same	   pressure	   for	   various	   fiber	   diameters	   is	   not	   only	   time	  
consuming,	   but	   also	   makes	   the	   current	   measurement	   procedure	   cumbersome	   and	  
sensitive	  to	  measurement	  artifacts.	  Clearly	  the	  use	  of	  a	  single	  measurement	  probe	  that	  is	  
capable	   of	   rapidly	   changing	   its	   effective	   aperture	  would	   be	   a	  major	   step	   forward.	  New	  
technological	  developments	  should	  overcome	  this	  problem	  in	  the	  near	  future	  and	  provide	  
true	   co-­‐localized	   measurement	   positions	   for	   various	   fiber	   diameters	   [29].	   Despite	   the	  
uncertainty	  in	  probe	  repositioning,	  the	  standard	  deviations	  for	  an	  individual	  mouse	  on	  the	  
MDSFR	  fitted	  values	  for	  µs’	  and	  γ	  (figure	  4.5a	  and	  b)	  are	  all	  within	  10%	  of	  the	  fitted	  value	  
(with	  the	  exception	  of	  µs’	  for	  skin),	  which	  is	  very	  encouraging.	  
	  
B-­‐	  Layered	  tissue	  
It	   is	  well	   known	   that	   skin	   and	  oral	  mucosa	   are	   comprised	  of	   layered	   tissue.	   In	   skin	   the	  
stratum	   corneum	   and	   epidermis	   overlay	   the	   underlying	   dermis.	   In	   the	   oral	   cavity	   the	  
normal	   tongue	   is	   comprised	   of	   a	   superficial	   keratinized	   layer	  with	   underlying	   epithelial	  
layer	  and	  deeper	   lying	  connective	   tissue	  comprised	  of	  orthogonal	  muscle	   fiber	  bundles.	  
The	  two,	  0.4	  and	  0.8	  mm,	  fibers	  are	  expected	  to	  probe	  the	  relatively	  homogeneous	  layers	  
of	  tissue	  comprising	  mouse	  epithelium	  and	  dermis	  in	  the	  skin	  and	  the	  tongue	  epithelium	  
and	  underlying	  connective	  tissue	  in	  normal	  tongue.	  OSC	  in	  the	  tongue	  develops	  beneath	  
the	   superficial	   keratinized	   layer	   but	   can	   potentially	   be	   overlain	   by	   a	   layer	   of	   epithelial	  
tissue	  of	  variable	   thickness.	  Microscope	   images	  of	   sections	  of	  OSC	   in	   the	   tongue	   (figure	  
4.2)	  show	  variation	  in	  thickness	  of	  the	  tissue	  layer	  covering	  the	  tumor	  between	  animals.	  










probe	  on	  a	  position	  where	  the	  tumor	  was	  visible	  minimized	  the	  distance	  between	  tumor	  
and	   fiber	   tip.	   Since	   the	  measurement	   volume	   and	   depth	   increase	  with	   increasing	   fiber	  
diameter,	  the	  smallest	  fiber	  diameter	  was	  specifically	  chosen	  to	  be	  0.4	  mm	  to	  incorporate	  
tumor	  within	  the	  measurement	  volume.	  However,	  the	  contribution	  of	  the	  top	  layer	  of	  the	  
tongue	   epithelium	   to	   the	   total	   acquired	   signal	   will	   be	   slightly	   different	   for	   each	   fiber	  
diameter.	  Given	  these	  concerns	  we	  analyzed	  spectra	  acquired	  using	  each	  fiber	  diameter	  
at	  a	  single	  location.	  This	  analysis	  showed	  consistent	  values	  for	  scattering	  power	  between	  
fiber	  diameters.	  While	  this	  result	  suggests	  that	  the	  influence	  of	  epithelium	  overlying	  the	  
tumor	  is	  small,	   it	  could	  be	  a	  reason	  why	  we	  observe	  only	  a	  relatively	  small	  difference	  in	  
scattering	  signature	  between	  normal	  tongue	  and	  tumor	  tissue.	  The	  potential	  confounding	  
effect	   of	   overlying	   epithelium	   could	  be	   removed	   in	   the	   future	  by	   studying	   a	   chemically	  
induced	  model	  of	  oral	  cancer	  in	  animals	  or	  interrogating	  superficial	  human	  OSC.	  	  
	  
FUTURE	  DEVELOPMENTS	  
Quantification	   of	   tissue	   optical	   properties	   does	   not	   only	   yield	   direct	   diagnostic	  
information,	  it	  also	  facilitates	  the	  use	  of	  quantitative	  in-­‐vivo	  fluorescence	  measurements.	  
To	   quantify	   the	   concentration	   of	   an	   (exogenous)	   fluorophore	   in	   tissue,	   for	   example	   to	  
monitor	  photodynamic	  therapy,	  knowledge	  of	  local	  tissue	  optical	  properties	  is	  necessary	  
to	  correct	  for	  the	  effects	  of	  scattering	  and	  absorption	  on	  the	  collected	  fluorescence	  [30].	  
Our	   setup	   allows	   for	   reflectance	   and	   fluorescence	  measurements	   to	   be	   taken	  with	   the	  
same	  probe,	  providing	  a	  method	  to	  determine	  fluorescence	  corrected	  for	  the	  influence	  of	  
tissue	   optical	   properties,	   which	   opens	   the	   way	   to	   quantitatively	   compare	   fluorescence	  
from	  different	  tissues	  and	  patients.	  
	  
CONCLUSION	  
In	  conclusion,	  we	  have	  presented	  the	  first	  in-­‐vivo	  MDSFR	  analysis	  of	  four	  different	  tissue	  
types,	   based	   on	   measurements	   of	   19	   animals.	   Analysis	   of	   scattering	   power,	   reduced	  
scattering	  at	  800nm	  and	  average	  γ	   resulted	   in	   significant	  differences	   for	   the	   four	   tissue	  
types	   studied.	   Future	   work	   will	   address	   the	   relation	   between	   µs’(λ)	   and	   γ(λ)	   and	   the	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Quantification	   of	   fluorescence	   in-­‐vivo	   is	   complicated	   by	   the	   influence	   of	   tissue	   optical	  
properties	   on	   the	   collected	   fluorescence	   signal.	   When	   tissue	   optical	   properties	   in	   the	  
measurement	   volume	   are	   quantified,	   one	   can	   obtain	   the	   intrinsic	   fluorescence,	   which	  
equals	  the	  product	  of	  fluorophore	  absorption	  coefficient	  and	  quantum	  yield.	  We	  applied	  
this	   method	   to	   in-­‐vivo	   single	   fiber	   fluorescence	   (SFF)	   spectroscopy	   measurements	   on	  
mouse	   tong,	   skin,	   liver	   and	   oral	   squamous	   cell	   carcinoma,	  where	  we	   detected	   intrinsic	  
fluorescence	  spectra	  of	  the	  photosensitizers	  chlorin	  e6	  (ce6)	  and	  Bremachlorin	  at	  t	  =	  [3	  4.5	  
6	   24	   48]	   hour	   incubation	   time.	   We	   observed	   a	   tissue	   dependent	   maximum	   of	   35%	  
variation	   in	   the	   total	   correction	   factor	   over	   the	   visible	   wavelength	   range.	   Significant	  
differences	   in	   spectral	   shape	   over	   time	   between	   sensitizers	   were	   observed.	  While	   the	  
wavelength	   position	   of	   the	   fluorescence	   intensity	  maximum	   for	   ce6	   shifted	   to	   the	   red,	  
Bremachlorin	   showed	  a	  blue-­‐shift.	   Furthermore,	   the	  Bremachlorin	  peak	  appeared	   to	  be	  
broader	   than	   the	   ce6	   fluorescence	   peak.	   Intrinsic	   fluorescence	   intensity,	   which	   can	   be	  
related	  to	  photosensitizer	  concentration,	  was	  decreasing	  for	  all	  time	  points,	  but	  showed	  
significantly	   more	   Bremachlorin	   present	   compared	   to	   ce6	   at	   long	   incubation	   times.	  
Results	   from	   this	   study	   can	   be	   used	   to	   define	   an	   optimal	   treatment	   protocol	   for	  
Bremachlorin-­‐based	  photodynamic	  therapy.	  











In-­‐vivo	   optical	   spectroscopy	   is	   under	   investigation	   both	   as	   a	   diagnostic	   tool	   and	   as	   a	  
method	   for	   monitoring	   a	   number	   of	   therapeutic	   modalities	   [1-­‐4].	   Reflectance	  
spectroscopy	   provides	   information	   on	   the	   presence	   and	   concentration	   of	   tissue	  
absorbers,	   while	   scattering	   can	   be	   related	   to	   information	   on	   morphology	   and	  
ultrastructure	   of	   tissue	   [5,	   6].	   Fluorescence	   spectroscopy	   enables	   the	   detection	   of	  
endogenous	  molecules	   such	   as	   collagen	   and	  NADH,	   as	  well	   as	   exogenous	   fluorophores	  
such	   as	   fluorescent	   labeled	   markers	   and	   drugs	   [7,	   8].	   The	   shape	   and	   intensity	   of	   the	  
fluorescence	   spectrum	   contain	   valuable	   information	   on	   fluorophore	   identity,	   its	  
concentration	   and	   the	   local	   environment.	   The	   interrogation	   of	   fluorescent	   drugs	   in	  
various	  tissue	  types	  is	  one	  of	  the	  major	  applications	  of	  in-­‐vivo	  fluorescence	  spectroscopy	  
and	  has	  been	  widely	  incorporated	  in	  photodynamic	  therapy	  (PDT)	  research	  and	  in	  clinical	  
practice.	   Photosensitizing	   agents	   are	   well	   known	   for	   their	   fluorescent	   properties.	   It	   is	  
shown	   that	   knowledge	   of	   photosensitizer	   fluorescence	   intensity	   and/or	   changes	   in	  
photosensitizer	   spectral	   properties	   before	   and	   during	   treatment	   may	   be	   related	   to	  
therapeutic	  efficacy	  and	  can	  be	  used	  to	  monitor	  PDT	  [9-­‐12].	  
	  
Despite	   the	   potential	   usefulness	   of	   in-­‐vivo	   fluorescence	   spectroscopy,	   the	   exact	  
quantification	   of	   fluorescent	   signals	   is	   proven	   to	   be	   very	   challenging.	  When	  measuring	  
fluorescence	   in-­‐vivo,	   the	   number	   of	   collected	   photons	   is	   strongly	   influenced	   by	   optical	  
properties	  of	  the	  tissue	  under	  investigation.	  The	  local	  fluence	  rate	  is	  influenced	  by	  tissue	  
optical	   properties	   at	   the	   excitation	   wavelength	   (λx),	   while	   the	   number	   of	   emitted	  
fluorescence	   photons	   detected	   depends	   on	   the	   optical	   properties	   at	   the	   emission	  
wavelength	   (λm).	  We	  are	   interested	   in	   the	   intrinsic	   fluorescence,	  where	   the	   influence	  of	  
tissue	  optical	  properties	  is	  removed	  from	  the	  measured	  fluorescence	  spectrum	  and	  which	  
can	   therefore	   be	   related	   to	   the	   fluorophore	   absorption	   coefficient	   and	   thereby	   to	  
fluorophore	   concentration.	   Intrinsic	   fluorescence	   enables	   quantitative	   comparison	   of	  
fluorescence	   intensity	   and	   spectral	   shape	   measured	   on	   tissues	   with	   different	   and/or	  
varying	  optical	  properties.	  	  
	  
Several	  methods	  have	  been	  developed	  previously	  to	  extract	  intrinsic	  fluorescence	  spectra	  
in	  turbid	  media	  such	  as	  biological	  tissue.	  To	  provide	  accessibility	  to	  various	  tissues,	  system	  
designs	   for	   in-­‐vivo	   use	   are	   generally	   based	   on	   fiber	   optic	   probes.	   Many	   techniques	  
combine	  white	   light	   reflection	  measurements	   to	   obtain	   tissue	   optical	   properties	  with	   a	  
fluorescence	  measurement,	   and	   then	   use	   analytical	   or	   empirical	   models	   [4,	   13,	   14]	   to	  









from	   a	   reflectance	   measurement	   to	   correct	   fluorescence	   data	   is	   the	   discrepancy	   of	  
measurement	  geometries	  between	  the	  two.	  Multi-­‐fiber	  fluorescent	  probes	  with	  separate	  
source(s)	  and	  detector(s),	  where	  the	  detected	  light	  is	  diffuse	  and	  the	  sampling	  volume	  is	  
in	   the	   order	   of	   mm3,	   have	   been	   extensively	   investigated	   [3,	   4,	   13,	   15,	   16].	   In	   this	  
geometry,	   both	   reflectance	   and	   (a	   large	   part	   of	   the)	   fluorescent	   light	   are	   diffusely	  
scattered.	  After	  determination	  of	   the	  optical	  properties,	   an	  analytical	  model	   to	   retrieve	  
intrinsic	   fluorescence	  can	  be	  used	  that	   is	   independent	  of	  specific	  probe	  design.	  Another	  
approach	   is	   to	   use	   a	   source	   and	   detection	   fiber	   with	   a	   small	   separation	   distance	   and	  
therefore	   probing	   a	   much	   smaller	   sample	   volume	   directly	   below	   the	   fiber	   tip.	   In	   this	  
configuration,	   the	   majority	   of	   detected	   reflectance	   and	   fluorescence	   photons	   have	  
undergone	   too	   few	   scattering	   events	   to	   apply	  diffusion	   theory	   and	   sample	   volumes	   for	  
reflectance	  and	   fluorescence	  differ	   significantly	   from	  each	  other.	  Therefore,	  approaches	  
to	   remove	   the	   influence	   of	   optical	   properties	   from	   fluorescence	   are	   based	   on	   (semi-­‐)	  
empirical	  models	  and	  are	  usually	  device	  and	  measurement	  geometry-­‐specific.	  A	  specific	  
situation	  of	  small	  source-­‐detector	  separation	   is	  to	  use	  a	  single	  fiber	  for	   illumination	  and	  
detection	  of	  both	  reflected	  and	  fluorescent	  light	  [17-­‐20].	  	  
	  
Our	  group	  has	  recently	  developed	  a	  fiber	  optic	  system	  based	  on	  the	  combination	  of	  multi-­‐
diameter	  single	  fiber	  reflectance	  (MDSFR)	  spectroscopy	  and	  single	  fiber	  fluorescence	  (SFF)	  
spectroscopy;	   the	   former	   functioning	   to	   determine	   tissue	   absorption	   and	   scattering	  
properties,	  the	  latter	  to	  detect	  tissue	  fluorescence	  [21-­‐23].	  Illumination	  and	  detection	  are	  
performed	   by	   a	   single	   optical	   fiber	   probe	   for	   both	   reflectance	   and	   fluorescence	  
measurements.	  The	  measurement	  volume	   is	  confined	  to	  shallow	  depths	  of	   the	  order	  of	  
the	   fiber	   diameter	   [24,	   25].	   It	   is	   shown	   that	   acquiring	   two	   successive	   single	   fiber	  
reflectance	   measurements	   with	   different	   fiber	   diameters	   (termed	   MDSFR)	   enables	  
quantification	   of	   both	   the	   reduced	   scattering	   coefficient	   and	   the	   phase	   function	  
parameter	  γ.	  This	  parameter	  is	  defined	  as	  
	  	  	   	   	   	   	   	   	   	   	  	  	  	  	  	  	  	  	  
	   	   	   	   	   	   	   	   (5.1)	  
where	  g1	  and	  g2	  are	  the	  first	  and	  second	  Legendre	  moment	  of	  the	  phase	  function,	  and	  has	  
to	  be	  included	  due	  to	  the	  shallow	  measurement	  geometry	  [21,	  26].	  Intrinsic	  fluorescence	  
is	   determined	   using	   a	   semi-­‐empirical	   model	   based	   on	   Monte	   Carlo	   simulations	   and	  
phantom	   studies.	   This	   model	   incorporates	   the	   effect	   of	   optical	   properties	   on	   local	  
excitation	   fluence	  and	   fluorescence	  photon	  escape	  probability	  within	   the	  whole	   sample	  














An	  important	  application	  field	  where	  measurement	  of	  intrinsic	  fluorescence	  is	  particularly	  
valuable	   is	   the	   determination	   of	   photosensitizer	   fluorescence	   before	   and	   during	  
photodynamic	   therapy.	   Since	   oxygen	   is	   depleted	   during	   PDT,	   saturation	   levels	   in	   the	  
measurement	  volume	  will	  change,	  and	  hence	  the	  optical	  properties.	  Other	  direct	  effects	  
of	   PDT	   include	   changes	   in	   blood	   volume	   fraction	   and	   vessel	   diameter	   influencing	  
absorption	   and	   the	   onset	   of	   acute	   edema,	   which	   influences	   scattering	   [11,	   28-­‐30].	  
Intrinsic	  fluorescence	  allows	  for	  reliable	  quantification	  and	  comparison	  of	  photosensitizer	  
fluorescence	  at	  various	  time	  points	  before,	  during	  and	  after	  PDT.	  
	  
Chlorins	  are	  a	   class	  of	   second	  generation	  photosensitizers	   that	  exhibit	   low	  dark	   toxicity	  
and	  have	  enhanced	  absorption	  in	  the	  optical	  window	  between	  600	  and	  800	  nm.	  Chlorin	  e6	  
(ce6)	  is	  a	  member	  of	  this	  family	  of	  photosensitizers	  and	  has	  been	  studied	  intensively	  for	  
over	  two	  decades	  [31-­‐33].	  Preclinical	  studies	  comparing	  localization	  and	  photo	  toxicity	  of	  
ce6	   with	   other	   photosensitizers	   are	   performed	   [34,	   35].	   Ce6-­‐PVP,	   in	   which	   the	   ce6	  
molecule	   is	   bound	   to	   a	   polyvinylpyrrolidone	   carrier,	   is	   used	   in	   PDT	   of	   urological	  
oncological	   lesions	   [36].	   The	   second-­‐generation	   photosensitizer	  mono-­‐L-­‐aspartylchlorin-­‐
e6	  has	  been	  used	  successfully	   in	  phase	  I	  studies	  for	  cutaneous	  lesions	  [37],	  solid	  tumors	  
[38]	  and	  mucosal	  surfaces	  [39].	  It	  is	  shown	  that	  in-­‐vitro	  analysis	  of	  cellular	  uptake	  of	  ce6	  
has	  a	   strong	  dependence	  of	   spectral	   shape	  on	  pH	  of	   the	  solution,	   resulting	   in	  a	   shift	  of	  
both	  the	  absorption	  and	  fluorescence	  spectrum	  and	  a	  decrease	  of	  fluorescence	  intensity	  
[32,	  33].	  By	  analyzing	  both	  intensity	  and	  spectral	  shape,	  we	  should	  be	  able	  to	  distinguish	  
between	  intensity	  decreases	  due	  to	  clearance	  of	  the	  photosensitizer	  from	  the	  tissue,	  and	  
intensity	   changes	   due	   to	   re-­‐localization	   to	   an	   environment	   with	   a	   different	   pH.	   One	  
important	  aspect	  of	   the	  use	  of	  ce6	   is	   its	   relatively	   low	   lipophilicity;	   this	  means	   that	   it	   is	  
metabolized	   rapidly	   and	   cleared	   from	   the	  body	  quickly	   via	   the	  urinary	   system.	   This	   has	  
advantages	   in,	   for	   example,	   reducing	   skin	   photosensitivity	   but	   a	   short	   clearance	   time	  
limits	   its	   effective	   localization	   in	   neoplastic	   tissue.	   A	   new	   photosensitizing	   compound,	  
Bremachlorin,	  consists	   largely	  (~80%)	  of	  ce6,	  combined	  with	  the	  photosensitizing	  agents	  
purpurin	   5	   (~15%)	   and	   chlorin	   p6	   (~5%)	   [40,	   41].	   The	   main	   active	   component	   of	  
Bremachlorin	   is	   thought	   to	  be	  purpurin	  5,	  because	  of	   its	   rapid	   interaction	  with	  albumin	  
and	   low-­‐density	   lipoproteins	   that	   enables	   it	   to	   be	   delivered	   to	   cancerous	   tissues	   [42].	  
Although	  purpurin	  5	  in	  itself	   is	  too	  hydrophobic	  to	  be	  administered	  in	  aqueous	  solution,	  
combined	   with	   ce6	   and	   cp6	   it	   achieves	   the	   chemical	   stability	   required	   for	   both	  
intravenous	  administration	  and	  storage.	  It	  is	  expected	  that	  the	  combined	  purpurin	  5	  and	  
ce6	   in	  Bremachlorin	   results	   in	  an	  overall	  photosensitizing	  effect	   that	   is	  greater	   than	  the	  










In	  the	  present	  study	  we	  have	  for	  the	  first	  time	  used	  quantitative	  single	  fiber	  fluorescence	  
spectroscopy	   in-­‐vivo	   to	   analyze	   fluorescence	   spectra	   of	   both	   ce6	   and	   Bremachlorin	   in-­‐
vivo.	   Analysis	   of	   variations	   in	   both	   fluorescent	   spectral	   shape	   and	   intensity	   yields	  
information	   on	   clearance	   and	   localization	   of	   both	   photosensitizers	   under	   investigation.	  
This	  analysis	   is	  applied	  on	  healthy	  tongue	  tissue,	  oral	  squamous	  cell	  carcinoma	  tissue	  at	  
the	   tip	   of	   the	   tongue,	   skin	   and	   liver,	   for	   time	   points	   ranging	   from	   3	   to	   48	   hours	   after	  
photosensitizer	  injection.	  
MATERIALS	  &	  METHODS	  
	  CORRECTION	  THEORY	  
To	   measure	   intrinsic	   fluorescence,	   it	   is	   necessary	   to	   correct	   the	   measured	   raw	  
fluorescence	  signal	  for	  the	  influence	  of	  µ’s	  and	  µa.	  The	  method	  of	  determining	  µ’s	  and	  µa	  
from	  MDSFR	  spectra	  has	  been	  described	  in	  detail	  elsewhere	  [21,	  22,	  43].	  Furthermore,	  a	  
semi-­‐empirical	   model	   is	   developed,	   based	   on	   Monte-­‐Carlo	   simulations	   and	   phantom	  
studies	  to	  account	   for	  the	   influence	  of	  tissue	  optical	  properties	  on	  a	   fluorescence	  signal	  
[23,	  27].	  To	  obtain	  the	  fluorescence	  in	  the	  absence	  of	  absorption	  F0SF	  from	  the	  measured	  
fluorescence	  FSF	  a	  modified	  form	  of	  Beer’s	  law	  is	  used	  [27]	  
FSF = FSF0 e
−µa,avg LSFF( )
.	   	  	  	  	   	   	   	   	   	   	  	  	  	  	  	  	  	  (5.2)	  
Here,	   µa,avg	   is	   the	   average	   µa	   at	   the	   excitation	   and	   emission	   wavelength	   and	   the	  
fluorescence	  photon	  path	  length	  LSFF	  is	  defined	  as	  	  
	  	  
,	   	   	   	   	   	  	  	  	  	  	  	  	  	  	  	  (5.3)	  
	  
where	   µ’s,avg	   is	   the	   average	   µ’s	   at	   excitation	   and	   emission	   wavelength,	   df	   is	   the	   fiber	  
diameter	   and	  κ	   represents	   a	   single	   fitted	  parameter	  which	  has	   a	   value	  of	  κ	   =1.81±0.01	  
[23].	  Z	  is	  the	  effective	  sampling	  depth,	  defined	  as	  
	  	  
,	   	  	  	  	   	   	   	   	   	  	  	  	  	  	  (5.4)	  
and	  can	  be	  related	  to	  the	  effective	  sampling	  volume	  
	   	  
V = A1 Z d f2 .	  	   	   	   	   	   	   	   	  	  	  	  	  	  	  	  (5.5)	  
In	  this	  equation,	  A1	   is	  a	  proportionality	  factor	  that	  depends	  on	  the	  geometrical	  shape	  of	  
the	   effective	   volume	   and	   A2	   and	   A3	   are	   determined	   empirically	   to	   be	   0.71±0.01	   and	  
0.36±0.01	  respectively	  [23,	  27].	  	  
	  
LSFF = Z
1+κ µs,avg, d f( )
1+ µa,avgd f( )











A	  model	   is	   previously	   developed	   to	   relate	   F0SF	   to	   the	   intrinsic	   fluorescence	   spectrum	  
µfaQf,	   which	   is	   the	   product	   of	   fluorophore	   absorption	   coefficient	   and	   quantum	   yield,	  
integrated	  over	  wavelength	  [27]	  
	  
.	   	   	   	   	  	  	  	  (5.6)	  
Here	   V ,	   φxV 	  and	   HmV 	  are	   the	   effective	   sampling	   volume,	   excitation	   fluence	   and	  
escape	  probability	  respectively,	  which	  can	  all	  be	  described	  as	  a	  function	  of	  µ’s	  and	  df.	  The	  
factor	   	  
λx
λm
accounts	   for	   difference	   in	   photon	   energy	   between	   emission	   and	   excitation	  
wavelength.	  FSFRatio	  is	  the	  ratio	  between	  the	  total	  excitation	  photons	  launched	  (related	  to	  
Plaser)	   and	   the	  emitted	  photons	  detected	   (related	   to	  F0SF).	   The	  product	  of	   equation	  5.6	  
and	  the	  expressions	  for	   V ,	   φxV 	  and	   HmV 	  yields	  
	   	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (5.7)	  
	  
where	   [ζ1 ζ2 ζ3]	   are	   fitted	  parameters	  with	   values	   [0.0935±0.003,	   0.31±0.01,	   1.61±0.05]	  
and	   λx	   and	   λm	   the	   excitation	   and	   emission	   wavelength	   respectively	   [27].	   Since	   our	  
measurements,	   and	   therefore	   the	   intrinsic	   fluorescence	   spectra	   did	   not	   only	   contain	  
photosensitizer	  fluorescence,	  but	  also	  included	  autofluorescence	  and	  gfp	  fluorescence	  in	  
measurements	   on	   tumor	   tissue,	   the	   contribution	   of	   the	   latter	   two	   to	   the	   intrinsic	  
fluorescence	   spectra	   was	   determined	   by	   spectral	   deconvolution	   and	   both	   components	  
were	  subtracted,	  resulting	  in	  photosensitizer	  intrinsic	  fluorescence	  spectra.	  We	  note	  that	  
equation	  5.7	   includes	  a	  value	  of	  0.00315	   to	  be	  able	   to	  apply	   the	  model	   in	   the	  very	   low	  
scattering	   regime.	   Including	   this	   factor	   results	   in	   a	   theoretical	   maximum	   value	   for	  
equation	   5.6	   of	   0.041	   for	  µ’s=0	  mm-­‐1,	   which	   corresponds	   with	   the	   analytically	   derived	  
maximum	   fluorescence	   in	   the	   situation	   of	   no	   scattering	   and	   no	   absorption	   using	   an	  
NA=0.22	  fiber	  in	  a	  medium	  with	  a	  refractive	  index	  of	  n0=1.33	  [44].	  	  
	  
MEASUREMENT	  SETUP	  
The	   illustration	   in	   figure	  5.1	   represents	  a	   single	  probe	  unit	  of	   the	  combined	  MDSFR-­‐SFF	  
spectroscopic	  setup.	  Two	  of	  those	  probe	  units	  were	  used,	  with	  the	  only	  difference	  in	  fiber	  
diameter	  of	  the	  probe	  and	  quadfurcation,	  to	  be	  able	  to	  perform	  measurements	  with	  both	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The	   measurements	   consisted	   of	   a	  
subsequent	   reflectance	   and	   fluorescence	  
measurement	  without	   probe	   repositioning.	  
During	   a	   reflectance	   measurement,	   white	  
light	  emitted	  by	  a	  halogen	  light	  source	  (HL-­‐
2000-­‐FHSA;	   Ocean	  Optics;	   Duiven,	   NL)	   was	  
directed	   through	   the	   first	   leg	   of	   a	  
quadfurcation	   into	   a	   solid	   core	   fiber	   optic	  
probe	   and	   guided	   onto	   the	   tissue.	   A	   small	  
fraction	   of	   the	   white	   light	   was	   reflected	  
from	  the	  tissue	  into	  the	  acceptance	  cone	  of	  
the	   probe	   fiber	   and	   directed	   via	   a	   second	  
leg	   of	   the	   quadfurcation	   into	   a	  
spectrometer	   (SD-­‐2000;	   Ocean	   Optics;	  
Duiven,	   NL)	   for	   detection	   and	   further	  
analysis.	   After	   the	   reflectance	   measurement,	   the	   fluorescence	   measurement	   was	  
performed,	   using	   low	   power	   405	   nm	   excitation	   light	   coupled	   into	   one	   leg	   of	   the	  
quadfurcation	   to	   illuminate	   the	   tissue	   through	   the	   same	   solid	   core	   probe	   as	   the	  
reflectance.	   The	   emitted	   fluorescence	   was	   then	   guided	   through	   the	   last	   leg	   of	   the	  
quadfurcation,	  which	  leads	  through	  a	  450	  nm	  long-­‐pass	  filter	  into	  a	  second	  spectrograph	  
(QE-­‐65000;	   Ocean	   Optics;	   Duiven,	   NL)	   by	   the	   use	   of	   a	   solid	   core	   0.2	   mm	   fiber.	   The	  
complete	  MDSFR-­‐SFF	  system	  consists	  of	  two	  identical	  probe-­‐units	  containing	  probe	  core	  
diameters	  of	  0.4	  and	  0.8	  mm,	  combined	  with	  a	  4x0.1	  mm	  and	  a	  4x0.2	  mm	  quadfurcation	  
respectively.	  The	   fiber	  probes	  were	  sequentially	  placed	   in	  contact	  with	  the	  tissue	  under	  
investigation.	   	   Both	   probes	   were	   polished	   under	   an	   angle	   of	   15o	   to	   minimize	   internal	  
specular	   reflections	   from	   the	   probe	   tip.	   The	   calibration	   procedure	   using	   a	   diluted	  
Intralipid	   20%	   phantom	   included	   correction	   for	   fiber	   alignment	   and	   transmission	  
efficiency	  and	  is	  described	  elsewhere	  [45].	  
	  
ANIMAL	  MODEL	  
For	   this	   study,	   19	   mice	   (BALB/c	   nu/nu	   female	   mice,	   aged	   4-­‐6	   weeks;	   Charles	   River	  
Laboratories)	  were	  injected	  with	  metastatic	  oral	  squamous	  cell	  carcinoma	  cell	  line	  OSC19,	  
lenti-­‐virally	   transfected	   with	   luc2	   (Biocat,	   Heidelberg,	   Germany)	   and	   Cop-­‐gfp	   (Evrogen,	  
Moscow,	   Russia).	   6x104	   cells,	   diluted	   in	   20	   µl	   PBS,	   were	   injected	   to	   induce	   an	   oral	  
squamous	  cell	  carcinoma	  at	  the	  tip	  of	  the	  tongue	  after	  an	  incubation	  period	  of	  10-­‐13	  days	  
[43,	  46-­‐48].	  Gfp	  was	  included	  in	  the	  cell	  line	  to	  easily	  assess	  the	  inclusion	  of	  tumor	  tissue	  
in	   the	   measurement	   volume.	   After	   tumor	   incubation,	   animals	   were	   restrained	   and	  
	  
Figure	   5.1:	   Schematic	   diagram	   of	   the	  
measurement	   setup.	   Reflectance	   and	  
fluorescence	  are	  measured	  through	  a	  single	  fiber	  
of	  either	  0.4	  or	  0.8	  mm.	  Two	  identical	  setups	  are	  










injected	  with	  chlorin	  e6	  (16	  mg	  kg
-­‐1	  in	  100	  µl	  PBS,	  Frontier	  Scientific,	  Inc.,	  Logan,	  USA)	  or	  
Bremachlorin	  (20	  mg	  kg-­‐1,	  form	  stock	  solution	  of	  3.5	  g	  l-­‐1,	  Rada-­‐pharma	  International	  BV,	  
The	  Netherlands).	  At	  t	  =	  [3	  4.5	  6	  24	  or	  48]	  hours	  after	  photosensitizer	   injection,	  animals	  
were	  anesthetized	  with	  an	   injection	  of	   ketamine/xylazine	  and	   spectroscopic	   reflectance	  
measurements	  with	   both	   fiber	   diameters	   and	   fluorescence	  measurements	  with	   the	   0.4	  
mm	  fiber	  were	  performed	  on	  normal	  tongue	  tissue,	  OSC	  tumor	  (both	  five	  measurements	  
per	   fiber	   diameter),	   skin	   and	   liver	   (both	   three	  measurements	   per	   fiber	   diameter),	   after	  
which	   the	   animals	   were	   sacrificed.	   The	   consecutive	   measurements	   were	   taken	   by	  
removing	  and	  carefully	  repositioning	  the	  fiber	  between	  measurements,	  without	  imparting	  
undue	  pressure	  on	  each	  tissue.	  For	  tumor,	  the	  fiber	  tip	  was	  positioned	  directly	  on	  top	  of	  
the	  visible	  tumor.	  The	  study	  protocol	  was	  approved	  by	  the	  Animal	  Welfare	  Committee	  of	  
the	   Leiden	   University	   Medical	   Center.	   Housing	   of	   BALB/c	   nu/nu	   female	   mice,	   the	  
experiments	  and	  euthanazation	  were	  performed	  in	  accordance	  with	  the	  guidelines	  of	  this	  
committee.	  Chlorophyll	  free	  food	  and	  sterilized	  water	  were	  provided	  without	  restriction.	  
	  
DATA	  ANALYSIS	  
All	   data	   analysis	   was	   performed	   using	   custom	   applications	   running	   in	   Matlab	   (release	  
2009b,	   The	   Mathworks,	   Natick,	   MA,	   USA).	   Reflectance	   spectra	   were	   fitted	   with	   a	  
combination	  of	  basis	  spectra	  by	  using	  a	  Levenberg-­‐Marquart	  non-­‐linear	   fit	  procedure	  to	  
estimate	   µa.	   µ’s	   was	   determined	   by	   averaging	   the	   absorption-­‐corrected	   reflectance	  
spectra	  per	  fiber	  diameter	  and	  fitting	  a	  model	  through	  those	  averaged	  reflectance	  spectra	  
of	  both	  fiber	  diameters,	  as	  previously	  described	  [43].	  Individual	  measurements	  that	  were	  
excluded	   from	   the	   MDSFR	   fit	   were	   excluded	   from	   SFF	   analysis	   as	   well.	   Spectra	   were	  
excluded	   from	   the	   analysis	   when	   (i)	   fluorescence	   measurements	   did	   not	   indicate	   the	  
presence	  of	  tumor	  tissue	  in	  the	  tumor	  measurement,	  (ii)	  we	  were	  unable	  to	  fit	  µa	  to	  the	  
individual	  reflectance	  spectrum	  (iii)	  we	  could	  not	  successfully	  fit	  µ’s	  or	  γ	  to	  the	  averaged	  
absorption-­‐corrected	   reflectance	   spectra.	   The	   fluorescence	   spectra	   from	   all	   individual	  
measurements	  were	   corrected	   for	   absorption	  and	   scattering	   as	  described	  above.	   These	  
corrected	  fluorescence	  spectra	  were	  then	  divided	  into	  autofluorescence,	  gfp	  fluorescence	  
and	   photosensitizer	   fluorescence	   by	   spectral	   deconvolution.	   The	   autofluorescence	   and	  
gfp	  were	  then	  subtracted	  to	  obtain	  the	  intrinsic	  fluorescence	  spectrum.	  Basis	  spectra	  for	  
gfp	   and	   autofluorescence	   were	   constructed	   from	   fluorescence	   measurements	   on	   >5	  
animals	  before	   fluorophore	   injection,	  where	  normal	   tongue	  and	   tumor	  were	   fitted	  with	  
an	   identical	   autofluorescence	   spectrum.	   Skin	   and	   liver	   were	   both	   analyzed	   with	   their	  
tissue-­‐dependent	   autofluorescence	   basis	   spectrum.	   Spectral	   deconvolution	   was	   again	  
based	   on	   a	   Levenberg-­‐Marquart	   non-­‐linear	   fit	   procedure.	   The	   resulting	   intrinsic	  









absorption	   coefficient	   and	   quantum	   yield	   µfaQf by	   integration	   over	   wavelength.	   To	  
quantify	  variations	  in	  the	  shape	  of	  the	  spectral	  emission,	  two	  Gaussians	  were	  fitted	  to	  the	  
main	   ce6/Bremachlorin	   peak	   present	   in	   the	   intrinsic	   photosensitizer	   fluorescence	  
spectrum;	  one	  covering	  the	  high-­‐intensity	  emission	  peak,	  fitted	  between	  650	  and	  680	  nm	  
and	  a	  skewed	  Gaussian	  to	  determine	  the	  width	  and	  intensity	  of	  the	  emission	  shoulder	  at	  
the	  right	  side	  of	  the	  maximum	  between	  680	  and	  800	  nm.	  This	  skewed	  function	  is	  defined	  
as	  	  
f λ( ) = b1e
− λ−b2( )
2












' .	   	   	   	   	   	  	  	  	  	  	  	  	  (5.8)	  
The	   parameters	   b1-b4	   were	   fitted	   using	   a	   least-­‐mean-­‐square	   method	   to	   describe	   the	  
shape	  of	  the	  right	  hand	  sight	  of	  the	  spectra.	  From	  these	  fitted	  Gaussian	  curves	  we	  were	  
able	   to	  determine	   the	   intrinsic	   fluorescence	   intensity,	  peak	  wavelength,	   FWHM	  of	  both	  
fitted	  Gaussians	  and	  the	  ratio	  between	  different	   fit	  parameters.	  The	  underlying	   reasons	  
for	  and	  implications	  of	  these	  spectral	  shifts	  are	  discussed	  below.	  	  
RESULTS	  
For	  this	  experiment,	  299	  spectra	  were	  included	  in	  the	  analysis.	  In	  biological	  tissue,	  largest	  
variations	   of	   absorption	   in	   the	   visible	   range	   is	   found	   in	   the	   400-­‐600	   nm	   range,	   while	  
scattering	  is	  decreasing	  with	  increasing	  wavelength.	  
Figure	  5.2	  shows	  a	  typical	  example	  of	  MDSFR	  spectra	  taken	  on	  tumor	  tissue,	  using	  
a	  0.4	  and	  0.8	  mm	  fiber,	  together	  with	  their	  corresponding	  scattering	  background	  model	  in	  
the	   absence	   of	   absorption.	   Around	   500	   nm,	   a	   peak	   could	   be	   distinguished,	   caused	   by	  
strong	  gfp	   fluorescence	  of	   the	  tongue	  tumor,	  excited	  by	  white	   light	  used	  to	  acquire	  the	  
reflectance	  spectra.	  
	  
THE	  MAGNITUDE	  OF	  THE	  CORRECTION	  FOR	  TISSUE	  OPTICAL	  PROPERTIES	  
The	  correction	   factor	  was	   calculated	  over	   the	  whole	   spectral	   range	   for	  both	  absorption	  
and	  scattering	  for	  the	  four	  different	  tissues,	  averaged	  over	  all	  mice.	  These	  are	  shown	  in	  










The	   correction	   factors	   were	   dependent	  
on	   the	   tissue	   type	   and	   illustrated	   the	  
importance	   of	   our	   technique	   for	   the	  
recovery	   of	   intrinsic	   fluorescence	   in	  
different	   tissue	   types:	   absorption	   was	  
significantly	  stronger	   in	   liver	  where	  there	  
was	   a	   high	   concentration	   of	   blood,	  
whereas	   skin	   had	   the	   lowest	   absorption.	  
Scattering	   correction	   did	   not	   vary	  
significantly	  with	  tissue	  type	  (figure	  5.3b).	  
The	  spectral	  variation	  of	  oxygenated	  and	  
deoxygenated	   blood	   was	   observed	   in	  
tumor	   and	   normal	   tongue	   absorption	  
coefficients.	   The	   variation	   in	   the	   total	  
correction	   factor	   over	   the	   visible	  
wavelength	  range	  for	  both	  the	  absorption	  and	  scattering	  is	  shown	  in	  figure	  5.4,	  where	  the	  
maximum	  value	  of	  the	  absorption	  or	  scattering	  based	  correction	  factor	  is	  divided	  by	  the	  
minimum	  value.	  This	  figure	  shows	  clearly	  that	  correction	  for	  tissue	  absorption	  was	  most	  
important	   with	   regards	   to	   analysis	   of	   spectral	   shape.	   Scattering	   varied	   less	   over	  
wavelength,	  although	  the	  contribution	  of	  the	  scattering	  correction	  to	  the	  total	  correction	  
procedure	  was	   larger	   than	   that	  of	  absorption.	  Therefore,	   incorrect	   scattering	  correction	  
will	   result	   in	  an	   incorrect	   calculation	  of	   the	   fluorophore	  concentration	  but	  much	   less	   in	  
incorrect	   conclusions	   on	   spectral	   shape.	   Applying	   both	   absorption	   and	   scattering	  
correction	  results	  in	  the	  intrinsic	  fluorescence	  spectrum.	  
	  
Figure	  5.3:	  (a)	  Average	   µa	  factor	  spectrum	  for	  four	  different	  tissues.	  Since µa	  was	  wavelength	  dependent,	  
the	   absorption	   correction	   is	   too.	   Calculation	   is	   based	   on	   equation	   5.2.	   (b)	   Average	   scattering	   correction	  
factor	  spectrum	  for	  four	  different	  tissues,	  resulting	  from	  equation	  5.7.	  
	  
	  
Figure	   5.2:	   Reflectance	   measurement	   of	   tongue	  
tumor	   tissue.	   Black)	   0.4	   mm	   fiber,	   Grey)	   0.8	   mm	  
fiber.	   Shown	   are	   the	   reflectance	   spectrum	   (o)	   and	  
the	  scattering	  background	  model	  (-­‐-­‐),	  averaged	  over	  
five	  consecutive	  measurements.	  














































































When	  comparing	  intrinsic	  fluorescence	  spectra	  of	  Bremachlorin	  and	  ce6	  of	  normal	  
and	  tongue	  tumor	  tissue	  in	  figure	  5.5,	  Bremachlorin	  showed	  higher	  fluorescence	  intensity	  
than	  ce6	  did	   for	  both	   tissues.	  Furthermore,	   the	   tumor	   tissue	   intensity	  was	  much	  higher	  
than	  that	  of	  normal	  tissue.	  
To	  illustrate	  the	  spectral	  variations	  of	  ce6	  and	  Bremachlorin	  in	  different	  tissues	  at	  
different	  time	  points,	  figure	  5.6a	  and	  b	  shows	  normalized	  spectra	  acquired	  from	  different	  
tissues	   and	   time	   points.	   Between	   3	   and	   24	   hours	   after	   injection	   the	   ce6	   peak	   shifted	  
towards	   longer	  wavelengths,	  while	   for	  Bremachlorin	   a	   shift	   towards	   lower	  wavelengths	  
was	  measured.	  Furthermore,	  clear	  differences	  in	  peak	  width	  and	  the	  contribution	  of	  the	  
longer	   wavelength	   shoulder	   were	   observed	   over	   time	   after	   photosensitizer	  
administration.	  
To	  quantify	   these	  spectral	  variations	   in	   the	   intrinsic	  photosensitizer	   fluorescence	  
spectrum,	   the	   fluorescence	   was	   characterized	   by	   two	   fitted	   Gaussian	   distributions	   as	  
shown	   in	   figure	   5.7;	   one	   covered	   the	   high-­‐intensity	   emission	   peak,	   fitted	   between	   650	  
and	  680	  nm	  and	  a	  skewed	  Gaussian	  determined	  the	  width	  and	  intensity	  of	  the	  emission	  
shoulder	  at	  the	  right	  side	  of	  the	  maximum	  between	  680	  and	  800	  nm.	  	  
	  
INTENSITY	  AND	  RATIO	  
Both	  ce6	  and	  Bremachlorin	  showed	  the	  highest	  intrinsic	  fluorescence	  intensity	  in	  liver	  and	  
lowest	  in	  normal	  tissue.	  	  
	  
	   	  
Figure	   5.4:	   Variation	   over	   the	   visible	   wavelength	  
range	   (400-­‐800	  nm)	  of	   the	   corrections	   for	  absorption	  
and	  scattering.	  Maximum	  value	   in	   that	   range	  divided	  
by	  minimum	  value.	  
Figure	  5.5:	  Typical	  ce6	  and	  Bremachlorin	  spectrum	  
in	   normal	   tongue	   and	   tumor,	   3	   hours	   after	  
photosensitizer	  injection.	  
	  


























































Figure	   5.6:	   (a)	   Characteristic	   intrinsic	   photosensitizer	   fluorescence	   spectrum	   for	   varying	   tissue,	   time	  and	  
photosensitizer,	  normalized.	  (b)	  Close	  up	  of	  peak	  position	  
	  
Furthermore,	  fluorescence	  intensity	  of	  Bremachlorin	  was	  significantly	  higher	  in	  all	  tissues	  
at	  all	  time	  points	  (except	  3	  and	  6	  hour	  measurements	  in	  liver,	  where	  the	  difference	  is	  not	  
significant),	  as	  can	  be	  seen	  in	  figure	  5.8a.	  The	  fluorescence	  intensity	  was	  measured	  as	  the	  
maximum	  value	  of	  the	  fluorophore	  intrinsic	  fluorescence	  spectrum.	  It	  is	  evident	  from	  the	  
data	  (figure	  5.8a)	  that	  there	  was	  relatively	  less	  ce6	  present	  in	  time	  as	  it	  was	  cleared	  more	  
rapidly	   than	   Bremachlorin.	   This	   may	   have	   significant	   implications	   for	   the	   use	   of	  
Bremachlorin	  as	  a	  photosensitizer	  and	  will	  be	  discussed	  in	  more	  detail	  elsewhere.	  Figure	  
5.8b	  shows	   the	   intensity	   ratio	  of	   the	  main	  peak	  and	   the	  shoulder	  on	   the	   right	   side.	  For	  
this,	   the	   maximum	   values	   of	   both	   fitted	   Gaussian	   distributions	   were	   divided	   by	   each	  
other.	   Ce6	   showed	   ratios	   between	   8.4	   and	   11.0,	   significantly	   larger	   than	   Bremachlorin	  
(ratios	  between	  5.9	  and	  7.5)	  for	  3,	  4.5	  and	  6	  hours	  after	  injection	  in	  all	  tissues,	  indicating	  a	  
lower	   shoulder	   for	   ce6	   compared	   with	   Bremachlorin	   (P<0.02	   for	   all	   time	   points	   and	  
tissues).	  	  
The	   24	   and	  48	  hour	   time	  points	  were	  
not	  considered	  in	  this	  analysis	  because	  
the	   fluorescence	   intensity	   of	   the	  
shoulder	  was	  in	  many	  cases	  too	  low	  to	  
be	   fitted	   accurately.	   For	   each	  
photosensitizer,	   differences	   over	   time	  
and	   tissue	   were	   small	   and	   rarely	  
significant,	  as	  indicated	  in	  figure	  5.8b.	  
	  






























































Figure	   5.7:	   Fluorescence	   intensity	   is	   fitted	   with	   a	  
Gaussian	  distribution	  between	  650	  and	   680	  nm,	   and	  a	  
skewed	  Gaussian	  distribution	  between	  680	  	  and	  800	  nm.	  
	  




























Figure	   5.8c	   shows	   that	   the	  wavelength	   of	   the	  maximum	   intrinsic	   fluorescence	   intensity	  
was	  shifted	  more	  towards	  the	  red	  for	  ce6	  compared	  with	  Bremachlorin	  for	  tongue	  tissue,	  
tumor	  tissue	  and	  skin.	  The	  peak	  position	  of	  Bremachlorin	  ranged	  from	  667-­‐665	  nm,	  while	  
ce6	  ranged	  from	  665-­‐671	  nm.	  	  This	  discrepancy	  was	  significant	  (P<0.05)	  for	  all	  time	  points	  
in	   normal	   tongue	   tissue,	   tumor	   tissue	   and	   skin.	   Liver	   showed	   a	   blue-­‐shift	   of	   the	   peak	  
wavelength	  over	  time	  for	  both	  photosensitizers,	  that	  did	  not	  significantly	  differ	  from	  each	  
other	  for	  t=	  [3	  6	  24]	  hours.	  Bremachlorin	  showed	  a	  decrease	  of	  peak	  position	  wavelength	  
over	   time	   for	   all	   four	   tissues,	   while,	   although	   not	   always	   significant,	   ce6	   showed	   an	  
increasing	   trend	   for	   tongue	   tissue,	   tumor	   and	   skin.	   From	   figure	   5.8b	   and	   5.8c,	   we	   can	  
conclude	  that	   for	  ce6,	  a	  shift	  of	   the	  peak	   to	  a	  higher	  wavelength	  corresponded	  with	  an	  
	  
Figure	   5.8:	   (a)	   Maximum	   intrinsic	   fluorescence	   intensity.	   This	   parameter	   correlates	   with	   the	   product	   of	  
photosensitizer	   concentration	   and	   quantum	   yield	   at	   the	   peak	   wavelength.	   (b)	   Ratio	   between	   maximum	  
intrinsic	  fluorescence	  intensity	  and	  the	  fitted	  intensity	  parameter	  of	  the	  skewed	  Gaussian.	  This	  represents	  the	  
ratio	   between	   peak	   and	   shoulder	   of	   the	   ce6	   /	   Bremachlorin	   fluorescence	   spectrum.	   (c)	   Wavelength	   that	  
represents	  maximum	  intrinsic	  fluorescence	  peak	  position.	  (d)	  FWHM	  of	  the	  Gaussian	  representing	  the	  main	  
intrinsic	  fluorescence	  peak.	  
	  












































































































increase	   in	   the	   peak/shoulder	   ratio.	   Possible	   explanations	   for	   the	   observed	  wavelength	  
shifts	  can	  be	  found	  in	  the	  discussion	  section.	  	  
	  
WIDTH	  
When	   comparing	   the	   width	   of	   the	   main	   fluorescence	   emission	   peak	   of	   both	  
photosensitizers	  in	  figure	  5.8d,	  it	  can	  be	  seen	  that	  in	  general	  the	  width	  of	  the	  spectrum	  of	  
ce6	  peak	  was	  significantly	  smaller	  than	  that	  of	  Bremachlorin.	  It	  should	  be	  noted	  that	  the	  
24	  and	  48	  hour	  measurements	  of	  ce6	  were	  associated	  with	   large	  uncertainty	  caused	  by	  
the	  very	   low	  fluorescence	  intensity,	  compared	  to	  Bremachlorin,	  as	  shown	  in	  figure	  5.8a.	  
This	  was	   reflected	   in	   an	   increased	   fit	   uncertainty.	  Over	   the	   first	   6	  hours	   after	   injection,	  
Bremachlorin	   showed	   a	   stable	   peak	  width	   for	   all	   tissues	   under	   investigation,	  while	   ce6	  
showed	  a	  steady	  but	  not	  significant	  decrease	  over	  time	  for	  tumor	  and	  normal	  tissue.	  
DISCUSSION	  
In	   this	   paper	  we	  have	  demonstrated	   for	   the	   first	   time	   that	   in-­‐vivo	   application	  of	   SFF	   is	  
possible.	  We	  report	  on	  variations	   in	   spectral	   shape	  of	   the	   fluorescence	  emission	  of	   two	  
photosensitizers	   ce6	   and	  Bremachlorin	   in	   various	   tissues	   after	   intravenous	   injection.	   To	  
compare	   fluorescence	   intensity	   and	   spectral	   shape	   in	   different	   tissues	   and	   of	   multiple	  
animals,	   we	   extracted	   the	   intrinsic	   fluorescence	   by	   removing	   the	   influence	   of	   tissue	  
optical	  properties	  on	  the	  raw	  fluorescence	  signal.	  
	  
SPECTRAL	  VARIABILITY	  IN	  CE6	  	  
It	  is	  shown	  in-­‐vitro	  that	  both	  the	  fluorescence	  peak	  intensity	  and	  the	  peak	  position	  of	  ce6	  
are	  strongly	  influenced	  by	  pH	  of	  the	  solution	  [32].	  For	  ce6	  in	  PBS	  a	  decrease	  in	  pH	  in	  the	  
range	  of	  7.5-­‐3.5	  results	  in	  a	  peak	  shift	  from	  661	  to	  647	  nm,	  combined	  with	  a	  decrease	  in	  
intensity	  of	  the	  main	  fluorescence	  peak	  when	  the	  spectrum	  is	  normalized	  at	  720	  nm	  [32].	  
The	  range	  of	  peak	  positions	  for	  ce6	  that	  we	  have	  observed	  was	  in	  the	  range	  of	  665-­‐671	  
nm,	   which	   is	   higher	   than	   reported	   by	   Cunderlikova	   et	   al.	   It	   is	   shown	   for	   the	   spectral	  
properties	   of	   ce6	   in	   more	   physiologically	   relevant	   environments	   containing	   serum	   (by	  
adding	  FCS,	  BSA,	  LDL/HDL)	  or	  measured	  in-­‐vivo,	  that	  the	  binding	  of	  ce6	  significantly	  shifts	  
the	  peak	  position	  to	  higher	  wavelengths	  [40].	  Studies	  of	  ce6	  or	  ce6-­‐conjugates	  in	  solution	  
show	  a	  peak	  wavelength	  range	  comparable	  with	  what	  was	  found	  in	  this	  study	  [35,	  40,	  49].	  
Changes	   in	   pH	   influence	   binding	   affinity	   and	   thus	   the	   spectral	   shape	   represents	   the	  
relative	   contributions	   of	   the	   differently	   bound	   ce6.	   The	   data	   in	   figure	   5.8b	   and	   5.8c	  









position	  wavelength	   in	  time	  after	  photosensitizer	   injection	  for	  tumor,	  normal	  tissue	  and	  
skin.	  According	  to	  Cunderlikova	  et	  al.	  [32],	  the	  increase	  of	  peak/shoulder	  ratio	  and	  peak	  
position	  suggests	  a	  transition	  into	  a	  higher	  pH	  environment	  in	  an	  in-­‐vitro	  situation.	  In	  the	  
range	   of	   biological	   relevant	   pH	   values,	   the	   peak	   shift	   associated	   with	   pH	   variations	   is	  
small.	  How	  this	  transfers	  to	  the	  in-­‐vivo	  situation	  remains	  to	  be	  determined.	  	  
	  
COMPARISON	  OF	  CE6	  AND	  BREMACHLORIN	  
It	   is	   clear	   from	   figure	  5.8b	  and	  5.8c	   that	  although	   ratio	  and	  peak	  position	   increased	   for	  
ce6,	  Bremachlorin	  showed	  the	  opposite;	  a	  blue-­‐shift	   in	  peak	  position	  accompanied	  by	  a	  
decrease	   in	   shoulder	   ratio.	   This	   might	   suggest	   re-­‐localization	   of	   the	   drug	   to	   an	  
environment	  with	  a	  lower	  pH.	  Furthermore,	  binding	  of	  ce6	  to	  low-­‐density	  lipoproteins	  is	  
also	   linked	  with	  a	  blue-­‐shift	  of	   the	  peak	  position,	  compared	  to	  albumin	  bound	  ce6.	  This	  
suggests	   that	   ce6	   in	   Bremachlorin	   may	   be	   preferably	   bound	   to	   these	   LDL	   proteins,	  
providing	   for	   uptake	   in	   (malignant)	   cells.	   Unbound	   ce6	   is	   mainly	   accumulated	   in	   the	  
plasma	  membrane	  of	  cells.	  The	  width	  of	  the	  peak,	  which	  could	  also	  be	  associated	  with	  pH,	  
did	  not	  change	  significantly.	  	  
	  
Bremachlorin	   consists	   of	   a	  mixture	   of	   ce6,	   purpurin	   5	   and	   cp6,	   in	  which	   both	   ce6	   and	  
purpurin	  5	  are	  know	  to	  have	  photodynamic	  effect.	  In	  the	  administered	  mixture,	  ce6	  also	  
acts	   as	   a	   solvent,	   since	   purpurin	   5	   is	   too	   hydrophobic	   to	   be	   administered	   in	   aqueous	  
solution.	  Purpurin	  has	  a	  high	  binding	  affinity	  to	  LDL	  proteins,	  allowing	  the	  drug	  to	  enter	  
malignant	   cells	   via	   endocytosis	   [50].	   Since	   ce6	   accounts	   for	   the	   largest	   fraction	   in	  
Bremachlorin,	  we	  expected	  the	  spectral	  shape	  to	  be	  dominated	  by	  ce6.	  	  The	  influence	  of	  
the	   other	   two	   components	   –	   purpurin	   5	   and	   chlorin	   p6	   –	   on	   the	   spectral	   shape	   and	  
behavior	   is	   unknown.	   Both	   purpurin	   5	   and	   chlorin	   p6	   are	   known	   to	   have	   an	   emission	  
spectrum	   similar	   to	   ce6	   when	   analyzed	   separately	   [51,	   52].	   Our	   results	   showed	   that	   a	  
mixture	   of	   ce6,	   cp6	   and	   purpurin	   5	   clearly	   behaved	   differently	   than	   pure	   ce6.	  
Bremachlorin	  is	  more	  lipophilic	  than	  pure	  ce6	  [42],	  and	  it	   is	  therefore	  expected	  that	  the	  
localization	  of	  Bremachlorin	  differs	   from	  pure	  ce6.	   It	  could	  not	  be	  determined	  from	  this	  
experiment	   if	   the	   spectral	   variations	   between	   Bremachlorin	   and	   ce6	   were	   a	   result	   of	  
spectral	  influences	  of	  the	  two	  extra	  components,	  or	  if	  they	  were	  variations	  in	  ce6	  spectra	  
caused	   by	   changes	   in	   environment.	   However,	   our	   experiments	   did	   show	   that	  
Bremachlorin	   has	   different	   spectral	   properties	   than	   pure	   ce6	   and	   should	   therefore	   be	  













FLUORESCENCE	  CORRECTION	  METHOD	  
The	  method	  to	  use	  MDSFR	  for	  measuring	  the	  absorption	  and	  reduced	  scattering	  in-­‐vivo	  to	  
recover	  the	  intrinsic	  photosensitizer	  fluorescence	  is	  developed	  based	  on	  the	  use	  of	  Monte	  
Carlo	   simulations	   and	   phantom	   studies.	   In	   these	   optimized	   circumstances,	   theory	   is	  
validated	  and	  empirical	  parameters	  are	  included	  in	  the	  model	  [23].	  However,	  applying	  this	  
method	   in-­‐vivo	   is	   much	   less	   straightforward	   considering	   spatial	   heterogeneity	   and	   the	  
potential	  for	  the	  confounding	  effects	  of	  tissue	  layers.	  In	  this	  study	  MDSFR	  was	  performed	  
using	  consecutive	  placement	  of	   two	  fiber	  diameters	  on	  the	  same	  spot.	  Therefore,	  slight	  
differences	   in	  measurement	  volume	  were	  not	  only	  due	   to	  different	   fiber	  diameters	  but	  
could	   also	   occur	   from	   measuring	   a	   slightly	   different	   sampling	   volume	   in	   each	  
measurement.	   Therefore	   the	   µ’s	   used	   to	   correct	   the	   fluorescence	   was	   based	   on	   an	  
average	  value	  and	  did	  not	  necessarily	  exactly	  represent	  the	  µ’s	  in	  the	  fluorescence	  sample	  
volume.	   New	   technological	   developments	   should	   overcome	   this	   problem	   in	   the	   near	  
future	   and	  provide	   true	   co-­‐localized	  measurement	  positions	   for	   various	   fiber	  diameters	  
[45].	  Although	  we	  repositioned	  the	  probe	  on	  each	  tissue	  up	  to	  five	  times	  per	  mouse,	  the	  
variation	   of	   variables	   compared	   within	  measurements	   of	   one	  mouse	   was	   at	   least	   four	  
times	   smaller	   than	   the	  maximum	  variation	  between	   animals.	   Therefore,	   the	   size	   of	   the	  
error	  bars	  was	  predominately	  due	  to	  inter-­‐animal	  variations.	  
	  
IMPLICATIONS	  AND	  FUTURE	  WORK	  
In	   this	   work	   we	   investigated	   spectral	   variations	   of	   chlorin	   e6	   and	   Bremachlorin.	   Clear	  
differences	   were	   observed	   in	   fluorescence	   intensity,	   peak/shoulder	   ratio	   and	   peak	  
position	   for	   both	   sensitizers	   over	   time	   after	   injection.	   Furthermore,	   although	  
Bremachlorin	  consists	  of	  approximately	  80%	  of	  ce6,	  spectra	  showed	  distinct	  differences,	  
suggesting	   variations	   in	   localization	   and/or	   clearance	   pathways.	   The	   more	   blue-­‐shifted	  
peak	  of	  Bremachlorin,	  together	  with	  the	  wider	  peak,	  suggests	  Bremachlorin	  was	  bound	  to	  
LDL	  proteins	  more	  than	  ce6.	  This	  might	  result	  in	  a	  higher	  uptake	  of	  the	  photosensitizer	  in	  
the	  cell.	  It	  is	  shown	  that	  internalization	  of	  the	  photosensitizer	  results	  in	  more	  PDT	  induced	  
damage	  than	  photosensitizers	  located	  on	  the	  cell	  membrane	  [53].	  Furthermore,	  this	  may	  
explain	  the	  prolonged	  detection	  of	  significant	  amounts	  of	  photosensitizer	  fluorescence	  in	  
tissue	  compared	  to	  ce6.	  	  
	  
Although	   results	   in	   this	   study	   look	   promising	   for	   using	   the	   ce6	   in	   Bremachlorin	   as	  
photosensitizer,	   purpurin	   5	   is	   known	   to	   have	   strong	   photodynamic	   activity	   as	   well.	  
Spectral	   analysis	   showed	   mainly	   variations	   in	   ce6.	   How	   this	   ce6	   behavior	   relates	   to	  









investigated.	  In	  future	  studies	  we	  aim	  to	  analyze	  the	  microscopic	  distribution	  of	  ce6	  and	  
Bremachlorin	  in	  tongue/tumor	  tissue.	  
	  
CONCLUSION	  
In	   the	   present	   study	   we	   used	   for	   the	   first	   time	   quantitative	   single	   fiber	   fluorescence	  
spectroscopy	   in-­‐vivo	   to	   analyze	   fluorescence	   spectra	   of	   both	   ce6	   and	   Bremachlorin	   in-­‐
vivo.	   Influence	   of	   optical	   properties	   on	   fluorescence	   varied	   up	   to	   35%	   over	   the	   visible	  
wavelength	  range	  and	  was	  tissue	  dependent.	  We	  analyzed	  variations	  in	  spectral	  shape	  of	  
the	   intrinsic	   fluorescence	   in	   normal	   tongue	   tissue,	  OSC	   tongue	   tumor,	   skin	   and	   liver	   at	  
t=[3	  4.5	  6	  24	  48]	  hours	  after	  photosensitizer	  injection.	  We	  observed	  significant	  differences	  
in	   spectral	   shape	   over	   time	   between	   sensitizers.	  While	   the	  wavelength	   position	   of	   the	  
fluorescence	   intensity	  maximum	  underwent	  a	   red-­‐shift	  over	   time	   for	   ce6,	  Bremachlorin	  
showed	  a	  blue-­‐shift.	   Furthermore,	   the	  Bremachlorin	  peak	  appeared	   to	  be	  broader	   than	  
the	   ce6	   fluorescence	   peak.	   Intrinsic	   fluorescence	   intensity,	   which	   can	   be	   related	   to	  
photosensitizer	  concentration,	  was	  decreasing	  for	  all	  time	  points,	  but	  showed	  significantly	  
more	   Bremachlorin	   present	   compared	   to	   ce6	   at	   long	   incubation	   times.	   In	   conclusion,	  
although	  Bremachlorin	  consists	  for	  ~80%	  of	  chlorin	  e6,	  they	  behaved	  significantly	  different	  
in-­‐vivo.	  These	  differences	  may	  be	  explored	   to	  define	  an	  optimal	   treatment	  protocol	   for	  
Bremachlorin-­‐based	  photodynamic	  therapy.	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The	   effect	   of	   photodynamic	   therapy	   (PDT)	   is	   dependent	   on	   the	   localization	   of	  
photosensitizer	   in	   the	   treatment	   volume	   at	   the	   time	   of	   illumination.	   Investigation	   of	  
photosensitizer	   pharmacokinetics	   in	   and	   around	   the	   treatment	   volume	   aids	   in	  
determining	  the	  optimal	  drug-­‐light	  interval	  for	  PDT.	  In	  this	  paper	  we	  have	  investigated	  the	  
distribution	  of	  the	  photosensitizers	  chlorin	  e6	  and	  Bremachlorin	  in	  the	  oral	  squamous	  cell	  
carcinoma	   cell-­‐line	   OSC19-­‐Luc-­‐Gfp	   in	   a	   tongue	   tumor,	   tumor	   boundary,	   invasive	   tumor	  
boundary	  and	  normal	  tongue	  tissue	  by	  the	  use	  of	  confocal	  microscopy	  of	  frozen	  sections.	  
Tongues	  were	  harvested	  at	  t	  =	  [3	  4.5	  6	  24	  48]	  hours	  after	  injection.	  Both	  photosensitizers	  
showed	  a	  decreasing	  fluorescence	  with	  increasing	  incubation	  time,	  and	  at	  all	  time	  points	  
higher	   fluorescence	   was	   measured	   in	   tumor	   boundary	   than	   in	   tumor	   itself.	   For	   short	  
incubation	  times,	  a	  higher	  fluorescence	  intensity	  was	  observed	  in	   invasive	  tumor	  border	  
and	   normal	   tissue	   compared	   to	   tumor	   tissue.	   Bremachlorin	   showed	   a	   small	   increase	   in	  
tumor	   to	  normal	   ratio	  at	  24	  and	  48	  hours	   incubation	   time.	  Ce6	  was	  undetectable	  at	  48	  
hours.	   We	   did	   not	   find	   a	   correlation	   between	   photosensitizer	   localization	   and	   the	  
presence	   of	   vasculature.	   It	   can	   be	   concluded	   that	   Bremachlorin	   at	   24	   and	   48	   hour	  
incubation	   times	   provides	   us	   with	   both	   a	   concentration	   suitable	   for	   PDT	   and	   a	   small	  
tumor/tumor	  boundary	  to	  normal	  selectivity	  of	  between	  1.2	  and	  2.5.	  This	  selectivity	  after	  
long	  incubation	  times	  provides	  the	  possibility	  to	  spare	  normal	  tissue	  and	  it	  may	  therefore	  



























Photodynamic	   therapy	   (PDT)	   is	   the	   treatment	  of	   choice	   for	   several	   (pre-­‐)malignant	   skin	  
lesions	  [1].	  There	  have	  been	  many	  (pre-­‐)clinical	  studies	  focusing	  on	  the	  use	  of	  PDT	  for	  the	  
treatment	  of	  epithelial	  malignancies	  and	  solid	  tumors	  and	  PDT	  has	  been	  used	  clinically	  for	  
the	  treatment	  of	  tumors	  of	  the	  head	  &	  neck	  and	  the	  prostate	  [2-­‐5].	  The	  principle	  of	  PDT	  is	  
based	  on	  the	  generation	  of	  reactive	  oxygen	  species	  (ROS).	  These	  ROS,	  which	  have	  a	  very	  
short	  life	  time	  and	  diffusion	  length,	  cause	  damage	  in	  nearby	  tissue	  structures	  resulting	  in	  
cellular,	   vascular	   and	   immunological	   responses	   [6].	   ROS	   are	   generated	   when	   a	  
photosensitizing	   agent,	   the	   photosensitizer,	   is	   illuminated	   with	   light	   of	   a	   specific	  
wavelength	   in	   the	   presence	   of	   molecular	   oxygen.	   The	   photosensitizer	   facilitates	   the	  
transfer	   of	   energy	   from	   light	   to	  molecular	   oxygen,	   resulting	   in	   the	   formation	   of	   highly	  
reactive	   singlet	   oxygen.	   Over	   the	   last	   30	   years,	   different	   photosensitizing	   agents	   have	  
been	  synthesized	  and	  tested.	  These	  photosensitizers	  vary	  in	  how	  reactive	  oxygen	  species	  
are	  generated,	  where	  they	  are	  located	  in	  tissue	  and	  how	  they	  are	  metabolized	  [7].	  
It	   is	   desirable	   for	   photosensitizers	   to	   have	   a	   preferential	   uptake	   in	   tumor	   tissue	  
over	   normal	   tissue.	  When	   the	   concentration	   photosensitizer	   is	   (much)	   higher	   in	   tumor	  
than	   in	   its	   surrounding	   tissue,	   selective	   tissue	  damage	  may	  be	   achieved	  when	  using	   an	  
appropriate	   illumination	  protocol	   [8,	  9].	  There	  are	  various	  ways	  to	  achieve	  this	  selective	  
tissue	   damage.	   Intravascular	   administered	   photosensitizers	   such	   as	   mTHPC	   rely	   for	  
selectivity	  on	  the	  leaky	  neovasculature	  in	  and	  surrounding	  the	  tumor.	  It	  is	  expected	  that	  
the	   somewhat	   loose	   structure	   of	   endothelial	   cells	   in	   tumor	   neovasculature	   allows	   for	  
easier	   passage	   of	   intravascular	   substances	   into	   the	   surrounding	   tissue,	   together	  with	   a	  
selective	   affinity	   for	   proliferating	   neovasculature.	   When	   performing	   PDT	   with	  
intravascular	   administrated	   chlorin	   e6	   (ce6)	   based	   photosensitizer,	   additional	  
environmental	  factors	  such	  as	  pH	  may	  enhance	  selectivity	  [10].	  In-­‐vitro	  it	  has	  been	  shown	  
that	  a	  decrease	  of	  pH	  from	  8.5	  to	  7.0	  enhances	  the	   lipophilicity	  and	  therefore	   increases	  
the	  binding	  prevalence	  of	  ce6	  from	  serum	  albumin	  towards	  low-­‐density	  lipoproteins	  (LDL)	  
in	   the	   blood	   stream	   [10,	   11].	   Lipoproteins,	   and	   therefor	   the	   photosensitizer,	   are	  
internalized	   via	   the	   endocytosis	   pathway.	   Since	   the	   pH	   of	   tumor	   stroma	   is	   decreased	  
compared	  to	  normal	  tissue	  [12],	  the	  liphophilicity	  may	  favor	  the	  cellular	  uptake	  of	  ce6	  by	  
tumor	  tissue.	  
	  
The	   localization	  of	   the	  photosensitizer	  at	   the	   time	  of	   therapy	  determines	  which	  cellular	  
and	   tissue	   structures	   are	   damaged	   by	   PDT	   generated	   reactive	   oxygen	   species.	   Some	  
(mainly	  intravenous	  administered)	  photosensitizers	  directly	  target	  the	  vasculature,	  which	  










nutrients	  to	  the	  tumor,	  resulting	  in	  its	  destruction	  [13].	  However,	  vascular	  shutdown	  and	  
blood	  flow	  changes	  during	  early	  stages	  of	  illumination	  decrease	  the	  transport	  of	  oxygen,	  
which	  may	  limit	  the	  production	  of	  singlet	  oxygen	  and	  thereby	  inhibit	  the	  induction	  of	  local	  
cellular	   and	   immunological	   responses.	   Treatment	   efficacy	   is	   therefore	   dependent	   on	   a	  
fine	   balance	   between	   the	   positive	   and	   negative	   effects	   of	   vascular	   damage.	   By	   varying	  
PDT	   treatment	   protocols,	   one	   can	   determine	   the	   effects	   on	   particular	   tissue	   structures	  
[8].	  Directly	  after	   intravenous	  administration	  of	  the	  photosensitizer	  one	  expects	   it	   to	  be	  
present	  in	  the	  vessels	  and	  partly	  in	  tissue	  closely	  surrounding	  the	  vasculature.	  The	  longer	  
the	   time	  between	  drug	   administration	   and	   illumination	   the	  more	   the	  photosensitizer	   is	  
expected	  to	  diffuse	   into	  the	  surrounding	  tissue	  and	  not	  only	   localize	  around	  vasculature	  
[8].	   However,	   differences	   in	   metabolism	   and	   clearance	   between	   tissues	   result	   in	  
concentration	  gradients	  several	  hours	  to	  days	  after	  injection.	  The	  investigation	  of	  in-­‐vivo	  
pharmacokinetics	  is	  therefore	  a	  very	  important	  tool	  to	  identify	  the	  drug	  distribution	  that	  
is	  thought	  to	  represent	  the	  most	  favorable	  treatment	  conditions	  [14].	  	  
	  
The	   photosensitizer	   ce6	   has	   been	   studied	   intensively	   for	   over	   two	   decades	   [15].	   It	   is	   a	  
second	   generation	   photosensitizer,	   which	   shows	   low	   dark	   toxicity	   and	   an	   enhanced	  
absorption	  in	  the	  red	  wavelength	  region	  between	  600	  and	  800	  nm.	  Ce6-­‐PVP,	  in	  which	  the	  
ce6	   molecule	   is	   bound	   to	   a	   polyvinylpyrrolidone	   carrier,	   has	   been	   used	   in	   PDT	   of	  
urological	   tumors	   [16].	   Various	   preclinical	   studies	   with	   the	   photosensitizer	   mono-­‐L-­‐
aspartylchlorin-­‐e6	   (Npe6)	   have	   been	   performed	   and	  NPe6	   is	   clinically	   approved	   for	   the	  
treatment	  of	  early	   stage	   superficial	   squamous	   cell	   carcinomas	   in	   lung	   in	   Japan	   [17,	  18],	  
and	   it	   is	  also	  under	   investigation	  for	  skin	  malignancies	   [19].	   It	   is	  known	  that	  the	   in-­‐vitro	  
spectral	  shape	  of	  ce6	  is	  strongly	  dependent	  on	  pH	  of	  the	  solution;	  variations	  in	  pH	  result	  
in	   a	   shift	   of	   both	   the	   absorption	   and	   fluorescence	   spectrum	   and	   a	   decrease	   of	  
fluorescence	   intensity	   [10,	   11].	   By	   analyzing	   both	   intensity	   and	   spectral	   shape,	   it	   is,	   in	  
theory,	   possible	   to	   distinguish	   between	   intensity	   decreases	   due	   to	   clearance	   of	   the	  
photosensitizer	   from	   the	   tissue,	   and	   intensity	   changes	   due	   to	   relocalization	   to	   an	  
environment	  with	  a	  different	  pH.	  An	   important	   characteristic	  of	   ce6	   is	   its	   relatively	   low	  
lipophilicity,	  resulting	  in	  rapid	  excretion	  from	  the	  body	  via	  the	  urinary	  system.	  A	  positive	  
effect	   of	   this	   short	   clearance	   time	   is	   reduced	   skin	   photosensitivity,	   which	   prevents	  
patients	  from	  spending	  days	  or	  even	  weeks	  in	  the	  dark.	  A	  drawback	  is	  that	  short	  clearance	  
times	  can	  limit	  the	  effective	  localization	  in	  neoplastic	  tissue.	  	  
A	  new	  photosensitizing	  compound,	  Bremachlorin,	   consists	   largely	   (~80%)	  of	   ce6,	  
combined	  with	  the	  photosensitizing	  agents	  purpurin	  5	  (~15%)	  and	  chlorin	  p6	  (~5%)	  [20].	  
The	  number	  of	  (pre-­‐)clinical	  studies	  performed	  with	  Bremachlorin	  is	  limited	  but	  covers	  a	  










Bremachlorin	   is	   thought	   to	   be	   purpurin	   5,	   partly	   because	   its	   rapid	   interaction	   with	  
albumin	  and	  low-­‐density	  lipoproteins	  that	  enables	  it	  to	  be	  delivered	  to	  cancerous	  tissues	  
[24].	   Although	   purpurin	   5	   in	   itself	   is	   too	   hydrophobic	   to	   be	   administrated	   in	   aqueous	  
solution,	  combined	  with	  ce6	  and	  cp6	  it	  achieves	  the	  chemical	  stability	  required	  for	  both	  
intravenous	   administration	   and	   storage.	   Although	   the	   exact	   role	   of	   the	   three	   separate	  
constituents	  of	  Bremachlorin	  on	  the	  biodistribution	  and	  potential	  PDT	  induced	  response	  is	  
unclear,	  it	  is	  expected	  that	  the	  combined	  purpurin	  5	  and	  ce6	  in	  Bremachlorin	  results	  in	  an	  
overall	  photosensitizing	  effect	   that	   is	  greater	   than	  the	   individual	  concentrations	  of	  both	  
photosensitizers	  [20].	  The	  confocal	  microscopy	  approach	  of	  the	  present	  manuscript	  does	  
not	   provide	   the	   possibility	   to	   discriminate	   between	   the	   individual	   constituents	   of	  
Bremachlorin.	  
	  
In	   this	   paper,	   we	   compare	   the	   localization	   of	   the	   clinically	   registered	   formulation	   of	  
Bremachlorin	  with	  ce6	  in	  oral	  squamous	  cell	  carcinomas	  and	  surrounding	  tissue	  in	  tongue,	  
at	  various	  time	  points	  after	  i.v.	  administration	  by	  means	  of	  confocal	  microscopy.	  Recently	  
we	  have	  reported	  on	  variations	  in	  intensity	  and	  spectral	  shape	  between	  Bremachlorin	  and	  
ce6	  while	  using	  non-­‐invasive	  in-­‐vivo	  fiber	  optic	  intrinsic	  fluorescence	  spectroscopy	  [25].	  In	  
this	   paper	  we	   continue	   that	   investigation	   by	   studying	   concentration	   gradients	   between	  
tumor,	   tumor	  boundary,	   invasive	   tumor	  border	  and	   tissue	   showing	  normal	  histology	  by	  
the	   use	   of	   confocal	   microscopy.	   Furthermore,	   localization	   of	   photosensitizer	   around	  
vasculature	   is	   investigated	  over	   time.	  The	  aim	  of	   this	   study	   is	   to	  distinguish	   localization	  
differences	  between	   the	   two	  photosensitizers	  on	  a	  microscopic	   scale,	  and	  compare	   this	  
with	  fiber	  optic	  results.	  	  
MATERIALS	  AND	  METHODS	  
ANIMAL	  MODEL	  	  
Forty	   BALB/c	   nu/nu	   hairless	   mice	   (aged	   4-­‐6	   weeks;	   Charles	   River	   Laboratories)	   were	  
incubated	  with	  orthotopic	  oral	   squamous	  cell	   carcinoma’s	  at	   the	   tip	  of	   the	   tongue.	  This	  
cell	   line	  was	   transduced	  with	   luciferase	   2	   (luc2)	   and	   green	   fluorescent	   protein	   (gfp)	   to	  
create	   the	   cell	   line	   OSC-­‐19-­‐luc2-­‐cgfp,	   as	   described	   previously	   [26-­‐28].	   6x104	   cells,	  
suspended	  in	  20	  μL	  phosphate-­‐buffered	  saline	  were	  submucosally	  implanted	  in	  the	  tip	  of	  
the	  tongue	  of	  the	  mice.	  Two	  weeks	  later,	  mice	  were	  randomized	  in	  10	  groups	  and	  injected	  
with	   either	   Bremachlorin	   (20	   mg	   kg-­‐1,	   from	   a	   3.5	   g	   L-­‐1	   stock	   solution;	   Rada-­‐pharma	  
International	  B.V.	  ,The	  Netherlands)	  or	  ce6	  (16	  mg	  kg-­‐1,	  dissolved	  in	  100	  µl	  PBS,	  Frontier	  










mice	  were	  anesthetized,	  sacrificed	  by	  cervical	  dislocation	  and	  tongues	  were	  removed	  and	  
snap	   frozen	   for	   further	   investigation.	   The	   study	   protocol	   was	   approved	   by	   the	   Animal	  
Welfare	   Committee	   of	   the	   Leiden	   University	   Medical	   Center.	   Housing	   of	   mice,	   the	  
experiments	  and	  euthanazation	  were	  performed	  in	  accordance	  with	  the	  guidelines	  of	  this	  
committee.	  Chlorophyll	  free	  food	  and	  sterilized	  water	  were	  provided	  without	  restriction.	  	  
	  
CONFOCAL	  IMAGE	  ANALYSIS	  
Tongues	   were	   harvested	   and	   snap	   frozen	   in	   liquid	   nitrogen	   at	   a	   preset	   time	   after	  
photosensitizer	   injection.	   Samples	  were	   stored	   in	   dark	   containers	   at	   -­‐80oC.	   From	   every	  
tongue,	  three	  frozen	  sections	  with	  a	  slice	  thickness	  of	  20	  µm	  were	  prepared	  for	  confocal	  
microscopy.	   Every	   slice	   was	   followed	   by	   a	   subsequent	   5	   µm	   thick	   slice	   to	   allow	   for	  
hematoxylin	   &	   eosin	   (H&E)	   staining	   and	   histological	   analysis.	   Sample	   preparation	   and	  
storage	   was	   performed	   under	   dark	   conditions	   to	   prevent	   photobleaching	   of	   the	  
photosensitizer	  present	  in	  the	  samples.	  Confocal	  microscopy	  was	  performed	  using	  a	  Zeiss	  
LSM	  510	  confocal	  laser	  scanning	  microscope	  equipped	  with	  an	  8-­‐channel	  photomultiplier	  
tube	   for	   semi-­‐spectral	   detection	   of	   fluorescence	   (Zeiss	   LSM510META,	   Carl	   Zeiss	   B.V.	  
Sliedrecht,	   the	   Netherlands).	   In	   every	   section,	   three	   locations	   containing	   various	   tissue	  
structures	   were	   chosen	   for	   analysis.	   Locations	   contained	   tumor	   and	   tumor	   boundary,	  
invasive	  tumor	  border	  or	  normal	  tongue	  tissue.	  	  
A	  spectral	  image	  of	  the	  photosensitizer	  fluorescence	  under	  405	  nm	  excitation	  was	  
generated	  recording	  fluorescence	  at	  16	  wavelengths	  ranging	  from	  588-­‐748	  nm.	  Confocal	  
images	   of	   gfp	   fluorescence	   and	   autofluorescence	   were	   recorded	   of	   the	   same	   location,	  
directly	  after	  each	  other.	  Detailed	  settings	  can	  be	  found	   in	  table	  6.1.	  Simultaneous	  with	  
each	   fluorescence	   image,	  a	  bright-­‐field	  514	  nm	  transmission	   image	  was	   recorded	  which	  
shows	   histological	   data.	   Exact	   coordinates	   of	   the	   measurement	   locations	   within	   a	  
Table	  6.1:	  Confocal	  microscopy	  settings	  










gfp,	  Tumor	  tissue	   488	   505-­‐530	  BP	   <10	  µm	   1.60	   200x	  
Autofluorescence	   405	   420-­‐480	  BP	   <10	  µm	   1.60	   200x	  
ce6	  /	  Bremachlorin	  	  
Spectral	  detection	  
405	   588-­‐748	  nm	  
10	  nm	  res.	  
<10	  µm	   1.60	   200x	  
CD31,	  endothelial	  
cells	  










microscope	   slide	   were	   carefully	   recorded.	   After	   this	   imaging	   session,	   samples	   were	  
stained	  with	  Alexa	  Fluor®	  647	  anti-­‐mouse	  CD31	   (2.5	  µg	  ml-­‐1;	  BioLegend	   Inc.,	   San	  Diego,	  
USA)	  for	  12	  hours	  at	  4oC.	  Afterwards,	  samples	  were	  rinsed	  with	  PBS	  and	  analyzed	  with	  the	  
confocal	   microscope	   to	   visualize	   vasculature	   at	   the	   exact	   same	   locations	   as	   the	   three	  
previous	  recordings	  were	  made.	  Details	  of	  the	  imaging	  parameters	  are	  shown	  in	  table	  6.1.	  	  
	  
DATA	  ANALYSIS	  
Analysis	   of	   the	   images	   was	   performed	   using	   Matlab	   (release	   2010b,	   The	   Mathworks,	  
Natick,	   MA,	   USA).	   The	   spectral	   fluorescence	   images	   were	   averaged	   over	   2x2	   pixels	   to	  
reduce	   noise	   levels.	   Every	   cluster	   of	   pixels	  was	   then	   spectrally	   deconvolved	   using	   basis	  
spectra	  for	  autofluorescence	  and	  ce6	  fluorescence.	  Autofluorescence	  was	  determined	  to	  
be	  a	  multiple	  of	  an	  exponential	  decay	  curve	  with	  a	  power	  of	  -­‐0.03,	  equation	  6.1,	  
	  	   	   	   	   	  ,	   	   	   	  	  	  	  	  	  	  (6.1)	  
where	   a	   is	   a	   fit	   factor	   and	   λ	   the	   wavelength.	   This	   autofluorescence	   basis	   spectrum	   is	  
based	   on	   spectra	   measured	   (in	   identical	   configuration	   as	   the	   measurements)	   on	   18	  
locations	  in	  three	  reference	  tongues	  without	  photosensitizer.	  One	  autofluorescence	  basis	  
spectrum	   could	   be	   applied	   to	   both	   tumor,	   normal	   tissue	   and	   invasive	   tumor	   border.	  
Photosensitizer	   basis	   spectra	   were	   derived	   from	   19	   locations	   containing	   a	   high	  
photosensitizer	   fluorescence	   intensity,	   after	   the	   removal	   of	   autofluorescence.	   Since	   the	  
spectral	   resolution	   of	   the	   microscope	   is	   quite	   low	   (10	   nm),	   we	   did	   not	   discriminate	  
between	   basis	   spectra	   for	   ce6	   and	   Bremachlorin.	   There	   was	   substantial	   variation	   in	  
autofluorescence	   between	   tissues.	   Spectrally	   deconvolving	   the	   photosensitizer	  
fluorescence	  images	  resulted	  in	  a	  measure	  of	  the	  photosensitizer	  present	  not	  influenced	  
by	  autofluorescence	  variations.	  	  
Images	  of	  autofluorescence	  and	  tumor	  cell	  gfp	  fluorescence	  aided	  in	  determining	  
which	  pixels	  to	  include	  in	  analysis.	  To	  discriminate	  between	  tissue	  autofluorescence	  or	  gfp	  
fluorescence	  and	  system	  or	  background	  noise,	   the	  Matlab	  function	   ‘grayslice’	  was	  used.	  
This	  function	  converts	  gray	  scale	  images	  to	  indexed	  images	  using	  multilevel	  thresholding.	  
Every	  pixel	  with	  threshold	  ≥1	  was	  included	  as	  tissue	  or	  tumor	  using	  autofluorescence	  or	  
gfp	   fluorescence	   respectively.	   If	   a	   location	   contains	   tumor	   (gfp-­‐positive)	   and	   tumor	  
boundary	  (gfp-­‐negative)	  pixels,	  pixels	  containing	  gfp	  fluorescence	  are	  counted	  as	  tumor,	  
while	  the	  rest	  of	  the	  image	  is	  considered	  boundary.	  	  
Pixels	   with	   very	   high	   intensity	   fluorescence	   spots	   in	   the	   photosensitizer	   and	  
autofluorescence	  images	  caused	  by	  section	  preparation	  artifacts	  were	  not	  included	  in	  the	  
analysis.	   The	   average	   photosensitizer	   concentration	   was	   calculated	   for	   the	   following	  
tissues:	   OSC	   tongue	   tumor	   (including	   only	   gfp-­‐fluorescence	   positive	   pixels),	   tumor	  
boundary,	  invasive	  tumor	  border	  and	  histologically	  normal	  tongue	  tissue.	  This	  resulted	  in	  










an	  average	  photosensitizer	  concentration	  for	  every	  tissue	  at	  each	  time	  point,	  for	  both	  ce6	  
and	  Bremachlorin.	  	  
	  
CO-­‐LOCALIZATION	  WITH	  VASCULATURE	  
To	   assess	   the	   degree	   of	   co-­‐localization	   of	   photosensitizer	   with	   vasculature,	   a	   vessel	  
staining	   procedure	   was	   used,	   where	   tissue	   was	   incubated	   with	   CD31	   for	   12	   hours.	  
However,	  due	  to	  the	  hydrophilic	  nature	  of	  ce6	  and	  Bremachlorin,	  this	  staining	  procedure	  
removed	   photosensitizer	   from	   the	   tissue.	   Therefore,	   images	   of	   photosensitizer	   and	   gfp	  
were	   recorded	   before	   staining.	   A	   514	   nm	   bright-­‐field	   transmission	   image	   of	   the	  whole	  
tongue	   was	   made	   to	   show	   tissue	   histology.	   Locations	   of	   fluorescence	   images	   were	  
mapped	   on	   these	   histological	   images.	   After	   staining	   of	   the	   vasculature,	   the	   tissue	   was	  
again	   imaged,	   at	   the	   exact	   same	   location.	   The	   required	   position	   of	   the	   slide	   was	  
determined	   based	   on	   the	   histological	   features	   in	   the	   bright-­‐field	   transmission	   image.	  
Resulting	   vasculature	   images	  were	   analyzed	   using	   the	   function	   ‘grayslice’	   to	   determine	  
which	  pixels	  were	  identified	  as	  vasculature	  (threshold	  ≥1).	  Only	  pixel	  clusters	  larger	  than	  
30	   bordering	   pixels	   were	   considered	   vasculature.	   In	   situations	   where	   there	   was	   non-­‐
specific	   staining	   of	   tissue,	   all	   pixel	   clusters	   belonging	   to	   vasculature	   were	   manually	  
selected	   and	   non-­‐specific	   staining	   was	   ignored.	   Automated	   analysis	   of	   photosensitizer	  
fluorescence	  intensity	  versus	  distance	  to	  nearest	  vessel	  was	  performed	  by	  calculating	  the	  
distance	   in	   pixels	   to	   the	   nearest	   pixel	   stained	   for	   vasculature.	  When	   the	   distance	   was	  
determined	   for	  all	  pixels,	   it	  was	  binned	   in	   steps	  of	  20	  pixels	   (=18	  µm)	  and	  pixels	  within	  
that	   distance	   were	   averaged	   per	   bin.	   This	   resulted	   in	   an	   intensity	   profile	   around	   the	  
vasculature.	   Since	   not	   all	   tissue	   locations	   had	   the	   same	   number	   of	   distance	   bins	   (less	  
vasculature	   results	   in	   larger	   distances),	   only	   the	   bins	   containing	   data	   points	   of	   at	   least	  
three	  different	  locations	  were	  included	  in	  the	  analysis.	  
RESULTS	  
A	  total	  of	  276	  locations	  on	  tongue	  coupes	  of	  36	  mice	  were	  analyzed.	  Every	  tongue	  was	  cut	  
into	   three	   slices,	   on	  which	   three	   locations	   per	   slice	  were	   analyzed.	   The	  different	   tissue	  
types	  were	   determined	   using	   the	   histological	   information	   from	   the	   514	   nm	  bright-­‐field	  












Figure	  6.1:	  Tongue	  overview	  (100x	  magnification).	  Green	  indicates	  tumor	  (gfp	  fluorescence).	  
Locations:	  1)	  tumor	  and	  tumor	  border	  2)	  invasive	  tissue	  3)	  normal	  tissue.	  
	  
All	   locations	   were	   labeled	   tumor/tumor	   boundary,	   invasive	   tumor	   border	   or	   normal	  
tissue.	  The	  tumor	  is	  located	  in	  the	  tip	  of	  the	  tongue,	  with	  islands	  of	  tumor	  cells	  invading	  
the	  tongue	  tissue.	  In	  this	  example	  tumor	  is	  clearly	  visible	  in	  the	  tip.	  Figure	  6.1,	  location	  1	  
indicates	   a	   possible	   microscopy	   location	   containing	   tumor	   and	   tumor	   boundary.	   The	  
majority	  of	  the	  tip	  of	  the	  tongue	  consisted	  of	  invasive	  tumor	  border	  (figure	  6.1,	  location	  
2),	  while	  only	  the	  most	  right	  part	  of	  the	  tongue	  showed	  normal	  tongue	  histology	  (figure	  
6.1,	   location	  3),	   consisting	  mainly	  of	  muscle	   fibers.	   	   The	  main	   tumor	   and	   tumor	   islands	  
showed	  an	  abrupt,	  easy	  distinguishable	  border.	  	  
	  
PHOTOSENSITIZER	  FLUORESCENCE	  
The	  average	  photosensitizer	  fluorescence	  intensities	  at	  t	  =	  [3	  4.5	  6	  24	  and	  48]	  hours	  were	  
determined	   for	   the	   four	   different	   histological	   tissue	   sites	   described	   above	   for	   ce6	   and	  
Bremachlorin.	   Figure	   6.2	   shows	   an	   example	   of	   the	   results	   of	   a	   fit	   over	   the	   average	  
spectrum	  of	  four	  pixels.	  	  
	  
We	   have	   previously	   shown	   that	  
Bremachlorin	  and	  ce6	  vary	  spectrally	  over	  
time	   using	   fiber	   optic	   spectroscopy	   [25].	  
However,	  the	  spectral	  resolution	  obtained	  
by	   the	   photomultiplier	   detector	   of	   the	  
confocal	  microscope	   is	   10	   nm,	  which	  was	  
not	   sensitive	   enough	   to	   distinguish	   these	  
changes.	   Therefore,	   only	   the	   intensity	   of	  
the	   fluorescence	   was	   analyzed.	   An	  
overview	   of	   average	   fluorescence	  





Figure	   6.2:	  Photosensitizer	   and	  background	   fit	   per	  
pixel.	  	  






































Figure	   6.3:	   a)	   Bremachlorin.	   Average	   per	   tissue	   type	   per	   time	   point.	   b)	   Chlorin	   e6.	  
Average	  per	  tissue	  type	  per	  time	  point.	  
	  
At	  the	  24	  and	  48	  hour	  time	  points	  of	  ce6	  in	  figure	  6.3b,	  the	  photosensitizer	  fluorescence	  
was	   very	   low	   compared	   to	   autofluorescence.	   This	   limited	   the	   possibilities	   for	  
deconvolution	  of	  the	  photosensitizer	  fluorescence	  spectral	  image	  and	  explains	  the	  lack	  of	  
significant	  differences	  between	  the	  two	  time	  points.	  For	  the	  late	  Bremachlorin	  time	  points	  
24	  and	  48	  hours	  (figure	  6.3a)	  a	  tumor/tumor	  boundary	  to	  normal	  selectivity	  of	  1.2	  to	  2.5	  
was	  observed;	  the	  photosensitizer	  fluorescence	  intensity	  of	  tumor	  tissue	  was	  higher	  than	  
that	  of	  normal	   tissue.	  After	   short	   incubation	   times,	   fluorescence	   intensity	  was	  higher	   in	  
normal	  tissue	  at	  most	  times	  a	  comparable	  or	  higher	  Bremachlorin	  fluorescence	  intensity	  
than	   normal	   tissue.	   For	   ce6	   we	   do	   not	   observe	   consistently	   higher	   values	   for	   invasive	  
tumor	  border	  compared	  to	  normal	  tissue,	  although	  both	  are	  significantly	  higher	  than	  the	  
photosensitizer	  fluorescence	  intensity	  in	  tumor	  tissue.	  	  
Figure	  6.3	  shows	  that	  for	  short	  incubation	  times	  the	  concentration	  of	  both	  ce6	  and	  
Bremachlorin	  was	  generally	  higher	   in	   the	   tumor	  boundary	   than	   in	   the	   tumor	   itself.	   The	  
invasive	  tumor	  border	  also	  showed	  higher	  photosensitizer	  concentration	  than	  tumor,	  for	  
both	   ce6	   and	   Bremachlorin.	   Histologically	   normal	   tissue	   showed	   relatively	   low	  
fluorescence	  intensity.	  The	  difference	  between	  tumor	  and	  tumor	  boundary	  concentration	  
was	  clearly	  visible	  at	  short	  incubation	  times.	  An	  example	  of	  this	  pattern	  of	  distribution	  is	  
shown	   in	   figure	   6.4,	  where	   figure	   6.4a	   and	   b	   show	   the	   gfp	   (green)	   and	   photosensitizer	  
(red)	  fluorescence	  on	  a	  background	  of	  histological	  information.	  Figure	  6.4c	  shows	  gfp	  and	  
photosensitizer	   fluorescence	   in	   one	   image,	   which	   shows	   the	   lack	   of	   photosensitizer	  
present	  in	  tumor	  tissue.	  	  	  
	  
When	  investigating	  the	  localization	  of	  ce6	  and	  Bremachlorin	  in	  normal	  and	  invasive	  tumor	  
border	  for	  short	  incubation	  time	  points,	  it	  was	  observed	  that	  both	  showed	  a	  high	  degree	  
of	  co-­‐localization	  with	  muscle	  fiber	  bundles.	  An	  example	  this	  effect	  for	  Bremachlorin	  at	  3	  
hours	  is	  shown	  in	  figure	  6.5a	  and	  b,	  where	  figure	  6.5b	  shows	  the	  localization	  in	  relation	  to	  	  
	  












































Figure	   6.5:	   Photosensitizer	   in	   normal	   tissue	   is	  
mainly	   located	   in	   muscle	   fiber	   bundles	   at	   3	  
hours	  after	   injection.	  a)	   transmission	  histology	  
image	  with	   a	   photosensitizer	   overlay	   (red).	   b)	  
photosensitizer	   fluorescence	   intensity	   in	  
relation	  to	  vessels	  (blue).	  
Figure	  6.4:	  Photosensitizer	  fluorescence	  intensity	  
in	   tumor	   and	   tumor	   border	   3	   hours	   after	  
injection.	   Red:	   Photosensitizer,	   Green:	   tumor,	  
Blue:	   vasculature.	   a,b)	   fluorescence	   overlay	   on	  
histological	  transmission	  image.	  c)	  localization	  of	  
photosensitizer	   and	   tumor	   tissue.	   d)	   localization	  




the	   vasculature	   (blue).	   A	   high	   degree	   of	   co-­‐localization	  was	   observed	   for	   both	   ce6	   and	  
Bremachlorin.	  
Comparison	  of	  24	  and	  48	  hour	  time	  points	  for	  both	  photosensitizers	  showed	  that	  
ce6	   was	   present	   in	  much	   lower	   concentrations	   than	   Bremachlorin.	   Furthermore,	   there	  
was	   no	   longer	   co-­‐localization	   of	   ce6	   and	   Bremachlorin	   with	   muscle	   fiber	   bundles.	  









Figure	  6.6:	  At	  48	  hour	  incubation	  time,	  photosensitizer	  is	  localized	  in	  relatively	  high	  intensity	  spots	  on	  
a	   low	   background.	   a)	   transmission	   histology	   image	   with	   a	   photosensitizer	   overlay	   (red).	   b)	  
photosensitizer	  fluorescence	  intensity	  in	  relation	  to	  vessels	  (blue).	  c)	  H&E	  stained	  microscopy	  image	  of	  















Figure	   6.7:	   Photosensitizer	   distribution	   around	   vessels.	   (solid	   line)	   Bremachlorin,	   (dashed	  
line)	  ce6.	  
	  
For	   both	   photosensitizers,	   the	   intensity	   ce6	   in	   the	   tumor	   remained	   lower	   than	   the	  
surrounding	   (invasive)	  boundary,	  while	   the	  Bremachlorin	  concentration	   in	  normal	   tissue	  
was	  even	  lower	  than	  in	  tumor.	  Interestingly,	  at	  these	  later	  time	  points,	  small	  spots	  of	  high	  
intensity	   fluorescence	   were	   present	   in	   all	   of	   the	   tissues	   investigated,	   although	   their	  
presence	  in	  tumor	  was	  significantly	  less.	  This	  punctate	  distribution	  did	  not	  co-­‐localize	  with	  
identifiable	   tissue	   structures	   in	   the	  bright-­‐field	   transmission	   images	   (figure	   6.6a)	   and	   in	  
particular	   was	   not	   coincident	   with	   the	   vasculature	   (figure	   6.6b).	   A	   comparison	   of	   the	  
location	   and	   pattern	   of	   these	   high	   concentrations	   of	   Bremachlorin	   and	   –	   to	   a	   lesser	  
extend-­‐	   ce6	  with	   H&E	   histological	   sections	   suggests	   that	   these	   high	   concentrations	   are	  
associated	  with	  cell	  nuclei	  (figure	  6.6c	  and	  d).	  
	  
VESSEL	  CO-­‐LOCALIZATION	  
Figure	   6.7	   shows	   the	   photosensitizer	   fluorescence	   intensity	   against	   distance	   from	   the	  
nearest	  vessel,	  averaged	  over	  all	  locations	  with	  that	  particular	  photosensitizer,	  tissue	  type	  
and	  incubation	  time.	  In	  figure	  6.7a	  to	  d,	  results	  for	  the	  different	  tissue	  types	  are	  shown.	  
The	   number	   of	   averaged	   tissue	   locations	   ranged	   from	   3	   to	   20.	   In	   general,	   the	  
Bremachlorin	  (solid	  lines)	  intensity	  was	  higher	  than	  the	  ce6	  intensity	  (dashed	  lines).	  For	  	  





































































































































	  tumor	   tissue	   and	   tumor	   boundary	   it	  was	   observed	   that	   for	   short	   incubation	   times	   the	  
photosensitizer	   concentration	   was	   highest	   around	   the	   vasculature	   and	   showing	   a	  
decreasing	   concentration	  gradient	  with	  distance	   from	   the	  vasculature.	  This	  dependency	  
decreased	  with	   increasing	   incubation	  time,	  suggesting	  a	   re-­‐localization	   from	  vasculature	  
to	  a	  homogenous	  distribution	  in	  the	  tissue.	  Invasive	  tumor	  border	  and	  normal	  tissue	  did	  
not	   show	   this	   relationship.	   Although	   the	   variation	   in	  measurements	  was	   large	   and	   the	  
observed	  relations	  were	  not	  significantly	  different,	  they	  represent	  an	  undeniable	  trend	  in	  
the	   data.	   When	   comparing	   ce6	   vessel	   co-­‐localization	   with	   that	   of	   Bremachlorin,	   a	  
difference	  in	  the	  concentration	  gradients	  was	  not	  observed	  in	  the	  graphs.	  It	  was	  observed	  
that	   tumor	  boundary	   contained	   relatively	  many	  vessels.	  Photosensitizer	  was	  distributed	  
around	   these	   vessels	   in	   the	   stroma.	   Some	   long	   incubation	   time	   locations	   showed	   a	  
negative	   relationship	   between	   vessel	   staining	   and	   photosensitizer	   in	   tumor	   stroma,	  
suggesting	  that	  the	  photosensitizer	  was	  present	  in	  the	  tissue,	  but	  not	  in	  the	  vasculature.	  	  
	  
Figure	  6.8	  and	  figure	  6.9	  show	  the	  highly	  vascularized	  tumor	  boundary.	  Figure	  6.8	  shows	  a	  
3	   hour	   Bremachlorin	   time	   point	   at	   which	   a	   decrease	   in	   photosensitizer	   concentration	  
around	  the	  vessel	  could	  not	  be	  discriminated	  (figure	  6.8d).	  Figure	  6.9	  shows	  Bremachlorin	  
at	  48	  hours,	  were	  it	  was	  observed	  that	  photosensitizer	  is	  localized	  around,	  but	  mostly	  not	  
coincident	  with	  the	  vasculature	  (figure	  6.9d).	  	  
	   	  	   	  
Figure	   6.8:	   Bremachlorin	   after	   3	   hour	   incubation	  
time.	   No	   direct	   correlation	   between	  
photosensitizer	  (red)	  and	  vasculature	  (blue)	  can	  be	  
seen.	  Photosensitizer	  is	  much	  lower	  in	  tumor	  tissue	  
(green).	  
Figure	  6.9:	  Bremachlorin	  after	  48	  hour	   incubation	  
time.	   No	   direct	   correlation	   between	  
photosensitizer	  (red)	  and	  vasculature	  (blue)	  can	  be	  



















In	   this	   paper	   we	   report	   on	   the	   microscopic	   localization	   of	   the	   photosensitizers	  
Bremachlorin	   and	   ce6.	   We	   have	   previously	   performed	   non-­‐invasive	   in-­‐vivo	   fiber	   optic	  
intrinsic	  fluorescence	  pharmacokinetics	  measurements	  on	  normal	  tongue	  and	  orthotopic	  
oral	  squamous	  cell	  carcinoma	  in	  the	  tip	  of	  the	  tongue	  [25].	  This	  study	  is	  an	  extension	  of	  
that	  analysis	  using	  confocal	  microscopy.	  	  
	  
PHOTOSENSITIZER	  LOCALIZATION	  
The	  concentration	  of	  photosensitizer	   in	   the	   four	   tissues	   that	  were	   investigated	   -­‐	   tumor,	  
tumor	  boundary,	  invasive	  tumor	  border	  and	  normal	  tissue-­‐	  showed	  a	  general	  decreasing	  
trend	  over	  time,	  although	  not	  all	  time	  points	  were	  significantly	  different	  from	  each	  other.	  
Photosensitizer	   fluorescence	   intensity	   was	   lower	   in	   tumor	   tissue	   than	   in	   the	   invasive	  
tumor	  border	  for	  both	  Bremachlorin	  and	  ce6.	  Normal	  tissue,	  consisting	  of	  muscle	  fibers,	  
showed	   a	   high	   fluorescence	   at	   short	   incubation	   times.	   Comparing	   photosensitizer	  
localization	  with	  the	  presence	  of	  vasculature	  showed	  a	  decrease	  in	  fluorescence	  intensity	  
with	   increasing	   distance	   from	   vessels	   for	   short	   incubation	   times	   in	   tumor	   and	   tumor	  
boundary.	   This	   suggests	   that	   photosensitizer	  was	   predominantly	   present	   in	   and	   around	  
the	  vasculature.	  The	  reason	  we	  did	  not	  observe	  this	  in	  invasive	  tumor	  border	  and	  normal	  
tissue	  might	  be	  due	  to	  the	  localization	  of	  photosensitizer	  in	  muscle	  fibers	  in	  these	  tissues,	  
where	  the	  pharmacokinetics	  may	  differ	   from	  those	   in	  tumor/tumor	  boundary.	  Since	  the	  
localization	  of	  vasculature	  and	  muscle	  fibers	  did	  not	  directly	  correlate,	  the	  photosensitizer	  
distribution	   around	   a	   vessel	   was	   mainly	   dependent	   on	   the	   presence	   of	   muscle	   fiber	  
bundles.	  A	  correlation	  between	  photosensitizer	   localization	  and	  vasculature,	  and	  then	  in	  
particular	   the	   smaller	   vessels	   surrounding	   muscle	   fibers,	   might	   be	   observed	   when	  
analyzing	  even	  shorter	  incubation	  times.	  
The	  localization	  of	  photosensitizer	  in	  bright	  spots	  after	  24	  and	  48	  hour	  incubation	  
time	  did	  not	  co-­‐localize	  with	  identifiable	  tissue	  structures	  in	  the	  bright-­‐field	  transmission	  
images.	  H&E	  images	  taken	  from	  slides	  of	  the	  same	  tong	  were	  compared	  with	  the	  bright-­‐
field	   transmission	   images.	   Direct	   comparison	   of	   these	   images	  was	   complicated,	   since	   i)	  
H&E	   and	   confocal	   images	   not	   being	   taken	   from	   the	   same	   coupes,	   and	   ii)	   although	   the	  
confocal	  and	  the	  H&E	  coupe	  consist	  of	  subsequent	  tissue	  slices,	  the	  processing	  of	  the	  two	  
methods	  results	  in	  differences	  in	  appearance.	  However,	  it	  allowed	  for	  qualitative	  analysis	  
of	  histological	  structures	  that	  matched	  the	  fluorescent	  pattern	  on	  size	  and	  localization.	  
It	   can	   be	   seen	   in	   figure	   6.6c	   and	   d	   that	   the	   relative	   location	   and	   density	   of	   the	  
bright	   spots	   in	   figure	   6.6d	   show	   close	   resemblance	   to	   the	   cell	   nuclei	   stained	   purple	   in	  










Furthermore,	   in	  areas	  where	  the	  bright	  spots	  do	  not	  coincide	  with	  muscle	  bundles,	  they	  
appear	  to	  be	  closely	  together	  present	  in	  a	  ribbon-­‐like	  structure.	  A	  qualitative	  comparison	  
of	   the	   location	   and	   pattern	   of	   these	   high	   photosensitizer	   concentrations	  with	   the	   H&E	  
histological	  sections	  suggested	  that	  the	  bright	  fluorescent	  photosensitizer	  spots	  visible	  at	  
24	   and	   48	   hour	   incubation	   time	   were	   associated	   with	   cell	   nuclei.	   Both	   ce6	   and	  
Bremachlorin	   are	   known	   to	   be	   internalized	   via	   endocytosis,	   after	   which	   the	  
photosensitizer	   is	   subcellular	   localized	   in	   the	   lysosomes.	   These	   intracellular	   vesicles	  
accumulate	  near	  the	  cell	  nucleus	  [29,	  30]	  and	  could	  therefore	  very	  well	  be	  the	  source	  of	  
the	  high	  fluorescent	  spots.	  
	  
COMPARISON	  WITH	  FIBER	  OPTIC	  RESULTS	  
We	   have	   previously	   reported	   on	   pharmacokinetics	   of	   Bremachlorin	   and	   ce6	   measured	  
with	   single	   fiber	   fluorescence	   spectroscopy	   (SFF)	   which	   enabled	   the	   discrimination	  
between	   normal	   and	   tumor	   tissue	   [25].	   Based	   on	   these	  measurements,	   a	  much	   larger	  
decrease	  of	  ce6	  and	  Bremachlorin	  over	  time	  than	  shown	  in	  figure	  6.3	  was	  expected	  in	  the	  
present	   study	   [25].	   Although	   quantitative	   comparison	   between	   fluorescence	   intensity	  
measured	  using	  confocal	  microscopy	  and	  fiber	  optic	  spectroscopy	   is	  not	  possible	  due	  to	  
differences	   in	   sample	   volume,	   light	   delivery	   and	   reflectance	   within	   the	   sample,	   it	   is	  
possible	   to	   perform	   qualitative	   analysis.	   The	   exact	   reason	   for	   this	   discrepancy	   is	   not	  
immediately	  clear.	  Sample	  degradation	  due	  to	  photobleaching	   is	  a	  potential	  explanation	  
for	   this	  observation.	  The	   fact	   that	  high	  photosensitizer	  concentration	  samples	  are	  more	  
prone	  to	  decreased	  intensity	  underlines	  this	  hypothesis.	  A	  larger	  decrease	  was	  observed	  
in	   the	   short	   incubation	   times,	   corresponding	   with	   high	   photosensitizer	   concentration.	  
Another	  factor	  that	  could	  contribute	  to	  the	  diminished	  fluorescence	  in	  early	  time	  points	  
using	   microscopy	   is	   the	   removal	   of	   most	   blood	   from	   the	   tissue.	   For	   short	   incubation	  
times,	   high	   concentration	   of	   photosensitizer	   might	   be	   expected	   to	   be	   present	   in	   the	  
blood,	   due	   to	   its	   hydrophilic	   nature.	   In	   SFF	   measurements,	   this	   is	   included	   in	   the	  
measurements,	   while	   for	   confocal	   imaging	   of	   tissue	   slides	   the	   contribution	   of	   blood	   is	  
expected	  to	  be	  much	  less.	  At	  late	  time	  points,	  the	  photosensitizer	  is	  already	  cleared	  from	  
the	  blood	  and	   therefore	   the	   variation	  between	  SFF	   and	   confocal	  measurements	  due	   to	  
the	  inclusion	  of	  blood	  should	  be	  minimal.	  	  
The	   fiber	   optic	   pharmacokinetic	   measurements	   showed	   a	   significantly	   higher	  
fluorescence	   intensity	   in	  tumor	  tissue	  compared	  to	  normal	  tissue	  both	  for	  Bremachlorin	  
and	   ce6.	   Furthermore,	   at	   long	   incubation	   times	   (24	   and	   48	   hours),	   there	   is	   still	   a	  
significant	   amount	   of	   Bremachlorin	   present,	   while	   ce6	   is	   (almost)	   completely	   cleared.	  
Comparing	  these	  results	  with	  our	  microscopic	  findings	  in	  the	  present	  study,	  tumor	  shows	  










the	  tongue	  (figure	  6.1)	  it	  can	  be	  seen	  that	  although	  the	  tumor	  is	  mostly	  located	  in	  the	  tip	  
of	   the	   tongue,	   there	   is	   still	   a	   layer	  of	   tumor	  boundary	  and	  some	   invasive	   tumor	  border	  
covering	   the	   tumor	  at	   the	   tongue	   tip.	  When	  performing	   fiber	  optic	  measurements,	   this	  
tissue	   is	   included	   in	   the	   measurement	   volume.	   We	   can	   therefore	   not	   discriminate	  
between	   tumor	   and	   tumor	   boundary	   in	   the	   fiber	   optic	   measurements.	   In	   the	   present	  
microscopic	   analysis	   the	   tumor	   boundary	   showed	   a	  much	   higher	   fluorescence	   intensity	  
than	  normal	   tissue.	  This	  explains	   the	  high	  concentration	  of	  photosensitizer	  measured	   in	  
what	   were	   identified	   as	   tumor	   measurements.	   A	   direct	   quantitative	   comparison	   of	  
fluorescence	   intensity	   acquired	   with	   fiber	   optic	   measurements	   and	   with	   confocal	  
microscopy	  is	  therefore	  not	  possible.	  Since	  the	  fiber	  optic	  measurements	  of	  normal	  tissue	  
were	   all	   taken	   at	   the	   back	   of	   the	   tongue	   we	   can	   safely	   compare	   those	   with	  
microscopically	  normal	  histology.	  In	  this	  paper	  we	  show	  that	  for	  long	  incubation	  times	  (24	  
and	   48	   hours),	   there	   is	   more	   Bremachlorin	   present	   in	   tumor	   than	   in	   normal	   tissue.	  
Although	   fiber	  optic	  measurement	  showed	  tumor-­‐selectivity	  at	  all	   incubation	   times,	   the	  
tumor	  to	  normal	  ratio	  of	  the	  photosensitizer	  increased	  significantly	  for	  Bremachlorin	  at	  24	  
and	  48	  hours.	  This	  corresponds	  with	  the	  trend	  found	  microscopically.	  Due	  to	  the	  relatively	  
low	   spectral	   resolution	  possible	   in	   the	  present	   study,	   a	   spectral	   comparison	  of	   the	   two	  
photosensitizers	  over	  time	  was	  not	  feasible.	  	  
When	   analyzing	   the	   microscopic	   distribution	   of	   photosensitizer,	   the	  
photosensitizer	  was	  much	  less	  homogenously	  distributed	  than	  was	  expected	  based	  on	  the	  
fiber	  optic	  measurements.	  We	  showed	  differences	   in	   localization	  that	  were	  not	  possible	  
using	  SFF.	  The	  presence	  of	  photosensitizer	  in	  muscle	  fiber	  bundles	  in	  normal	  and	  invasive	  
tumor	   border	   is	   somewhat	   surprising.	   Although	   the	   photosensitizer	   distribution	   is	  
investigated	   extensively	   in-­‐vitro	   [29,	   30],	   microscopic	   analysis	   of	   localization	   in	   an	  
orthotropic	  tumor	  model	  was	  necessary	  to	  reveal	  this.	  The	  same	  was	  true	  for	  the	  highly	  
vascularized	   tumor	   boundary,	   where	   the	   highest	   concentration	   photosensitizer	   was	  
shown	   to	   be	   present.	   This	   border	   is	   for	   example	   not	   clearly	   distinguishable	   when	  
implanting	   the	   same	   tumor	   cell	   line	   in	   a	   dorsal	   skinfold	  window	   chamber	   [unpublished	  
data].	   It	   is	   important	   to	   perform	   pharmacokinetic	   measurements	   in	   an	   (orthotopic)	  
environment	  as	  close	   to	   the	   (pre-­‐)clinical	   situation	  as	  possible.	   In	  clinical	  mTHPC-­‐PDT	  of	  
the	  oral	  cavity,	  damage	  to	  normal	  tissue	   is	  a	   limiting	   factor.	  The	  tongue	  model	  used	  for	  
this	   study	   is	   therefore	   of	   significant	   interest	   to	   study	   the	   potential	   for	   Bremachlorin	  
biodistribution	   and	   PDT	   effects	   on	   normal	   tissue.	   The	   high	   photosensitizer	   uptake	   of	  
muscle	   compared	   to	   tumor	   after	   short	   incubation	   times	   suggests	   that	   long	   incubation	  












COMPARISON	  WITH	  OTHERS	  	  
Ce6	  has	   been	   extensively	   researched	   in	   vitro.	   It	   is	   known	   that	   both	   quantum	  yield	   and	  
spectral	   shape	   are	   pH	   dependent;	   reducing	   the	   pH	   in	   the	   range	   pH7-­‐pH9	   results	   in	   a	  
decrease	   in	   fluorescent	  quantum	  yield	  and	  a	   red	  shift	  of	   the	   fluorescence	  emission	   [10,	  
11].	   A	   decrease	   in	   pH	   also	   causes	   an	   increase	   in	   lipophilicity,	   resulting	   in	   a	   preferred	  
binding	   to	   low	   density	   lipoproteins	   (LDL)	   over	   albumin.	   These	   LDL	   are	   considered	   a	  
delivery	  system	  of	  lipophilic	  photosensitizers,	  where	  internalization	  occurs	  via	  LDL-­‐specific	  
endocytosis.	   It	   has	   been	   suggested	   that	   the	   relatively	   low	   pH	   of	   tumor	   environment,	  
together	   with	   an	   over-­‐expression	   of	   LDL-­‐receptors	   on	   the	   cell	   surface	   in	   proliferating	  
tissue,	   results	   in	   a	   higher	   photosensitizer	   accumulation	   in	   tumor	   than	   in	   normal	   tissue	  
[31].	   Our	   results	   in	   OSC	   tumors	   did	   not	   show	   this	   effect.	   In	   fact	   we	   found	   a	   lower	  
photosensitizer	  concentration	  in	  tumor	  than	  in	  normal	  tissue.	  A	  reason	  for	  this	  might	  be	  
relatively	  low	  vascularization	  of	  the	  encapsulated	  tumor	  in	  the	  mouse	  tongue.	  It	  should	  be	  
noted	  that	  humans	  have	  a	  different	  HDL/LDL	  profile	  than	  rodents	  and	  further	  studies	  are	  
necessary	  in	  other	  species	  to	  confirm	  the	  results	  above.	  
Mitra	  et	  al.	  [32]	  investigated	  the	  microscopic	  distribution	  of	  NPe6,	  a	  derivative	  of	  
ce6,	  in	  an	  intradermal	  EMT6	  tumor	  model	  in	  mouse	  skin	  using	  intra-­‐vital	  microscopy.	  They	  
showed	  NPe6	   is	   localized	   in	   the	  vasculature	   for	   the	   first	  hours	  after	   administration	  and	  
redistributes	  throughout	  the	  extravascular	  regions	  between	  1	  and	  3	  hours.	  This	  effect	   is	  
observed	   for	   both	   tumor	   and	   normal	   vasculature.	   Although	   our	   study	   focused	   on	   a	  
different	   range	   of	   incubation	   times	   starting	   at	   3	   hours,	   the	   distribution	   of	   NPe6	   versus	  
distance	   is	   similar	   to	   our	   findings	   in	   OSC	   tumors	   in	   the	   tongue;	   a	   slight	   but	   steady	  
decrease	   with	   distance	   from	   vessel	   over	   time.	   The	   fact	   that	   we	   have	   shown	   different	  
pharmacokinetics	  of	  ce6	  and	  Bremachlorin	  in	  normal	  tissue	  may	  be	  a	  consequence	  of	  the	  
differences	  in	  tumor	  models.	  Another	  possibility	  is	  that	  the	  different	  pharmacokinetics	  are	  
a	   consequence	   of	   differences	   between	   NPe6	   and	   ce6	   and	   Bremachlorin.	   Large	  
experimental	  tumors	  in	  the	  tongue	  are	  known	  to	  have	  a	  higher	  interstitial	  pressure	  than	  
the	  relatively	  flat	  tumors	  grown	  in	  a	  window	  chamber	  [33].	  This	  influences	  the	  results	  of	  
preclinical	   pharmacokinetic	   studies.	   We	   have	   already	   observed	   that	   in	   normal	   tongue,	  
most	  photosensitizer	  was	   located	  in	  the	  muscle	  bundles	  present	   in	  tongue,	  whereas	  the	  
larger	  vessels	  were	  quite	  randomly	  distributed	  in	  tissue.	  This	  resulted	  in	  high	  fluorescence	  
intensity	   peaks	   at	   random	   distances	   from	   vasculature,	   which	   was	   evened	   out	   when	  
averaging	   over	   multiple	   locations.	   When	   focusing	   an	   investigation	   on	   the	   relation	  
between	  photosensitizer	   localization	  and	  vasculature,	  more	  appropriate	  models	   such	  as	  
mouse	  skin	  in	  a	  dorsal	  skinfold	  chamber	  may	  be	  considered.	  However,	  when	  determining	  
pharmacokinetics	   to	   optimize	   PDT,	   it	   is	   advised	   to	   study	   the	   tissue	   that	   is	   treated	  with	  










tongue	  tissue	  (muscle)	  that	  needs	  to	  be	  spared.	  The	  current	  model	  is	  appropriate	  for	  that.	  
When	  investigating	  other	  head	  and	  neck	  areas	  that	  are	  treated	  with	  PDT,	  such	  as	  the	  floor	  
of	  mouth	  or	  the	  lining	  mucosa,	  other	  models	  might	  be	  more	  appropriate.	  	  
	  
CONFOCAL	  MICROSCOPY	  
Analyzing	  thin	  tissue	  samples	  on	  the	  presence	  of	  a	  photosensitizer	  without	  bleaching	  the	  
sample	   remains	   challenging.	   To	   prevent	   bleaching,	   samples	   were	   prepared	   under	  
conditions	   as	   dark	   as	   possible	   and	   the	   samples	  were	   stored	   in	   a	   closed	  dark	   container.	  
When	  performing	  confocal	  microscopy,	  determining	  of	  the	  right	  location	  and	  placing	  the	  
sample	  in	  focus	  was	  done	  visually	  using	  a	  very	  small	  amount	  of	  light.	  With	  the	  sample	  in	  
the	  right	  location,	  the	  first	  image	  acquired	  was	  always	  that	  to	  determine	  the	  distribution	  
of	   photosensitizer	   fluorescence.	   Furthermore,	   multiple	   locations	   on	   one	   same	   sample	  
were	   chosen	   to	   be	   located	   away	   from	   each	   other	   to	   prevent	   photobleaching	   due	   to	  
previous	  recordings.	  	  
Localization	   of	   vasculature	   was	   performed	   by	   staining	   with	   CD31.	   Since	   this	  
procedure	   involved	   washing	   and	   incubating	   with	   PBS,	   this	   had	   to	   be	   performed	   after	  
recording	  of	  photosensitizer;	  the	  hydrophilicity	  of	  ce6	  and	  to	  a	  lesser	  extend	  Bremachlorin	  
caused	   the	   photosensitizer	   to	   be	   removed	   from	   the	   tissue	   during	   the	   vessel	   staining.	  
Finding	   the	   exact	   same	   location	   when	   re-­‐imaging	   the	   sample	   after	   vascular	   staining	  
proved	  challenging	  but	  not	   impossible.	  Due	   to	  hydration	  of	   the	   tissue	   the	   structure	  did	  
change	  somewhat,	  but	  not	  significantly.	  Therefore	  the	  location	  of	  the	  vasculature	  in	  one	  
recording	  is	  very	  likely	  to	  identify	  vasculature	  in	  other	  recordings.	  	  
	  
IMPLICATIONS	  OF	  CE6	  AND	  BREMACHLORIN	  PHARMACOKINETICS	  FOR	  PDT	  
An	  important	  result	  of	  the	  present	  study	  is	  the	  relatively	  low	  concentrations	  for	  ce6	  and	  
Bremachlorin	   in	   tumor	   itself.	   This	   may	   be	   a	   concern	   when	   we	   consider	   therapeutic	  
efficacy.	   We	   have	   found	   however	   that	   the	   OSC	   tumor	   boundary	   contained	   high	  
concentrations	   of	   photosensitizer.	   This	  well	   vascularized	   tissue	  maintains	   the	   supply	   of	  
blood	   and	   nutrients	   to	   the	   tumor.	   Although	  we	   did	   not	   find	   a	   co-­‐localization	   between	  
photosensitizer	  and	  vascular	  wall,	  the	  high	  local	  photosensitizer	  concentration	  may	  result	  
in	   damage	   to	   the	   vasculature	   of	   the	   tumor	   boundary	   when	   performing	   PDT.	   This	  may	  
indirectly	  destroy	   tumor	   tissue.	  At	  early	   time	  points,	   the	  concentration	  of	  both	  ce6	  and	  
Bremachlorin	  was	  higher	   in	  normal	  tissue	  than	   in	  tumor.	  At	   long	   incubation	  times	  of	  24	  
and	   48	   hours,	   the	   Bremachlorin	   concentration	   in	   tumor	   appears	   to	   be	   higher	   than	   in	  
normal	   tissue,	   although	   the	   total	   amount	   of	   photosensitizer	   present	   in	   tissue	   at	   these	  
time	  points	  was	  much	  lower.	  However,	  it	  has	  been	  shown	  before	  that	  clinical	  efficacy	  of	  










concentrations	  found	  at	  24	  and	  48	  hours	  might	  very	  well	  result	  in	  efficient	  PDT.	  	  Clinically,	  
PDT	  with	  ce6	  and	  its	  derivatives	  is	  usually	  combined	  with	  an	  incubation	  time	  of	  <6	  hours	  
[17,	  34].	  Results	   form	  this	   study	  suggest	   that	   this	   is	  not	   the	  most	  optimal	   time	  point	   to	  
directly	  damage	   tumor	   tissue,	  while	  preventing	  normal	   tissue	  damage.	  A	  24	  hour	  drug-­‐
light	   interval	   appears	   to	   be	   an	   encouraging	   option	   for	   Bremachlorin	   PDT,	   showing	   a	  




In	  this	  paper	  we	  report	  on	  the	  microscopic	  analysis	  of	  the	  photosensitizers	  Bremachlorin	  
and	  ce6	  in	  mouse	  tongues	  containing	  OSC	  tumors.	  Incubation	  times	  of	  t	  =	  [3	  4.5	  6	  24	  and	  
48]	  hours	  were	  investigated.	  For	  both	  photosensitizers,	  more	  fluorescence	  was	  measured	  
in	  tumor	  boundary	  than	  in	  tumor	  itself.	  Normal	  and	  invasive	  tumor	  border	  showed	  higher	  
fluorescence	   intensity	   than	   tumor	   tissue	   for	   short	   incubation	   times.	   Only	   at	   24	   and	   48	  
hour	  incubation	  times,	  the	  Bremachlorin	  concentration	  in	  tumor	  and	  tumor	  boundary	  was	  
higher	  than	  that	  in	  normal	  tissue,	  providing	  the	  possibility	  for	  selective	  tissue	  damage.	  In	  
normal	  tissue	  and	  the	  invasive	  tumor	  border	  tissue,	  photosensitizer	  was	  mainly	  present	  in	  
normal	   muscle,	   although	   for	   longer	   incubation	   times	   the	   distribution	   became	   more	  
homogenous.	  For	  the	  investigated	  time	  points	  between	  3	  and	  48	  hours,	  we	  did	  not	  find	  a	  
correlation	   between	   the	   localization	   of	   photosensitizer	   and	   vasculature.	   It	   can	   be	  
concluded	  that	  Bremachlorin	  at	  24	  and	  48	  hour	  incubation	  time	  provides	  us	  with	  both	  a	  
concentration	  suitable	  for	  PDT	  and	  a	  small	  tumor/tumor	  boundary	  to	  normal	  selectivity	  of	  
between	   1.2	   and	   2.5.	   This	   tumor	   selectivity	   opens	   up	   the	   possibility	   to	   investigate	  
Bremachlorin	  PDT	  with	   long	   incubation	  times,	  where	  normal	  muscle	  may	  be	  spared	  and	  
only	  tumor	  tissue	  is	  affected	  by	  PDT.	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The	  effect	  of	  photodynamic	  therapy	  (PDT)	  is	  dependent	  on	  the	  presence	  of	  oxygen,	  light	  
and	   photosensitizer	   in	   the	   treatment	   volume.	   It	   has	   been	   recently	   shown	   that	   for	   the	  
chlorin	   e6-­‐based	   photosensitizer	   Bremachlorin,	   pharmacokinetics	   showed	   promising	  
results	  for	  PDT	  using	  a	  drug-­‐light	   interval	  of	  24-­‐48	  hours.	  In	  this	  paper,	  the	  effect	  of	  the	  
drug-­‐light	   interval	   on	   PDT	   using	   chlorin	   e6	   and	   Bremachlorin	   was	   investigated.	   Oral	  
squamous	  cell	  carcinomas	  were	  induced	  in	  dorsal	  window	  chambers	  on	  the	  back	  of	  mice	  
and	   treated	  with	  PDT	  after	  a	  drug-­‐light	   interval	  of	  5	  or	  24	  hours.	  Acute	  vascular	  effects	  
were	  analyzed	  using	  recordings	  of	  the	  window	  chamber	  vasculature	  during	   illumination.	  
Two	  hours	  after	   illumination,	  vascular	   leakage	  and	  stasis	  were	   investigated	  by	   intra-­‐vital	  
confocal	  microscopy.	  48	  hours	  after	  treatment,	  chambers	  were	  inspected	  for	  microscopic	  
vascular	   damage	   such	   as	   hemorrhage	   and	   tissue	   was	   removed	   and	   sectioned	   for	  
histological	   analysis	   of	   PDT-­‐related	   cell	   damage.	   Most	   acute	   vascular	   effects	   were	  
observed	  during	  Bremachlorin	  PDT	  with	  a	  24	  hour	  drug-­‐light	  interval,	  followed	  by	  ce6	  PDT	  
5	   hours	   after	   injection.	   Leakage	   and	   stasis	   were	  more	   evident	   in	   Bremachlorin	   treated	  
animals	   independent	   of	   incubation	   time.	   The	   PDT-­‐induced	   histological	   responses	   were	  
most	  severe	  in	  Bremachlorin	  PDT	  with	  a	  24	  hour	  drug-­‐light	  interval.	  PDT-­‐related	  damage	  
to	  tumor	  cells	  was	  related	  to	  the	  onset	  of	  acute	  vascular	  effects	  during	  PDT	  illumination.	  
We	   can	   conclude	   that	   for	   both	   ce6	   and	   Bremachlorin	   PDT	   with	   a	   24	   hour	   drug-­‐light	  
interval	  was	  most	  effective	  in	  inducing	  damage	  to	  tumor	  cells.	  This	  is	  in	  contrast	  with	  the	  
short-­‐incubation	   times	   that	   are	   currently	   used	   for	   ce6-­‐based	   photosensitizers	   in	   (pre-­‐
)clinical	  research.	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Photodynamic	   therapy	   (PDT)	  has	  been	  under	   investigation	   for	  over	   four	  decades	  and	   is	  
now	   applied	   clinically	   for	   the	   treatment	   of	   various	   (pre-­‐)malignant	   lesions	   [1-­‐4].	   Its	  
working	   principle	   is	   based	   on	   the	   interaction	   between	   a	   photoactive	   drug,	   the	  
photosensitizer,	  oxygen	  and	  light	  of	  an	  appropriate	  wavelength.	  Treatment	  light	  energy	  is	  
absorbed	  by	  the	  photosensitizer,	  which	  is	  promoted	  to	  an	  excited	  singlet	  state.	  One	  of	  the	  
ways	  for	  this	  unstable	  molecule	  to	  lose	  its	  excess	  energy	  is	  to	  transform	  into	  a	  triplet	  state	  
by	  intersystem	  crossing.	  In	  this	  triplet	  state,	  the	  photosensitizer	  can	  interact	  with	  oxygen	  
to	   generate	   highly	   reactive	   oxygen	   species,	   notably	   singlet	   oxygen,	  which	   causes	   direct	  
tissue	  damage	  [5].	  	  
	   PDT-­‐induced	   direct	   cell	   damage	   can	   result	   in	   two	   distinct	   response	   pathways:	  
apoptosis,	  and	  necrosis	   [6].	  Apoptosis	   is	   the	  process	  of	   regulated	  cell	  death,	   involving	  a	  
series	  of	  biological	  events.	  Many	  pathways	  and	  signals	  can	  induce	  apoptosis,	  including	  the	  
release	   of	   hormones,	   cytokines	   and	   stress.	   Direct	   mitochondrial	   damage	   results	   in	   the	  
release	   of	   cytochrome	   C	   into	   the	   intra-­‐cellular	   space,	   which	   represents	   the	   onset	   of	  
apoptotic	  cell	  death.	  Several	  photosensitizers	  are	  known	  to	  directly	   target	  mitochondria	  
(PpIX	  [7]),	  or	  activate	  the	  translocation	  of	  damage-­‐inducing	  proteins	  to	  the	  mitochondria	  
(NPe6	  [8]),	  resulting	  in	  apoptosis	  of	  tumor	  cells.	  Necrosis	  is	  cell	  death	  resulting	  from	  acute	  
tissue	   injury	   and	   is	   characterized	   by	   pyknotic	   nuclei,	   cytoplasmic	   swelling	   and	  
disintegration	   of	   cell	   membranes.	   Necrosis	   is	   associated	   with	   the	   induction	   of	   a	   wide	  
range	   of	   immunological	   responses	   that	   can	   have	   a	   significant	   influence	   on	   the	   overall	  
outcome	  of	  PDT	  [6].	  The	  extent	  to	  which	  PDT	  indices	  apoptosis	  and/or	  necrosis	  depends	  
on	   many	   factors	   including	   cell	   type,	   subcellular	   photosensitizer	   localization,	   oxygen	  
tension	  (apoptosis	  requires	  the	  availability	  of	  oxygen)	  and	  light	  fluence	  rate;	  high	  fluence	  
rates	  tend	  to	   induce	  necrosis,	  while	   low	  fluence	  rates	  are	  associated	  with	  apoptotic	  cell	  
death	   [9].	   Immunological	   responses	   to	   PDT	   include	   the	   activation	   of	   autophagy,	   but	  
exactly	   how	   these	   autophagic	   effects	   influence	   the	   outcome	   of	   PDT	   are	   still	   under	  
investigation	   [10].	   In	   general	   cells	   use	   autophagy	   as	   a	   defense	   against	   ROS	   mediated	  
damage	  by	   clearing	   the	   cell	  of	  damaged	  organelles.	  Depending	  on	   the	   type	  of	  ROS	  and	  
degree	  of	  oxidative	  injury,	  PDT	  may	  stimulate	  autophagy	  and	  induce	  cell	  death	  [11]. 
	  
Many	  different	  photosensitizers	  have	  been	  used	  clinically	  for	  a	  variety	  of	  applications	  [2,	  
3,	  12,	  13].	  Although	  all	  photosensitizers’	  mechanism	  of	  action	  are	  based	  on	  the	  principle	  
of	  generation	  of	  reactive	  oxygen	  species,	  exactly	  which	  tissue	  or	  cellular	  structures	  these	  
ROS	   interact	   with	   depends	   on	   their	   localization	   [14,	   15].	   Most	   photosensitizers	   are	  









at	   which	   this	   occurs	   is	   dependent	   on	   the	   physiochemical	   properties	   of	   the	  
photosensitizer,	   but	   varies	   from	   hours	   (for	   example	   chlorin	   e6)	   to	   days	   (for	   example	  
mTHPC	  and	  Photofrin)	  [16-­‐19].	  Pre-­‐formed	  photosensitizers	  such	  as	  m-­‐THPC,	  ce6	  and	  its	  
derivatives	  are	  normally	  administered	  intravascular,	  but	  have	  tumor	  tissue	  as	  their	  target.	  
In	  certain	  circumstances	  the	  uptake	  of	  photosensitizer	  in	  tumor	  tissue	  may	  be	  higher	  than	  
in	  normal	  tissue.	  The	  underlying	  mechanism	  for	  this	  selectivity	  is	  the	  EPR	  effect,	  caused	  by	  
the	   leaky	   nature	   of	   the	   neovasculature	   and	   reduced	   lymphatic	   drainage	   in	   tumors	  
compared	  to	  normal	  tissue	  [20].	  Furthermore,	  ce6	  is	  thought	  to	  profit	  from	  the	  relatively	  
low	  pH	  of	  tumor	  stroma,	  resulting	  in	  a	  shift	  in	  binding	  affinity	  and	  a	  more	  efficient	  cellular	  
internalization	  [21,	  22].	  	  
	   Photosensitizer	  pharmacokinetics,	  cellular	  uptake	  and	  subsequent	  localization	  are	  
critical	   determinants	   of	   PDT	   efficacy.	   The	   first	   determines	   how	   the	   amount	   of	  
photosensitizer	   present	   in	   a	   tissue	   under	   investigation	   develops	   over	   time	   and	   is	  
influenced	  by	  metabolism	  and	  clearance	  of	  the	  photosensitizer.	  	  
	   Many	  photosensitizers	  are	  known	  to	  not	  only	  affect	  tumor	  cells	   in	  the	  treatment	  
volume,	   but	   also	   have	   the	   vasculature	   itself	   as	   a	   target	   [23].	   Previous	   studies	   with	  
topically	   applied	   5-­‐aminolevulinic	   acid	   (ALA),	   a	   precursor	   for	   the	   endogenous	  
photosensitizer	   protoporphyrin	   IX	   (PpIX)	   showed	   that	   PpIX	   is	   synthesized	   in	   the	  
mitochondria	   of	   cells	   in	   the	   epidermis	   and	   dermis	   [24].	   It	   is	   known	   that	   even	   (epi-­‐)	  
dermally	   located	   endothelial	   cells	   generate	   PpIX,	   which	   upon	   illumination	   results	   in	  
damage	  to	  the	  vasculature	   [25,	  26].	  NPe6,	  a	  ce6	  conjugate,	   is	  known	  to	   induce	  stasis	   in	  
tissue	  vasculature	  [27].	  Although	  this	  disrupts	  the	  blood	  and	  nutrient	  supply	  to	  the	  tumor	  
and/or	   lesion,	   which	   can	   be	   favorable	   for	   treatment	   outcome,	   the	   oxygen	   supply	  
necessary	   for	   PDT	   is	   also	   disrupted.	   The	   effect	   of	   PDT	   induced	   vascular	   damage	   is	  
therefore	  multifaceted	  and	  the	  overall	   result	   is	  known	  to	  depend	  strongly	  on	  treatment	  
parameters	  such	  as	  fluence,	  fluence	  rate	  and	  drug-­‐light	  interval	  [25,	  28-­‐30].	  	  
	  
Photosensitizers	   based	   on	   chlorin	   e6	   are	   known	   to	   be	   quite	   hydrophilic.	   Since	   this	  
prevents	  the	  photosensitizer	   from	  being	   internalized	  by	  cells,	  ce6	   is	  quickly	  metabolized	  
and	   cleared	   from	   the	   tissue	   via	   the	   urinary	   system.	   The	   in-­‐vivo	   response	   of	   tumors	  
following	  ce6	  based	  PDT	  has	  been	  investigated	  in	  a	  limited	  number	  of	  studies	  [31].	  Many	  
more	  studies	  have	  been	  performed	  with	  ce6-­‐based	  conjugates	  such	  as	  ce6-­‐PVP,	  in	  which	  
ce6	  is	  conjugated	  with	  a	  polyvinylpyrrolidone	  carrier	  [32],	  or	  ce6	  derivatives	  such	  as	  NPe6	  
(mono-­‐L-­‐aspartylchlorin-­‐e6)	   [18].	   These	   chemical	  modifications	   are	  designed	   to	   increase	  
the	  cellular	  uptake	  of	  the	  photosensitizer,	  thereby	  increasing	  efficacy.	  Various	  preclinical	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NPe6	   is	  approved	   for	  clinical	  use	  on	  early	   stage	  superficial	   squamous	  cell	   carcinomas	   in	  
lung	  in	  Japan	  [35,	  36],	  and	  it	  is	  also	  under	  investigation	  for	  skin	  malignancies	  [13,	  37].	  
	   Bremachlorin	  is	  a	  mixture	  of	  photosensitizers	  consisting	  of	  ce6	  (~80%),	  chlorin	  p6	  
(~5%)	  and	  purpurin	  5	  (~15%)	  [38].	  It	  is	  less	  hydrophilic	  than	  ce6	  and	  is	  therefore	  expected	  
to	   have	   a	   higher	   binding	   affinity	   for	   low	   density	   lipoproteins	   (LDL)	   and	   thereby	   being	  
internalized	   in	  cells	  by	  means	  of	  endocytosis	  and	   intra-­‐cellular	  transported	   in	   lysosomes	  
towards	  the	  nucleus	  [39].	  The	  number	  of	  (pre-­‐)clinical	  tests	  performed	  with	  Bremachlorin	  
is	  limited	  but	  covers	  a	  number	  of	  malignancies	  and	  treatment	  protocols	  [38,	  40-­‐43].	  	  	  
	  
Previously,	   we	   have	   studied	   the	   fluorescence	   of	   both	   ce6	   and	   Bremachlorin.	   In-­‐vivo,	  
photosensitizer	  intrinsic	  fluorescence	  spectra	  were	  acquired	  in	  mouse	  tissue	  (tongue	  and	  
oral	   squamous	  cell	   carcinoma	   in	   tongue)	  using	  single	   fiber	   fluorescence	  spectroscopy	  at	  
various	  times	  after	  photosensitizer	  injection	  [44].	  Furthermore,	  we	  have	  investigated	  the	  
microscopic	  localization	  of	  ce6	  and	  Bremachlorin	  in	  frozen	  tongue	  samples	  using	  confocal	  
microscopy	   [45].	   We	   showed	   that	   for	   both	   ce6	   and	   Bremachlorin	   the	   photosensitizer	  
concentration	  is	  highest	  in	  the	  tumor	  border.	  The	  photosensitizer	  concentration	  in	  normal	  
tissue	  is	  much	  lower,	  and	  microscopically	  we	  found	  that	  although	  tumor	  border	  has	  a	  high	  
concentration,	  the	  tumor	  itself	  contains	  a	  relatively	  low	  concentration	  of	  photosensitizer.	  
However,	   24	   hours	   after	   administration	   the	   concentration	   of	   Bremachlorin	   in	   tumor	  
exceeds	  that	  of	  normal	  tissue.	  At	  this	  time	  point,	  ce6	   is	  mostly	  excreted	  from	  the	  body.	  
After	   short	   incubation	   times	   in	   normal	   and	   the	   invasive	   tumor	  border,	   photosensitizers	  
are	  preferentially	  located	  in	  muscle	  fiber	  bundles.	  After	  24	  or	  48	  hours,	  this	  effect	  is	  less	  
pronounced,	   showing	   a	   more	   homogenous	   level	   of	   photosensitizer	   concentration	   for	  
Bremachlorin.	   Ce6	   is	   undetectable	   at	   these	   time	   points.	   Clinically,	   ce6-­‐based	  
photosensitizers	  usually	  have	  a	  drug-­‐light	  interval	  of	  4-­‐6	  hours	  [13].	  These	  results	  suggest	  
that	   a	   longer	   drug-­‐light	   interval	   may	   be	   more	   favorable	   for	   Bremachlorin	   based	   PDT,	  
which	  takes	  advantage	  of	  the	  higher	  selectivity	  in	  tumor	  compared	  to	  normal	  tissue.	  	  
In	  the	  present	  study	  we	  have	  performed	  PDT	  in	  dorsal	  skinfold	  chambers	  in	  mice	  
containing	  OSC19	  oral	  squamous	  cell	  carcinoma.	  The	  primary	  purpose	  of	   the	  study	   is	   to	  
determine	   if	   our	   previous	   findings	   on	   the	   pharmacokinetics	   of	   ce6	   and	   Bremachlorin	  
result	  in	  more	  effective	  photodynamic	  therapy	  after	  a	  long	  drug-­‐light	  interval	  (24	  hours),	  
compared	  to	  a	  short	  5	  hour	  drug-­‐light	  interval.	  Treatment	  efficacy	  is	  measured	  based	  on	  a	  











MATERIALS	  AND	  METHODS	  
ANIMAL	  MODEL	  
A	  dorsal	  skin	  fold	  window	  chamber	  was	  prepared	  on	  the	  back	  of	  28	  mice	  (BALB/c	  nu/nu	  
female	  mice,	  aged	  4-­‐6	  weeks;	  Charles	  River	  Laboratories)	  using	  a	  procedure	  described	  in	  
detail	   elsewhere	   [46-­‐48].	   In	   short,	  mice	  were	   anesthetized	   (ketamine,	   100	  mg	   kg-­‐1	   b.w.	  
and	  xylazine,	  20	  mg	  kg-­‐1	  b.w.	  in	  a	  volume	  mixture	  of	  2:1:1	  saline,	  ketamine,	  xylazine)	  and	  
the	   skin	  was	  dissected	   leaving	   the	   fascia	   and	   the	  opposing	   skin.	   The	   skin-­‐fold	  was	   then	  
sandwiched	  between	  two	  frames,	  fixed	  with	  two	  light	  metal	  bolts	  and	  sutures.	  Cells	  from	  
the	   oral	   squamous	   cell	   carcinoma	   cell	   line	   OSC19,	   transfected	   with	   luc2	   (Biocat,	  
Heidelberg,	  Germany)	  and	  Cop-­‐gfp	  (Evrogen,	  Moscow,	  Russia),	  were	  injected	  in	  the	  fascia	  
(4x105	   cells)	   [49-­‐52].	   Afterwards,	   both	   sides	   of	   the	   frame	  were	   covered	  with	   a	   12	  mm	  
microscope	   cover	   glass	   to	   allow	   for	   analysis	   of	   tumor	   and	   vasculature	   over	   time.	   All	  
experiments	  were	  performed	  under	  isoflurane	  (2-­‐3%)	  anesthesia.	  The	  study	  protocol	  was	  
approved	  by	  the	  Animal	  Welfare	  Committee	  of	   the	  Erasmus	  Medical	  Center.	  Housing	  of	  
BALB/c	  nu/nu	  mice,	   the	  experiments	  and	  euthanazation	  were	  performed	   in	  accordance	  
with	   the	   guidelines	   of	   this	   committee.	   Chlorophyll	   free	   food	   and	   sterilized	  water	   were	  
provided	  without	  restriction.	  
	  
TUMOR	  SIZE	  DETERMINATION	  
After	  a	  6-­‐7	  days	  incubation	  time,	  24	  hours	  before	  PDT,	  tumor	  size	  was	  analyzed	  by	  means	  
of	   bioluminescence	   imaging	   (IVIS,	   PerkinElmer,	   Walthma,	   MA,	   USA).	   Animals	   were	  
anesthetized	   (2-­‐3%	   isoflurane),	   injected	   with	   luciferin	   (150	   mg	   kg-­‐1,	   VivoGlo,	   Promega	  
Corporation,	  Madison,	  WI,	  USA)	  and	  tumor	  size	  was	  determined	  after	  five	  minutes	  using	  
bioluminescence	  imaging.	  This	  process	  was	  repeated	  two	  days	  after	  therapy,	  after	  which	  
the	  animals	  were	  euthanized	  and	  tissue	  harvested	  for	  further	  investigation.	  
	  
PHOTODYNAMIC	  THERAPY	  
Animals	  were	  divided	  into	  four	  treatment	  groups	  1-­‐4	  (n=6)	  and	  one	  control	  group	  0	  (n=4).	  
Two	  photosensitizers,	  ce6	  (16	  mg	  kg-­‐1	  in	  100	  µl	  PBS,	  Frontier	  Scientific,	  Inc.,	  Logan,	  USA)	  
and	  Bremachlorin	  (20	  mg	  kg-­‐1,	  form	  stock	  solution	  of	  3.5	  g	  l-­‐1,	  Rada-­‐pharma	  International	  
B.V.,	   The	   Netherlands)	   were	   investigated	   at	   two	   drug-­‐light	   intervals	   (5	   and	   24	   hours).	  
Treatment	  parameters	  were	  as	  follows:	  all	  animals	  received	  200	  J	  cm-­‐2	  at	  a	  fluence	  rate	  of	  
150	   mW	   cm-­‐2	   (corresponding	   to	   23	   minutes	   illumination)	   using	   a	   532	   nm	   laser	   light	  
source.	  Group	  1:	  Bremachlorin,	  5	  hours.	  Group	  2:	  ce6,	  5	  hours.	  Group	  3:	  Bremachlorin,	  24	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rate	  as	  all	  other	  groups,	  without	   the	  administration	  of	  photosensitizer.	   Illumination	  was	  
performed	  with	   the	  mouse	  placed	   in	  a	  specially	  designed	  setup,	  shown	   in	   figure	  7.1,	   so	  
that	   the	  window	  chamber	   could	  be	   illuminated	  homogenously	   from	   the	   top	   (skin-­‐side),	  
while	  recording	  the	  chamber	  from	  below	  (muscle	  and	  vascular	  layer)	  to	  monitor	  vascular	  
effects	  during	   treatment.	  Before	   illumination,	   fluorescent	   images	  of	   the	   treatment	  area	  
were	  recorded	  to	  analyze:	   i)	  photosensitizer	   fluorescence	   (λex	  532	  nm,	  λdetection	  bandpass	  
640-­‐680	   nm	   detection	   filter)	   and	   ii)	   gfp	   (tumor)	   fluorescence	   (λex	   405	   nm,	   λdetection	  
bandpass	   480-­‐520	   nm	   filter).	   The	   treatment	   efficacy	   was	   determined	   based	   on	   tumor	  
reduction	   as	   measured	   from	   comparing	   tumor	   bioluminescence	   before	   and	   after	  
treatment.	   Furthermore,	   macroscopic	   damage	   (necrosis,	   crust	   formation	   etc.)	   was	  
recorded	  two	  days	  after	  treatment.	  Tissue	  from	  the	  window	  chamber	  was	  harvested	  after	  
euthanazation	  of	  the	  animal	  and	  processed	  for	  H&E	  staining.	  This	  allowed	  for	  microscopic	  
analysis	  of	  damage	  to	  the	  target	  tissue.	  	  	  
	  
VASCULAR	  EFFECTS	  
Vascular	   effects	   during	   and	   after	   PDT	   were	   determined	   in	   three	   ways:	   acute	   vascular	  
damage,	  short	  term	  vascular	  leakage	  and	  stasis,	  and	  long	  term	  (vascular)	  damage.	  
	  
Acute	  vascular	  effects	  
Acute	  vascular	  damage	  was	  determined	  by	  recording	  window	  chamber	  vasculature	  during	  
illumination	  using	  532	  nm	  bright-­‐field	  transmission	  imaging.	  Images	  were	  recorded	  every	  
10	   sec.	   These	   images	   were	   separately	   inspected	   to	   determine	   arterial	   closure,	   venous	  
closure,	  reopening	  of	  vessels,	  muscular	  movement	  or	  hemorrhage.	  	  
	  
Short	  term	  leakage	  and	  stasis	  
Two	   hours	   after	   PDT,	   blood	   flow	   and	  
vasculature	   were	   investigated	   using	   intravital	  
microscopy	  (Zeiss	  LSM510META,	  Carl	  Zeiss	  B.V.	  
Sliedrecht,	  the	  Netherlands)	  where	  the	  mouse	  
was	   anesthetized	   using	   Isoflurane	   2-­‐3%.	  Mice	  
were	   i.v.	   injected	   with	   100	   µl	   (48	   µmol	   kg-­‐1)	  
long	   half	   life	   Rho-­‐PEG-­‐L	   liposomes	   [48]	   to	  
visualize	  the	  chamber	  vasculature	  and	  vascular	  
leakage.	   Vascular	   leakage	   becomes	   visible	  
when	   the	  vascular	  dye	   is	  extraverted	   into	   the	  
extravascular	   regions	   showing	   diffuse	  
fluorescence	  rather	  than	  a	  vascular	  angiogram.	  
	  









Various	   locations	   in	   and	   outside	   the	   tumor	   were	   recorded	   and	   analyzed	   for	   vascular	  
damage.	  The	  vascular	  dye	  was	   imaged	  with	   the	   following	   confocal	  parameters:	   (λex	   633	  
nm,	  650	  LP	  filter,	  optical	  slice	  thickness	  <12	  µm).	  Tumor	  gfp	  was	  imaged:	  λex	  488	  nm,	  505-­‐
550	   BP	   filter,	   optical	   slice	   thickness	   <48	   µm.	   The	   optical	   slice	   thickness	   for	   tumor	  
detection	  was	  purposely	  chosen	  to	  be	  large	  to	  include	  the	  complete	  tumor	  thickness	  in	  an	  
overview	   image.	   Where	   possible,	   several	   areas	   within	   tumor	   and	   normal	   tissue	   were	  
recorded.	  Chambers	  were	  inspected	  for	  the	  presence	  of	  leakage	  (the	  blood	  marker	  flows	  
out	   of	   the	   contained	   vessel	   area)	   or	   stasis	   (the	   blood	   marker	   does	   not	   reach	   certain	  
vessels).	  
	  
	  (VASCULAR)	  DAMAGE	  AT	  48	  HOURS	  
Two	   days	   after	   the	   therapeutic	   illumination,	   the	   IVIS	  measurement	  was	   repeated.	   This	  
provided	  an	  indication	  on	  PDT	  efficacy	  in	  the	  way	  of	  tumor	  size	  reduction.	  Furthermore,	  
IVIS	  measurements	   provided	   an	   image	   of	   the	  window	   chamber	   vasculature,	  which	  was	  
compared	  with	   the	   image	   before	   PDT.	   Finally,	   images	   of	   the	  window	   chambers	   before	  
animal	  euthanization	  were	  visually	  inspected.	  
	  
MICROSCOPIC	  TISSUE	  DAMAGE	  AT	  48	  HOURS	  
After	   euthanization,	   the	   tissue	   from	   window	   chambers	   was	   removed,	   embedded	   in	  
paraffin,	   cut	   in	   4	   µm	   sections	   and	   stained	   with	   H&E.	   Sections	   were	   digitalized	  
(Nanozoomer,	   Hamamatsu)	   and	   inspected	   to	   asses	   the	   tissue	   for	   the	   presence	   of	  
apoptotic,	   necrotic	   and	   inflammatory	   markers,	   together	   with	   a	   general	   assessment	   of	  
tumor	  and	  normal	  tissue	  viability.	  
RESULTS	  
ACUTE	  VASCULAR	  EFFECTS	  
For	   every	   animal,	   we	   determined	   the	   occurrence	   and/or	   time	   point	   of	   the	   following	  
events	   during	   illumination:	   arterial	   constriction,	   venule	   constriction,	   relaxation	   of	   the	  
vascular	  lumen,	  cutaneous-­‐muscle	  contraction	  and	  hemorrhage.	  As	  expected,	  the	  control	  
group	   (no	   photosensitizer)	   did	   not	   show	   any	   of	   these	   events	   during	   illumination.	   The	  
occurrence	   of	   these	   events	   is	   shown	   in	   figure	   7.2.	   One	   animal	   of	   group	   2	   died	   before	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For	   Bremachlorin	   with	   a	   5	   hour	   drug-­‐light	  
interval	   we	   observed	   arterial	   constriction	  
for	  two	  animals,	  occurring	  between	  130	  and	  
170	   s	   after	   the	   start	   of	   illumination.	   Both	  
arteries	   returned	   to	   their	   initial	   condition	  
respectively	   150	   and	   1070	   s	   later.	   Muscle	  
contraction	  and	  bleeding	  did	  not	  occur.	  	  
Animals	   treated	   with	   Bremachlorin	  
PDT	  at	  24	  hours	   showed	  vascular	  effects	   in	  
five	   of	   the	   six	   animals.	   We	   observed	   both	  
arterial	   and	   venule	   constriction.	   In	   animals	  
that	  showed	  both,	  we	  also	  observed	  severe	  
muscle	   contraction,	   visible	   by	   the	  
displacement	   of	   the	   vasculature	   in	   the	  
window	   chamber.	   Sometimes	   this	  
displacement	   happened	   gradually	   during	   the	   later	   half	   of	   PDT	   illumination	   (figure	   7.3,	  
vessels	   in	   lower	   right	   corner),	   in	   other	   situations	   all	   vasculature	   could	   be	   completely	  
rearranged	  within	   two	  minutes,	  as	  can	  be	  seen	   in	   figure	  7.5	  One	  animal	   showed	  strong	  
hemorrhage	   and	   leaking	   vessels	   during	   illumination.	   Some	   example	   image	   sequences	  
during	   therapy	   are	   presented	   in	   figure	   7.3-­‐7.5,	   where	   figure	   7.5	   shows	   severe	   muscle	  
contraction	  and	  hemorrhage.	  	  
A	  5	  hour	  drug-­‐light	  interval	  using	  ce6	  resulted	  in	  three	  out	  of	  five	  animals	  showing	  
acute	   vascular	   effects.	   In	   the	   only	   animal	   showing	   muscular	   contraction,	   we	   observed	  
both	  arterial	  and	  venule	  constriction.	  	  
Ce6	   PDT	   after	   a	   24	   hour	   drug-­‐light	   interval	   did	   not	   result	   in	   significant	   vascular	  
constriction.	  We	  observed	  arterial	  constriction	  in	  two	  animals	  and	  muscle	  contraction	  in	  
two	   animals,	   of	   which	   one	   did	   not	   show	   any	   acute	   vascular	   effects.	   The	   animals	   that	  
exhibited	  both	   arterial	   constriction	   and	  muscle	   contraction	  did	  however	   show	  dramatic	  
shifts	  in	  dermal	  layers,	  followed	  by	  copious	  bleeding	  that	  originated	  from	  the	  tumor.	  	  
	  
	  
Figure	   7.3:	   Chlorin	   e6	   PDT	   after	   5	   hour	   drug-­‐light	   interval.	   Acute	   vascular	   effects	   like	   arterial	  
constriction	  (A),	  venule	  constriction	  (V)	  and	  constriction	  of	  cutaneous	  muscles	  (M).	  
	  





Figure	  7.2:	  Overview	  of	  acute	  vascular	  effects	  
during	  PDT	  illumination	  for	  individual	  mice.	  The	  
effects	  scored	  are	  arterial	  closure	  (AC),	  venous	  
closure	  (VC),	  vascular	  relaxation	  (O),	  cutaneous	  
muscle	  contraction	  (MC)	  and	  hemorrhage	  (H).	  
Observed	  effects	  are	  indicated	  with	  a	  black	  box.	  
	  









































Figure	   7.4:	   Bremachlorin	   PDT	   after	   24	   hour	   drug-­‐light	   interval.	   Acute	   vascular	   effects	   like	   arterial	  




Figure	   7.5:	   Bremachlorin	   PDT	   after	   24	   hour	   drug-­‐light	   interval.	   Immediate	   vascular	   shutdown	   (V,A)	  
followed	  by	  severe	  muscle	  contractions	  and	  hemorrhage	  (H).	  
	  
Only	  four	  animals	  (2x	  Bremachlorin	  5	  hours,	  1x	  Bremachlorin	  24	  hours	  and	  1x	  ce6	  5	  hours)	  
showed	  relaxation	  of	  the	  vessels	  during	  treatment.	  	  
	  
VASCULAR	  LEAKAGE	  AND	  STASIS	  
The	  detection	  of	  vascular	  effects	  by	  confocal	  microscopy	  was	  in	  some	  cases	  confounded	  
by	   the	   formation	  of	   edema	  directly	   after	   therapy.	   This	   prevented	   focusing	  on	   the	   focal	  
plain	  containing	  the	  vasculature.	  Therefore,	  the	  present	  analysis	  only	  includes	  a	  partial	  set	  
of	  animals.	  Where	  possible,	  animals	  not	  suitable	  for	  confocal	  microscopy	  were	  analyzed	  
using	  conventional	  white	  light	  microscopy.	  	  
	  
During	   confocal	  microscopy	   various	   vascular	   responses	   were	   observed.	   Some	   locations	  
showed	   stasis	   (figure	   7.6),	   others	   showed	   vascular	   leakage	   (figure	   7.7)	   and	   visually	   we	  
observed	  vessel	   constriction	  and	  hemorrhage	   in	   the	  window	  chambers.	  However,	   there	  
were	  also	  animals	  where	  these	  effects	  did	  not	  occur.	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There	  were	  relatively	  more	  vascular	  effects	  visible	  for	  animals	  treated	  with	  Bremachlorin	  
compared	   to	   Ce6.	   An	   overview	   of	   this	   is	   shown	   graphically	   in	   figure	   7.8	   where	   we	  
discriminate	  between	  leakage	  (L)	  and	  stasis	  (S).	  	  
	  
VASCULAR	  RESPONSE	  AFTER	  48	  HOURS	  
Forty	  eight	  hours	  after	  illumination	  the	  most	  damage	  was	  observed	  in	  the	  group	  treated	  
with	  Bremachlorin	  and	  a	  drug-­‐light	  interval	  of	  24	  hours.	  Four	  of	  the	  five	  animals	  showed	  
macroscopic	   vascular	   damage	   in	   the	   form	   of	   hemorrhage	   and	   discontinuity	   of	   the	  
vasculature.	   However,	   every	   treatment	   group	   showed	   at	   least	   one	   animal	   with	   similar	  
observations.	   We	   found	   that	   animals	   showing	   these	   macroscopic	   characteristics	   of	  
discontinuous	   vasculature	   two	   days	   after	   treatment	   all	   showed	   acute	   vascular	   effects	  
during	   treatment.	   The	   animals	   in	  which	   this	   effect	  was	   found	  were	   distributed	   over	   all	  
treatment	  groups,	  including	  both	  photosensitizers	  and	  incubation	  times.	  However,	  not	  all	  
animals	   with	   acute	   vascular	   effects	   showed	  macroscopic	   vascular	   damage.	  We	   did	   not	  
find	  a	  correlation	  between	  the	  vascular	  effects	  during	  treatment	  and	  the	  observation	  of	  
hemorrhage	  and	  partial	  occlusion	  of	  the	  vasculature	  48	  hours	  after	  illumination.	  	  	  
Tumor	   size	   reduction	  was	   only	  measured	   qualitatively,	  where	  we	   compared	   the	  
area	  of	  the	  tumor	  bioluminescence	  signal	  one	  day	  before	  and	  two	  days	  after	  treatment.	  A	  
relation	   between	   tumor	   size	   reduction	   and	   treatment	   group	   was	   not	   observed.	   It	   is	  
interesting	   to	   note	   that	   all	   animals	   showing	   a	   lower	   tumor	  mass	   after	   treatment	  were	  
	  
Figure	   7.7:	  Vasculature	   (Red)	   and	   Tumor	   (Green).	  Vascular	   stasis	   (upper	   left)	   and	   leakage	   (lower	  
left)	  of	  vessels	  2	  hours	  after	  PDT.	  
	  
	  










animals	   in	   which	   we	   observed	  
vascular	  damage	  and	  therefore	  acute	  
vascular	   effects.	   Again,	   we	   also	  
observed	   animals	   with	   vascular	  
damage	  having	  a	  much	  higher	  tumor	  
load	  than	  before	  treatment.	  	  
	  
HISTOLOGICAL	  RESPONSE	  AT	  48	  HOURS	  
The	   normal	   histological	   state	   of	  
control	   window	   chambers	   differs	  
from	   healthy	   normal	   skin	   due	   to	  
inflammatory	   reactions	   caused	   by	  
the	   window	   chamber.	   These	   include	  
a	  thickening	  of	  the	  stratum	  corneum	  
and	   lymphocyte	   infiltration	   in	   the	  
upper	   and	   lower	   dermis.	   The	   fascia,	  
in	  contact	  with	  the	  cover	  glass	  of	  the	  window,	  may	  show	  abundant	  infiltration	  and	  edema	  
irrespective	  of	  the	  presence	  of	  tumor.	  
	  
Figure	  7.8:	  Overview	  of	  vascular	  leakage	  and	  stasis	  as	  
observed	  using	  confocal	  microscopy	  2	  hours	  after	  PDT	  
illumination.	  (L)	  leakage,	  (S)	  stasis	  (LS)	  leakage	  and	  stasis.	  
	  
Figure	  7.9:	  histological	  PDT-­‐induced	  tissue	  effects.	  a)	  control	  no	  treatment.	  b)	  Group	  2	  ce6	  5	  hours.	  c)	  Group	  
4	  ce6	  24	  hours.	  d)	  Group	  1	  Bremachlorin	  5	  hours.	  e)	  Group	  3	  Bremachlorin	  24	  hours.	  All	  magnifications	  100x	  
f)	  Group	  3,	  300x	  magnification.	  Infiltrate	  consist	  of	  both	  lymphocytes	  and	  neutrophils.	  Arrows	  indicate	  
abnormal	  histological	  structures:	  (E)	  loss	  of	  cell	  structure	  in	  epithelium	  (A)	  apoptotic	  bodies	  (H)	  damaged	  
hair	  follicle	  (R)	  extravagated	  red	  blood	  cells	  (T)	  tumor	  tissue	  (N)	  neutrophils	  (L)	  lymphocytes	  (OE)	  edema	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Typical	   pathological	   characteristics	   for	   PDT	   induced	   damage	   are	   the	   presence	   of	  
interstitial	  inflammatory	  infiltrate	  consisting	  of	  polymorphonuclear	  cells	  (neutrophils	  and	  
eosinophils)	   and	   mononuclear	   cells	   (lymphocytes,	   monocytes,	   and	   plasma	   cells)	   in	   the	  
tissue,	  apoptotic	  bodies,	  necrosis-­‐related	  homogenization	  of	  the	  tissue	  structure	  and	  loss	  
of	  cell	  borders,	   the	   loss	  of	  cell	  adhesion,	  damaged	  cells	  and	  edema.	  Vascular	  damage	   is	  
indicated	  by	  red	  blood	  cell	  extravasation	  throughout	  the	  tissue.	  The	  vitality	  of	  the	  tumor	  
after	  PDT	   is	  determined	  based	  on	  damaged	   tumor	  cells,	   infiltration	  of	   lymphocytes	  and	  
neutrophils,	   the	   presence	   of	   red	   blood	   cells,	   apoptotic	   bodies	   and	   the	   observation	   of	  
pyknotic	  nuclei	  and	  eosinophilic	  homogeneous	  cytoplasm.	  	  	  
Figure	  7.9	  shows	  some	  typical	  examples	  of	  PDT	  affected	  normal	  and	  tumor	  tissue	  
in	   relation	   to	   a	   section	   of	   a	   control	   animal.	   Figure	   7.9a	   shows	   histological	   state	   of	   a	  
window	   chamber.	   Some	   inflammatory	   infiltration	   can	   be	   seen	   in	   the	   upper	   dermis	   and	  
the	   fascia.	   The	  epidermis	  was	   completely	   intact	   and	  hair	   follicles	   and	   sebaceous	   glands	  
were	  present	  throughout	  the	  whole	  dermis.	  The	  lower	  dermis	  (adipose	  cell	  layer)	  showed	  
intact	  cells,	  which	  were	  closely	  connected	  to	  each	  other.	  The	  muscle	  layer	  was	  continuous	  
and	  showed	  the	  striped	  pattern	  characteristic	  for	  cutaneous	  muscle.	  	  	  
	  
Homogenization	   of	   the	   tissue	   structure	   in	   the	   epithelial	   layer	   for	   PDT	   treated	   animals	  
(figure	   7.9b-­‐e)	   was	   observed,	   indicated	   by	   the	   loss	   of	   hematoxylin	   staining	   and	  
recognizable	   cellular	   shapes.	   This	  effect	  was	   reported	   in	  12	  PDT	   treated	  animals,	  which	  
included	  all	  animals	  treated	  in	  group	  3,	  and	  half	  of	  the	  animals	  in	  group	  1,	  2	  and	  4.	  Most	  
of	  these	  animals	  combined	  the	  loss	  of	  cell	  structures	  in	  the	  epidermis	  with	  damaged	  hair	  
follicles	  and	  sebaceous	  glands.	  The	  observation	  of	  a	  severed	  epithelial	   layer	  was	  in	  most	  
cases	  linked	  to	  abnormal	  tissue	  histology	  in	  dermis	  and	  adipose	  layer	  as	  well.	  	  
	   PDT	   related	   damage	   to	   the	   upper	   dermis	   included	   inflammatory	   infiltrate,	   both	  
lymphocytes	   and	   neutrophils,	   edema,	   clusters	   of	   apoptotic	   bodies	   and	   extravasation	   of	  
red	  blood	  cells	  throughout	  the	  tissue.	  The	  extravasation	  of	  RBCs,	  indicating	  hemorrhages	  
and/or	   leaking	   vasculature,	   appeared	  more	   often	   after	   treatment	  with	   a	   24	   hour	   drug-­‐
light	  interval	  for	  both	  photosensitizers.	  	  
The	  lower	  dermis	  (adipose	  cell	  layer)	  showed	  the	  most	  PDT	  related	  damage	  when	  
animals	  were	  treated	  with	  a	  24	  hour	  drug-­‐light	  interval	  (group	  3	  and	  4).	  This	  included	  the	  
loss	  of	  the	  characteristic	  round	  shape	  of	  the	  adipose	  cells	  (as	  in	  figure	  7.9c),	  infiltrate	  and	  
apoptotic	   bodies	   through	   the	   whole	   layer.	   Animals	   treated	   with	   a	   5	   hour	   drug-­‐light	  
interval	  (groups	  1	  and	  2)	  showed	  an	  increase	  in	  inflammatory	  infiltrate	  compared	  to	  the	  










The	   normal	   structure	   of	   the	   cutaneous	   muscle	   was	   partially	   lost	   in	   three	   of	   the	   four	  
animals	  in	  group	  3.	  Other	  groups	  did	  not	  show	  any	  abnormal	  muscle	  tissue,	  except	  from	  
some	  edema	  around	  the	  muscle	  fibers.	  The	  fascia	  of	  three	  animals	  showed	  some	  edema,	  
while	  in	  three	  other	  animals,	  all	  part	  of	  group	  3	  or	  4,	  we	  observed	  extravasation	  of	  RBCs,	  
apoptosis	  and	  loss	  of	  cell	  structure	  in	  the	  fascia.	  	  
	  
To	  determine	  the	  vitality	  of	  the	  tumor	  after	  PDT,	  tumor	  tissue	  in	  the	  histological	  sections	  
was	   analyzed.	   Viability	   of	   tumor	   and/or	   normal	   tissue	   was	   determined	   in	   histological	  
sections	  from	  23	  animals	  (in	  four	  animals	  harvesting	  of	  tissue	  two	  days	  after	  illumination	  
was	   not	   possible).	   In	   15	   samples	   tumor	   tissue	   was	   identified	   in	   the	   sections	   under	  
analysis,	  from	  which	  three	  were	  unaffected	  control	  animals.	   In	  only	  six	  of	  the	  remaining	  
12	  mice	  vital	  tumor	  tissue	  was	  observed.	  
An	  overview	  of	   the	   impact	   of	   PDT	  on	  normal	   and	   tumor	   tissue	   for	   the	  different	  
treatment	   schemes	   is	   shown	   in	   table	   7.1.	   The	   percentage	   of	   animals	   per	   group	   that	  
showed	  PDT	   effects	   in	   normal	   or	   tumor	   tissue	   is	   shown.	  Animals	   categorized	   as	   having	  
affected	   normal	   tissue	   showed	   PDT-­‐related	   deviation	   from	   normal	   tissue	   histology,	   as	  
described	  above.	  In	  mice	  having	  affected	  tumor	  tissue	  the	  tumor	  did	  show	  only	  little	  vital	  
tumor	  cells.	  The	  PDT-­‐induced	  histological	  abnormalities	  in	  both	  normal	  and	  tumor	  tissue	  
were	   more	   severe	   when	   the	   illumination	   was	   performed	   after	   a	   24	   hour	   drug-­‐light	  
interval	   for	   both	   photosensitizers.	   Ce6	   PDT	   with	   a	   5	   hour	   drug-­‐light	   interval	   was	   least	  
effective	   in	  causing	  damage,	  both	   in	  normal	  and	  tumor	  tissue.	  None	  of	   the	   four	   tumors	  
present	   appeared	   to	   be	   affected	   by	   PDT,	   while	   two	   of	   the	   four	   animals	   showed	   PDT-­‐
induced	   histological	   markers	   in	   normal	   tissue.	   We	   did	   not	   observe	   selective	   tumor	  
damage,	  in	  which	  normal	  tissue	  was	  still	  intact	  but	  tumor	  tissue	  was	  destroyed.	  	  
	  



















Bremachlorin	   5	   67	   4	  :	  6	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   3	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   24	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   5	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In	   this	   paper	   we	   have	   investigated	   PDT	   induced	   damage	   on	   OSC19	   tumor	   in	   dorsal	  
window	  chambers	  in	  mice.	  The	  photosensitizers	  under	  investigation	  are	  Bremachlorin	  and	  
ce6,	   and	   drug-­‐light	   intervals	   of	   5	   and	   24	   hours	   are	   applied.	   Previous	   findings	   on	  
photosensitizer	  pharmacokinetics	  suggest	  that	  long	  drug-­‐light	  intervals	  may	  result	  in	  more	  
effective	   PDT.	   Here	   we	   showed	   that	   illuminating	   24	   hours	   after	   photosensitizer	  
administration	  was	  more	   effective	   than	   a	   5	   hour	   drug-­‐light	   interval	   in	   causing	   vascular	  
and	  tissue	  responses	  for	  both	  ce6	  and	  Bremachlorin.	  Furthermore,	  Bremachlorin	  caused	  
an	   increase	   in	  acute	  vascular	  effects	  during	  PDT	   illumination	  compared	  to	  ce6,	   together	  
with	  more	   evidence	  of	  microscopically	   and	  macroscopically	   PDT-­‐induced	   tissue	  damage	  
two	  days	  after	  illumination.	  
	  
ACUTE	  EFFECTS	  OF	  PDT	  IN	  THE	  DORSAL	  SKINFOLD	  WINDOW	  CHAMBER	  
During	   the	   therapeutic	   illumination	   we	   were	   able	   to	   detect	   acute	   vascular	   and	   tissue	  
response	   by	   imaging	   the	   vasculature	   and	   tissue	   in	   the	  window	   chamber.	  We	   observed	  
constriction	  of	  arteries	  and	  venules,	  some	  constrictions	  lasted	  for	  at	  least	  2	  hours,	  other	  
constricted	  arteries	  relaxed	  within	  2	  hours.	  Relaxation	  of	  the	  vessel	  lumen	  during	  PDT	  has	  
been	  observed	  previously	  by	  Fingar	  et	  al.	  [53]	  during	  Photofrin	  PDT	  using	  a	  24	  hour	  drug-­‐
light	   interval.	   In	   the	   present	   study,	   two	   animals	   showed	   severe	   hemorrhage	   in	   the	  
window	  chamber	  during	  illumination.	  Direct	  vascular	  effects	  were	  most	  often	  observed	  in	  
animals	   treated	  with	  Bremachlorin	  using	  a	  24	  hour	  drug-­‐light	   interval,	  and	  ce6	  with	  a	  5	  
hour	  drug-­‐light	  interval.	  	  
Even	   though	   it	   is	  known	   from	  previous	  studies	   that	   the	  amount	  of	  Bremachlorin	  
present	   in	   the	   vasculature	   is	   highest	   after	   short	   incubation	   times	   [44],	   the	   acute	  
vasoconstriction	  and	  tissue	  displacement	  that	  we	  observe	  for	  Bremachlorin	  in	  the	  present	  
study	   are	   more	   pronounced	   using	   a	   24	   hour	   drug-­‐light	   interval.	   Furthermore,	   the	  
investigation	   of	   the	   response	   of	   the	   vasculature	   2	   hours	   following	   PDT	   using	   confocal	  
microscopy	  combined	  with	   the	   injection	  of	  a	   fluorescent	  dye	   in	   the	  vasculature	  showed	  
vascular	  leakage	  and	  stasis.	  These	  effects	  were	  observed	  for	  both	  ce6	  and	  Bremachlorin,	  
but	   were	   more	   pronounced	   for	   24	   and	   5	   hours	   Bremachlorin	   PDT,	   where	   all	   animals	  
under	  investigation	  showed	  leakage	  and/or	  stasis.	  Our	  results	  are	  contrary	  to	  the	  absence	  
of	  vascular	  constriction	  reported	  in	  a	  study	  by	  McMahon	  et	  al.	  on	  the	  effect	  of	  NPe6	  PDT	  
on	  vasculature	  in	  the	  rat	  cremaster	  muscle	  using	  a	  4	  and	  24	  hour	  drug-­‐light	  interval	  [27].	  
The	   complete	   vascular	   stasis	   as	   reported	   by	   McMahon	   does	   correspond	   with	   our	  
observations,	  although	  we	  observed	  similar	  results	  in	  the	  groups	  with	  both	  the	  4	  hour	  and	  









a	   role	   in	   the	   induction	  of	   stasis,	  as	  previously	  described	   for	  ALA-­‐PDT	   [54]	  and	  Photofrin	  
PDT	  [55].	  
	  
A	   number	   of	   animals	   showed	   severe	   muscle	   contraction	   in	   the	   window	   chamber	   that	  
caused	  displacement	  of	   the	  vasculature	  and	   in	   some	  cases	   the	   tumor.	   In	   two	  cases	   this	  
included	   the	   dislocation	   of	   the	   fascia	   relative	   to	   the	   (epi)dermal	   layer.	   This	  movement	  
suggests	   that	   the	   cutaneous	   muscle	   layer	   was	   strongly	   affected	   during	   the	   PDT	  
illumination.	   Although	   the	  mechanism	  behind	   this	  muscle	   activation	   is	   unknown,	   it	   is	   a	  
well	   known	   effect	   that	   arteries,	   including	   their	  muscle	   layer,	   often	   constrict	   as	   a	   acute	  
response	   to	   PDT	   [56].	   We	   have	   previously	   observed	   severe	   muscle	   spasms	   during	   the	  
treatment	  of	  anal	  intraepithelial	  neoplasia	  using	  systemic	  mTHPC	  [1],	  which	  also	  suggests	  
a	  reaction	  of	  muscle	  fibers	  as	  a	  PDT	  related	  effect.	  The	  activation	  of	  muscle	  fibers	  during	  
PDT	  is	  probably	  related	  to	  the	  presence	  of	  Bremachlorin	  and	  ce6	  that	  we	  have	  previously	  
observed	  in	  OSC19	  tumors	  in	  muscle	  after	  a	  24	  hour	  drug-­‐light	  interval	  [45].	  	  
	  
HISTOLOGICAL	  EFFECTS	  AFTER	  PDT	  AT	  48	  HOURS	  
The	  microscopic	   observations	   on	   histological	   PDT-­‐induced	   effects	  made	   two	   days	   after	  
illumination	   corresponded	  with	  what	   has	   previously	   been	   reported	   [57,	   58]	   in	   humans.	  
PDT	  results	  in	  a	  combination	  of	  apoptotic	  and	  necrotic	  cell	  death.	  In	  PDT	  treated	  animals,	  
we	  observed	   signs	  of	  apoptotic	  and	  necrotic	   cell	  death	   in	  normal	   tissue	   in	  15	  of	   the	  19	  
chambers.	  In	  tumor	  tissue,	  apoptotic	  and	  necrotic	  markers	  were	  only	  observed	  in	  6	  of	  the	  
12	  sections	  containing	  tumor	  material.	  Animals	  treated	  after	  a	  24	  hour	  drug-­‐light	  interval	  
showed	   more	   cell-­‐kill	   related	   effects	   than	   those	   treated	   5	   hours	   after	   photosensitizer	  
administration.	  Although	  the	  probability	  of	  PDT	  effects	  in	  normal	  or	  tumor	  tissue	  is	  higher	  
in	   animals	   showing	  acute	   vascular	   effects	   after	   illumination,	  we	   found	  no	   clear	   relation	  
between	   the	   two.	   It	   should	  be	  noted	   that	  we	  analyzed	  six	   tissue	   sections	  per	   chamber,	  
with	  an	  equal	   intermittent	  histological	  slice	  separation.	  How	  these	   locations	  correspond	  
with	   the	  regions	  of	   interest	  showing	  vasoconstriction	  or	   tissue	  movement	  during	  PDT	   is	  
unknown	   and	   small	   tumors	   may	   not	   have	   always	   been	   included	   in	   our	   analysis	   of	  
histological	  sections.	  	  	  	  
	  
There	   appears	   to	   be	   no	   correlation	   between	   vascular	   effects	   during	   or	   2	   hours	   after	  
illumination	   and	   the	   histological	   response	   48	   hours	   after	   illumination.	   Analysis	   showed	  
most	  histological	  characteristics	  of	  direct	  cell	  damage,	  both	  for	  tumor	  and	  normal	  tissue	  
cells,	  for	  24	  hour	  incubation	  time	  for	  both	  Bremachlorin	  and	  ce6.	  This	  is	  in	  contrast	  with	  
what	  might	  be	  expected	  for	  ce6.	  Apparently,	  the	  very	  low	  concentration	  of	  ce6	  present	  24	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Previous	  studies	  have	  reported	  that	  the	  efficacy	  of	  PDT	  is	  greater	  when	  it	  is	  applied	  using	  
short	  drug-­‐light	   intervals.	   It	   is	   important	  to	  note	  that	   in	  the	  present	  study	  we	  have	  only	  
investigated	  the	  histological	   tissue	  response	  after	  two	  days,	  while	  tumor	  re-­‐growth	  may	  
be	  a	  better	  assessment	  of	  treatment	  efficacy.	  McMahon	  et	  al.	  [27]	  have	  reported	  similar	  
tissue	  response	  for	  both	  4	  and	  24	  hour	  incubation	  times	  in	  NPe6-­‐PDT	  after	  48	  hours,	  only	  
to	  show	  tumor	  regrowth	  for	  the	  24	  hour	  group.	  	  
The	   relationship	   between	   acute	   vascular	   effects	   and	   histological	   PDT	   effects	   is	  
relevant,	  since	  it	  provides	  an	  indication	  of	  tumor	  vitality.	  Analysis	  of	  acute	  vascular	  effects	  
in	  animals	  from	  which	  we	  were	  able	  to	  determine	  histological	  PDT	  effects	  on	  normal	  and	  
tumor	  cells	  showed	  that	  in	  4	  out	  of	  6	  and	  10	  out	  of	  15	  animals	  we	  observed	  both	  vascular	  
effects	  and	  histological	  damage	  to	  tumor	  and	  normal	  cells	  respectively.	  Similarly,	  from	  the	  
animals	   that	   did	   not	   show	   histological	   indications	   of	   apoptosis	   or	   necrosis	   to	   tumor	   or	  
normal	   tissue,	   respectively	   4	   out	   of	   6	   and	   3	   out	   of	   4	   animals	   did	   not	   show	   any	   acute	  
vascular	   effects.	   Therefore,	   although	   not	   significant,	   the	   observation	   of	   acute	   vascular	  
effects	   during	   PDT	   illumination	   correlates	   with	   PDT	   induced	   tissue	   damage	   on	   a	  
microscopic	  level.	  
	  
Microscopic	   analysis	   of	   the	   cutaneous	  muscle	   layer	   did	   in	   most	   cases	   not	   show	   direct	  
response	   in	  muscle	   fibers.	  Only	   two	  animals	   showed	  a	  disruption	  of	   the	   layer,	  although	  
edema	  and	   inflammatory	   infiltrate	  were	   in	  more	  cases	  observed	  around	   the	  bundles.	   If	  
pharmacokinetics	   in	   skin	   compare	   with	   those	   observed	   in	   the	   tongue	   [44,	   45],	   muscle	  
fiber	   should	   contain	   a	   relatively	   high	   concentration	   of	   photosensitizer,	   but	   does	   not	  
appear	   to	   be	   substantially	   affected.	   The	   valid	   theory	   for	   ALA-­‐PDT	   suggests	   that	  muscle	  
fibers	   are	   more	   susceptible	   for	   PDT	   damage	   than	   epithelial	   layers	   surrounding	   it	   [59]	  
which	   results	   in	   intact	   epithelial	   layers	   on	   top	   of	   severely	   damaged	  musculature	   in	   the	  
esophagus.	  For	  ce6-­‐PDT	  however,	  this	  theory	  does	  not	  seem	  to	  apply.	  	  
	  
COMPARISON	  WITH	  PREVIOUS	  EXPERIMENTS	  
We	  have	   recently	   reported	  on	   the	  pharmacokinetics	  of	  Bremachlorin	  and	   ce6	   in	  OSC19	  
tumors	   in	   the	  mouse	   tongue	   [44,	   45].	  We	   showed	   that	   the	   amount	   of	   photosensitizer	  
present	   is	   highest	   in	   the	   tumor	   border,	   while	   the	   concentration	   in	   normal	   and	   tumor	  
tissue	   is	   much	   lower.	   It	   is	   only	   after	   incubation	   times	   of	   24	   hours	   or	   longer	   that	   the	  
concentration	  in	  normal	  tongue	  tissue	  becomes	  lower	  than	  in	  tumor	  tissue.	  Although	  ce6	  
is	   at	   those	   time	   points	   almost	   completely	   metabolized	   and	   cleared	   from	   tissue,	  
Bremachlorin	   is	   still	   present	   in	   significant	   amounts.	   When	   comparing	   in-­‐vivo	   intrinsic	  
fluorescence	  measurements	   using	   single	   fiber	   fluorescence	   spectroscopy	   (SFF)	   [44]	   and	  









found	  in	  microscopic	  sections	  was	  much	  smaller	  than	  in	  SFF	  measurements.	  Therefore,	  it	  
has	  been	  hypothesized	  that	  most	  of	  the	  photosensitizer	  is	  present	  in	  the	  vasculature	  after	  
short	  incubation	  times.	  
	   Although	  specific	  tumor	  targeting	  of	  PDT	  effects	  was	  not	  observed,	  it	  is	  clear	  that	  
24	   hour	   incubation	   time	   induced	   more	   effect	   than	   5	   hours	   did.	   Even	   ce6,	   which	   was	  
mostly	   metabolized	   at	   24	   hours	   after	   administration,	   showed	   acute	   vascular	   effects	  
during	  and	   tissue	  damage	  after	   illumination	  at	   late	   time	  points,	  more	   so	   than	  observed	  
after	  a	  5	  hour	  incubation	  time.	  	  
	   The	  study	  presented	  in	  this	  paper	  was	  designed	  to	  show	  PDT-­‐effects	  related	  to	  cell	  
death	  after	  treatment	  of	  an	  oral	  squamous	  cell	  carcinoma.	  In	  this	  study,	  the	  mouse	  dorsal	  
skinfold	  chamber	  was	  our	  model	  of	  choice,	  due	  to	   its	  accessibility	  and	  visualizing	  ability	  
during	   imaging.	   Although	   this	   study	   was	   designed	   based	   on	   pharmacokinetics	   in	   the	  
tongue,	  it	  provides	  us	  with	  important	  insights	  into	  PDT	  in	  OSC19	  tumors	  in	  general.	  Since	  
the	   induction	   of	   the	   tumor	   in	   a	   different,	   non-­‐orthotopic	   environment	   may	   result	   in	  
different	  pharmacokinetics,	  these	  insights	  could	  not	  automatically	  assumed	  to	  be	  true	  for	  
OSC19	   tumors	   in	   tongue.	   The	   next	   step	   in	   the	   investigation	   of	   long	   drug-­‐light	   interval	  
Bremachlorin	   and	   ce6	   PDT	   of	   oral	   squamous	   cell	   carcinoma	  will	   be	   performing	   PDT	   an	  
orthotopic	  model,	  where	   PDT	   efficacy	   is	   determined	   based	   on	   growth	   delay.	   However,	  
execution	  of	  growth	  delay	  studies	  is	  complicated	  by	  the	  large	  natural	  variability	  present	  in	  
biological	  tissue	  and	  treatment	  response.	  Analysis	  of	  acute	  PDT	  response	  as	  performed	  in	  
this	   study	   provides	   us	   with	   insights	   that	   cannot	   easily	   be	   derived	   from	   growth	   delay	  
studies.	  	  	  	  
	  
IMPLICATIONS	  FOR	  CLINICAL	  USE	  
Based	  on	   in-­‐vivo	  pharmacokinetic	   studies,	  ce6-­‐based	  photosensitizers	  are	   (pre-­‐)clinically	  
used	   in	   combination	   with	   a	   short	   drug-­‐light	   interval	   of	   around	   5	   hours	   [13].	   However,	  
most	   studies	   apply	   a	   ce6-­‐based	   conjugate	   to	   reduce	   the	  hydrophilicity	   of	   pure	   ce6	   and	  
increase	  cellular	   internalization.	  Bremachlorin	  consists	  of	  a	  solution	   in	  which	  pure	  ce6	   is	  
the	   photo-­‐active	   substance.	   This	   and	   previous	   studies	   showed	   that	   when	   using	  
Bremachlorin	  as	  photosensitizer,	  investigation	  of	  drug-­‐light	  intervals	  in	  the	  order	  of	  days	  
is	  worthwhile.	  	  
	  
CONCLUSION	  
For	   the	   photosensitizer	   mixture	   Bremachlorin	   and,	   to	   a	   lesser	   extend,	   ce6,	   most	   PDT-­‐
related	  effects	  were	  observed	  after	  a	  24	  hour	  incubation	  time.	  This	  was	  the	  case	  for	  acute	  
vascular	  effects	  during	  PDT	  and	  2	  hours	  after	  PDT,	  and	  histological	  analysis	  of	  PDT	  treated	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practice,	   in	   which	   mostly	   short	   drug-­‐light	   intervals	   are	   used	   for	   PDT	   with	   ce6-­‐based	  
photosensitizers,	   based	   on	   the	   much	   higher	   concentration	   photosensitizer	   present	   at	  
those	   time	   points.	   How	   the	   observation	   of	   PDT-­‐effects	   after	   48	   hours	   relates	   to	   tumor	  
reduction	  and/or	  cure	  is	  the	  topic	  of	  future	  research.	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This	  thesis	  focuses	  on	  the	  application	  of	  quantitative	  fiber	  optic	  spectroscopy	  and	  optical	  
imaging	   techniques	   to	  provide	  an	   insight	   into	   various	  PDT-­‐related	  processes,	  which	   can	  
contribute	   to	   the	   optimization	   of	   photodynamic	   therapy.	   It	   can	   be	   divided	   into	   three	  
principle	  sections.	  
 The	   investigation	   of	   the	   relationship	   between	   vascular	   responses	   during	   light	  
fractionated	   ALA-­‐PDT	   and	   treatment	   efficacy	   using	   optical	   imaging	   and	  
spectroscopy.	  
 The	   development	   of	   quantitative	   fiber	   optic	   fluorescence	   spectroscopy	   and	   its	  
application	  in	  measuring	  in-­‐vivo	  photosensitizer	  pharmacokinetics.	  
 A	   comparison	   of	   the	   pharmacokinetics	   and	   spectral	   properties	   of	   chlorin	   e6	   and	  
Bremachlorin	   based	   on	   in-­‐vivo	   measurements	   and	   their	   relationship	   to	   PDT	  
efficacy.	  
The	   primary	   goal	   is	   to	   use	   results	   from	   these	   investigations	   to	   optimize	   treatment	  
protocols	   for	   PDT	   with	   the	   aim	   of	   maximizing	   treatment	   efficacy	   and	   minimizing	   side	  
effects.	  Although	  this	  thesis	  only	  covers	  preclinical	  research,	  it	  demonstrates	  the	  first	  in-­‐
vivo	   implementation	   of	   fully	   quantitative	   reflectance	   and	   fluorescence	   fiber	   optic	  
spectroscopy.	   The	   next	   translational	   step:	   fully	   quantitative	   clinical	   spectroscopy	  would	  
clearly	  benefit	  clinical	  PDT	  research.	  
	  
This	  chapter	  provides	  the	  reader	  with	  a	  general	  discussion	  of	  conclusions	  of	  the	  individual	  
studies,	   how	   they	   relate	   to	   each	   other	   and	   how	   they	   relate	   to	   the	   overall	   goal	   of	  
optimization	  of	  PDT.	  
	  
INVESTIGATION	  OF	  THE	  ROLE	  OF	  THE	  FIRST	  LIGHT	  FRACTION	  IN	  LIGHT	  FRACTIONATED	  ALA-­‐PDT	  
In	  chapter	  2	  and	  chapter	  3	  the	  extensive	  research	  on	  light	  fractionated	  ALA-­‐PDT	  that	  has	  
been	  carried	  out	  over	  the	  last	  two	  decades	  is	  extended.	  Interest	  in	  light	  fractionated	  ALA-­‐
PDT	   was	   piqued	   by	   the	   clinical	   observation	   that	   PpIX	   fluorescence	   re-­‐appeared	   after	  
therapeutic	   illumination	   [W.M.	   Star,	   personal	   communication].	   This	   led	   to	   numerous	  
studies	   investigating	   (a)	   the	   mechanism(s)	   underlying	   light	   fractionation	   and	   (b)	   how	  
efficacy	   might	   be	   maximized	   by	   changing	   the	   length	   of	   the	   dark	   interval	   and	   light	  
treatment	   parameters.	   Preclinical	   results	   applying	   this	   treatment	   protocol	   have	   been	  
promising	  [1].	  It	  has	  been	  shown	  that	  the	  increase	  in	  response	  is	  highest	  when	  a	  low	  dose	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choice	  of	  fluence	  (rate)	  for	  the	  first	  fraction	  has	  been	  shown	  to	  be	  critical.	  The	  increased	  
effect	   of	   light	   fractionated	   ALA-­‐PDT	   was	   subsequently	   confirmed	   in	   a	   clinical	   study	   of	  
treatment	  of	  superficial	  basal	  cell	  carcinomas	  [3].	  The	  exact	  mechanism(s)	  underlying	  the	  
increased	   response	   are	   still	   under	   investigation,	   but	   we	   have	   shown	   that	   cells	   are	  
rendered	   sensitive	   to	   the	   second	   light	   fraction	   by	   a	   small	   PDT	   dose	   and	   a	   2	   hour	   dark	  
interval	   [4].	   This	   is	   the	   reason	   why	   the	   light	   treatment	   parameters	   of	   the	   first	   light	  
fraction	  and	  their	  influence	  on	  the	  acute	  physiological	  response	  to	  PDT	  are	  critical.	  
	   The	  higher	  efficacy	  of	  a	  low	  dose	  first	  fraction	  over	  a	  high	  dose	  first	  fraction	  may	  
be	  explained	  by	  the	  onset	  of	  vascular	  constriction	  early	  in	  the	  treatment,	  which	  then	  has	  
the	  chance	  to	  recover	  during	  the	  dark	  interval.	  Vasoconstriction	  is	  thought	  to	  be	  caused	  
by	   rapid	   oxygen	   depletion	   during	   the	   first	   few	   minutes	   of	   PDT	   and	   therefore	   a	   lower	  
fluence	  rate	  is	  expected	  to	  lead	  to	  less	  or	  slower	  vasoconstriction.	  When	  the	  vasculature	  
is	   damaged,	   the	   oxygen	   supply	   to	   the	   target	   tissue	   is	   severed	   and	   PDT	   is	   rendered	  
ineffective.	  Therefore,	  it	  would	  be	  expected	  that	  lower	  fluence	  rates	  increase	  the	  efficacy	  
of	  fractionated	  PDT	  even	  more.	  An	  additional	  advantage	  of	  using	   low	  fluence	  PDT	  is	  the	  
reduced	   pain	   experienced	   by	   the	   patient.	   ALA-­‐PDT	   is	   known	   to	   be	   very	   painful	   during	  
treatment,	  which	   in	   some	   cases	   leads	   to	   discontinuation	   of	   the	   treatment.	   It	   has	   been	  
reported	  that	  illumination	  with	  a	  lower	  fluence	  rate	  results	  in	  less	  painful	  side	  effects	  [5].	  
	   In	   chapter	   2	  we	   compare	  PDT	  damage	   to	  normal	   tissue	   for	   various	   fractionated	  
PDT	   illumination	   protocols,	   including	   20	   and	   50	   mW	   cm-­‐2.	   This	   study	   confirms	   the	  
increased	   damage	   of	   fractionated	   PDT	   over	   a	   single	   illumination	   and	   demonstrates	   the	  
importance	  of	  the	  choice	  of	  fluence	  as	  the	  fluence	  rate	  is	  reduced.	  	  
In	   chapter	   3	   the	   focus	   lies	   on	   a	   thorough	   investigation	   of	   the	   onset	   of	  
vasoconstriction	  during	  the	  first	  fraction	  of	  PDT.	  Fluence	  rates	  of	  26,	  65	  and	  130	  mW	  cm-­‐2	  
(corresponding	  to	  20,	  50	  and	  100	  mW	  cm-­‐2	  corrected	  for	  green	  vs.	  red	  laser	  light	  photon	  
energy)	   are	   investigated.	   Although	   vasoconstriction	   is	   observed,	   these	   observations	   are	  
present	   in	   all	   three	   groups.	   A	   control	   group	   without	   ALA	   application	   does	   not	   show	  
vasoconstriction.	  The	  results	  of	  these	  two	  studies	  suggest	  that	  fluence	  rate	  does	  not	  play	  
a	  key	  role	  in	  occurrence	  of	  vascular	  effects	  and	  the	  increased	  efficacy	  of	  fractionated	  PDT.	  	  
Although	   low	   fluence	   rate	   20	   mW	   cm-­‐2	   PDT	   may	   not	   result	   in	   increased	   tissue	  
damage	  and	  vasoconstriction,	  it	  does	  not	  differ	  significantly	  in	  damage	  from	  50	  mW	  cm-­‐2,	  
which	  is	  currently	  used	  clinically	  for	  the	  treatment	  of	  superficial	  basal	  cell	  carcinomas.	  The	  
positive	   effect	   of	   decreasing	   the	   fluence	   rate	   to	   20	  mW	   cm-­‐2	   is	   that	   it	   is	   suggested	   to	  
reduce	   the	   pain	   patients	   experience	   when	   undergoing	   treatment	   [5].	   However,	  
decreasing	  fluence	  rate	  from	  50	  mW	  cm-­‐2	  to	  20	  mW	  cm-­‐2	  while	  simultaneously	  achieving	  
the	  same	  total	  dose	   is	  clinically	  unfeasible	  due	  to	  the	  2.5	  times	   longer	   illumination	  time	  










of	   20	  mW	   cm-­‐2	   a	   total	   dose	   of	   50	   J	   cm-­‐2	   leads	   to	   similar	   tissue	   damage	   as	   100	   J	   cm-­‐2.	  
Therefore,	   with	   only	   a	   small	   increase	   in	   clinical	   illumination	   time	   it	  may	   be	   feasible	   to	  
reduce	   the	   pain	   patients	   experience	   during	   treatment.	   Although	   clinical	   research	   is	  
required	  to	  confirm	  the	  decrease	  in	  pain	  sensation	  while	  maintaining	  treatment	  efficacy,	  
these	  results	  may	  lead	  to	  a	  significant	  improvement	  in	  how	  patients	  experience	  ALA-­‐PDT.	  
	   Recently	   it	   is	   discovered	   in-­‐vitro	   that	   cells	   incubated	  with	   low	   concentrations	   of	  
ALA	  show	  enhanced	  cell	  death	  after	  light	  fractionated	  PDT	  over	  incubation	  with	  high	  ALA	  
concentrations	  [4].	  It	  is	  suggested	  that	  the	  delivery	  of	  a	  small	  PDT	  dose	  followed	  by	  a	  dark	  
interval	  will	  bring	  the	  tumor	  cells	  in	  a	  pre-­‐lethal	  phase	  making	  them	  more	  vulnerable	  for	  
death	  by	  apoptosis	  or	  autophagy.	  PpIX	  concentrations	  measured	  in	  the	  dermis	  in	  general	  
and	  dermal	  epithelial	  cells	  in	  particular	  are	  low,	  but	  may	  therefore	  be	  more	  vulnerable	  for	  
light	   fractionated	  PDT.	  A	  possible	  application	  of	   this	   result	   is	   to	  use	  the	  amount	  of	  PpIX	  
synthesis	   as	   a	   measure	   for	   the	   optimum	   drug-­‐light	   interval	   compared	   to	   the	  
predetermined	  two	  hours	  period	  that	  is	  currently	  used	  in	  the	  clinic.	  Intrinsic	  fluorescence	  
measurements	   by	   single	   fiber	   fluorescence	   spectroscopy	   (SFF)	   could	   be	   used	   in	   this	  
context	   to	   monitor	   PpIX	   fluorescence	   before	   and	   during	   treatment.	   Recently,	  
spectroscopic	  measurements	  of	  PpIX	  using	  SFF	  have	  been	  performed	  during	  clinical	  ALA-­‐
PDT	  of	  actinic	  keratosis	  [T.	  Middelburg,	  manuscript	  submitted].	  It	  should	  be	  noted	  that	  it	  
is	   probably	   not	   feasible	   to	   determine	   small	   differences	   in	   localization	   associated	   with	  
differences	  in	  PpIX	  between	  dermal	  tissue	  and	  endothelial	  cells.	  
	  
DEVELOPMENT	  OF	  QUANTITATIVE	  IN-­‐VIVO	  FLUORESCENCE	  SPECTROSCOPY	  
Fluorescence	   spectroscopy	   is	   under	   investigation	   both	   as	   a	   diagnostic	   tool	   and	   as	   a	  
method	  for	  monitoring	  a	  number	  of	  therapeutic	  modalities.	  The	  (semi-­‐)quantification	  of	  
fluorescent	   drugs	   in	   various	   tissue	   types	   is	   one	   of	   the	   major	   applications	   of	   in-­‐vivo	  
fluorescence	   spectroscopy	   and	   is	   widely	   incorporated	   in	   PDT	   research	   and	   in	   clinical	  
practice.	  Despite	  the	  potential	  usefulness	  of	  in-­‐vivo	  fluorescence	  spectroscopy,	  the	  exact	  
quantification	   of	   fluorescent	   signals	   is	   complicated	   by	   the	   effect	   of	   tissue	   optical	  
properties	   on	   light.	   This	   thesis	   therefore	   focuses	   on	   intrinsic	   fluorescence,	   where	   the	  
influence	  of	   those	   tissue	  optical	  properties	   is	   removed	   from	  the	  measured	   fluorescence	  
spectrum	  and	  which	  can	  be	   related	   to	   fluorophore	  concentration.	   Intrinsic	   fluorescence	  
enables	  quantitative	  measurement	  of	  fluorescence	  intensity	  and	  spectral	  shape	  in	  tissues	  
with	   different	   and/or	   varying	   optical	   properties.	   A	   limiting	   factor	   in	   determining	   the	  
intrinsic	  fluorescence	  in-­‐vivo	  up	  to	  now	  has	  been	  the	  need	  for	  quantitative	  information	  on	  
tissue	   scattering	   properties.	   With	   the	   development	   of	   multi-­‐diameter	   single	   fiber	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scattering	  properties,	  and	   -­‐with	  minimal	  adaptation	  of	   the	  device-­‐	   intrinsic	   fluorescence	  
measurements	  are	  feasible.	  
Chapter	  4	  reports	  on	  the	  first	  in-­‐vivo	  demonstration	  of	  MDSFR.	  In-­‐vivo	  values	  for	  
scattering	  power	  are	  determined	   for	   four	  different	   tissues,	   together	  with	   the	   scattering	  
phase	   function	   parameter	   γ.	   This	   illustrates	   the	   potential	   for	   the	   use	   of	   optical	  
spectroscopy	   as	   diagnostic	   tool	   to	   discriminate	   tissue	   types.	   Although	   the	   skin	   types	  
compared	   in	   this	   thesis	   are	  easily	  distinguishable	  even	  without	   the	   inclusion	  of	  MDSFR,	  
the	  development	  of	  this	  method	  paves	  the	  way	  for	  the	  possibility	  to	  discriminate	  normal	  
from	  dysplastic	  tissue.	  This	  application	  is	  very	  promising	  in,	  among	  other	  things,	  selecting	  
biopsy	   sites	   to	  prevent	   the	   taking	  of	   false	  negative	  biopsies,	  or	   for	   first	   line	  health	  care	  
providers	  to	  use	  optical	  diagnostics	  to	  determine	  referral	  of	  patients	  with	  suspect	  lesions	  
in	  the	  skin	  or	  in	  the	  oral	  cavity	  and	  oropharynx.	  
The	   physical	   interpretation	   of	   reduced	   scattering	   and	   especially	   γ	   are	   difficult.	  
Scattering	  of	  light	  is	  caused	  by	  changes	  in	  refractive	  index	  between	  the	  different	  cellular	  
and	  intracellular	  compartments	   in	  tissue.	   It	  should	  therefore	  theoretically	  be	  possible	  to	  
relate	   scattering	   to	   morphological	   parameters	   as	   size	   and	   shape	   of	   scatterers.	   Tumor	  
morphology	   differs	   significantly	   from	   that	   of	   normal	   tissue,	   which	   makes	   scattering	   a	  
potentially	   diagnostic	   tool.	   Recently,	   research	   in	   this	   area	   has	   shifted	   towards	   the	  
consideration	   of	   the	   refractive	   index	   correlation	   function,	   which	   is	   modeled	   by	   the	  
Whittle-­‐Matérn	  correlation	  function	  [6].	  This	  is	  a	  generic	  phase	  function	  model,	  of	  which	  
the	   often	   used	  Henyey-­‐Greenstein	   phase	   function	   is	   one	   of	   the	   possible	   solutions.	   The	  
Whittle-­‐Matérn	  correlation	  function	  contains	  three	  variables:	  the	  deterministic	  factor	  D,	  
the	  length	  scale	  of	  the	  correlation	  lc,	  and	  the	  scaling	  factor	  Nc.	  While	  the	  scattering	  power	  
is	   directly	   related	   to	   the	  deterministic	   factor	  D,	   the	   length	   scale	   of	   the	   correlation	   lc	   is	  
related	   to	   both	  µs’	   and	   γ.	   It	   is	   possible	   to	   express	   γ	   and	   its	  wavelength	   dependence	   in	  
terms	   of	   lc	   and	   use	   the	   combined	  measurements	   of	  µs’	   and	   γ	   to	   calculate	   the	   physical	  
properties	  of	  the	  correlation	  function,	  D	  and	  lc.	  Knowledge	  on	  D	  and	  lc	  can	  be	  related	  to	  
morphological	   features,	   which	   enables	   spectroscopic	   measurements	   to	   provide	  
information	  on	  tissue	  micro-­‐	  and	  ultrastructure.	  In	  early	  carcinogenesis,	  tissue	  undergoes	  
small-­‐scale	  morphological	   and	   architectural	   changes	   that	   occur	   even	  before	  histological	  
abnormalities	   become	   apparent.	   By	   characterizing	   the	   effects	   of	   light	   scattering,	   these	  
changes	  may	  be	  detectable	  [7].	  The	  changes	  may	  even	  be	  present	  beyond	  the	  site	  of	  the	  
lesion	  [8].	  
Extending	   MDSFR	   to	   fluorescence	   spectroscopy	   requires	   the	   addition	   of	   an	  
excitation	  laser,	  two	  extra	  bifurcations	  of	  the	  fiber	  and	  a	  separate	  spectrograph	  equipped	  
with	  a	   filter	   to	  block	  excitation	   light.	  A	   semi-­‐empirical	  model	   is	  developed	   in	  which	   the	  










and	   removed,	   which	   provides	   the	   intrinsic	   fluorescence.	   This	   process	   is	   described	   and	  
applied	   in	   chapter	   5.	   When	   discriminating	   between	   the	   influence	   of	   scattering	   and	  
absorption,	   it	   is	   observed	   that	   the	   absorption	   correction	   is	   responsible	   for	   a	   spectral	  
correction	  while	  scattering	  correction	  mainly	  results	  in	  an	  adaptation	  of	  the	  fluorescence	  
intensity.	  
	   The	   intrinsic	   fluorescence	   as	   outcome	   of	   SFF	   measurements	   is	   wavelength	  
dependent	   and	   proportional	   to	   the	   product	   of	   the	   fluorophore	   quantum	   yield	   and	  
absorption	   at	   the	   excitation	   wavelength.	   This	   can	   be	   easily	   linked	   to	   fluorophore	  
concentration	  when	  fluorophore	  quantum	  yield	  and	  its	  absorption	  spectrum	  are	  known.	  
When	   measuring	   fluorescence	   in	   vivo,	   fluorophore	   concentration	   is	   much	   harder	   to	  
obtain,	  since	  both	  quantum	  yield	  and	  absorption	  of	  the	  fluorophore	  can	  be	  dependent	  on	  
environmental	   factors	   such	  as	  pH.	  Chapter	   5	   therefore	   focuses	  on	   the	  measurement	  of	  
the	  intrinsic	  fluorescence	  Qfµaf.	  
	   The	   fluorescence	   measurements	   presented	   in	   this	   thesis	   are	   still	   based	   on	  
subsequent	  measurements	  with	  two	  different	  fiber	  diameters	  on	  the	  same	  location.	  This	  
situation	   is	   not	   ideal;	   repositioning	   of	   fibers	   inevitably	   leads	   to	   a	   variation	   in	  
measurement	  volume	  between	  both	  fibers.	  The	  development	  of	  a	  fiber	  bundle	  probe	  to	  
partially	  overcome	  this	  problem	  is	  in	  progress,	  where	  measurements	  can	  be	  done	  without	  
replacing	  the	  probe.	  Probe	  design	   is	  based	  on	  a	  coherent	  fiber	  bundle	  acting	  as	  a	  single	  
fiber	   with	   a	   variable	   diameter	   [9].	   It	   is	   obvious	   that	   measurement	   volumes	   of	  
measurements	  performed	  with	  different	  fiber	  diameters	  are	  never	  exactly	  the	  same.	  But	  
the	  coherent	  fiber	  bundle	  allows	  for	  inclusion	  of	  the	  complete	  small	  diameter	  volume	  into	  
the	   large	   diameter	   volume,	   which	   is	   a	   vast	   improvement	   over	   the	   repositioning	   of	   a	  
different	   fiber	   as	   applied	   in	  chapter	   5	   of	   this	   thesis.	  Before	   finalization	  of	   the	   coherent	  
fiber	   bundle,	   two	   intermediate	   solutions	  have	  been	  used	   in	   (pre-­‐)clinical	   investigations.	  
The	  first	  being	  a	  probe	  with	  two	  adjacent	  fibers	  very	  close	  to	  each	  other,	  which	  removed	  
the	  variation	  in	  localization	  between	  fibers.	  Second,	  a	  probe	  with	  three	  concentric	  rings	  –	  
imitating	  fiber	  diameters	  -­‐	  containing	  a	  total	  of	  19	  fibers	  is	  used,	  which	  has	  the	  advantage	  
of	  having	  the	  measurement	  volume	  of	  the	  small	  fiber	  diameter	  included	  in	  the	  volume	  of	  
larger	  fiber	  diameters	  [10].	  First	  results	  of	  liquid	  phantom	  sample	  measurements	  use	  with	  
the	   coherent	   fiber	   bundle	   are	   promising,	   but	   a	   carefully	   designed	   robust	   and	   often	  
repeated	   calibration	   procedure	   appears	   critical.	   Slight	   variations	   in	   fiber	   positioning	   or	  
laser	  output	  result	  in	  significant	  variations	  in	  measured	  fluorescence.	  	  
The	  dependency	  on	  calibration	  is	  expected	  to	  also	  be	  an	  important	  factor	  for	  the	  
SFF	   procedure	   described	   in	   chapter	   5.	   Its	   influence	   is	   somewhat	   overshadowed	   by	   the	  
relocation	   of	   fibers	   and	   consecutive	   averaging	   of	   measurements.	   Furthermore,	   the	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deviations	  are	  not	  expected	  to	  originate	  from	  this	  calibration	  error.	  However,	  the	  design	  
of	  a	  stable	  system	  configuration	  and	  a	  validated	  and	  robust	  calibration	  method	  are	  critical	  
factors	  for	  the	  correct	  use	  of	  SFF	  measurements.	  
The	   introduction	   of	   intrinsic	   fluorescence	   as	   the	   parameter	   of	   choice	   when	  
performing	   in-­‐vivo	   fluorescence	  measurements	   allows	   for	   quantification	   of	   fluorophore	  
concentration.	   The	   determination	   of	   photosensitizer	   in	   a	   PDT	   treatment	   volume	   is	   an	  
important	   application	   of	   SFF	   in	   a	   clinical	   environment.	   Initial	   photosensitizer	  
concentration	   and	   the	   rate	   of	   photobleaching	   during	   treatment	   provide	   important	  
information	  that	  could	  potentially	  help	   in	  determining	  a	  patient-­‐dependent	  optimal	  PDT	  
treatment	  protocol.	  Since	  it	  is	  expected	  that	  tissue	  absorption	  and	  scattering	  are	  affected	  
by	   PDT	   itself,	   intrinsic	   fluorescence	   is	   the	   logical	   option	   to	   monitor	   photosensitizer	  
concentration.	  	  	  
	   A	   rapidly	   emerging	   field	   in	   medical	   practice	   is	   fluorescence	   imaging,	   where	  
fluorescent	  dyes	  are	  accumulated	  in	  tumor	  tissue	  and	  tumor	  resection	  is	  performed	  under	  
excitation	  light	  to	  visualize	  the	  tumor	  and	  its	  margins.	  However,	  the	  superiority	  of	  intrinsic	  
fluorescence	  over	  the	  simple	  detection	  of	  emitted	  fluorescence	  light	  is	  not	  yet	  recognized	  
in	  this	  field.	  One	  could	  argue	  that	  for	  tumor	  visualization	  the	  latter	  is	  more	  than	  sufficient,	  
however	  this	  reasoning	  is	  contradicted	  by	  the	  development	  of	  very	  sensitive	  fluorescent	  
systems	   for	   exactly	   this	   purpose.	   Tumor	   resection	   takes	   place	   in	   a	   bloody	   environment	  
that	  causes	  very	  large	  differences	  in	  optical	  properties,	  which	  will	  severely	   influence	  the	  
detected	  fluorescence.	  Combining	  image	  guided	  surgery	  with	  point	  measurements	  of	  SFF	  
provides	   a	   very	   useful	   concept	   where	   the	   bulk	   tumor	   is	   removed	   based	   on	   the	  
fluorescence	   imaging,	   and	   the	   cavity	   from	  which	   the	   tumor	   is	   resected	   is	   analyzed	   for	  
remaining	  tumor	  tissue,	  invisible	  due	  to	  absorption	  of	  blood,	  using	  SFF.	  
	  
DETERMINING	  THE	  OPTIMAL	  DRUG-­‐LIGHT	  INTERVAL	  FOR	  CHLORIN	  E6	  AND	  BREMACHLORIN	  PDT	  
In	  this	  thesis,	  the	  SFF	  method	  is	  applied	  preclinically	  to	  investigate	  two	  photosensitizers.	  
The	  first,	  chlorin	  e6	  (ce6),	  has	  been	  under	  investigation	  for	  many	  years.	  The	  relatively	  high	  
hydrophilicity	  of	   ce6	  means	   that	   it	   is	   rapidly	   cleared	  and	  may	  not	   accumulate	   in	   tumor	  
tissue.	  The	  second	  photosensitizer,	  Bremachlorin,	  is	  a	  solution	  that	  consists	  for	  80%	  ce6.	  
The	   remaining	   20%	   is	   composed	   of	   purpurin	   5	   and	   chlorin	   p6,	   both	   photosensitizing	  
agents	   in	   themselves.	   Furthermore,	   these	   two	   substances	   are	   side	   products	   of	   ce6	  
synthesis.	  Therefore,	  less	  purification	  steps	  are	  necessary	  for	  Bremachlorin,	  which	  makes	  
it	   commercially	   interesting.	   The	   behavior	   of	   both	   photosensitizers	   is	   compared	   in-­‐vivo	  
using	   intrinsic	   SFF	   measurements	   (chapter	   5)	   and	   confocal	   microscopy	   (chapter	   6)	   to	  
analyze	  localization	  over	  different	  length	  scales.	  It	  can	  be	  concluded	  that	  there	  are	  subtle	  










hour	   incubation	   times.	   Ce6	   is	   almost	   completely	   metabolized	   and	   removed	   from	   the	  
tissues	  after	  24	  hours.	  Bremachlorin	   is	   still	  present	   in	   significant	  quantities	  at	  48	  hours.	  
The	   tumor-­‐to-­‐normal	   ratio	   of	   2-­‐3	   for	   these	   late	   time	   points,	   is	   higher	   than	   for	   short	  
incubation	  times	  and	  might	  be	  utilized	  for	  performing	  tumor	  selective	  PDT.	  However,	  it	  is	  
questionable	   whether	   these	   tumor-­‐to-­‐normal	   ratios	   are	   sufficient	   to	   achieve	   this.	   The	  
spectral	   variations	   observed	   between	   Bremachlorin	   and	   ce6	   over	   time	   suggest	   a	  
relocalization	   of	   the	   photosensitizer	   in	   a	   different	   environment.	   Ce6	   behaves	   in	   a	   way	  
similar	   to	   previously	   reported	   in-­‐vitro	   [11,	   12].	   We	   have	   observed	   a	   red-­‐shift	   of	   the	  
fluorescence	  peak	  position	  accompanied	  by	  an	  increase	  in	  peak/shoulder	  ratio.	  According	  
to	  Cunderlikova	  et	  al.	  [11]	  this	  indicates	  a	  shift	  to	  an	  environment	  with	  a	  higher	  pH.	  It	  is	  
shown	  however,	  that	  peak	  shift	  with	  pH	  change	  is	  absent	  in	  solutions	  containing	  FCS.	  How	  
this	  translates	  to	  an	  in-­‐vivo	  situation	  remains	  to	  be	  determined.	  Bremachlorin	  shows	  the	  
opposite	   effect;	   a	   blue-­‐shift	   accompanied	   by	   a	   decrease	   in	   peak/shoulder	   ratio.	   This	  
suggests	   that	   Bremachlorin	   relocates	   to	   a	   lower	   pH	   environment	   over	   time.	   When	  
comparing	   these	   observations	   with	   our	  microscopic	   results,	   we	   do	   not	   see	   an	   obvious	  
relocation	  during	  the	  first	  6	  hours	  of	  incubation.	  We	  again	  find	  Bremachlorin	  present	  after	  
24	  and	  48	  hours,	  while	  ce6	  has	  been	  almost	  completely	  removed	  from	  the	  tissue.	  
	  
Microscopic	   analysis	   shows	   that	   although	   it	   is	   concluded,	   based	   on	   fiber	   optic	  
measurements,	  that	  there	  is	  more	  photosensitizer	  present	  in	  tumor	  than	  in	  normal	  tissue,	  
this	   is	   not	   actually	   the	   case	   at	   the	   microscopic	   level.	   Photosensitizer	   concentration	   in	  
tumor	  tissue	  is	  relatively	  low,	  only	  at	  24	  and	  48	  hours	  is	   it	  higher	  than	  normal	  tissue	  for	  
Bremachlorin.	   Rather	   it	   is	   the	   immediate	   tumor	   border	   that	   contains	   most	  
photosensitizer.	   When	   performing	   fiber	   optic	   measurements,	   this	   border	   is,	   due	   to	  
measurement	  geometry,	   included	   in	  measurements	   containing	   tumor	   tissue,	   incorrectly	  
showing	  a	  high	  photosensitizer	  concentration	  in	  tumor	  tissue.	  This	  example	  shows	  that	  no	  
matter	  what	  optical	  measurement	  method	   is	  used,	   the	   interpretation	  of	   the	   results	  will	  
always	  be	  dependent	  on	  the	  sample	  volume	  of	  that	  particular	  method.	  Many	  fiber	  optic	  
fluorescence	   devices	   require	   multiple	   fibers	   and	   are	   based	   on	   diffusion	   theory.	   This	  
requires	   a	   large	   interrogation	   volume	   in	   the	   order	   of	   mm3.	   For	   our	   superficial	  
measurements	  of	  mouse	  tongue,	  the	  sample	  volume	  of	  SFF	  (around	  200	  µm	  in	  depth)	  is	  
much	  more	  suitable.	  A	  diffuse	  reflectance	  measurement	  volume	  would	  include	  almost	  the	  
whole	   thickness	   of	   the	   tongue.	   However,	   to	   determine	   photosensitizer	   localization	   on	  
tissue	  level,	  SFF	  sample	  volume	  may	  still	  be	  too	  large.	  It	  is	  therefore	  important	  to	  choose	  
a	  method	  that	  fits	  the	  volume	  of	  interest.	  Another	  option	  is	  to	  relinquish	  the	  non-­‐invasive	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Intrinsic	   fluorescence	   measurements	   which	   can	   reveal	   spectral	   variations	   in-­‐vivo	   over	  
time	  are	  very	  useful	  in	  increasing	  our	  understanding	  of	  photosensitizer	  pharmacokinetics.	  
Based	   on	   extensive	   knowledge	   of	   these	   pharmacokinetics,	   an	   informed	   decision	   on	  
duration	  of	  the	  drug-­‐light	  interval	  in	  PDT	  can	  be	  made.	  	  
	  
PDT	  EFFECTS	  ON	  TISSUE	  AND	  VASCULATURE	  AFTER	  VARIOUS	  DRUG-­‐LIGHT	  INTERVALS	  
Based	   on	   the	   pharmacokinetics	   of	   ce6	   and	   Bremachlorin	   in-­‐vivo	   in	   various	   tissues	  
presented	   in	   chapter	   6,	   we	   have	   designed	   a	   therapeutic	   study	   (chapter	   7).	   Ce6	   PDT	   is	  
performed	   with	   short	   drug-­‐light	   intervals,	   varying	   from	   4-­‐6	   hours	   [13].	   Previous	  
measurements	   show	   that	   this	   drug-­‐light	   interval	   is	   well	   chosen	   because	   ce6	   is	   hardly	  
detectable	  after	  24	  hours.	  Similar	  measurements	  suggest	   that	   for	  Bremachlorin,	  a	  drug-­‐
light	  interval	  of	  24	  hours	  may	  be	  favorable,	  which	  shows	  a	  tumor-­‐to-­‐normal	  ratio	  of	  2-­‐3.	  
Although	  the	  primary	  cellular	  targets	  of	  ce6-­‐based	  photosensitizers	  are	  lysosomes,	  acute	  
vascular	   effects	   during	   PDT	   are	   reported	   for	   these	   photosensitizers	   [14].	   To	   be	   able	   to	  
draw	   conclusions	   with	   respect	   to	   vascular	   effects,	   the	   vasculature	   is	   recorded	   during	  
treatment	  and	  vessel	   leakage	  and	  stasis	  are	  analyzed	  two	  hours	  after	   illumination	  using	  
confocal	  microscopy.	  PDT-­‐related	  effects	  on	  tumor	  and	  normal	  tissue	  are	  assessed	  based	  
on	  histology	  two	  days	  after	  illumination.	  
	   The	   results	   from	   chapter	   7	   confirm	   the	   hypothesis	   which	   followed	   from	   the	  
research	  performed	  in	  chapter	  5	  and	  chapter	  6:	  Bremachlorin	  PDT	  after	  a	  24	  hour	  drug-­‐
light	   interval	   does	   induce	  more	   (acute)	   vascular	   effects	   and	   cell	   damage	   than	   after	   a	   5	  
hour	  drug-­‐light	  interval.	  Confocal	  microscopy	  two	  hours	  after	  illumination	  proves	  that	  not	  
only	  is	  vasoconstriction	  observed	  during	  illumination,	  but	  also	  that	  PDT	  induces	  stasis	  and	  
vascular	   leakage	   in	  most	  of	   the	  animals	   treated	  with	  Bremachlorin	  and	  a	  24	  hour	  drug-­‐
light	   interval.	  Furthermore,	   the	  observation	  of	  acute	  vascular	  effects	  during	   illumination	  
is,	   although	   not	   significant,	   related	   to	   histological	   characteristics	   of	   PDT-­‐induced	   tissue	  
damage.	   Unexpectedly	  we	   found	   that	   ce6	   produces	  more	   damage	   to	   both	   normal	   and	  
tumor	  tissue	  after	  24	  hour	  incubation	  than	  after	  5	  hours,	  when	  very	  little	  photosensitizer	  
is	   measured	   with	   in-­‐vivo	   spectroscopy	   and	   microscopic	   analysis.	   This	   underlines	   the	  
hypothesis	   that	   PDT-­‐related	   damage	   is	   not	   only	   dependent	   on	   the	   photosensitizer	  
concentration	   present,	   but	   that	   there	   are	   other	   factors	   that	   influence	   PDT-­‐related	  
damage,	  such	  as	  subcellular	  localization	  and	  vascularization.	  Investigation	  and,	  if	  required,	  
monitoring	  of	  those	  factors	  before	  and	  during	  PDT	  may	  aid	  in	  defining	  the	  most	  effective	  
treatment	  protocol.	  
	   The	   conclusion	   that	   Bremachlorin-­‐PDT	   is	   more	   effective	   after	   a	   24	   hours	  
incubation	   time,	   is	  predicted	  based	  on	   intrinsic	   fluorescence	  measurements	   in-­‐vivo,	  but	  










Spectroscopy	  proves	  to	  be	  a	  useful	  tool	  in	  photosensitizer	  concentration	  and	  localization	  
analysis.	  Vessel	  analysis	  during	  PDT	  by	  the	  use	  of	  (confocal)	  microscopy	  provides	  relevant	  
insight	   in	   vascular	   PDT	   effects	   and	   can	   be	   related	   to	   PDT	   outcome.	   This	   shows	   that	   a	  
thorough	  investigation	  of	  the	  PDT	  related	  parameters	  can	  aid	  in	  therapy	  optimization.	  
	  
APPLICATION	  OF	  SPECTROSCOPIC	  METHODS	  TO	  OPTIMIZE	  AND	  MONITOR	  PDT	  
In	   this	   thesis,	   it	   is	   demonstrated	  how	   various	   spectroscopic	  methods	   can	  be	   applied	   to	  
research	   on	   the	   optimization	   of	   photodynamic	   therapy.	   Tissue	   saturation	   and	   vessel	  
diameters	  can	  be	  determined	  by	  single	  fiber	  reflectance	  and	  MDSFR,	  which	  provide	  useful	  
information	  on	   the	   availability	   of	   oxygen.	   In	   this	   thesis,	  monitoring	   the	   vascular	   effects	  
that	  occur	  during	  fractionated	  ALA-­‐PDT	  has	  been	  facilitated	  using	  optical	  microscopy.	  At	  a	  
later	   stage,	   when	   the	   importance	   of	   vascular	   effects	   is	   better	   understood,	   fiber	   optic	  
spectroscopy	  could	  play	  a	  critical	  role	  in	  monitoring	  vascular	  effects	  during	  PDT.	  	  
	   Intrinsic	   fluorescence	   spectroscopy	   performed	   with	   SFF	   provides	   a	   quantitative	  
measure	  of	  photosensitizer	  concentration.	  This	   is	  a	  powerful	   tool	   in	  preclinical	   research	  
for	  the	  measurement	  of	  photosensitizer	  pharmacokinetics	  and	  in	  the	  optimization	  of	  the	  
PDT	   treatment	   protocol.	   Knowledge	   of	   tissue	   scattering	   and	   absorption	   and	   their	  
variation	   during	   treatment	  may	   be	   applied	   in	   order	   to	   compensate	   the	   delivered	   light	  
dose	   in	  the	  treatment	  volume	  real-­‐time.	  However,	   this	   technique	   is	  not	  yet	  ready	  to	  be	  
implemented	   in	   a	   clinical	   application.	   A	   more	   realistic	   solution	   may	   be	   to	   adjust	   the	  
illumination	  protocol	  before	  treatment	  based	  on	  patient-­‐dependent	  optical	  properties.	  	  
	   An	  important	  factor	  to	  be	  considered	  in	  the	  application	  of	  fiber	  optic	  spectroscopic	  
methods	  to	  monitor	  PDT	  is	  the	  interference	  with	  the	  PDT	  illumination	  field.	  Depending	  on	  
the	   dimensions	   of	   the	   treatment	   area	   and	   the	  measurement	   probe,	   shielding	   of	   tissue	  
from	   light	  may	   prove	   problematic.	   Therefore,	  most	   studies	   applying	   SFFL	   are	   based	   on	  
pre-­‐	  and	  post	  measurements	  only,	  or	  by	  shortly	  interrupting	  the	  therapeutic	  illumination	  
to	  take	  a	  measurement.	  In	  large	  solid	  tumors	  treated	  with	  interstitial	  PDT,	  for	  example	  in	  
the	   head	  &	  neck	   area,	  multiple	   catheters	   are	   implemented.	   It	   is	   common	  practice	   that	  
illumination	  is	  performed	  in	  one	  or	  more	  catheters	  at	  the	  time,	  while	  the	  other	  catheters	  
contain	  monitoring	  devices	   to	  measure	  changes	   in	   tissue	  during	   therapy	   [15].	  Here,	   the	  
change	  in	  the	  light	  field	  is	  relatively	  minor.	  For	  superficial	  tumors,	  an	  improvement	  can	  be	  
made	  by	   the	  equipment	  of	   fluorescence	   imaging	  devices	  with	   the	   technology	   to	  detect	  
tissue	   optical	   properties.	   Although	   this	   brings	   us	   some	   very	   interesting	   theoretical	   and	  
technical	   challenges,	   the	   development	   of	   imaging	   devices	   capable	   of	   detecting	   intrinsic	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The	   aim	  of	   this	   thesis	   is	   to	   optimize	   photodynamic	   therapy	   (PDT)	   by	   the	   application	   of	  
spectroscopic	  and	  microscopic	  techniques.	  Treatment	  efficacy	  of	  PDT	  is	  dependent	  on	  the	  
interaction	   between	   light,	   oxygen	   and	   a	   photoactive	   agent,	   the	   photosensitizer.	   Only	  
when	   these	   three	   components	   are	   present	   in	   a	   certain	   concentration	   or	   amount	   will	  
tissue	  damage	  -­‐the	  goal	  of	  PDT-­‐	  occur	  in	  the	  treatment	  volume.	  However,	  the	  availability	  
of	   all	   three	   components	   is	   dependent	   on	   various	  biological	   processes.	   In	   this	   thesis	  we	  
apply	  various	  spectroscopic	  and	  microscopic	  methods	  to	  determine	  the	  optimal	  and	  most	  
effective	  treatment	  protocol	  for	  performing	  PDT.	  	  
	  
Chapter	  2	  and	  Chapter	  3	  focus	  on	  the	  first	  light	  fraction	  in	  light	  fractionated	  ALA-­‐PDT	  in	  
mice.	   Previous	   studies	   show	   the	   timing	   and	   duration	   of	   this	   fraction	   to	   be	   critical	   for	  
treatment	  efficacy.	  
Chapter	   2	   reports	   on	   in-­‐vivo	   monitoring	   of	   photosensitizer	   fluorescence	   during	  
ALA-­‐PDT.	  Six	  treatment	  groups	  are	  investigated	  and	  the	  length	  of	  the	  first	  light	  fraction	  is	  
dependent	   on	   photobleaching	   of	   photosensitizer.	   Fluence	   rates	   of	   20	   and	   50	  mW	   cm-­‐2	  
and	  total	  fluences	  of	  50	  and	  100	  J	  cm-­‐2	  are	  considered,	  together	  with	  a	  single	  50	  mW	  cm-­‐2,	  
100	  J	  cm-­‐2	  group	  and	  a	  variable	  fluence	  rate	  group.	  No	  significant	  differences	  in	  damage	  
scores	   are	   observed	   between	   all	   fractionated	   illumination	   groups,	   while	   a	   single	  
illumination	   induced	   significantly	   less	   damage.	   The	   finding	   that	   a	   lower	   fluence	   rate	  
accompanied	   with	   a	   lower	   fluence	   did	   induce	   the	   same	   damage	   is	   very	   valuable	   for	  
clinical	   PDT;	   a	   lower	   fluence	   rate	   is	   thought	   to	   cause	   less	   pain	   during	   therapy,	   and	  
combined	  with	   a	   lower	   fluence	   the	   increase	   of	   treatment	   time	   is	   thought	   to	   be	  within	  
practical	  limits.	  
	   In	  Chapter	  3,	  vascular	  effects	  during	  the	  first	  light	  fraction	  of	  ALA-­‐PDT	  by	  confocal	  
microscopy	  are	  investigated.	  ALA-­‐PDT	  is	  performed	  in	  a	  dorsal	  skinfold	  window	  chamber	  
on	   the	   back	   of	   a	   mouse.	   Confocal	   microscopy	   is	   used	   to	   measure	   variations	   in	   vessel	  
diameter	  and	  red	  blood	  cell	  velocity	  during	  the	  first	  13	  J	  of	   the	  treatment	  using	  fluence	  
rates	  of	  26,	  65	  and	  130	  mW	  cm-­‐2.	  For	  all	   fluence	  rates,	  vascular	  effects	  occur	   in	  at	   least	  
one	   animal	   and	   set	   in	   quickly	   after	   the	   start	   of	   illumination.	   Only	   when	   a	   vessel	   is	  
completely	  constricted	  does	  red	  blood	  cell	  velocity	  drop.	  	  Because	  the	  therapeutic	  effects	  
of	  PDT	  are	  dependent	  on	  a	   fine	  balance	  between	  a	  need	  for	  oxygen	  during	   illumination	  
and	  disruption	  of	   the	   vasculature,	   understanding	   acute	   vascular	   effects	  during	  ALA-­‐PDT	  









The	  application	  of	  multi-­‐diameter	  single	  fiber	  reflectance	  spectroscopy	  (MDSFR)	  in-­‐vivo	  is	  
described	  in	  Chapter	  4.	  Using	  multiple	  fibers	  of	  various	  diameters	  allows	  for	  quantitative	  
measurements	   of	   tissue	   scattering	   and	   the	   phase	   function	   parameter.	   Reflectance	  
measurements	  are	  successfully	  performed	  with	  0.4	  and	  0.8	  mm	  fibers	  on	  mouse	  tongue,	  
skin,	   liver	   and	   on	   oral	   squamous	   cell	   carcinoma	   induced	   in	   the	   tip	   of	   the	   tongue.	   The	  
reduced	   scattering	   coefficient	   µs’	   and	   phase	   function	   parameter	   γ	   show	   significant	  
differences	  between	  tissues.	  	  	  
	  
In	  Chapter	  5	  and	  Chapter	  6,	  the	  focus	  is	  on	  application	  of	  fluorescence	  spectroscopy	  and	  
microscopy	  to	  acquire	  knowledge	  on	  the	  pharmacokinetics	  of	  the	  photosensitizers	  chlorin	  
e6	  and	  Bremachlorin.	  	  
	   Chapter	   5	   reports	   on	   the	   in-­‐vivo	   application	   of	   single	   fiber	   fluorescence	  
spectroscopy.	   We	   have	   investigated	   pharmacokinetics	   and	   spectral	   variation	   of	   both	  
photosensitizers	  chlorin	  e6	   (ce6)	  and	  Bremachlorin	   in	  mouse	   tongue,	   skin,	   liver	  and	  oral	  
squamous	   cell	   carcinoma	   for	   incubation	   times	   of	   t=[3	   4.5	   6	   24	   48]	   hours.	   With	  
determination	  of	  quantitative	  scattering	  as	  described	  in	  chapter	  4,	  it	  is	  possible	  to	  correct	  
the	   detected	   fluorescence	   signal	   for	   tissue	   absorption	   and	   scattering,	   resulting	   in	   the	  
intrinsic	   fluorescence.	   Between	   the	   two	   photosensitizers,	   significant	   differences	   in	  
spectral	   shape,	   peak	   position	   and	   fluorescence	   intensity	   are	   observed.	   There	   is	  
significantly	  more	  Bremachlorin	  present	  compared	  to	  ce6	  at	  long	  incubation	  times.	  Insight	  
in	   photosensitizer	   pharmacokinetics	   may	   aid	   in	   determining	   the	   optimal	   drug-­‐light	  
interval	  for	  PDT	  of	  a	  particular	  tissue.	  	  
	   A	  microscopic	  analysis	  of	   the	   localization	  of	  ce6	  and	  Bremachlorin	   in	  tongue	  and	  
tongue	  tumor	  is	  presented	  in	  Chapter	  6,	  again	  after	  t=[3	  4.5	  6	  24	  and	  48]	  hour	  incubation	  
times.	   Photosensitizer	   fluorescence	   intensities	   are	   determined	   in	   frozen	   tissue	   slices,	  
where	  we	  discriminate	  tumor,	  tumor	  boundary,	  invasive	  tissue	  and	  normal	  tissue.	  Highest	  
photosensitizer	  concentrations	  are	  found	  in	  the	  tumor	  border,	  while	  concentration	  in	  the	  
tumor	  itself	   is	  very	  low.	  For	  Bremachlorin,	  the	  photosensitizer	  concentration	  is	  higher	  in	  
tumor	   than	   in	   normal	   tissue	   after	   24	   and	   48	   hours.	   In	   normal	   and	   invasive	   tissue,	  
photosensitizer	   is	  mainly	   localized	   in	  muscle	   fibers,	  while	   after	   longer	   incubation	   times	  
photosensitizer	   is	   spread	   more	   homogenously.	   There	   is	   no	   direct	   correlation	   between	  
location	  of	  vasculature	  and	  photosensitizer	  for	  both	  ce6	  and	  Bremachlorin.	  	  
	  
In	  Chapter	   7	   some	   of	   the	   analyses	   described	   in	   previous	   chapters	   are	   combined	  when	  
performing	   PDT	   in	   mouse	   window	   chambers.	   Both	   ce6	   and	   Bremachlorin	   are	   under	  
investigation	   with	   5	   and	   24	   hour	   incubation	   times	   (chapter	   5	   and	   6).	   Vascular	   effects	  









disrupted	   vasculature,	   vascular	   leakage	  and	   stasis	   and	  histological	   characteristics	  of	   cell	  
damage	  as	   indications	  of	   treatment	  efficacy.	   Bremachlorin	  PDT	  after	   24	  hour	  drug-­‐light	  
interval	  is	  most	  effective	  in	  inducing	  acute	  vascular	  effects,	  followed	  by	  ce6	  with	  a	  5	  hour	  
drug-­‐light	  interval.	  Cellular	  tissue	  damage	  is,	  although	  not	  significant,	  related	  to	  the	  onset	  
of	  acute	  vascular	  effects	  during	  illumination.	  The	  positive	  effect	  of	  PDT	  on	  tissue	  damage	  
after	  a	  24	  hour	  drug-­‐light	  interval	  with	  Bremachlorin	  was	  hypothesized	  based	  on	  research	  
conducted	  in	  previous	  chapters,	  and	  the	  research	  in	  chapter	  7	  confirms	  this.	  	  
	  
A	  general	  discussion	  on	  the	  results	  of	   the	  studies	  presented	   in	   this	   thesis	   is	  provided	   in	  
Chapter	  8.	   	  Results	  are	  discussed	  in	  relation	  to	  each	  other	  and	  on	  their	  contributions	  to	  
the	   optimization	   of	   photodynamic	   therapy.	   It	   concludes	   with	   a	   brief	   insight	   in	   future	  
technological	  perspectives.	  
SAMENVATTING	  
Het	  doel	  van	  dit	  proefschrift	  is	  het	  optimaliseren	  van	  fotodynamische	  therapie	  (PDT)	  door	  
het	   gebruik	   van	   microscopische	   en	   spectroscopische	   technieken.	   Hoe	   effectief	   PDT	   is	  
wordt	  bepaald	  door	  de	  interactie	  tussen	  licht,	  zuurstof	  en	  de	  fotosensitizer,	  een	  stof	  die	  
wordt	   geactiveerd	   door	   licht.	   Uitsluitend	   wanneer	   deze	   drie	   componenten	   voldoende	  
aanwezig	  zijn	  in	  het	  te	  behandelen	  gebied	  zal	  schade	  aan	  het	  weefsel	  optreden,het	  doel	  
van	  PDT.	  Of	  de	  componenten	  ook	  in	  de	  juiste	  hoeveelheid	  aanwezig	  zijn	  is	  afhankelijk	  van	  
verschillende	   biologische	   processen.	   In	   dit	   proefschrift	   gebruiken	   we	   verschillende	  
spectroscopische	   en	   microscopische	   technieken	   om	   de	   optimale	   omstandigheden	   voor	  
PDT	   te	   bepalen.	   De	   resultaten	   kunnen	   worden	   gebruikt	   in	   het	   opstellen	   van	   een	   zo	  
effectief	  mogelijk	  behandelprotocol.	  	  
	  
In	  Hoofdstuk	  2	  en	  Hoofdstuk	  3	   ligt	  de	  nadruk	  op	  de	  eerste	  belichting	  van	  ALA-­‐PDT	  met	  
een	  gefractioneerd	  belichtingsprotocol	  in	  muizen.	  Het	  is	  eerder	  aangetoond	  dat	  de	  timing	  
en	  duur	  van	  de	  eerste	  belichting	  voor	  een	  groot	  deel	  de	  effectiviteit	  van	  PDT	  bepalen.	  	  
Hoofdstuk	  2	  beschrijft	  het	  in-­‐vivo	  monitoren	  van	  de	  hoeveelheid	  fotosensitizer	  in	  
het	  behandelvolume	  tijdens	  ALA-­‐PDT.	  We	  onderzoeken	  zes	  behandelgroepen,	  waarbij	  de	  
lengte	   van	   de	   eerste	   belichting	   wordt	   bepaald	   door	   de	   afname	   van	   de	   fotosensitizer	  
fluorescentie.	  De	  behandelgroepen	  zijn	  verdeeld	  in	  een	  lichtintensiteit	  van	  20	  of	  50	  mW	  
cm-­‐2	  en	  een	  totale	   lichtdosis	  van	  50	  of	  100	   J	  cm-­‐2,	  één	  groep	  met	  een	  enkele	  belichting	  
van	   50	  mW	   cm-­‐2	   bij	   100	   J	   cm-­‐2	   en	   een	   groep	  met	   variabele	   lichtintensiteit.	   Tussen	   de	  
verschillende	   groepen	   met	   gefractioneerde	   belichting	   is	   geen	   significant	   verschil	   in	  








Het	   feit	   dat	   belichting	   met	   een	   lagere	   lichtintensiteit	   en	   een	   lagere	   totale	   lichtdosis	  
resulteert	   in	  gelijke	  weefselschade	  is	  goed	  nieuws	  voor	  de	  klinische	  toepassing	  van	  ALA-­‐
PDT	  bij	  huidaandoeningen.	  Een	  lagere	  lichtintensiteit	  wordt	  geassocieerd	  met	  minder	  pijn	  
tijdens	   de	   behandeling,	  maar	  was	   niet	   praktisch	   toepasbaar	   door	   de	   significant	   langere	  
behandeltijd.	  Nu	  blijkt	  dus	  dat	  met	  een	  lagere	  lichtdosis	  hetzelfde	  resultaat	  wordt	  bereikt	  
met	  een	  minimale	  toename	  van	  behandeltijd	  ten	  opzichte	  van	  het	  huidige	  protocol.	  	  	  
In	   Hoofdstuk	   3	   worden,	   met	   behulp	   van	   confocale	   microscopie,	   vaateffecten	  
tijdens	  de	  eerste	  belichting	  van	  gefractioneerde	  ALA-­‐PDT	  onderzocht.	  Voor	  dit	  onderzoek	  
hebben	  muizen	  een	   kamertje	   op	  de	   rug	  waardoor	  de	   vaatstructuur	   in	   de	  huid	   in	   beeld	  
gebracht	   kan	   worden	   met	   een	   microscoop	   tijdens	   PDT.	   Tijdens	   de	   belichting	   worden	  
variaties	  in	  vaatdiameter	  en	  snelheid	  van	  rode	  bloedcellen	  gemeten	  tijdens	  de	  eerste	  13	  J	  
van	   de	   behandeling	  met	   lichtintensiteiten	   van	   26,	   65	   en	   130	  mW	   cm-­‐2.	   In	   alle	   groepen	  
vaateffecten	  treden	  vaateffecten	  op	  bij	  een	  aantal	  muizen,	  vrij	  snel	  na	  het	  starten	  van	  de	  
belichting.	   Als	   vaten	   compleet	   dichtklappen	   stoppen	   ook	   de	   rode	   bloedcellen	   met	  
stromen,	   maar	   bij	   gedeeltelijke	   vaatversmalling	   is	   geen	   significante	   afname	   van	   de	  	  
snelheid	  van	  rode	  bloedcellen	  te	  zien.	  Het	  effect	  van	  PDT	  wordt	  tweezijdig	  beïnvloed	  door	  
vaateffecten	   in	   de	   zin	   dat	   de	   zuurstof	   –	   en	   dus	   intacte	   vasculatuur-­‐	   nodig	   is	   voor	   PDT,	  
maar	  schade	  aan	  de	  vaten	  ook	  schade	  aan	  de	  tumor	  oplevert.	  Het	  is	  daarom	  van	  belang	  
de	   interactie	   tussen	  deze	  effecten	   te	  begrijpen	  en	  hiermee	  gefractioneerde	  ALA-­‐PDT	   te	  
optimaliseren.	  
	  
De	   eerste	   in-­‐vivo	   toepassing	   van	   multi-­‐diameter	   single	   fiber	   reflectie	   spectroscopie	  
(MDSFR)	  wordt	   beschreven	   in	  Hoofdstuk	   4.	   Door	   het	   gebruik	   van	  meerdere	   fibers	  met	  
een	   verschillende	   diameter	   kan	   op	   een	   kwantitatieve	   manier	   verstrooiing	   in	   weefsel	  
gemeten	  worden.	  Deze	  metingen	  zijn	  uitgevoerd	  met	  fiber	  diameters	  van	  0.4	  en	  0.8	  mm	  
op	  tong,	   tong	  tumor,	  huid	  en	   lever	  van	  muizen.	  De	  verstrooiings-­‐coëfficiënt	  µs’	  en	   fase-­‐
functie	   parameter	   γ	   verschillen	   significant	   van	   elkaar	   voor	   de	   verschillende	   weefsels,	  
waaruit	  geconcludeerd	  kan	  worden	  dat	  MDSFR	  gebruikt	  kan	  worden	  voor	  diagnostiek.	  
	  
Hoofdstuk	  5	  en	  Hoofdstuk	  6	   richten	  zich	  op	  fluorescentie	  spectroscopie	  en	  microscopie	  
voor	  het	  onderzoeken	  van	  de	  verspreiding	  van	  de	   fotosensitizer	   in	  het	  weefsel	  over	   tijd	  
(farmacokinetiek).	   Dit	   onderzoek	   omvat	   de	   fotosensitizers	   chlorine	   e6	   (ce6)	   en	  
Bremachlorine.	  
	   In	   Hoofdstuk	   5	   wordt	   het	   eerste	   gebruik	   van	   single	   fiber	   fluorescentie	  
spectroscopie	  beschreven.	  Voor	  beide	   fotosensitizers	   zijn	  de	   intensiteit	   en	  de	  vorm	  van	  
het	  fluorescentiespectrum	  onderzocht,	  waarbij	  gekeken	  is	  naar	  tong,	  tong	  tumor,	  huid	  en	  









kwantificering	  van	  de	  weefselverstrooiingscoëfficiënt	  zoals	  beschreven	  in	  hoofdstuk	  4	  kan	  
het	  gemeten	  fluorescentiesignaal	  worden	  gecorrigeerd	  voor	  absorptie	  en	  verstrooiing	  van	  
het	  weefsel.	   Dit	   resulteert	   in	   de	   intrinsieke	   fluorescentie,	   een	   kwantitatieve	  maat	   voor	  
fluorescentie.	  De	  twee	  fotosensitizers	  verschillen	  significant	  in	  vorm,	  intensiteit	  en	  positie	  
van	  het	  fluorescentiespectrum.	  Er	  is	  significant	  meer	  Bremachlorine	  dan	  ce6	  aanwezig	  in	  
weefsel	  na	   lange	   incubatietijd.	   Inzicht	   in	   farmacokinetiek	  van	  de	   fotosensitizers	   is	  nodig	  
om	  de	  optimale	  tijd	  tussen	  toediening	  van	  het	  medicijn	  en	  belichting	  te	  bepalen	  voor	  een	  
specifiek	  weefsel.	  	  
	   De	   lokalisatie	   van	   ce6	   en	   Bremachlorine	   na	   t	   =	   [3	   4.5	   6	   24	   48]	   uur	   is	   op	  
microscopisch	   niveau	   onderzocht	   voor	   tong	   en	   tongtumor	   in	   Hoofdstuk	   6.	   De	  
fluorescentie	  van	  fotosensitizers	  is	  gemeten	  in	  vriescoupes	  van	  tongen,	  waarbij	  we	  tumor,	  
tumorrand,	   invasief	   weefsel	   en	   normaal	   weefsel	   onderscheiden.	   De	   concentraties	  
fotosensitizer	  is	  het	  hoogst	  in	  tumorrand,	  terwijl	  de	  concentratie	  in	  tumor	  relatief	  laag	  is.	  
Pas	   na	   24	   en	   48	   uur	   is	   de	   concentratie	   Bremachlorine	   in	   tumor	   hoger	   dan	   in	   normaal	  
weefsel.	   In	   normaal	   en	   invasief	   weefsel	   wordt	   de	   fotosensitizer	   vooral	   gevonden	   in	  
spierweefsel,	  maar	   voor	   langere	   incubatietijden	   verdeelt	   het	   zich	  meer	  homogeen	  over	  
het	  weefsel.	  Voor	  beide	   fotosensitizers	   lijkt	  er	  geen	  directe	  correlatie	   te	  bestaan	  tussen	  
de	  lokalisatie	  van	  fotosensitizer	  en	  vasculatuur.	  	  
	  
In	  Hoofdstuk	  7	  worden	  een	  aantal	  analyses	  uit	  vorige	  hoofdstukken	  gebruikt	  tijdens	  PDT	  
in	   het	   kamertjesmodel	   in	   muizen,	   waarin	   we	   een	   tumor	   hebben	   geïnduceerd.	   We	  
onderzoeken	   ce6	   en	   Bremachlorine	   voor	   een	   incubatietijd	   van	   5	   en	   24	   uur.	   Tijdens	   de	  
belichting	  zijn	  acute	  vaateffecten	  geanalyseerd	  en	  deze	  zijn	  gerelateerd	  aan	  de	  volgende	  
kenmerken	   van	   PDT-­‐gerelateerde	   schade:	   bloedingen,	   onderbreking	   van	   vaten,	  
vaatlekkage,	   stroomsnelheid	   van	   rode	   bloedcellen	   en	   histologische	   kenmerken	   van	  
weefselschade.	  De	  meeste	   acute	   vaateffecten	  werden	   geïnduceerd	   door	   Bremachlorine	  
na	   een	   incubatietijd	   van	   24	   uur,	   gevolgd	   door	   ce6	   na	   5	   uur	   incubatie.	   Cellulaire	  
weefselschade	   is	   gerelateerd	   aan	   het	   optreden	   van	   acute	   vaateffecten	   tijdens	   de	  
belichting,	  al	  is	  dit	  resultaat	  niet	  significant.	  De	  hypothese	  van	  verhoogde	  effectiviteit	  van	  
Bremachlorine-­‐PDT	   na	   24	   uur	   incubatietijd	   was	   gebaseerd	   op	   onderzoek	   uit	   de	   vorige	  
hoofdstukken,	  en	  het	  onderzoek	  van	  hoofdstuk	  7	  bevestigt	  dit	  vermoeden.	  
	  
Dit	   proefschrift	   sluit	   af	  met	   een	   algemene	   discussie	   van	   de	   resultaten	   in	  Hoofdstuk	   8.	  
Zowel	  de	  samenhang	  tussen	  resultaten	  in	  verschillende	  hoofdstukken	  als	  de	  bijdrage	  aan	  
het	   optimaliseren	   van	   fotodynamische	   therapie	   worden	   besproken.	   Tenslotte	   wordt	   er	  









Het	   dankwoord.	   Misschien	   wel	   het	   meest	   gelezen	   hoofdstuk	   van	   een	   proefschrift,	   de	  
afsluiting.	  En	  zo	  voelt	  het	  ook,	  want	  verder	  is	  alles	  klaar.	  Met	  een	  bijna	  euforisch	  gevoel	  
en	  een	  goed	  glas	  wijn	  kan	  ik	  nu	  reflecteren	  op	  de	  afgelopen	  ruim	  vijf	  jaar.	  Want	  er	  is	  veel	  
gebeurd,	   en	   er	   is	   ook	   zeker	   zoveel	   niet	   gebeurd.	   Grootse	   plannen	   moesten	   bijgesteld	  
worden,	   om	   uiteindelijk	   als	   eenzaam	   puntje	   op	   de	   publicatielijst	   te	   eindigen.	  
Daartegenover	   staat	   dat	   resultaten	   van	   een	   klein	   experiment	   de	   grondslag	   kunnen	  
vormen	  van	  een	  compleet	  proefschrift.	  Het	  resultaat	  heeft	  u	  hier	  in	  uw	  handen.	  Maar	  wat	  
het	  uiteindelijke	  onderwerp	  van	  het	  onderzoek	  ook	   is,	  één	  ding	  staat	  vast:	  alleen	  had	   ik	  
het	  niet	  kunnen	  volbrengen.	  	  
Allereerst	   wil	   ik	   Dick	   Sterenborg	   bedanken,	   als	  mijn	   promotor,	  maar	   vooral	   ook	   als	   de	  
persoon	   die	   alles	   in	   een	   breder	   daglicht	   plaatst.	   Je	   laat	   je	   niet	   beperken	   door	   de	  
(on)mogelijkheden	  binnen	  de	  medische	   technologie;	   tomaten	  en	  zelfs	  melk	  kunnen	  ook	  
interessant	   zijn!	   De	   vele	   lunchdiscussies	   leidden	   vaker	   wel	   dan	   niet	   tot	   ideeën	   voor	  
verrassende	  toepassingsgebieden	  van	  bekende	  natuurkundige	  verschijnselen.	  	  
Where	  Dick	  showed	  me	  how	  to	  broaden	  my	  scientific	  horizon,	  Dominic	  Robinson	  helped	  
me	  to	  determine	  the	  exact	  direction	  of	  my	  research.	  Dom,	  I	  couldn’t	  have	  found	  a	  better	  
co-­‐promotor	  if	   I	  tried.	  Your	  calm,	  determined	  confidence	  in	  a	  positive	  ending	  of	  my	  PhD	  
was	  what	  kept	  me	  going	  on	  many	  occasions.	  You	  were	  always	  available	  for	  any	  questions	  I	  
had,	   took	   time	   to	   review	   -­‐and	   greatly	   improve-­‐	   my	   writing	   and	   of	   course	   for	   the	  
occasional	  Belgium	  Beer	  at	  a	  sidewalk	  café.	  Thank	  you	  for	  everything	  Dom,	  it	  is	  very	  much	  
appreciated.	  
Ute,	   too	  bad	  you’re	  not	  here	   to	  stand	  next	   to	  me,	  but	   I	  know	  you	   think	  of	  me	  anyway.	  
Together	  we	   shared	   the	   though	   life	   of	   being	   a	   PhD	   student:	   driving	   along	   the	   US	   East	  
coast,	  cycling	  across	  a	  tiny	  island	  in	  Sweden	  and	  even	  the	  crazy	  idea	  of	  playing	  roller	  derby	  
together.	   You	   made	   the	   office	   a	   lot	   less	   quit	   in	   the	   beginning,	   and	   we	   kept	   that	   up	  
through	  the	  years.	  You	  were	  a	  great	  roomie	  and	  colleague,	  and	  you	  are	  a	  great	  friend	  –	  
albeit	  somewhat	  far	  away	  at	  the	  moment.	  Thanks	  for	  everything!	  
En	  dan	  de	  lange	  dagen	  in	  het	  lab,	  die	  zonder	  de	  geweldige	  steun	  van	  Riëtte	  en	  Lique	  niet	  
mogelijk	  geweest	  zouden	  zijn.	  Allereerst	  vanwege	  jullie	  kennis	  en	  kunde	  –	   je	  denkt	  toch	  
niet	  dat	   ik	  een	  muis	  oppak!?	  –	  en	  zeker	  niet	  onbelangrijk,	  doordat	  we	  de	  lange	  donkere	  
uren	  wachten	  gezellig	  hebben	  volgekletst	  zonder	  dat	  we	  in	  slaap	  vielen.	  Ontzettend	  veel	  









boekje,	  jullie	  hebben	  daarin	  een	  sleutelrol	  gespeeld!	  Riëtte,	  natuurlijk	  ook	  bedankt	  dat	  je	  
mijn	  paranimf	  wil	  zijn.	  	  
Of	  course	  I’d	  like	  to	  thank	  all	  colleagues	  and	  ex-­‐colleagues	  at	  the	  CODT.	  Arjen,	  you	  were	  
my	   hero	  when	   it	   came	   to	   technical	   problems:	   calibration	   of	   setups,	   higher-­‐level	   tissue	  
optics	  and	  those	  bloody	  confidence	  intervals	  on	  fit	  parameters,	  you	  always	  got	  me	  out	  of	  
the	  woods.	  Chad,	  Chris	  and	  Jan	  Bonne,	  you	  all	  helped	  me	  in	  some	  way	  to	  get	  to	  the	  point	  
where	   I	   am	   now.	   And	   Sander,	   Threes,	   Jasper,	   Giju,	   Robert,	   Slavka,	   Manzoor,	   Zoë	   and	  
Bastiaan,	  without	  you	  the	  office	  just	  wouldn’t	  have	  been	  the	  same!	  
Verder	   wil	   ik	   ook	   mijn	   collega’s	   van	   het	   LUMC	   bedanken	   voor	   de	   gezellige	   maar	   ook	  
productieve	  samenwerking.	  Thomas,	  Pieter,	   Isabel,	  prof.	  Löwik,	  en	  natuurlijk	  de	  rest	  die	  
aan	  het	  project	  mee	  heeft	  gewerkt,	  ontzettend	  bedankt.	  
Ook	  wil	  ik	  graag	  alle	  leden	  van	  mijn	  commissie	  bedanken.	  
Dan	   is	   het	   nu	   tijd	   voor	   de	   personen	   voor	   wie	   de	   wetenschappelijke	   inhoud	   van	   dit	  
proefschrift	  ondergeschikt	  is	  aan	  dit	  dankwoord.	  Rianne,	  Leonie,	  Elsbeth,	  Aimee,	  Anna	  en	  
Mariska,	   al	   weer	   12	   jaar	   geleden	   zijn	   we	   over	   het	   hele	   land	   uitgewaaid,	   maar	   de	  
gezamenlijke	  middagen	  en	  etentjes	   blijven.	  Dat	   er	   nog	  maar	   veel	   vriendinnenmiddagen	  
mogen	  volgen!	  
Kasper,	  mijn	   paranimf,	   je	  moet	   er	  maar	   durven	   staan.	   En	   dat	   doe	   je!	  Merel,	   ik	   ben	   de	  
trotste	  tante	  die	  je	  kan	  bedenken.	  En	  de	  trotste	  zus!	  
Pap	   en	   Mam,	   jullie	   hebben	   me	   altijd	   mijn	   eigen	   weg	   laten	   gaan,	   en	   stonden	   daarbij	  
vooraan	  om	  te	  helpen	  verhuizen.	   Jullie	   zijn	  nog	  net	   zo	  geïnteresseerd	   in	  en	  enthousiast	  
over	  waar	  ik	  mee	  bezig	  ben	  als	  dag	  één	  op	  de	  universiteit,	  ook	  al	  kost	  uitleggen	  nu	  soms	  
wat	  meer	  tijd.	  Zonder	  jullie	  onvoorwaardelijke	  steun	  en	  vertrouwen	  in	  een	  goede	  afloop,	  
had	  ik	  hier	  niet	  gestaan.	  Jullie	  zijn	  de	  beste!	  
En	  lieve	  Bas,	  hier	  een	  hele	  alinea	  speciaal	  voor	  jou.	  Maar	  dat	  is	  te	  kort	  om	  op	  te	  noemen	  
waarvoor	  ik	   je	  allemaal	  wil	  bedanken.	  Daarom	  hierbij	  de	  belangrijkste	  redenen:	  Bedankt	  
dat	   je	   het	  woordje	   ‘the’	   altijd	  weghaalt	   uit	  mijn	   teksten	   en	   dat	   je	   zulke	  mooie	   plaatjes	  
hebt	  gemaakt.	  Bedankt	  ook	  dat	  je	  me	  toch	  maar	  weer	  door	  liet	  typen	  als	  jij	  al	  sliep.	  Maar	  
vooral	  ook	  bedankt	  voor	  je	  troostende	  schouder	  en	  opbeurende	  woorden	  als	   ik	  het	  niet	  
zag	  zitten.	  Voor	  de	  gezellige	  avonden	  en	  heerlijke	  vakanties	  waarin	   ik	  geen	  seconde	  aan	  
werk	  dacht.	  En	  boven	  alles,	  bedankt	  dat	  je	  mijn	  ontzettend	  lieve	  man	  bent.	  Dit	  feestje	  heb	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